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1Something new and significant is going on in the world drugs market. In last year's World Drug Report we made the
argument that drug control is working and the world drug problem is being contained. This 2007 Report provides
further robust evidence of this trend. For almost every kind of illicit drug - cocaine, heroin, cannabis and amphet-
amine-type stimulants (ATS) - there are signs of overall stability, whether we speak of cultivation, production or con-
sumption. Hopefully, within the next few years evidence to support this claim will become statistically and logically
incontrovertible. 
This does not mean that the drug problem has been solved or that we can become complacent. Nor is the good
news universal. Progress made in some areas is often offset by negative trends elsewhere. But overall, we seem to have
reached a point where the world drug situation has stabilized and been brought under control. 
The first encouraging sign is that coca cultivation in the Andean countries continues to fall, driven by significant
declines in Colombia. Global demand for cocaine has also stabilized, although the decline in the United States is
offset by alarming increases in some European countries. Secondly, the production and consumption of ATS has
levelled off, with a clear downward trend in North America and, to a lesser degree, Europe.  Thirdly, the health warn-
ings on higher potency cannabis, delivered in past World Drug Reports, appear to be getting through. For the first
time in years, we do not see an upward trend in the global production and consumption of cannabis. Fourthly,
opium production, while significant, is now highly concentrated in Afghanistan's southern provinces. Indeed, the
Helmand province is on the verge of becoming the world's biggest drug supplier, with the dubious distinction of
cultivating more drugs than entire countries such as Myanmar, Morocco or even Colombia. Curing Helmand of its
drug and insurgency cancer will rid the world of the most dangerous source of its most dangerous narcotic, and go
a long way to bringing security to the region. 
Another source of good news is that drug law enforcement has improved: almost half of all cocaine produced is now
being intercepted (up from 24% in 1999) and more than a quarter of all heroin (against 15% in 1999). 
These positive developments are not attributable to a single specific factor: drug trends respond to long-term policy
and to changes in society at large, not to individual causes. Yet chronologically there is a clear correlation between
UN-led drug control efforts and the current recession in the drug economy. In other words, the world seems to be
taking seriously the commitment made at a UN General Assembly Special Session in 1998 to take enhanced action
to reduce both the illicit supply of, and the demand for drugs by 2008. 
The situation, while stable, is fragile and could be undone by any number of factors. More importantly, since there
are still 25 million problem drug users in the world, there is plenty of room for improvement.  
Supply: Southeast Asia is closing a tragic chapter that has blighted the Golden Triangle for decades - the region is
now almost opium free. Yet it is not free of poverty and therefore farmers remain vulnerable to the temptations of
illicit incomes. Much more assistance - for alternative crops and also for viable income substitution - is needed to
ensure that drug-free development is sustained in the greater Mekong basin. The same logic applies in Afghanistan
and the Andean countries. Rewarding licit rural activity and promoting development will encourage farmers to vol-
untarily give up their illicit crops in a way that will offer them brighter, and longer-lasting prospects than forced
eradication.
The general political context also shapes drug supply. Drug cultivation thrives on instability, corruption and poor
governance. The world's biggest drug producing centres are in regions beyond the control of the central govern-
ment, like South Afghanistan, South-West Colombia and East Myanmar. Until government control, democracy and
the rule of law are restored, these regions will remain nests of insurgency and drug production - and represent the
biggest challenge to containment. 
Preface
2Trafficking: Organized crime seeks the path of least resistance. Many trafficking routes traverse zones of instability,
and where corruption negates interdiction. The challenge is to block these routes by increasing law enforcement,
stopping the diversion of precursor chemicals, improving the integrity of the judicial system, and - not least -- fight-
ing corruption among officials at borders and in local administrations. Otherwise, as in parts of Central America,
the Caribbean and the Balkans, countries will be caught in the crossfire of drug-related crime. As this Report shows,
there are warning signs that Africa is also under attack, targeted by cocaine traffickers from the West (Colombia)
and heroin smugglers in the East (Afghanistan). This threat needs to be addressed quickly to stamp out drug-related
crime, money-laundering and corruption, and to prevent the spread of drug use that could cause havoc across a con-
tinent already plagued by other tragedies. 
All over the world, regional cooperation is essential. In 2007, UNODC looks forward to the opening of regional
counter-narcotic information-sharing centres in Central Asia and the Gulf. The time is ripe to consider the creation
of a similar mechanism to facilitate drug-related intelligence cooperation in South East Asia.  
Seizing cannabis and ATS is more difficult because of short supply routes. In many cases, these drugs are produced
and consumed in the same country, even the same town, making them available, affordable, and in some cases pub-
licly acceptable.  That suggests that for these, as for other types of controlled substances, the greatest challenge is to
raise awareness about the damage to health and reduce demand. 
Demand: To move beyond containment and to reduce the risk of drugs to public health and public security, more
attention must be paid to drug prevention and treatment. While much of this 2007 Report looks at world drug trends
in terms of cultivation, production, seizures and prices, these are just the symptoms. If the drug problem is to be
reduced in the longer term, there must be more intervention at the level of consumption, to treat the problem at
its source - the drug users. 
Drug addiction is an illness that can be prevented and treated. Early detection, greater prevention efforts, better
treatment of addiction, and integration of drug treatment into public health and social services programs, can free
people from the nightmare of addiction. Treating those who suffer from drugs is an investment in the health of our
nations as much as treating HIV, diabetes or TB.
Also, because drugs are a health problem that tends to turn into a social problem, their abuse must be addressed by
all of society. As parents, teachers, co-workers and good citizens we must help people take control of their lives, rather
than have them controlled by drugs.  
Looking forward, while containment of the drug problem seems to be a reality, further changes are needed to create
a paradigm shift. This is a shared responsibility: internationally - between producing and consuming states;
regionally - among neighbouring countries; and nationally - among all sectors of society. Let us each assume our share
of that responsibility, in order to improve both public health and public security across the world.  
Antonio Maria Costa
Executive Director
United Nations Office on Drugs and Crime
3The United Nations Office on Drugs and Crime (UNODC) is a global leader in the multilateral effort against
illicit drugs and international crime. The three pillars of its work programme are:   
• Research and analytical work to increase knowledge and understanding of drugs and crime issues and 
expand the evidence-base for policy and operational decisions; 
• Normative work to assist States in the ratification and implementation of the international treaties, the 
development of domestic legislation on drugs, crime and terrorism, and the provision of secretariat and 
substantive services to the treaty-based and governing bodies; and 
• Field-based technical cooperation projects to enhance the capacity of Member States to counteract 
illicit drugs, crime and terrorism.
Recognizing the importance of comprehensive, factual and objective information in the field of international
drug control, the General Assembly entrusted UNODC with the mandate to publish "comprehensive and
balanced information about the world drug problem" in 1998. UNODC has published such assessments
annually since 1999.
This year, the Report has been reworked into a one-volume format. The detailed seizures tables which were
previously presented in the second section of Volume II under the title "Seizures," are now available on
UNODC's website. A PDF file containing the detailed seizure tables is available for review and downloading
at: www.unodc.org/unodc/en/world_drug_report.html (the same location as the Report). The detailed seizure
tables are also available on CD by request. CDs can be ordered via the following email address: RAS@unodc.org
The Report continues to provide trend analysis of the global situation and of the four main drug markets in its
first section. In addition, this year’s Report contains an in depth look into the relationship between translational
organised crime and drug trafficking. The report also contains a small statistical annex which provides detail on
production, prices and consumption. The Report's coverage remains comprehensive and it tries to give the
reader a complete picture of the  world's drug problem. 
As in previous years, the Report is based on data obtained primarily from the Annual Reports Questionnaire
(ARQ) sent by Governments to UNODC in 2006, supplemented by other sources when necessary and where
available. Two of the main limitations herein are: (i) that ARQ reporting is not systematic enough, both in
terms of number of countries responding and of content, and (ii) that most countries lack the adequate
monitoring systems required to produce reliable, comprehensive and internationally comparable data. National
monitoring systems are, however, improving and UNODC has contributed to this process.
Electronic copies of the World Drug Report 2007 report can be accessed via the UNODC website at
www.unodc.org. Comments and feedback on the report can be sent to: worlddrugreport@unodc.org.
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5This report has been reproduced without formal editing.
The designations employed and the presentation of the material in this publication do not imply the expression of
any opinion whatsoever on the part of the Secretariat of the United Nations concerning the legal status of any
country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.   
Countries and areas are referred to by the names that were in official use at the time the relevant data were collected.
In various sections, this report refers to a number of regional designations. These are not official designations. They
are defined as follows: West and Central Europe: EU 25 plus EFTA plus San Marino and Andorra; East Europe:
European CIS countries; Southeast Europe: Turkey and the non-EU Balkan countries; North America: Canada,
Mexico and United States of America.
The following abbreviations have been used in this report:
ARQ         Annual reports questionnaire
ATS         Amphetamine-type stimulants
CICAD       Inter-American Drug Abuse Control Commission
CIS        Commonwealth of Independent States
DEA         United States of America, Drug Enforcement Administration
DELTA Database on Estimates and Long Term Trend Analysis
DUMA Drug Use Monitoring in Australia
EMCDDA     European Monitoring Centre for Drugs and Drug Addiction
ESPAD European School Survey Project on Alcohol and other Drugs
F.O. UNODC Field Office
Govt. Government
ICMP UNODC Global Illicit Crop Monitoring Programme
INCB        International Narcotics Control Board
INCSR United States of America, International Narcotics Control Strategy Report
Interpol   International Criminal Police Organization
LSD         lysergic acid diethylamide
NAPOL National Police
PCP         phencyclidine
THC tetrahydrocannabinol
UNAIDS  Joint and Co-sponsored United Nations Programme on Human   
Immunodeficiency Virus/Acquired Immunodeficiency Syndrome
UNODC         United Nations Office on Drugs and Crime
WCO World Customs Organization 
WHO         World Health Organization
Weights and measurements
u. Unit
lt. Litre
kg Kilogram
ha Hectare
mt Metric ton
Explanatory notes

71.1 Overview
Evolution of the world drug problem
The world’s drug problem is being contained. In
2005/06, the global markets for the main illicit drugs –
the opiates, cocaine, cannabis, and amphetamine-type
stimulants – remained largely stable. Particularly
notable is the stabilisation seen in the cannabis market,
which had been expanding rapidly for some time. In
line with a long-term trend, the share of total drug pro-
duction that is seized by law enforcement has also
increased – some 42 per cent of global cocaine produc-
tion and 26 per cent of global heroin production never
made it to consumers.
Of course, within this aggregated picture, there remains
considerable variation. Most notably, heroin production
continued to expand in the conflict-ridden provinces of
southern Afghanistan. While global heroin consump-
tion does not appear to be growing, the impact of this
surge in supply needs to be monitored carefully.
How is drug production changing?
Most of the world’s drug markets start with the farmer.
Unlike other crops, however, the cultivation of opium
poppy, coca leaf and cannabis take place under threat of
eradication, and so the location and the number of
hectares tilled vary substantially from year to year.
UNODC, in cooperation with the relevant national
authorities, conducts drug crop monitoring surveys in
all of the world’s major opium poppy and coca produc-
ing countries. Changes in the number and location of
hectares under cultivation, as well as crop yields, can
thus be tracked with some precision.
Around 92 per cent of the world’s heroin comes from
poppies grown in Afghanistan. Despite a massive
increase in opium poppy cultivation in Afghanistan in
2006, the global area under poppy was actually 10 per
cent lower than in 2000. This decline was mainly due to
sustained success in reducing cultivation in South-East
Asia. Poppy cultivation in the Golden Triangle has fallen
by some 80 per cent since 2000.
Most of the world’s cocaine comes from coca leaf culti-
vated in Colombia, Peru and Bolivia. The global area
under coca cultivation fell by 29 per cent to some
156,900 hectares between 2000-2006, largely due to
reductions of coca cultivation in Colombia. The areas
under coca cultivation in Peru and Bolivia increased
over this period but remained significantly below the
levels reported a decade earlier. 
As discussed in last year’s World Drug Report, it is impos-
sible to accurately estimate the location and total
number of hectares under cannabis, because it is grown
in at least 172 countries, often in small plots by the users
themselves. The one country where reliable estimates are
available is Morocco, the source of about 70 per cent of
the hashish consumed in Europe. UNODC and the
Government of Morocco have been monitoring large-
scale hashish production since 2003. Based on these sur-
veys, cannabis cultivation in Morocco has declined in
recent years, from a peak of 134,000 hectares in 2003
to just 76,400 hectares in 2005. Outside Morocco, there
have been few national or regional studies of the extent
of cannabis cultivation. 
There is an important distinction between the extent of
drug crop cultivation and the extent of drug produc-
tion, however. Crop yields can be affected by weather
conditions and changes in production technology,
among other things. As a result, long-term declines in
cultivated area do not necessarily translate into declines
in total production. Opium production in Afghanistan
rose almost 50 per cent in 2006, bringing gobal heroin
production to a new record high of 606 mt in 2006,
exceeding the previous high (576 mt in 1999) by 5 per
cent. Similarly, the success in the reduction of coca cul-
tivation from 2000 to 2006 has not led to a commen-
surate decline in cocaine production, apparently due to
improvements in coca cultivation and cocaine produc-
tion technology. Cocaine production has remained
largely stable over the last few years, estimated at 984 mt
in 2006.
Amphetamine-type stimulants are manufactured illicitly
using legally-produced precursors, and thus global pro-
duction can only be estimated indirectly. This produc-
tion appears to be stable, however, at about 480 mt in
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2005. At the same time, seizures of ATS labs and pre-
cursors declined dramatically, likely a result of improved
precursor control and significant reductions in domes-
tic production operations in key markets such as the
USA.
How is drug interdiction changing?
An increasingly large share of the world’s drug supply is
being seized by law enforcement agencies each year. In
2005, 42 per cent of global cocaine production and 26
per cent of global heroin production was intercepted by
the authorities. With regard to heroin, this means that
the amount available to the consumer in 2005 was actu-
ally 5 per cent lower than in 2000 and 8 per cent lower
than a decade before. Cocaine seizures have increased
even more markedly, up from just 24 per cent of pro-
duction in 2000. Improved cooperation among law
enforcement bodies has led to improved seizures close to
the source. In fact, 58 per cent of global cocaine seizures
took place in South America, the Caribbean and Cen-
tral America in 2005.
In the last decade, the most significant seizure trend has
been the increase in the number of seizures of amphet-
amine-type stimulants (ATS). These seizures peaked in
2000 at 49 mt, before dropping over the following four
years. In 2005, they began to rise again, to 43 mt.
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Herbal cannabis seizures, in contrast, were down in
2005, a trend seen across continents. The reasons for
this decline are due to increased eradication and are
occurring in the context of stabilised demand and may
be related to decreased transnational trafficking due to
a growing reliance on domestic cultivation. Cannabis
resin seizures were also down, but this can be directly
tied to the decline in hashish production in Morocco.
How is drug use changing?
While a large share of the world’s population uses illicit
drugs each year (about 5 per cent of the population
between the ages of 15 and 64), only a small share of
these can be considered “problem drug users” (0.6%).
About 200 million people use drugs each year globally.
Unsurprisingly, the main problem drugs at the global
level continue to be the opiates (notably heroin), fol-
lowed by cocaine. For most of Europe and Asia, opiates
continued to be the main problem drug; in South-
America, drug related treatment demand continued to
be mainly linked to the abuse of cocaine; and in Africa,
the bulk of all treatment demand is linked to cannabis.
9
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World population age 15-64:
4,177 million people (100%*)
Problem drug use:
age 15-64:
25 million people (0.6%*)
Monthly prevalence of drug use:
110 million people (2.6%*)
Annual prevalence of drug use:
200 million people (4.8%*)
Total world population:
6,475 million people
* in per cent of population age 15-64
Non-drug using population
age 15-64:
3,977 million people (95.2%*)
Illegal drug use at the global level (2005/2006)
Cannabis
Amphetamine-type
stimulants
Cocaine Opiates
of which
heroin
Amphetamines Ecstasy
(million people) 158.8 24.9 8.6 14.3 15.6 11.1
in % of global 
population age 15-64
3.8% 0.6% 0.2% 0.3% 0.4% 0.3%
Extent of drug use (annual prevalence*) estimates 2005/6 (or latest year available)
* Annual prevalence is a measure of the number/percentage of people who have consumed an illicit drug at least once in the 12 month-
period preceding the assessment.
1.2 Opium/Heroin Market
At least in the short-term, conditions in the world’s
heroin markets will be determined by what happens in
southern Afghanistan, as the country was responsible for
92 per cent of global opium production in 2006. For no
other drug is production so concentrated in a single
area. This concentration went hand in hand with a
remarkable long-term progress in eliminating other
sources of supply, principally in South-East Asia. Poppy
cultivation in South-East Asia is down by more than 85
per cent over the last decade. Between 2005 and 2006
alone, poppy cultivation in South East Asia declined
from 35,000 hectares to 24,000 hectares. 
The significance of the contraction in opium cultivation
in Myanmar and Laos cannot be overstated. Although
opium poppy cultivation in Afghanistan increased mas-
sively in 2006, the global area under illicit poppy culti-
vation was still 10 per cent lower in 2006 than in 2000,
due to reduction in South-East Asia. But despite the
reduction in the area under cultivation, potential heroin
production is up, because Afghan fields are more pro-
ductive than fields in South-East Asia. In 2006, global
opium production soared to a new record high of 6,610
mt, a 43 per cent increase over 2005. 
Under these conditions, with a surge in supply and
stable demand, a price decline would be expected near
the source, but opiate prices are not easy to predict,
10
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Main problem drugs (as reflected in treatment demand), 2005 (or latest year available)
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because the global dynamics of this market are not well
understood. Despite the 49 per cent increase in pro-
duction in Afghanistan in 2006, opium prices actually
fell by just 17 per cent in the country. This could sug-
gest that there is substantial stockpiling, but there is
little evidence as to where and how it is occurring.
In recent years, the world heroin market has been
divided into three regional submarkets. Afghan opiates
have supplied the markets of neighbouring countries,
Europe, the Near and Middle East, and Africa. Opiates
produced in South-East Asia have supplied the markets
of China and other South-East Asian countries, as well
as Oceania. Opiates produced in Latin America sup-
plied the North American market. However, it appears
that cross-regional trafficking is gaining in importance.
For example, there are indications that a small but
increasing proportion of opiates from Afghanistan are
being trafficked to North America, either via eastern
and western Africa, or via Europe. 
Overall, the consumer market has remained encourag-
ingly stable, despite important increases in the countries
along major trafficking routes. Countries experiencing
an increase in heroin usage include those surrounding
Afghanistan (Pakistan, Iran and Central Asia), as well as
Russia, India and parts of Africa. Many of these areas
have high levels of poverty and HIV, leaving them vul-
nerable to the worst effects of this drug. It is important
that these trends are carefully monitored over the
coming years.
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1.3 Coca/Cocaine Market
The global cocaine market is largely stable in terms of
both supply and demand. Supply stability has been
achieved only through intensive eradication efforts,
especially in Colombia. The area under coca cultivation
fell by 29 per cent between 2000-2006, including a 52
per cent reduction in the area under coca cultivation in
Colombia. The areas under coca cultivation in Peru and
Bolivia increased over this period but remained signifi-
cantly below the levels reported a decade earlier, reflect-
ing long-term supply reduction.
Though contained, there are indications that the supply
side of this market remains adaptive. The success in the
reduction of coca cultivation from 2000 to 2006 did not
lead to a decline in cocaine production. In recent years,
the use of fertilizers and pesticides, and better produc-
tion technology, have improved coca yields, leaving
cocaine production largely stable over the last few years
(1,008 mt in 2004, 980 mt in 2005, 984 mt in 2006).
With production largely stable, there are encouraging
signs that progress is being made at reducing supply
through growing rates of interdiction. Overall, the
interception rate rose from 24 per cent in 2000 to 42
per cent in 2006. Improved cooperation among law
enforcement bodies in and across countries appears to
have led to an increase in seizures in and around the pro-
ducer countries. In fact, 58 per cent of global cocaine
seizures took place in South America, the Caribbean
and Central America in 2005. North America and
Western/Central Europe, the two main cocaine con-
sumption regions, also continued to seize large amounts
of the drug (28 per cent and 14 per cent of global
seizures respectively). The world’s largest cocaine
seizures in 2005 were, once again, made by Colombia,
followed by the USA, Venezuela, Spain, Ecuador and
Mexico. 
Cocaine is frequently trafficked to Europe via the
Caribbean region and, increasingly, via Africa. Over the
2000-2005 period, the largest increases in cocaine
seizures were reported by countries in Africa and West-
ern/Central Europe. In Africa, seizures rose sixfold, and
in West and Central Europe they rose fourfold. The
largest cocaine seizures in Europe in 2005 were made by
Spain, followed by Portugal and the Netherlands,
reflecting both strong national law enforcement activi-
ties and the increase in trafficking towards these coun-
tries – which contain vibrant consumer markets and
which are the main entry points of cocaine into the
European Union. 
12
World Drug Report 2007
Changes in the use of heroin and other opiates, 2005 (or latest year available)
Similarly, rising levels of seizures in Africa reflect the fact
that this continent, notably countries along the Gulf of
Guinea and off the coast of Cape Verde, is increasingly
being used as a transhipment point for cocaine from
South America to markets in western Europe.  
While the consumer market in North America has
ceased to expand, cocaine is making worrying inroads
into new and growing markets. Consumption increased
significantly in Europe, doubling or tripling in several
countries over the last decade. In Africa, notably in the
countries of western Africa, cocaine use has also
increased. Overall cocaine consumption levels in Europe
are still significantly lower than in North America.
However, Spain recently reported that, for the first time,
cocaine annual prevalence levels exceeded those of the
USA in 2005. High and rising levels of cocaine use have
also been reported from the UK and Italy. 
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Changes in the use of cocaine, 2005 (or latest year available)
Global coca cultivation, 1990-2006 Global cocaine production*, 1990-2006
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1.4 Cannabis Market
Cannabis is the largest illicit drug market by far, includ-
ing roughly 160 million annual consumers. The wide-
spread nature of production and consumption make it
very difficult to define and quantify. Reports received by
UNODC suggest that cannabis production is taking
place in at least 172 countries and territories.1 Indica-
tions of an overall stabilisation in the market in 2005 are
extremely encouraging but it remains to be seen whether
this will emerge as a long-term trend. 
The production of cannabis resin (also known as
hashish) is concentrated in North Africa (Morocco) and
in the South-West Asia/Middle East region, particularly
in Afghanistan and Pakistan. UNODC surveys con-
ducted in collaboration with the Moroccan authorities
revealed a fall in the area of cannabis resin cultivation in
that country in recent years, from a peak of 134,000 ha
in 2003 to 76,400 ha in 2005. Resin production
declined even more strongly, from 3,070 mt in 2003 to
1,070 mt by 2005. Most of this production is consumed
in Europe. 
Cannabis herb seizures continue to be mainly concen-
trated in North America (66% of global seizures in
2005), followed by Africa (16%). Global seizures of
cannabis herb showed a strong increase over the 2000-
2004 period, a probable reflection of rising cannabis
herb production, trafficking and consumption. How-
ever, in 2005, cannabis herb seizures declined substan-
tially to the levels reported back in 2000. The decline
was reported across all continents. Eradication played a
role but other factors are not yet fully known. Sustained
declines could also indicate a growing reliance on
domestically produced cannabis.
Global cannabis resin seizures also declined in 2005
due to lower production of cannabis resin in Morocco.
The world’s largest cannabis resin seizures continued to
be reported by Spain (52% of global hashish seizures
in 2005), followed by Pakistan (7%) and Morocco
(7%).
The consumer markets in North America appear to
have contracted somewhat. A decline of cannabis use
was also found in the Oceania region, which has the
world’s highest levels of prevalence rates for cannabis.
But there has been a reported increase of cannabis use
in Africa and in most countries of South America. The
situation in Europe and Asia is mixed. The number of
all countries reporting increases in cannabis use fell from
58 per cent of all countries reporting in 2000 to 45 per
cent in 2005, while the number of countries reporting
declines increased from 7 per cent in 2000 to 21 per
cent in 2005.
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Estimates of global cannabis herb production, 1988-2005
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1 A total of 82 countries explicitly reported the illicit cultivation of cannabis on their territory over the 1995-2005 period. In addition, Member
States identified 134 source countries for the production of cannabis. Moreover, 146 countries reported seizing cannabis plants over the 1995-
2005 period, which is an indirect indicator for the existence of cannabis plant production in a country, as cannabis plants are usually not trafficked
across borders (only the end-products are). Combining these data suggests that cannabis production is taking place in at least 172 countries and
territories.
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Trafficking in cannabis resin, 2005 (countries reporting seizures of more than 10 kg)
Trafficking in cannabis herb, 2005 (countries reporting seizures of more than 100 kg)
1.5 Amphetamine-type Stimulants Market
There has been an overall stabilisation of the ATS
market. The alarming increases in the production of
ATS throughout the 1990s seem to have levelled off
over the last few years. This is likely a result of recent
efforts to monitor and improve precursor control.  
The largest production areas for methamphetamine
continue to be in South-East Asia (including Myanmar,
China and the Philippines) and in North America. Tra-
ditionally, the majority of methamphetamine in the
USA was produced domestically, with the precursor
chemicals smuggled into this country via Canada or
Mexico. Improved controls in Canada and further tight-
ening of controls in the USA have led to a decline in the
number of clandestine laboratories operating within the
USA and a shift of production across the border to
Mexico. However, Mexico has now also improved its
precursor control regime, prompting drug trafficking
organizations to exploit other areas, such as Central
America and possibly Africa. 
In South Africa, where methamphetamine is produced
for the domestic market, both production and con-
sumption have increased. The Oceania region, notably
Australia and New Zealand, continue to be important
producers and consumers of methamphetamine, but
there are no indications that these drugs are exported
from there. 
Amphetamine production continues to be primarily
located in Europe, notably in the Netherlands and
Poland, followed by the Baltic region and Belgium.
Amphetamine production also takes place in North
America (notably in the USA) and in South-East Asia.
Ecstasy production also continues to be largely concen-
trated in Europe, though the expansion of ecstasy pro-
duction, in recent years, has mainly taken place outside
Europe, notably in North America and in East and
South-East Asia. 
Global seizures of ATS continue to be dominated by
seizures of methamphetamine. Over the 2000-2005
period, 49 per cent of ATS seizures were in the form of
methamphetamine, 15 per cent in the form of amphet-
amine, and 14 per cent in the form of ecstasy. The trend
in recent years, however, has been towards rising pro-
portions of amphetamine and falling proportions of
methamphetamine, reflecting improved control over the
two main methamphetamine precursors, ephedrine and
pseudo-ephedrine.    
Global demand for amphetamines (methamphetamine
and amphetamine), which increased strongly in most
parts of the world in the 1990s, is now showing signs of
overall stabilisation. At close to 25 million people, the
global amphetamines consumer market is larger than
16
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Changes in the use of cannabis, 2005 (or latest year available)
the markets for cocaine or heroin. Between 15-16 mil-
lion of these users are thought to consume metham-
phetamine. Following the expansion of the consumer
market throughout the 1990’s, there have been consis-
tent signs of slow down and stabilisation over the last
few years, particularly in North America.
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Trafficking in ecstasy, 2005 (countries reporting seizures* of more than 1 kg)
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Changes in the use of ecstasy (MDMA, MDA, MDEA), 2005 (or latest year available)
Changes in the use of “amphetamines” (methamphetamine, amphetamine and related substances), 2005 
(or latest year available)
Is transnational drug trafficking in the hands of large
and organized criminal groups or is it mainly conducted
by smaller and looser associations of smugglers? The
answer to this question has implications for the way
drug interdiction is approached. This question might be
answered through existing indicators, particularly
seizure figures, price data and drug use trends. In order
to assess the potential of this approach, these indicators
are explored in two of the world’s largest value drug
flows: the transhipment of cocaine via Central America
to the USA and the trafficking of heroin through Cen-
tral Asia to the Russian Federation.
Cocaine via Central America to the USA
This drug flow has surely become less centralised than
it was during the days of the Cali and Medellin cartels,
which dominated the cocaine market at all levels. But
the size of the seizures made in this region, as well as low
levels of drug use in the transit zone countries, suggest
that cocaine trafficking remains highly organized and
dominated by some very large organizations.
The USA remains the world’s largest cocaine consumer,
and some 88 per cent of the cocaine destined for the
USA transits the Central America/Mexico corridor,
about 50 per cent along the Pacific and 38 per cent
along the Caribbean coast of Central America. Most of
the cocaine flow today is maritime and given the cost
and complexity of trafficking on the high seas, this fact
alone suggests high levels of organization.
The largest cocaine seizures, as reflected in the
UNODC Individual Drug Seizure database, involve
multiple tons of the drug and are worth tens or even
hundreds of millions of dollars. Such shipments are
clearly beyond the scope of small networks of individ-
ual traffickers. The share of large seizures in national
seizure totals highlight the fact that, while smaller scale
trafficking does take place, the backbone of the market
remains in the hands of more sophisticated operators.
For example, in 2004, more than 25 per cent of the
cocaine seized in Honduras came from just one mar-
itime seizure, while 42 per cent of that seized in
Nicaragua came from two major seizures on the Atlantic
Coast.
The presence of large loads can be inferred from the
volatility of national seizure totals even where individ-
ual seizure details are not available. For example, El Sal-
vador seized 32 kg in 2001 before increasing seizure
totals to two or three tons annually between 2002 and
2004. In 2005, the country seized only 32 kg. It is
unlikely that either the real flows of cocaine through the
country or the enforcement efforts made to interdict
drugs varied so greatly from year to year, so seizure totals
likely reflect the presence or absence of a small number
of large seizures.
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2. Invisible empire or invisible hand? 
Organized crime and transnational drug trafficking
Trafficking in cocaine, 2005 
(countries reporting seizures*
of more than 10 kg)
Since drug trafficking organizations would ideally like to
deliver all the drugs produced to their highest value des-
tinations, “spillage” of cocaine into the lower value mar-
kets of transit countries represents a kind of inefficiency,
often associated with diffuse networks of body couriers
who are paid in kind rather than cash. Relatively low
drug use levels among transit countries suggest that drug
flows through this region remain highly organized.
Finally, federal arrest figures in the USA show that the
cocaine trafficking is dominated by syndicates of two
nationalities: Mexican and Colombian. While this indi-
cates less centralisation than would be the case if the
drug producers controlled the entire supply chain, it
demonstrates that the drugs are not simply percolating
northward, exchanging hands multiple times. Arrest
figures suggest that there is very little involvement
within the USA of transit country (Central American)
nationals.
Heroin via Central Asia to the Russian Federation 
In contrast, trafficking through Central Asia appears to
be relatively disorganized. Estimates suggest a small
share of heroin bound for Russia is seized (perhaps
10%), leaving open the possibility that large shipments
are occurring under cover of corruption. Most of the
seizures that are made, however, are very small with 95
per cent totalling less than six kg. This amount can be
purchased in Afghanistan for about US$10,000, well
within the reach of smaller syndicates.
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It would appear that Afghans are involved in bringing
the drug out of Afghanistan. From there, the heroin
may change hands to Kyrgyz or Kazakh nationals until
reaching Kazakhstan, and thereafter Kazakh or Russian
groups transport it to Russia. It would appear that
Kyrgyz and Kazakh nationals are reliant on the Tajik
and Uzbek groups to provide the drugs for further traf-
ficking. In general, transport through the transit zone
often appears to be controlled by the nationals of the
transit zone, with border crossings involving groups of
both states. 
Few Tajik nationals are arrested in Kazakhstan for drug
trafficking but a large share of major seizures in Russia
involve Tajik nationals. Of 954 heroin seizures of over
100 grams reported to the UNODC between 1999 and
2004 in which the nationalities of the traffickers were
specified, 252 involved Tajik nationals (26%), operating
either alone or in concert with traffickers of other
nationalities. However, while Tajik groups are important
in both cross-border operations with Afghanistan and
trafficking within Russia, the small numbers arrested in
Kazakhstan leave open the possibility that they do not
control the heroin during the intermediate trafficking
period.
Finally, drug use rates have been growing rapidly in
Central Asia, suggesting that the smuggling is indeed
being conducted by a large number of small couriers,
with the possibility that the heroin is sold-on multiple
times before reaching its final destination. 
The two examples discussed above highlight two
extremes of a spectrum: on the one hand, the highly
organized groups active in shipping multi-million dollar
consignments of cocaine from Colombia to the USA;
on the other, the many, uncoordinated players who,
responding to market incentives, move heroin from
Afghanistan to Russia. It appears that the two regions
are vaguely converging, however - cocaine trafficking
has become less organized since the days of the Medellin
and Cali Cartels, and the heroin trade in Afghanistan, is
growing increasingly and is getting more organized.
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1. TRENDS IN THE WORLD DRUG MARKETS
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Continued containment of the drug problem
The global drug problem is being contained.  The pro-
duction and consumption of cannabis, cocaine,
amphetamines and ecstasy have stabilized at the global
level – with one exception. The exception is the contin-
uing expansion of opium production in Afghanistan.
This expansion continues to pose a threat -  to the secu-
rity of the country and to the global containment of
opiates abuse.  Even in Afghanistan, however, the large
scale production of opium is concentrated and expand-
ing in a few southern provinces where the authority of
the central government is currently limited and insur-
gents continue to exploit the profits of the opium trade.   
On the whole, most indications point to a levelling of
growth in all of the main illegal drug markets. This is
good news and may indicate an important juncture in
long term drug control. A stable and contained problem
is easier to address than one which is expanding chaoti-
cally, provided it is seen as an opportunity for renewed
commitment rather than an excuse to decrease vigilance. 
Most indications are, however,  that Member States do
have the will to re-commit to drug control. Although it
is outside of the scope of this Report to assess policy, the
estimates and trends which are provided in the follow-
ing pages contain several examples of progress forged on
the back of international collaboration. The extent of
international collaboration, the sharing of intelligence,
knowledge and experience,  as well as the conviction
that the global drug problem must be tackled on the
basis of a ‘shared responsibility’ seem to be growing and
bearing fruit.  
Following  stabilization in 2005, opium production
increased in 2006 ... 
The total area under opium cultivation was 201,000
hectares in 2006. This is clearly higher than a year ear-
lier (+33%) though still below the level in 1998
(238,000 ha) and some 29 per cent lower than at the
peak in 1991 (282,000 ha). Given higher opium yields
in Afghanistan than in South-East Asia, global opium
production is, however,  higher than in the 1990s. 
Following a small decline of global opium production in
2005 (-5%), global opium production increased again
strongly in 2006 (+43%) to reach 6610 mt, basically
reflecting the  massive expansion of opium production
in Afghanistan (+49%). Afghanistan accounted for 92
per cent of global illicit opium production in 2006.  As
a result global heroin production is estimated to have
increased to 606 mt in 2006. The bad news from
Afghanistan also overshadows the good news from
South East Asia. Opium production in the Golden Tri-
angle (mainly Myanmar and Laos) declined by 77 per
cent between 1998 and 2006 and by 84 per cent since
the peak in 1991.  
… while cocaine production remained stable 
If only the area under coca cultivation is considered,  a
small decline by 2 per cent to 157,000 hectares was
reported for the year 2006. As compared to the year
2000, the area under coca cultivation in the Andean
region declined by 29 per cent;  in Colombia, it fell by
as much as 52 per cent. This progress was, however, not
translated into a decline of global cocaine production,
due to improved yields and production techniques.
Global cocaine production is estimated to have
remained basically unchanged in 2006 as compared to
a year earlier or two years earlier. Following a revision of
yield estimates, global production is now estimated at
984 mt.  A decline in Colombia (-5 %) was compen-
sated by increases reported from Bolivia (+18%) and
Peru (+8%). 
Cannabis production declined in 2005 ...
Estimates for both cannabis herb and cannabis resin
showed a decline for the year 2005.  This decline follows
several years of sustained growth. Global cannabis herb
production is now estimated at 42,000 mt, down from
45,000 mt in 2004.  Global cannabis resin production
1.1 Overview
1.1.1 Evolution of the World Drug Problem
declined from 7,500 mt in 2004 to 6,600 mt in 2005,
reflecting mainly the decline of cannabis resin produc-
tion in Morocco.  
... and ATS production stabilized 
Global production of amphetamine-type stimulants
seems to have stabilized at around 480 mt in 2005,
slightly down from 500 mt in 2000. There has been a
decline in ecstasy production (from 126 mt in 2004 to
113 mt in 2005), and a small decline in methampheta-
mine production (from  291 to 278 mt) which was
offset by an increase in global amphetamine production
(from 63 to 88 mt).  
Member States reported 1.5 million drug seizure cases
to UNODC 
Member States reported 1.5 million drug seizure cases
to UNODC for the year 2005,  21 per cent more than
a year earlier. Some of the increase was due to improved
reporting. One hundred and twelve countries provided
detailed statistics on seizure cases in 2005, up from 95
countries in 2004.  If only the data of those countries
that reported in both 2004 and 2005 is considered, the
increase amounts to 10 percent. 
More than half (57 %) of all seizure cases involved
cannabis (herb, resin, oil,  plants and seeds). Opiates
(opium, morphine, heroin, synthetic opiates and poppy
seeds), accounted for 17 per cent, with heroin alone
accounting for 14 per cent of the total. This is followed
by seizures of the amphetamine-type stimulants (12 %).
About half of these seizures (or 5.5 % of the total) is
accounted for by methamphetamine, followed by
amphetamine (2.5  %) and ecstasy (2%); the rest (2 %)
includes ‘Captagon’ tablets (Near East) and ‘Maxiton
Forte’ (Egypt), ‘ephedrone’ (methcathinone) and vari-
ous undefined amphetamines. Coca products account
for 9 percent of global seizure cases; the bulk of coca
related seizure cases concern cocaine (8 % of total).  
Depressants account for 1 per cent of global seizure
cases and other drugs for 4 per cent. This includes sub-
stances such as methaqualone, khat, various synthetic
narcotics, LSD, ketamine, various non-specified psy-
chotropic substances, and inhalants. Some of these sub-
stances (such as khat,  ketamine and some of the
psychotropic substances) are not under international
control, but are under national control in several
Member States.   
Largest quantities of drugs seized are cannabis, cocaine
and opiates 
Information on the quantities of drugs seized was pro-
vided by 118 countries for the year 2005 in reply to
UNODC’s Annual Reports Questionnaire. Supple-
menting ARQ data with information obtained from
other sources1, UNODC has compiled data and infor-
mation from 165 countries and territories. This forms
the basis for the analysis which follows.  
The largest seizures worldwide are for cannabis (herb
and then resin), followed by cocaine, the opiates and
ATS. All cannabis related seizures amounted to more
than 9,700 mt in 2005, including 5,947 mt for
cannabis end products (herb, resin and oil). Cocaine
seizures amounted to 752 mt, opiate seizures, expressed
in heroin equivalents, amounted to 125 mt and ATS
seizures (methamphetamine, amphetamine, non-
defined amphetamines and ecstasy) amounted to 43 mt.   
Increases in 2005 were reported for coca leaf, cocaine,
the amphetamines as well as GHB and LSD.  As global
cocaine production remained unchanged, the strong
increase in cocaine seizures is likely to have been the
exclusive result of effective and successful law enforce-
ment. Though amphetamines seizures increased in 2005
they are still below the peak levels of 2000 and 2001.
Global trafficking in amphetamines over the last five
years has remained basically stable. 
Opiates seizures as a whole remained stable in 2005 –
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Fig. 1: Breakdown of seizure cases in 2005 by 
substance (N = 1.51 million)
Opiates
17% Cannabis
57%
Amphetamines
10%
Ecstasy
2%
Depressants
1%
Other
4%
Coca
9%
Source: UNODC, Government reports.
1 Government reports, HONLEA reports, UNODC Field Offices, Drug Abuse Information Network for Asia and the Pacific (DAINAP),
ICPO/Interpol, World Customs Organisation (WCO), CICAD, EMCDDA, United States Department of State, International Narcotics Control
Strategy Report, etc. 
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reflecting stable global opium production in that year.
Rising seizures of opium offset declines in heroin and
morphine seizures. For 2006, however, preliminary data
indicate a strong increase in opiates seizures,  in line
with growing levels of opium production in
Afghanistan.
In 2005, global seizures of cannabis herb,  resin  and oil
declined. The decline in cannabis herb seizures seems to
be linked to intensified eradication efforts in a number
of countries across the globe. The decline in cannabis
resin seizures can be linked to the decline of cannabis
resin production in Morocco.  
Drug seizures in unit terms decline in 2005
As the quantities of drugs seized are not directly com-
parable, it is difficult to draw general conclusions on
overall drug trafficking patterns from them. Since the
ratio of weight to psychoactive effects varies greatly from
one drug to another (the use of one gram of heroin is
not equivalent to the use of one gram of cannabis herb),
the comparability of the data is improved if the weight
of a seizure is converted into typical consumption units,
or doses, taken by drug users. Typical doses tend, how-
ever, to vary across countries (and sometime across
regions within the same country), across substances
aggregated under one drug category (e.g. commercial
cannabis herb and high-grade cannabis herb), across
user groups and across time. There are no conversion
rates which take all of these factors into account. Com-
parisons made here are based on global conversion rates,
of milligrams per dose,2 found in scientific literature or
used among law enforcement agencies as basic rules of
thumb. The resulting estimates should be interpreted
with some caution.    
1. Overview
Fig. 2: Global cannabis seizures, 2004-2005 
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Fig. 3: Global drug seizures, excluding cannabis, 
2004-2005
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2 For the purposes of this calculation, the following typical consumption units (at street purity) were assumed: cannabis herb: 0.5 grams per joint;
cannabis resin: 0.135 grams per joint; cocaine: 0.1 grams per line;  ecstasy: 0.1 grams per pill, heroin: 0.03 grams per dose;  amphetamines: 0.03
grams per pill; LSD:  0.00005 grams  (50 micrograms).
Fig. 4: Global drug seizures in ‘unit equivalents’, 
2000-2005
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Fig. 5: Trends in the world seizures, 1995 - 2005
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1. Overview
Based on such calculations, global seizures were equiva-
lent to 32.5 billion units in 2005, down from 35.8 bil-
lion units a year earlier (-9%). As the number of drug
seizure cases increased in 2005, the decline of seizures in
unit equivalents cannot be attributed to reduced law
enforcement activity. It most likely reflects the first signs
of stabilization in global drug trafficking flows parallel
to the stabilization in global drug production and drug
consumption.
In units terms, more than half of all seizures (59 %) are
cannabis, followed by coca related substances (24 %),
opiates (12 %) and amphetamine-type stimulants (4%).
While cannabis leads the table, irrespective of the meas-
urement used, it may be interesting to note that in terms
of drug units seized, cocaine ranks second. In terms of
reported drug seizure cases, cocaine ranked fourth,
behind the opiates and behind the ATS.  This reflects
the fact that, while there are many multi-ton seizures of
cocaine every year, other drugs are usually trafficked in
far smaller quantities.     
A regional breakdown shows that 44 per cent of all
drugs, expressed in unit equivalents, were seized  in the
Americas, 29 per cent in Europe, 18 per cent in Asia,  9
per cent in Africa  and 0.2 per cent in the Oceania
region. Seizures declined in 2005 in Africa, in the Ocea-
nia region, in Europe and in North America but
increased in South America and in Asia. 
On a per capita basis, drug trafficking is most wide-
spread in North America, reflecting higher abuse levels
and/or the fact that law enforcement in North America
is the most active in fighting drug trafficking. The
largest amounts of drugs per inhabitant are seized in
North America (19 doses per inhabitant), followed by
South America (13 doses) and Europe (11 doses).  The
global average is 5 doses per inhabitant per year. Africa,
Oceania and Asia are all below the global average.
Within Asia, however, data differ among the various
subregions. For the Near & Middle East / South-West
Asia region, seizures amount to 11 doses per inhabitant,
which is almost the same level as reported from Europe. 
Overall stabilization in global drug use 
The estimated level of drug use in the world has
remained more or less unchanged for the third year in a
row. Approximately 200 million people or 5 per cent of
the world’s population aged between 15 and 64 years
have used drugs at least once in the previous 12 months.
Fig. 6: Regional breakdown of seizures ‘in unit 
equivalents’, 1985 -2005 (N = 32.5 billion 
units)
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Fig. 7: Regional breakdown of drug seizures in 
‘unit equivalents’, 1985-2005
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Fig. 8: Drug units/doses seized per inhabitant in 
2005
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This continues to be a far lower level than tobacco use
(28 %).  UNODC’s estimate of the global number of
problem drug users also remains unchanged at around
25 million people or 0.6% of the global population age
15-64.   
With the exception of a small increase in cocaine use
(based on prevalence estimates), use of all illicit drugs
was either stable or declined slightly in 2005/6. The
increases in cannabis and ecstasy use which were
recorded in 2004/5 were not carried over into the
2005/6 period. 
Consumed by almost 4 per cent of the population or
close to 160 million persons, cannabis continues to
account for the vast majority of illegal drug use. Global
cannabis use estimates are slightly lower than last year’s
estimates, due to ongoing declines in North America
and – for the first time - some declines in the largest
cannabis markets of Western Europe. Cannabis use in
the Oceana region also continued to decline. In addi-
tion, a number of new household surveys found lower
prevalence rates than UNODC had previously esti-
mated for the countries concerned. Growth in cannabis
use occurred in Africa, several parts of South America,
some parts of Asia (South-West Asia, Central Asia and
South-Asia) and parts of Eastern and South-eastern
Europe. Although it is too early to speak of general
decline, signs of a stabilization of cannabis use at the
global level are apparent.
Amphetamine-type stimulants (ATS), including
amphetamines, methamphetamine and ecstasy, remain
the second most widely consumed group of substances.
Over the 2005/6 period 25 million people are estimated
to have used amphetamines (including methampheta-
mine) at least once in the previous 12 months, about the
same as a year earlier. An estimated 9 million people
used ecstasy over the 2005/6 period, down from 10 mil-
lion in 2004/5. Declines in ecstasy use occurred prima-
rily in North America. 
The number of opiates users remained stable at 2004/5
levels. As in that period, 16 million persons or 0.4 per
cent of the global population aged 15 to 64 consumed
Fig. 9: Use of illicit drugs compared to the use of 
tobacco (in % of world population age 15-64)
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Fig. 10: Illegal drug use at the global level (2005/2006)
World population age 15-64:
4,177 million people (100%*)
Problem drug use:
age 15-64:
25 million people (0.6%*)
Monthly prevalence of drug use:
110 million people (2.6%*)
Annual prevalence of drug use:
200 million people (4.8%*)
Total world population:
6,475 million people
* in per cent of population age 15-64
Non-drug using population
age 15-64:
3,977 million people (95.2%*)
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1. Overview
opiates. Out of these 16 million persons, 11 million or
0.3 per cent of the population abuse heroin.  Overall,
consumption declined or stabilized in established mar-
kets, including those of Western Europe and North
America,  but increased in countries in the vicinity of
Afghanistan as well as in new markets, such as  Africa.
In most of the countries of East and South-East Asia
opiate abuse stabilized or declined.   
UNODC’s estimate of the global level of cocaine use
increased slightly to 14 million persons or 0.3 per cent
of the global population.  Continued increases in South
America, Africa and Europe were partially offset by
decreases reported from North America. UNODC also
compiles data based on use trends as perceived by
experts. Results from these data are not always identical
to actual reported information.3 Trend estimates pro-
vided by Member States to UNODC differ slightly, and
indicate that global cocaine use declined slightly in
2005.
Treatment demand continues to be highest in North
America 
The demand for drug abuse treatment is an important
indicator for assessing the world drug situation because
it reveals the drugs which place the largest burden on
national health systems. Member States reported a total
of 4.5 million people under treatment for drug abuse to
UNODC. Of the 25 million people (0.6% of the
world’s population age 15-65) estimated to be heavily
Cannabis
Amphetamine-type
stimulants
Cocaine Opiates
of which
heroin
Amphetamines Ecstasy
(million people) 158.8 24.9 8.6 14.3 15.6 11.1
in % of global population
age 15-64
3.8% 0.6% 0.2% 0.3% 0.4% 0.3%
Annual prevalence is a measure of the number/percentage of people who have consumed an illicit drug at least once
in the 12 month-period preceding the assessment.
Table 1: Extent of drug use (annual prevalence*) estimates 2005/6 (or latest year available)
3 A detailed explanation of this can be found in the Methodology section of this Report.XXXXXXXXX                                XXXXXXXXXXXXXX
Fig. 11: UNODC estimates of illicit drug use, late 1990s to 2005/2006
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drug dependent, about 1 out of 5 are treated for their
problem.  
The number of persons under treatment is higher than
was reported in last year’s World Drug Report (3.7 mil-
lion). Most of the increase is due to better reporting
(notably from countries in South America). The actual
world total may be higher given the large number of
countries which do not have comprehensive registry sys-
tems.
Based on reported data, some 700 out of every million
persons were treated for drug abuse in 2005. The high-
est numbers of drug treatment (per million inhabitants)
are found in the Americas (3,670), the Oceania region
(2,290), and Europe (850). Within the Americas, treat-
ment levels in North America are the highest (5,050),
and within Europe treatment is far more frequent in
Western Europe (1,400) than in the rest of the conti-
nent (360). Treatment levels in Asia (120) and in Africa
(30) are low.   In recent years much of the progress made
at the global level in stabilizing or reducing drug con-
sumption occurred in North America, the Oceania
region and Western Europe, where more treatment
capacity was created.
Treatment demand for opiates abuse continues to be
highest in Asia and in Europe 
In Asia and Europe – home to more than 70 per cent of
the world’s total population – opiates account for the
bulk of drug-related treatment demand (62% and 58%,
respectively in 2005.)4 Within Europe, treatment
demand for opiates abuse is higher in Eastern Europe
(61%) and lower in Western Europe (55%). The pro-
portion of opiates-related treatment in overall treatment
demand has been declining in both regions since the late
1990s5. In Europe this reflects increasing abuse of
cannabis, cocaine and ATS; in Asia increasing abuse of
ATS and some increase in cannabis. The decline in Asia
is also linked to the decline of opium production in
South East Asia. In Oceania, the proportion of treat-
ment for opiates addiction in overall treatment demand
is declining. This began after the Australian heroin
shortage of 2001. The only exception to this downward
trend is Africa. Heroin related treatment increased from
8 per cent of treatment demand in the late 1990s to 15
per cent in 2005. Most of this rise was reported from
countries in eastern and southern Africa. 
Treatment of cocaine abuse remains highest in the
Americas – but the strongest increase is recorded in
Europe 
In South America, cocaine continues to account for
most of the drug abuse related treatment demand (48%)
though the proportion has declined since the late 1990s
(from 65%). High proportions of cocaine related treat-
ment demand are also encountered in North America
(40%). In the USA, cocaine related treatment demand
has shown a marked decline over the last decade.
Because this was not the case for Canada or Mexico, the
unweighted average for North America declined only
slightly. The strongest increase in cocaine related treat-
ment demand was observed in Europe (rising from 3 %
to 8 %). Data also show that cocaine is still mainly a
problem of Western Europe, where it now accounts for
13 per cent of treatment demand.  In Eastern Europe
the proportion is 2 per cent and in Africa 10 per cent.
In Asia, in contrast, cocaine related treatment is still
negligible (0.3%). 
Fig. 12: Drug treatment per million inhabitants in 
2005 (N = 4.5 million)
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Source: UNODC, Government reports.
4 While some countries have a comprehensive treatment registry system, others only provide data from a few clinics. Simply adding up such num-
bers of people treated for specific substances would give a strong bias in favour of the countries which have nationwide monitoring systems. In
order to overcome this problem, the proportions at the country level were first calculated and based on these results, the (unweighted) averages of
the respective region were derived. The data shown are those reported for the year 2005. In case no data for a specific country were reported for
2005, data obtained in previous years were used instead.   
5 The subsequent comparisons are based on treatment data statistics compiled and published in the World Drug Report, 2000.
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Fig. 13: Proportion of people in drug related treatment for specific substances: 1997/98 and 2005*
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1. Overview
Consolidating achievements
While there has been a long term geographical contrac-
tion of cultivation and production centers for
opium/opiates and coca/cocaine, there has been a dis-
persion of production locations for cannabis and ATS.
While the world has witnessed overall stabilization in
the established consumer markets for each of the four
illicit drugs, there are also indications of growing levels
of abuse in some regions. It will be important to care-
fully monitor the markets to see whether this stabiliza-
tion trend is being sustained. The goal, of course, is to
move from containment to overall reduction. Under-
standing some of the threats and enabling conditions in
relation to this goal will be critical to this achievement.  
Development of new trafficking routes 
The development of new trafficking routes is something
which should be anticipated and monitored carefully.
Illicit drug organizations, independent of their level of
organization and sophistication, are adaptive and cre-
ative when it comes to distribution. Over the course of
the last few years new routes have appeared in some
regions.  In particular Africa is increasingly being
exploited by drug traffickers and this trend can be
expected to continue. The trafficking routes from
Afghanistan via Pakistan and Central Asia to China (in
order to compensate for the lower production levels in
Myanmar)  are  another potential growth area that will
need more careful monitoring.       
Development of new consumer markets 
Within the context of overall stabilization of demand,
incipient consumer markets can probably be identified
for each of the four drug markets. In the case of opiates
they seem to be forming along trafficking routes and in
African countries, in the case of amphetamines and
ATS, there are indications of some emerging markets in
South-East Europe and the Near and Middle East, and
cocaine continues to find new markets in South Amer-
ica, Europe and Africa. There have also been reports of
the emergence of  cocaine markets in some of the Asian
countries.   Opiate use is increasing in Africa, notably in
countries of eastern Africa and in South Africa and
cocaine use is increasing in countries of western and
southern Africa. 
Opium/heroin market
Developments in Afghanistan will continue to deter-
mine the levels of  global opium production.  With no
indication that production will rise significantly in any
of the other opium producing countries, where supply
has been contracting, Afghanistan’s share in global
opium production could rise again this year. Early indi-
cations suggest there could be another increase in opium
production in that country in 2007. 
New trafficking routes are likely to develop or come to
light. Routes into and through China and India are
examples of this. Increases in abuse in countries border-
ing Afghanistan and along major trafficking routes are
likely, while demand can be expected to remain stable in
established markets. 
Coca/cocaine market
Production levels are likely to remain stable with
Colombia retaining its share of overall production.
Developments in Bolivia will continue to influence the
market. In the absence of increased prevention efforts,
the current upward trend in use in Europe could con-
tinue.
Cannabis
The insidiousness of this market will not change in the
near term. In the mid-term, the production of resin
could continue declining, given the ongoing efforts
made by Morocco. The production of cannabis herb
may well increase again, after the decline in 2005.
Growth in hydroponic production, and thus growth in
production in the developed world, is likely to continue.
Despite the overall stabilization of use in 2005/06, it is
too soon to predict an end to growth in the consump-
tion of cannabis. 
ATS
Although ATS production is flexible in the sense that
technology is simple and infrastructure can be tempo-
rary, it is rather inflexible when it comes to the chemi-
cal inputs required to produce the final product. As long
as the controls on these are effective and can be sus-
tained their lack of availability will hamper global pro-
1.1.2 Outlook for world drug markets
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duction. In 2005/2006 these controls increased, with
impressive results in several regions. If this is sustained
into the next few years growth of supply in this market
could indeed be suppressed.  On the other hand, one
can also observe some circumvention strategies, as the
necessary precursor chemicals are increasingly being
produced out of chemicals that remain readily available
on the market.
Although amphetamine, methamphetamine and ecstasy
are likely to continue to find new consumers it is likely
that, overall, the market will remain stable. Ecstasy use
could continue declining in established, developed
world markets, and increasing in markets in developing
countries.
Policy momentum at the national and international
level
If one takes the Hague Opium Convention of 1912 as
a starting point, the struggle against the drug problem
has been long indeed. When it has been effective, and
successes have been enumerated in previous editions of
this Report, one of the pillars of success has been sus-
tained political commitment and resource allocation at
the national and international level. 
Trends revealed in the pages of this Report indicate that
the current stabilization could be an important juncture
for drug control. Significant stabilizations have occurred
and have been sustained in the short term. Continued
commitment and momentum at the international level
will be one element in continuing these trends and pos-
sibly effecting sustainable, long term contraction in each
of these markets. 
In this context assistance, approaches and policy need to
be appropriately holistic and sequenced.  In 1998, at the
General Assembly Special Session on Drugs
(UNGASS), Illicit Trafficking, there was a general con-
sensus among the international community that the
drug problem could only be effectively addressed holis-
tically. The first step to achieving this was to ensure that
interventions were made both on the supply and the
demand sides of the problem. Almost ten years on, it is
apparent that this central tenet now forms the basis of
much drug policy. Similarly, it has been increasingly
recognised that drug policy and drug control interven-
tions must be holistic in nature. In order to address the
problem of supply in Afghanistan, for example, demand
in Europe and the neighbouring countries of
Afghanistan needs to be controlled, as does the growing
problem of use in Afghanistan itself, and the develop-
ment of new trafficking routes through Central Asia –
which, in turn, could address the increase in IDU
related HIV infection rates in the region. Each of those
problems, also need to be addressed in their proper con-
text. In some cases this will mean ensuring that the drug
problem is approached in the broader human security
and development framework. This type of approach is
more complex, and will need international coordina-
tion, but should  yield sustainable benefits.  
As the international community moves increasingly
toward this type of approach one of the main elements
of its success is going to be ensuring that interventions
are properly sequenced.  To ensure efficacy, the basis of
this sequencing must be built on knowledge of drug
market dynamics. As this knowledge advances, strategy
can become more sophisticated. At what stage in a drug
epidemic, for example, should treatment efforts be
increased, or when would it be most effective to aim for
a sharp reduction in supply?  None of these issues is
straight forward. However, over the last ten years the
steady accumulation of knowledge on the drug situation
has led to the advancement of our understanding of
drug market dynamics.  If momentum on this contin-
ues, strategic policy of this nature could become an
effective tool for reducing the drug problem rather than
merely containing it.
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1.2 Opium / Heroin Market
1.2.1 Summary trend overview
Record levels of supply of illicit opiates from Afghanistan
continue to threaten the stabilisation of demand which
has occurred in all of the illicit drug’s major consumer
markets.  With 82 per cent of global opium cultivation
now concentrated in Afghanistan the supply side of the
market is determined by production in and distribution
from this country.  This level of supply side concentration
is unique amongst the four illicit markets and occurred
over the last decade mainly due to sustained success in
reducing cultivation in South-East Asia - the area known
as the Golden Triangle - where poppy cultivation declined
by 87 per cent over the last decade. Between 2005 and
2006, poppy cultivation in South-East Asian declined
from 35,000 ha to 24,000 ha. The significance of the con-
traction in opium cultivation in Myanmar and Laos
cannot be underestimated.  Although opium poppy culti-
vation in Afghanistan increased massively in 2006, the
global area under illicit poppy cultivation was still 10 per
cent lower in 2006 - slightly more than 200,000 ha - than
in 2000, and more than 20 per cent lower than in 1996.  
Despite successes in the reduction of cultivation and pro-
duction in the Golden Triangle, the global production of
opium has increased by one half since 1998. Afghanistan
now accounts for 92 per cent of global illicit opium pro-
duction, up from 70 per cent in 2000 and 52 per cent a
decade earlier. Exacerbating the problem, higher yields in
Afghanistan as compared to other opium producing
regions, have brought global opium production to a new
record high of 6,610 mt in 2006, a 43 per cent increase
over 2005. This level of production concentration and the
potential for a damaging supply push are two reasons to
continue monitoring and understanding opiates traffick-
ing patterns and routes. The global opiate interception
rate rose from just 9 per cent in 1990 to 15 per cent in
1995,  21 per cent in 2000 and  26 per cent in 2005 –
reflecting the increased efforts made by Member States to
curb trafficking in opiates.  The strong expansion in
seizures meant that the actual amount of opiates available
for consumption in 2005 was 5 per cent lower than in
2000 and 8 per cent lower than a decade earlier.  
Recently, one of the defining characteristics of this market
has been that price behaviour and other indicators were
less indicative of supply and demand fluctuations than one
would expect.  With a surge in supply and stable demand,
a price decline would be expected near the source, but opi-
ates prices are not easy to predict, because the global
dynamics of this market are not well understood. Despite
the 49 per cent increase in production in Afghanistan
2006, opium prices fell by just 17 per cent in country.
This could suggest there is significant stock piling, but
there is little evidence as to where and how this is occur-
ing.
Afghan opiates supply the markets of neighbouring coun-
tries, Europe, the Near and Middle East and Africa. Opi-
ates produced in South-East Asia mainly supply the
markets of China and other South-East Asian countries as
well as Oceania. Opiates produced in Latin America are
mainly destined for the North American market. How-
ever, it appears that cross-regional trafficking is gaining in
importance. There are indications that a small but increas-
ing proportion of opiates from Afghanistan are being traf-
ficked to North America, either via eastern and western
Africa, or via Europe. 
Overall, the consumer market has remained encouragingly
stable despite important increases in consumption in the
countries along major trafficking routes. Opiate con-
sumption is increasing in the countries surrounding
Afghanistan: Pakistan, Iran and Central Asia.  Abuse is
also increasing in some transit and consumer countries,
including Russia, India, and countries of eastern, southern
and western Africa. 
Though the bulk of opiates for the Chinese market con-
tinue to originate in Myanmar, there are reports of rising
levels of Afghan opiates being trafficked to China, pre-
sumably to replace declining production in Myanmar.
This supply loss is unlikely to have been completely offset
by new Afghan supplies and overall demand in China is
heading towards stabilization. In several of the other
South-East Asian and Pacific countries, which relied heav-
ily on supplies from the Golden Triangle, demand for opi-
ates is falling. 
Despite the overall increase in the global supply of opiates
there is an ongoing stabilization, or slow-down, in most of
the main consumer markets, including West and Central
Europe, North America, East and South-East Asia and the
Oceania region. The consumer market for heroin in North
America seem to be stable to declining, possibly reflecting
a lower supply push from producer countries in South
America and the shortage of opiates from South-East Asia. 
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The sixth straight year of decline in opium cultivation
in South-East Asia could not offset an increase in cul-
tivation in Afghanistan
Worldwide, the estimated area under illicit opium
poppy increased by 33 per cent in 2006, mainly due to
a sharp increase in Afghanistan. Opium poppy cultiva-
tion in South-East Asia continued to decline for the
sixth consecutive year, but could not offset the increase
in Afghanistan. Since 1998, global opium poppy culti-
vation has decreased by 15 per cent to 201,000 ha in
2006.
The area under opium poppy cultivation in Afghanistan
increased by 59 per cent from 104,000 ha in 2005 to
165,000 ha in 2006. This is the largest area under
opium poppy cultivation ever recorded in Afghanistan.
As cultivation around the world declines, the share of
Afghanistan in global opium poppy cultivation has con-
sequently increased: an overwhelming 82 per cent of
global opium cultivation took place in just one country
in 2006. 
Sixty-two per cent of cultivation in Afghanistan was
concentrated in the southern region. Opium cultivation
spread again at the provincial level with only six out of
Afghanistan’s 34 provinces being found free of opium
poppy cultivation in 2006. In the 12 years since the start
of the UNODC opium surveys in 1994, opium culti-
vation increased in eight years, and decreased in only
four. In Pakistan, where opium poppy is grown in the
Afghan-Pakistan border region, the Government
reported a 59 per cent reduction of opium poppy culti-
vation bringing the total to just 1,545 ha. 
Cultivation in South-East Asia continues to decline.
Since 1998, South-East Asia’s share of world opium
poppy cultivation has fallen from 67 per cent to only 12
per cent in 2006. Much of this has been due to large
declines in cultivation in Myanmar, where cultivation
declined a further 34 per cent to 21,500 ha in 2006.
There are several important elements to this decline.
Remarkably, no opium cultivation was observed in the
Wa region in 2006, which had accounted for 30 per
cent of  national opium poppy cultivation in the previ-
ous year. Also, contrary to the national trend, a large
increase in cultivation was observed in the South Shan
State, which increased its share of national cultivation
from 34 per cent in 2005 to 73 per cent in 2006. Based
on 2006 figures, Myanmar now represents only 11 per
cent of the world opium poppy cultivation. In Lao
PDR, opium poppy cultivation remained at very low
levels in 2006 despite a 700 ha increase to 2,500 ha. 
In the Americas, opium poppy continues to be culti-
vated for use in the illicit markets in North America,
although at a much lower level compared to South-West
and South-East Asia. Estimates by the Government of
Colombia put the area under opium poppy cultivation
at about 1,000 ha. The situation as regards opium
poppy cultivation in Peru is difficult to quantify as the
UNODC supported national illicit crop monitoring
system has not yet established a reliable methodology
for the detection of opium poppy. The Governments of
Colombia, Mexico and Peru all continue to eradicate
opium poppy cultivation. 
Low levels of opium poppy cultivation continue to exist
in many regions and countries such as the Caucasian
region, Guatemala, Russian Federation, Thailand,
India, Ukraine and Viet Nam. 
Opium production continues to increase due to higher
yields
Contrary to the downward trend in opium poppy cul-
tivation, global opium production has increased by one
half since 1998. In 2006, global opium production
increased by 43 per cent, over 2005, to 6,610 mt. The
increase in global opium production is more pro-
nounced due to the higher yields achieved by opium
poppy farmers in Afghanistan compared to other grow-
ing regions. In 2006, Afghanistan alone accounted for
92 per cent of global production, producing 6,100 mt
of opium at an average opium yield of 37 kg/ha. 
Opium yields in Myanmar ranged from 8.9 kg/ha in
East Shan State to 16.6 kg/ha in South Shan State,
where the trend towards improved cultivation tech-
niques seems to continue. The national average is 14.6
kg/ha. Yield increases over the last years have kept pro-
duction figures stable despite the decreases in cultiva-
tion. At 315 mt in 2006, therefore, the level of opium
production remained close to 2005 levels.
1.2.2 Production
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Prices decrease overall in Afghanistan and increase in
contracting markets 
In Afghanistan, farm-gate prices for dry opium declined
slowly but steadily, reaching US$ 125/kg in December
2006 compared to US$ 150/kg one year earlier.
Regional price differences continued to exist with con-
siderably higher prices in eastern Afghanistan than in
the South, where the bulk of production takes place.
Price in all regions except the North decreased in the
course of the year 2006. The overall price decrease,
although moderate when compared to the large pro-
duction increase, is thought to reflect the increased
supply of opium in the market. 
In Myanmar, the farm-gate price for opium increased by
23 per cent from US$ 187/kg in 2005 to US$ 230/kg
in 2006 at harvest time. Lao PDR has by far the high-
est price level for opium with over US$ 500/kg, reflect-
ing the scarcity of opium in the country. 
Most laboratories dismantled in the Russian Federa-
tion, Republic of Moldova and Afghanistan, with the
number increasing in Afghanistan
In 2005, eight countries reported the destruction of lab-
oratories involved in the illicit manufacture of opiates
with a total of 844 laboratories destroyed. As in 2004,
most laboratories were reported destroyed by the Russ-
ian Federation (43 per cent) followed by the Republic
of Moldova (33 per cent) and Afghanistan (22 per cent).
Laboratories in the Russian Federation and the Repub-
lic of Moldova mostly produced acetylated opium from
locally cultivated opium poppy straw, whereas laborato-
ries in Afghanistan produced morphine and partly
heroin. Smaller numbers of destroyed opium/heroin
laboratories were reported by Colombia (6), Myanmar
(4), Belarus, India, and Latvia (all one each). 
The increasing number of heroin laboratories disman-
tled in Afghanistan and the virtual disappearance of
heroin laboratories from the statistics of other countries
on the trafficking route seems to confirm that Afghan
opium is increasingly being processed into morphine
and heroin within Afghanistan. Preliminary reports of
an even higher number heroin laboratories destroyed in
Afghanistan in 2006 further corroborate this hypothe-
sis. Seizures of acetic anhydride, a precursor for con-
verting opium into heroin, confirm the availability of
this substance in Afghanistan. As acetic anhydride is not
produced locally and given the evidence of heroin pro-
duction within Afghanistan, it can be assumed that the
substance is trafficked into the country. Still, none of
the countries bordering Afghanistan, with the exception
of China, reported seizures of acetic anhydride during
2005 and 2006. Large seizures of morphine in some
neighbouring countries (notably Pakistan and Iran) sug-
gested, however, that significant amounts of morphine
are still being processed into heroin in countries outside
Afghanistan as well.
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1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Afghanistan - - - - 400 121 - - 21,430 * 5,103 15,300
Colombia 3,466 6,885 6,988 2,901 8,249 9,254 2,385 3,577 3,266 3,866 2,121 569
Egypt - - - - - - - 15 34 65 45 50
Guatemala - - - - - - - - - 48 47
Lao PDR - - - - - - - - 4,134 3,556 2,575 1,518
Mexico 5,389 14,671 17,732 17,449 15,461 15,717 15,350 19,157 20,034 15,926 20,803 6,831
Myanmar 3,310 1,938 3,093 3,172 9,824 1,643 9,317 7,469 638 2,820 3,907 3,970
Pakistan - 867 654 2,194 1,197 1,704 1,484 - 4,185 5,200 391 354
Peru - - - 4 18 26 155 14 57 98 92 88
Thailand 580 886 1,053 716 808 757 832 507 767 122 110 153
Venezuela - - - - - - - - - 87 154 -
Vietnam 477 1,142 340 439 - 426 - - - 32 - -
Table 2: Significant opium poppy eradication reported (hectares), 1995-2006
* Although eradication took place in 2004, it was not officially reported to UNODC.
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Table 3: Global illicit cultivation of opium poppy and production of opium, 1990-2006
(a) Opium poppy harvestable after eradication.
(b) Due to small production, cultivation and production were included in the category " Other", for Viet Nam as of  2000 and for Thailand as of 
2003.
(c) As its survey system is under development, the Government of Mexico indicates it can neither provide cultivation estimates nor endorse those 
published by UNODC, which are derived from US Government surveys. 
(d) Includes  Russia, Ukraine, Central Asia, Caucasus region, other C.I.S. countries, Baltic countries, Guatemala, Peru, Viet Nam
(as of 2000), Thailand (as of 2003), India, Egypt and Lebanon.
(e) All figures refer to dry opium.
(f ) Heroin estimates for Afghanistan are based on the Afghanistan Opium Survey (since 1994). For other countries, a 10:1 ratio is used for conver
sion from opium to heroin.
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
SOUTH-WEST ASIA
   Afghanistan 41,300 50,800 49,300 58,300 71,470 53,759 56,824 58,416 63,674 90,583 82,171 7,606 74,100 80,000 131,000 104,000 165,000
   Pakistan 7,488 7,962 9,493 7,329 5,759 5,091 873 874 950 284 260 213 622 2,500 1,500 2,438 1,545
   Subtotal 48,788 58,762 58,793 65,629 77,229 58,850 57,697 59,290 64,624 90,867 82,431 7,819 74,722 82,500 132,500 106,438 166,545
SOUTH-EAST ASIA
   Lao PDR 30,580 29,625 19,190 26,040 18,520 19,650 21,601 24,082 26,837 22,543 19,052 17,255 14,000 12,000 6,600 1,800 2,500
   Myanmar 150,100 160,000 153,700 165,800 146,600 154,070 163,000 155,150 130,300 89,500 108,700 105,000 81,400 62,200 44,200 32,800 21,500
   Thailand (b) 1,782 3,727 3,016 998 478 168 368 352 716 702 890 820 750
   Viet Nam (b) 18,000 17,000 12,199 4,268 3,066 1,880 1,743 340 442 442
   Subtotal 200,462 210,352 188,105 197,106 168,664 175,768 186,712 179,924 158,295 113,187 128,642 123,075 96,150 74,200 50,800 34,600 24,000
 LATIN AMERICA
Colombia 1,160 6,578 5,008 15,091 5,226 4,916 6,584 7,350 6,500 6,500 4,300 4,100 4,100 3,950 2,000 1,000
   Mexico (c) 5,450 3,765 3,310 3,960 5,795 5,050 5,100 4,000 5,500 3,600 1,900 4,400 2,700 4,800 3,500 3,300 n/a
   Subtotal 5,450 4,925 9,888 8,968 20,886 10,276 10,016 10,584 12,850 10,100 8,400 8,700 6,800 8,900 7,450 5,300 4,300
 OTHER 
Combined (d) 8,054 7,521 2,900 5,704 5,700 5,025 3,190 2,050 2,050 2,050 2,479 2,500 2,500 3,000 5,190 5,162 6,155
GRAND TOTAL 262,754 281,560 259,686 277,407 272,479 249,919 257,615 251,848 237,819 216,204 221,952 142,094 180,172 168,600 195,940 151,500 201,000
SOUTH-WEST ASIA
   Afghanistan 1,570    1,980    1,970    2,330    3,416    2,335    2,248    2,804    2,693    4,565    3,276    185      3,400    3,600    4,200 4,100 6,100
   Pakistan 150      160      181      161      128      112      24        24        26        9          8          5          5          52        40 36 39
   Subtotal 1,720 2,140 2,151 2,491 3,544 2,447 2,272 2,828 2,719 4,574 3,284 190 3,405 3,652 4,240 4,136 6,139
SOUTH-EAST ASIA
   Lao PDR 202      196      127      169      120      128      140      147      124      124      167      134      112      120      43 14 20
   Myanmar 1,621    1,728    1,660    1,791    1,583    1,664    1,760    1,676    1,303    895      1,087    1,097    828      810      370 312 315
   Thailand (b) 20        23        14        17        3          2          5          4          8          8          6          6          9          
   Viet Nam (b) 90        85        61        21        15        9          9          2          2          2          
   Subtotal 1,933    2,032    1,862    1,998    1,721    1,803    1,914    1,829    1,437    1,029    1,260    1,237    949      930 413 326 335
 LATIN AMERICA
Colombia 16        90        68        205      71        67        90        100      88        88        80        76        76        56        28 14
   Mexico © 62        41        40        49        60        53        54        46        60        43        21        91        58        101      73        71 n/a
   Subtotal 62        57        130      117      265      124      121      136      160      131      109      171      134      177 129 99 85
 OTHER
Combined (d) 45        45        -       4          90        78        48        30        30        30        38        32 32 24        68 59 51
GRAND TOTAL 3,760     4,274     4,143     4,610     5,620     4,452     4,355     4,823     4,346     5,764     4,691     1,630     4,520     4,783     4,850 4,620 6,610
Potential HEROIN (f) 376        427        414        461        562        445        436        482        435        576        469        163        452        478        495 472 606
HEROIN
CULTIVATION(a) IN HECTARES
 POTENTIAL PRODUCTION IN METRIC TONS
OPIUM (e) 
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Fig. 14: Global opium poppy cultivation (hectares), 1990-2006
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Fig. 15: Global opium production (metric tons), 1990-2006
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Fig. 16: Annual opium poppy cultivation and opium production in main producing countries, 1990-2006
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Differences in opium yield between Afghanistan and Myanmar are due to differences in opium
poppy varieties and growing conditions. Variations of yields from year to year in the same country
are mostly caused by changes in weather conditions and/or, as in the case of Afghanistan in 2001,
by a shift in the relative distribution of cultivation from irrigated to rain-fed land.
2006
7%
11%
82%
Afghanistan
 (165,000 ha)
Myanmar
(21,500 ha)
Rest of the World
 (14,500 ha)
37
24
40
50
4546
32
39
15
1081010 10 10
13
1999 2000 2001 2002 2003 2004 2005 2006
Afghanistan Myanmar
2005
Rest of the World
 (208 mt)
Myanmar
 (312 mt)
Afghanistan
(4,100 mt)
89%
7%
4%
2006
3%
92%
5%
Afghanistan
(6,100 mt)
Myanmar
(315 mt)
Rest of the World
(195 mt)
Fig. 17: Opium poppy cultivation
Fig. 18: Opium yields in Afghanistan and Myanmar (kg/ha), 1999-2006
Fig. 19: Opium production
Opiates are trafficked along three major routes 
There are three distinct production centres for opiates
which supply three distinct markets, namely:
• Afghanistan supplying neighbouring countries,
the Middle East, Africa and, in particular, Europe;
• Myanmar/Lao PDR supplying neighbouring
countries, in particular China, and Oceania
(mainly Australia); and,
• Latin America (Mexico, Colombia, Guatemala
and Peru) supplying North America, in particular
the USA. 
In 2006, out of all opiates that left Afghanistan, 53 per
cent went via Iran, 33 per cent via Pakistan and 15 per
cent via Central Asia (mainly Tajikistan). If only heroin
and morphine are considered, the bulk is estimated to
have left Afghanistan via Pakistan (48%), followed by
Iran (31%) and Central Asia (21%).1
The route from Afghanistan continues to go mainly via
Pakistan, Iran, Turkey and the Balkan countries to dis-
tribution centres in West Europe. However, alternative
routes have also been established to circumvent the
border between Turkey and Bulgaria, some via Ukraine
to Romania and along the Balkan route to West Europe.   
While seizure data and intelligence information sug-
gested that the West Balkan route gained significance
over the 2000-2004 period, this trend did not appear to
continue in 2005.  Furthermore, seizures rose along the
East Balkan route, mainly reflecting rising seizures
reported by Romania and Hungary, while seizures made
in both Bulgaria and Turkey declined.    
The route to the Russian Federation and other C.I.S.
countries goes mainly via Central Asia; heroin destined
for the Baltic and Nordic countries is also shipped along
this route.  Other direct air routes go to Europe via Pak-
istan (notably to the UK), via the Middle East, eastern
and western Africa, as well as (according to Interpol) via
western Africa to North America.   
In 2005/06, new heroin routes have emerged from
Afghanistan via Pakistan to China and India, as well as
via Central Asia to China. This has partly offset a
decline in the supply of heroin from Myanmar to
China.
The global interception rate for opiates continues to
increase …
In 2005, global seizures were: 342 mt opium (up from
212 in 2004), 32 mt morphine (down from 39 in 2004)
and 59 mt heroin (60 in 2004). All opiate seizures com-
bined (heroin, morphine and opium, as expressed in
heroin equivalents2), amounted to 125 mt in 2005, rep-
resenting a 3 per cent increase from 121 mt in 2004. 
Over the last decade, the annual growth in opiates-
seizures averaged 6 per cent, which exceeded growth in
global opium production and resulted in an increase in
the global interception rate for opiates from 15 per cent
in 1995 to 26 per cent in 2006.
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1.2.3 Trafficking
Fig.20: Global opiate seizures, expressed in heroin 
equivalents, by substance, 1985-2005
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Source: UNODC, Annual reports Questionnaire Data / DELTA.
1 UNODC, Afghanistan Opium Survey 2006, October 2006. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
2 For the purposes of this calculation it is assumed that 10 kg of opium are equivalent to 1 kg of morphine or 1 kg of heroin. 
… with the bulk of seizures close to the areas of pro-
duction…
In 2005, the majority of opiate seizures (67%) took
place in the countries surrounding Afghanistan. When
seizures made in Europe are added these seizures com-
bined accounted for 87 per cent of the global total. The
remaining seizures were made in East and South-East
Asia and Oceania (10%), with the Americas accounting
for 4 per and Africa 0.2 per cent. Africa’s opiate supplies
are increasingly arriving from South-West Asia. 3
Opiate seizures increased in South-West Asia in 2005
(up 22%), but declined in East and South-East Asia
(down 12%), reflecting the decreasing production in
Myanmar and Lao PDR.  The strong increase in seizures
in South-West Asia also helped stabilize the European
market, where opiate seizures declined by 10 per cent. 
Meanwhile, opiate seizures rose by 17 per cent in East
Europe (defined as the European C.I.S. countries),
which is supplied with Afghan opiates via Central Asia.
Seizures in Central Asia declined by 38 per cent in
2005, mostly because of Tajikistan (down 51 per cent).
This decline was associated with the transitional
arrangements following the transfer of border control to
the Tajik authorities. Nonetheless, Tajikistan seized the
bulk of all opiates in Central Asia  (almost 60 per cent
in 2005). Kyrgyzstan, Uzbekistan and Kazakhstan all
reported increases in seizures, as did the Russian Feder-
ation.
… and primarily along the Afghanistan-Europe traf-
ficking route.
Between 2002 and 2005, the proportion of opiate
seizures along the Afghanistan–Europe trafficking route
increased from 78 to 87 per cent, reflecting rising
opium production in Afghanistan. Seizures along the
other two main routes decreased, from 15 to 10 per cent
for South-East Asia/Oceania and from 7 to 4 per cent
from Latin America to North America. These reflect
production declines in South-East Asia and Latin Amer-
ica.
Opiate trafficking levels from South-East Asia to North
America and Europe, as well as from Latin America to
Europe, remained low. As of 2005/06, however, Afghan-
produced opiates were trafficked to China in increasing
amounts.
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Fig. 21: Global opiate seizures, expressed in heroin 
equivalents*, regional breakdown,
1985-2005
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3 UNODC, Annual Reports Questionnaire data.xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
*  For the purposes of this calculation it is assumed that 10 kg
of opium are equivalent to 1 kg of morphine and 1 kg of heroin. 
Source: UNODC, Annual Reports Questionnaire Data / DELTA
Fig. 22: Global opiate seizures, expressed in heroin 
equivalents*, regional breakdown in 2005
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Source: UNODC, Annual Reports Questionnaire Data / DELTA
*  For the purposes of this calculation it is assumed that 10 kg
of opium are equivalent to 1 kg of morphine and 1 kg of heroin.
The world’s largest opiate seizures are made by Iran
and Pakistan 
In 2005, Iran made the world’s largest opiate (heroin,
morphine and opium in heroin equivalents) seizures (29
%), followed by Pakistan (20%), Afghanistan (15 %),
China (7.5%), Turkey (7%), the Russian Federation
(4%) and Tajikistan (2%). The UK4 accounted for 1.8
per cent, the USA 1.4 per cent and Italy 1.1 per cent of
global opiates seizures. 
Although Afghanistan accounted for only 2 per cent of
global opiate seizures in 2002, this proportion rose to 4
per cent in 2004 and to 15 per cent in 2005, represent-
ing the largest increase globally that year. 
If the opiate seizures of 2005 are broken down by sub-
stance, the following picture emerges:
• Opium (342 mt): Iran 68 per cent (reflecting large
domestic consumption), Afghanistan 27 per cent
and Pakistan 2 per cent. 
• Heroin and morphine together (91 mt): Pakistan
27 per cent, Iran 14 per cent, China, Afghanistan
and Turkey 10 per cent each, the Russian Federa-
tion 5 per cent and Tajikistan 3 per cent. 
• Morphine (32 mt): Pakistan 69 per cent, Iran 22
per cent, Afghanistan 6 per cent and Turkey 2 per
cent. As drug users do not typically consume mor-
phine, the large seizures indicate subsequent
heroin manufacturing. The large seizures of mor-
phine reported by Afghanistan’s neighbours also
indicate that significant quantities of heroin are
still being produced outside Afghanistan. How-
ever, Pakistan, Iran or Turkey did not report any
dismantling of clandestine heroin laboratories in
2005, thus leaving open the question of where the
manufacturing is actually taking place.    
• Heroin (59 mt): China 15 per cent, Turkey 14 per
cent, Afghanistan 12 per cent, Iran 10 per cent,
the Russian Federation 8 per cent, as well as Tajik-
istan, the UK5 and Pakistan 4 per cent each, the
USA 3 per cent and Italy 2 per cent. This shows
that China is the largest heroin market in East and
South-East Asia; the Russian Federation is by far
the largest in East Europe; the UK and Italy are
the largest markets in western Europe; and the
USA is the largest market in the Americas.  
South-West Asia reports record seizures in 2006 …
Preliminary data from Iran and Pakistan suggest a fur-
ther increase of 46 per cent in total opiate seizures in
2006. While this shows continued efforts in both coun-
tries it also reflects the 49 per cent increase in
Afghanistan’s opium production in 2006, mainly in the
southern provinces close to Pakistan and Iran. Opiate
seizures also increased in Turkey in 2006, by almost 25
per cent, suggesting that the ‘traditional’ route via Pak-
istan, Iran, Turkey and the Balkan countries regained
importance.  
… while opiate seizures remain flat in Central Asia
In contrast, preliminary seizure data from the countries
of Central Asia shows a stabilization of opiate seizures
with a 1 per cent increase, following a 38 per cent
decline in 2005. UNODC estimates suggest, however,
that trafficking via Central Asia increased by some 12
per cent in 2006.     
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Fig. 23: Distribution of opiate seizures (expressed in 
heroin equivalents*), 2002-2004 
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Source: UNODC, Annual reports Questionnaire Data / DELTA.
4 Data reported from the UK refer to the year 2004; these data are used here as a proxy for seizures made in 2005.
5 ibid.
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Fig. 25: Opiate seizures in Central Asia, 1995-2006
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have been practically no morphine seizures reported from countries of Central Asia in recent years. 
Source: UNODC, Annual Reports Questionnaire Data / DELTA
Fig. 24: Opiate seizures in heroin equivalents* in
Pakistan and Iran, 1995-2006
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Fig. 26: USA: Heroin retail and whole sale prices, 
1990-2005 (US$/gram)
Fig. 27: EUROPE: Heroin retail and wholesale prices, 
1990-2006 (US$/gram)
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Fig. 28: Wholesale heroin prices in Europe and the USA, 1990-2006 (US$/gram)
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Fig. 29: Global illicit supply of opiates, 1994 - 2005
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Fig. 30: Global seizures of opium 1995 - 2005
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(a) Seizures as reported (street purity)
Year 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Metric ton 
Equivalents
(a) Seizures as reported (street purity)
(b) 1 kg of morphine is assumed to be equivalent to 1 kg of heroin
 (c ) data refer to  2004
(b) metric ton equivalents. 1 kg of morphine is assumed to be equivalent to 1 kg of heroin
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Fig. 31: Global seizures of heroin (a) and morphine (b) , 1995 - 2005
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Global abuse of opiates remains essentially stable
Global opiate abuse has stabilised at an estimated 15.6
million people, or 0.4 per cent of the world’s population
aged 15-64. Opiates continue to be the main problem
drug worldwide, accounting for some 60 per cent of
treatment demand in Asia and in Europe.  
More than half of the world’s opiates using population
lives in Asia, with the highest levels of abuse occurring
along the main drug trafficking routes out of
Afghanistan. Annual prevalence of opiates, including
heroin, is high in the Islamic Republic of Iran where the
number of drug abusers is said to exceed 1.2 million
(2.8 percent of the general population aged 15-64). The
abuse of opiates is also high in Central Asia. The latest
surveys undertaken in cooperation with UNODC’s
Global Assessment Programme on Drug Abuse (GAP),
found that prevalence rates of opiates abuse in 2006
ranged from 0.5 per cent of the population aged 15-64
in Tajikistan to 0.8 per cent in Uzbekistan and Kyr-
gyzstan and 1.0 per cent in Kazakhstan. The total
number of opiates users in Central Asia is close to
300,000 persons. 
A new study conducted in Pakistan estimated a preva-
lence rate of 0.7 per cent for the four main provinces of
the country (range: 400,000 – 600,000 persons) in the
year 2006. Extrapolating from these results, UNODC
estimates that there are approximately 640,000 opiates
users in Pakistan; of these about 500,000 are heroin
users. Theses findings mirror those of a study under-
taken in 2000/01. Given the massive increase of opium
and heroin production in neighbouring Afghanistan
this stability in prevalence rates is a notable achieve-
ment. The prevalence rates for opiates use range from
0.4 per cent in the provinces of Punjab and Sind to 0.7
per cent in the North-West Frontier Province and 1.1
per cent in Baluchistan.1 The latter two provinces share
a direct border with Afghanistan. While the overall rate
of abuse has not changed much in Pakistan, the pro-
portion of injecting drug users has increased alarmingly,
from 3 per cent in 1993 to 15 per cent in 2000/01 and
29 per cent in 2006.   
A study published in India in 2004 revealed opiate
prevalence rates of around 0.7 per cent for males2, which
is equivalent to an annual prevalence of around 0.4 per
cent of the general population aged 15-64, or slightly
less than 3 million people. Opiate abuse in India
increased in 2005, fuelled by the increasing availability
of heroin smuggled from Afghanistan.  
Annual prevalence in China (2004) is estimated to be
less than 0.2 per cent or 1.7 million people. The
number of officially registered ‘active’ drug users in
China was 785,000 in 2005 of which 700,000 (or 78%)
were heroin users, 2.28 per cent were opium users and
0.19 per cent were morphine users. The Chinese opiates
market is reported to have stabilized in 2005/06.3
Opiates abuse is basically stable or declining in West and
Central Europe. The annual prevalence rate remained
close to 0.5 per cent of the population aged 15-64 (1.5
million people). Major opiates markets in Western
Europe are the United Kingdom (some 350,000 per-
sons) and Italy (300,000), followed by France
(170,000), Germany (120,000) and Spain (70,000).
Data for Spain suggest that opiates abuse has declined
in recent years. These data are derived from problem
drug use estimates. Household survey results in all of
the countries mentioned above show substantially lower
figures (with prevalence rates typically around 0.2%).
Household surveys, however, may not provide the opti-
mal measure of the number of opiates abusers as many
heroin addicts do not have a fixed or permanent resi-
dence.
The largest opiates market in East Europe is  most likely
the Russian Federation.  However, estimates of the
number of opiate users vary substantially4. UNODC
1.2.4 Abuse
1 UNODC, Global Assessment Programme on drug Abuse (GAP),  National Assessment of Problem Drug Use in Pakistan 2007, preliminary
results, May 2007. 
2 UNODC and Ministry of Social Justice and Empowerment, Government of India, The Extent, Pattern and Trends of Drug Abuse in India, National
Survey, 2004.
3 Zhao Wanpeng, Deputy Director of International Cooperation Division, Narcotics Control Bureau, Ministry of Public Security, ‘Measures Imple-
mented in China for the Prevention of Illicit Production of Synthetic Drugs and their Precursors’,   presentation given to the conference  ‘Europe-
Asia - Cooperation on Synthetic Drugs and their Precursors’,  6-7 March 2007. 
4 This also reflects major differences on the estimates of total drug use in the Russian Federation. A review of current estimates of the total number
of drug users showed a range from 1.5 million to 6 million people (UNODC, Illicit Drug Trends in the Russian Federation, 2005).
5 This was derived from an estimate of the total number of drug users in the Russian Federation of 2.3 million (UNODCCP, Country Profile on
Drugs and Crime in the Russian Federation, 2002) and estimates of the proportion of registered opiate users among all registered drug users. 
continues to use the estimate provided by the Russian
authorities for 2000/01, which suggested that there
could be some 2 million opiates users5 in the country
(equivalent to 2% of the population age 15-64). Of
these some 1.5 million use heroin.  The number of drug
abusers registered with the country’s treatment institu-
tions amounted to 343,509 in 2005 or 0.24 per cent of
the country’s total population. Above average use levels
(0.5% to 0.7%) were reported from several provinces
close to the border with Kazakhstan (Samara, Khanty-
Mani, Kemerovo, Tyumen, Primorsky, Novosibirsk).
High levels were also reported from Irkutsk (Far East;
0.5%), Tomsk (southern Siberia) and from Krasnodar
(Caucasus region; 0.4%).6 The country’s first national
survey is being planned in 2007.    
In the Americas, the largest opiates market is the USA
with about 1.2 million heroin users (0.6% of the popu-
lation aged 15-64). This is based on estimates of chronic
and casual heroin users for the year 2000. More recent
estimates of overall heroin use in the USA are not avail-
able. Trend data suggest, however, that heroin use has
declined since 2000. Household survey results appear to
confirm this. They show that there were 380,000 heroin
users in 2005 (or 0.2% of the general population age 12
and above), down from 400,000 in 2002.  
Brazil is the largest opiates market in South America
( 600,000 people or 0.5% of the general population age
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Fig. 32: Regional breakdown of opiate abusers in 
2005
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Sources: UNODC, Annual Reports Questionnaire Data, Govern-
ment reports, reports of regional bodies, UNODC estimates.
Sources: UNODC, Annual Reports Questionnaire Data, Government reports, reports of regional bodies, UNODC estimates.
Abuse of opiates ... ... of which abuse of heroin
population in million
in % of population
15-64 years
population in million
in % of population
15-64 years
EUROPE 3,860,000 0.7 3,250,000 0.6
West & Central
Europe
1,420,000 0.5 1,370,000 0.4
South-East Europe 184,000 0.2 130,000 0.2
Eastern Europe 2,300,000 1.6 1,750,000 1.2
AMERICAS 2,130,000 0.4 1,480,000 0.3
North America 1,310,000 0.5 1,245,000 0.4
South America 830,000 0.3 230,000 0.1
ASIA 8,480,000 0.3 5,350,000 0.2
OCEANIA 90,000 0.4 30,000 0.1
AFRICA 980,000 0.2 980,000 0.2
GLOBAL 15,550,000 0.4 11,090,000 0.3
Table 4: Annual prevalence of opiates abuse, 2005
Above global average Around global average Below global average
6 Ministry of Health, quoted in UNODC, Illicit drug Trends in the Russian Federation 2005. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
12-65), according to 2005 national household survey
results. This market is largely linked to the use of syn-
thetic opiates and the heroin prevalence rate is less than
0.05 per cent.
Heroin accounts for more than 70 per cent of opiates
abuse
About 71 per cent of the world’s 15.6 million opiates
users abuse heroin.  This amounts to 11 million people.
The proportions, however, vary significantly by region.
Whereas almost all opiates consumers in Africa report-
edly use heroin, only one third consume that substance
in Oceania. This particular pattern is due to difficulties
in accessing heroin and the availability of synthetic opi-
ates.
Heroin abuse in West and Central Europe has  stablized
at 1.4 million. In East Europe levels are higher than in
West and Central Europe. Estimates of the number of
heroin abusers in Europe as a whole (3.3 million people)
are higher than the corresponding estimates for the
Americas (1.5 million).  The largest numbers of heroin
abusers are found in Asia, which accounts for almost
half of all heroin use worldwide (5.4 million). Asia and
Europe together account for more than three quarters of
the world’s heroin abuse.
Injecting heroin exposes drug users to HIV/AIDS.
According to the Joint United Nations Programme on
HIV/AIDS, injecting drug use has contributed to HIV
epidemics in India, Indonesia, the Islamic Republic of
Iran, Libyan Arab Jamahiriya, Pakistan, Spain, Ukraine,
Uruguay and Viet Nam. In China, Central Asia and sev-
eral countries of East Europe, injecting drug use has
been the most frequently cited mode of transmission of
HIV in recent years.  
Countries in East Africa, particularly Kenya, Mozam-
bique and United Republic of Tanzania, have reported
large increases in heroin abuse in recent years. An
increase in opiate abuse has also been  reported by South
Africa and a number of countries in West Africa. In gen-
eral, these increases are linked to greater amounts of
heroin transiting these regions.
Opiate abuse continues rising in Asia, mainly among
countries close to Afghanistan ...
While the new global estimate of opiate abuse (15.6
million people) is marginally lower than the one
reported in last year’s World Drug Report (15.8 million),
UNODC’s drug use perception indicator suggests that
opiate use expanded slightly at the global level in 2005.
This mainly reflects increases in opiate abuse reported
from Afghanistan, Iran, Pakistan, India, the Central
Asian countries, the Russian Federation and many
countries in eastern and southern Africa. 
… but is falling in East and South-East Asia  
Most countries of East and South-East Asia reported
declines in opiate abuse in 2005, reflecting the strong
declines of opium production in Myanmar and Lao
PDR. The Chinese market was reported to have been
stable, as declining levels of opiates from Myanmar were
offset by a rising opiate supply from Afghanistan.  From
1992 to 2005, the drug use perception indicator for
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Fig. 33: Composite opiate use perception trends, 
1992-2005
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Fig. 34: Opiate use perception trends, 1992-2005 
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Asia followed the global trend until the last few years,
when the increase was far above the global average. 
Opiate use stable to declining in West and Central
Europe but rising in East Europe ... 
Use of opiates remained stable or declined in the coun-
tries of West and Central Europe in 2005. It was
reported to be rising, however, in East Europe (C.I.S.
countries), notably the Russian Federation, as well as a
few countries in south-eastern Europe along the Balkan
route. This led to a small increase in the drug use per-
ception indicator for Europe for the second year in a
row. Following the opium poppy ban in Afghanistan in
2001, abuse in Europe declined until 2003 but  recov-
ered slighly to 2000 levels. Following years of strong
increases in the 1990s, consumption of opiates has basi-
cally stabilized.  Europe’s perception trend indicator is
basically in line with the global average.
… declining in the Americas ...
The drug use perception indicator shows a small decline
in opiate abuse in the Americas for 2005 and significant
decline since 2001/02. This trend is also reflected in
school survey results from the USA and Canada which
showed that heroin use is falling subsequent to increases
in the 1990s. In the USA, the annual prevalence of
heroin consumption among 12th grade students declined
from 1.5 per cent to 0.8 per cent between 2000 and
2005/06. Falling opium production levels in Latin
America as well as in South-East Asia – the two tradi-
tional suppliers for the North American market – seem
to have contributed to this.  
… and in Oceania
Following strong increases in the 1990s, opiate use
trends in Oceania changed direction after 2000. The
trend indicator is now below the levels of a decade ear-
lier. These trends primarily reflect the situation in Aus-
tralia. The Oceania region, and notably Australia, used
to have among the highest prevalence rates of opiate
abuse worldwide. This changed in the early years of the
new millennium, following a major heroin shortage in
2001. The so-called ‘heroin drought’ prompted a fall in
purity levels while heroin prices rose strongly, thus
squeezing large numbers of heroin users out of the
market. The number of drug related deaths declined
substantially. Fears that higher prices would result in
more crime, and that supply-induced changes would be
short-lived, never materialized. The 2004 National
Drug Strategy Household Survey showed that the
annual prevalence of heroin use – after having fallen
drastically in 2001 - remained at the lower level in 2004.
The ongoing Drug Use Monitoring in Australia project
(DUMA), shows that heroin use remained at the lower
level in 2005 and declined even further in 2006.
Whereas in 1999 and 2000 around 30 per cent of
people arrested had used heroin, in 2005 the proportion
declined to 16 per cent (and to less than 10 per cent
over the last two quarters of 2006). 
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Fig. 35: Annual prevalence of heroin use among 
12th graders in US high-schools, 1980-2005 
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Source: NIDA, Monitoring the Future, Overview of Key Findings
2005.
Fig. 36: Heroin use among the general population
(age 14 and above), Australia, 1993-2004
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Source: AIHW, 2004 National Drug Strategy – Household Survey. 
Opiate use continues rising in Africa 
Opiate use continued rising in Africa, notably in coun-
tries of eastern and southern Africa. This is most likely
linked to more heroin trafficking.  The increase in Africa
was the second highest after Asia and Africa is now
slightly above the global average on the drug use per-
ception indicator.  
The upward trend over the last decade is best docu-
mented by the South African Community Epidemiol-
ogy Network on Drug Use (SACENDU). Heroin
accounted for less than 1 per cent of treatment demand
(including alcohol) in 1996. By the first two quarters of
2006 this proportion increased to 7 per cent. Over the
last few years, there has been a large increase in treat-
ment admissions for heroin as the primary drug of abuse
in the Western Cape region (Cape Town), Gauteng
(Pretoria and Johannesburg), Mpulanga and KwaZulu-
Natal (Durban, Pietermaritzburg). Preliminary data for
the third and fourth quarters of 2006 suggest that the
increase was particularly pronounced in Gauteng and in
KwaZulu-Natal. Heroin is mostly smoked in South
Africa. However, of patients with heroin as the primary
drug of abuse in Western Cape, Mpuglanga and Gaut-
eng,  11 per cent,  33 per cent and 42 per cent, respec-
tively, reported injecting it in the second half of 2006.7
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Fig. 37: Testing of arrestees for heroin abuse in Australia* 
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* unweighted average of results from Western Australia (East Perth), South Australia (Adelaide and Elisabeth), New South Wales
(Sydney) and Queensland (Brisbane and Southport). 
Source: Australia Institute of Criminology, Drug Use Monitoring in Australia (DUMA). 
Fig. 38: South Africa – heroin as primary drug in 
treatment demand*, 1996-2006
* unweighted average of treatment (incl. alcohol) in 6 provinces.
Source: SACENDU, Research Brief, Vol. 9 (2), 2006.
7 SACENDU, Update, 25 May 2007. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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1.3 Coca / Cocaine Market
1.3.1 Summary trend overview
The global cocaine market is largely stable with indicators
on both the supply and demand side holding, more or less,
at the levels of previous years.  The global area under coca
cultivation fell by 29 per cent to some 157,000 hectares
between 2000-2006, reflecting a strong decline (-52 per
cent) of coca cultivation in Colombia – due to large-scale
eradication. The areas under coca cultivation in Peru and
Bolivia increased over this period but remained significantly
below the levels reported a decade earlier (-45 per cent for
Peru and Bolivia over the 1995-2006 period).  
Though contained, there are indications that the supply
side of this market remains adaptive. The success in the
reduction of coca cultivation from 2000 to 2005 did not
lead to a decline in cocaine production. In recent years, the
use of fertilizers and pesticides, and the refinement of
knowledge and skill in processing the leaf, have improved
coca yields, leaving cocaine production largely stable. In
2006, the area under coca cultivation in Bolivia, Colombia
and Peru amounted to 156,900 ha, a 2 per cent contraction
over 2005. The overall production of cocaine also remained
largely unchanged at 984 mt in 2006.
With the supply side of the market largely stable, there are
encouraging signs that progress is being made in reducing
supply through interdiction. Seizures of cocaine continue
to remain high. Overall, the interception rate  rose from 24
per cent in 2000 to 42 per cent in 2006. Improved coop-
eration among law enforcement bodies in and across coun-
tries appears to have led to an increase in seizures in and
around the producer countries. In fact, 50 per cent of
global cocaine seizures took place in South America
(including the Caribbean and Central America) in 2005.
North America and Western and Central Europe, the two
main cocaine consumption regions, also continued to seize
large amounts of the drug (28 per cent and 14 per cent of
global seizures respectively).The world’s largest cocaine
seizures in 2005 were, once again, made by Colombia, fol-
lowed by the USA, Venezuela, Spain, Ecuador and Mexico.
The bulk of cocaine enters the USA via Mexico. In terms
of trafficking organisations,  there seems to have been a shift
from Colombian towards Mexican organized crime groups,
which now dominate the wholesale trade to the United
States.
The distribution patterns within this market continue to
evolve. Cocaine is trafficked to Europe via the Caribbean
and, increasingly, via Africa.  Over the 2000-2005 period
the largest increases in cocaine seizures were reported by
countries in Africa and West and Central Europe. In both
regions, cocaine seizures almost quadrupled over the 2000-
2005 period. This highlights the relevance of closely mon-
itoring the new consumer markets and transit routes as they
develop. The largest cocaine seizures in Europe in 2005
were made by Spain, followed by Portugal and the Nether-
lands, reflecting both strong national law enforcement
activities and the increase in trafficking towards these coun-
tries – which contain vibrant consumer markets and which
are the main entry points of cocaine into the European
Union. 
Similarly, rising levels of seizures in Africa reflect the fact
that this continent, notably countries along the Gulf of
Guinea and off the coast of Cape Verde, is increasingly
being used as a transhipment point for cocaine from South
America to markets in western Europe.   
The global consumer market for cocaine is estimated at 14
million people. While the consumer demand in North
America has ceased to expand, cocaine is making worrying
inroads into new and growing markets. Consumption
increased significantly in Europe, doubling or tripling in
several countries over the last decade. In Africa, notably in
the countries of West Africa, cocaine use has also increased.
Overall cocaine consumption levels in Europe are still sig-
nificantly lower than in North America. However, Spain
recently reported that, for the first time, cocaine annual
prevalence levels exceeded those of the USA in 2005. High
and rising levels of cocaine use have also been reported from
the UK and Italy. 
Increases in cocaine use have been reported from a number
of countries in South America, Central America and the
Caribbean, reflecting the growth of consumer markets
along the distribution chain. These increases must be 
monitored carefully with a view to halting any further
increase on both the supply and the demand sides. 
Cocaine use levels in Asia and in eastern Europe are still
very low. The price to income ratio in these countries is very
high and, although this may have suppressed demand
slightly in the past, increases have been reported in some of
these markets as well. Taking into account some of the
trends in these new markets an ongoing geographical
spread in the use of cocaine is clearly identifiable. However,
one thing that has changed is that the number of countries
showing rising levels of cocaine use has indeed fallen from
62 per cent of all reporting countries in 2000 to 40 per cent
in 2005, and  the number of countries reporting stable or
declining cocaine use levels has increased. 
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1.3.2 Production
Table 5: Global illicit cultivation of coca bush and production of cocaine
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
CULTIVATION(a) OF COCA BUSH IN HECTARES
 Bolivia (b) 50,300 47,900 45,300 47,200 48,100 48,600 48,100 45,800 38,000 21,800 14,600 19,900 21,600 23,600 27,700 25,400 27,500
 Colombia (c) 40,100 37,500 37,100 39,700 44,700 50,900 67,200 79,400 101,800 160,100 163,300 144,800 102,000 86,000 80,000 86,000 78,000
 Peru (d) 121,300 120,800 129,100 108,800 108,600 115,300 94,400 68,800 51,000 38,700 43,400 46,200 46,700 44,200 50,300 48,200 51,400
Total 211,700 206,200 211,500 195,700 201,400 214,800 209,700 194,000 190,800 220,600 221,300 210,900 170,300 153,800 158,000 159,600 156,900
POTENTIAL PRODUCTION OF DRY COCA LEAF IN METRIC TONS (e)
  Bolivia 77,000 78,000 80,300 84,400 89,800 85,000 75,100 70,100 52,900 22,800 13,400 20,200 19,800 27,800 38,000 28,200 33,200
  Colombia 45,300 45,000 44,900 45,300 67,500 80,900 108,900 129,500 165,900 261,000 266,200 236,000 222,100 186,054 164,280 164,280 154,130
  Peru 196,900 222,700 223,900 155,500 165,300 183,600 174,700 130,600 95,600 69,200 46,200 49,300 52,500 72,800 101,000 97,000 105,100
Total  319,200 345,700 349,100 285,200 322,600 349,500 358,700 330,200 314,400 353,000 325,800 305,500 294,400 286,654 303,280 289,480 292,430
POTENTIAL MANUFACTURE(f) OF COCAINE IN METRIC TONS
 Bolivia 189 220 225 240 255 240 215 200 150 70 43 60 60 79 98 80 94
 Colombia 92 88 91 119 201 230 300 350 435 680 695 617 580 550 640 640 610
 Peru (g) 492 525 550 410 435 460 435 325 240 175 141 150 160 230 270 260 280
Total 774 833 866 769 891 930 950 875 825 925 879 827 800 859 1,008 980 984
(a) Potentially harvestable, after eradication
(b) Sources: 1990-2002: CICAD and US Department of State, International Narcotics Control Strategy Report; 2003-2006: National
Illicit Crop Monitoring System supported by UNODC. 
(c) Sources: 1990-1998: CICAD and US Department of State, International Narcotics Control Strategy Report; 1999-2006: National
Illicit Crop Monitoring System supported by UNODC.
(d) Sources: 1990-1999: CICAD and US Department of State, International Narcotics Control Strategy Report; 2000-2006: National
Illicit Crop Monitoring System supported by UNODC.
(e) Refers to the potential dry coca leaf production available for cocaine production, i. e. after deducting the amount, which govern
ments report as being used for traditional or other purposes allowed under national law. In the absence of a standard definition of 
"dry coca leaf" and given considerable differences in the processing of the fresh coca leaf harvested, the figures may not always be
comparable across countries.
(f) Amounts of cocaine that could be manufactured from locally produced coca leaf (due to imports and exports actual amounts of 
cocaine manufactured in a country can differ).
(g) Figures from 2003 to 2005 were revised based on updated information available on the amount of coca leaf necessary to produce
one kg of cocaine HCl, at 100% purity.
Global cultivation of coca remained essentially stable
in 2006 …
In 2006, the area under coca cultivation in Bolivia,
Colombia and Peru amounted to 156,900 ha. While
this represents a small decline of 2 per cent compared to
2005, the decrease in Colombia was almost entirely
offset by increases in Bolivia and Peru. The cultivation
estimates show that the global area under coca has been
essentially stable since 2003. However, global coca cul-
tivation continues to be lower than in any year of the
1990s and 29 per cent below the level recorded in 2000
(221,300 ha). 
Colombia remained the country with the world’s largest
coca cultivation, which represented half of the global
area under coca bush. Coca cultivation in Colombia
declined by 9 per cent from 86,000 ha in 2005 to
78,000 ha in 2006. Overall, despite the fluctuations in
recent years, coca cultivation in Colombia has proven to
be relatively stable since 2003.
In Peru, however, coca cultivation increased by 7 per
cent to 51,400 ha. Despite this increase, cultivation
remained well below the levels registered in the mid-
1990s, when Peru was the world’s largest cultivator. Peru
is now the second largest coca cultivating country
behind Colombia, and accounted for one third of global
cultivation in 2006.
Bolivia, the third largest producer of coca leaf, still trails
far behind Colombia, and accounted for only 18 per
cent of global coca cultivation. Similar to Peru, the area
under coca in Bolivia increased by 8 per cent compared
to 2005, and reached 27,500 ha in 2006, which is
almost as high as the level reached in 2004. 
There are no indications of large-scale coca cultivation
outside the three main coca growing countries.  Coca
cultivation in neighbouring countries such as Ecuador
and Venezuela is thought to be marginal. 
… leaving the level of potential cocaine production
largely unchanged …
The overall potential production of cocaine reached 984
mt in 2006, about the same as a year earlier, with levels
amounting to 610 mt in Colombia, 280 mt in Peru and
94 mt in Bolivia. Potential production is practically
unchanged from the levels of a decade ago. 
… while farm-gate prices for coca products decreased
in most areas
In Peru, farm-gate prices for sun-dried coca leaf declined
from a national average of US$ 2.9/kg in 2005 to only
US$ 2.5/kg in 2006. The monthly average prices for
sun-dried coca leaf at the farm-gate in 2006 remained
in the price range of US$ 2-3/kg observed since 2001. 
In Bolivia, farm-gate prices for sun-dried coca leaf fell
below the already low prices of 2005 and remained at an
average of US$ 3.9/kg well below the price level of over
US$ 5/kg between 2000 and 2004. Coca leaf prices in
Bolivia continued to be considerably higher than in
neighbouring Peru.
In Colombia, the yearly average price for coca paste
amounted to US$ 879/kg, and US$ 1,762/kg for
cocaine HCI. Farm-gate prices for coca paste, which
had fallen to pre-2001 levels at the start of 2006
(US$750/kg) recovered during the year and reached a
new high of over (US$ 1,010/kg) in December 2006.
Most clandestine laboratories for cocaine HCl are
located in South America
In 2005, governments reported the destruction of 5,737
clandestine coca processing laboratories (excluding coca
maceration pits), a four-fold increase since 2000, when
only 1,314 laboratories were dismantled. In addition to
clandestine laboratories, large numbers of coca macera-
tion pits were destroyed in Bolivia and Peru. 
Over 99 per cent of all dismantled clandestine labora-
tories in 2005 were in Bolivia, Colombia and Peru.
This shows that almost the complete cocaine produc-
tion chain, from coca paste to cocaine base and finally
cocaine HCl, is located close to the cultivation areas in
the three countries. An analysis by type of laboratory
reveals that laboratories in Bolivia and Peru, with very
few exceptions, produced coca paste and cocaine base,
whereas in Colombia a substantial number of laborato-
ries produced cocaine HCl. Preliminary figures for 2006
show a similar pattern.
The discovery of clandestine cocaine laboratories out-
side the coca cultivating countries demonstrates that a
small amount of cocaine is produced in other countries
as well. However, a large majority of the 210 clandestine
cocaine laboratories destroyed worldwide in 2005 were
located in Colombia (163), a further 33 in other South
American countries, and only 14 in other parts of the
world, such as Spain (11), France, South Africa and the
United States of America (one each). 
During 2005, Colombia’s role as the major cocaine pro-
ducing country was further demonstrated by the fact
that the largest seizures of potassium permanganate, a
precursor chemical necessary for the production of
cocaine HCl, took place in Colombia (141 mt). Given
the small amount of clandestine potassium perman-
ganate laboratories discovered in Colombia in 2005, it
is unlikely that all the potassium permanganate needed
to produce cocaine originates from sources within
Colombia. However, no seizures of any significance
have been reported in ports of entry into the country
and little is known about the sources and routes of the
potassium permanganate smuggling into Colombia. 
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Fig. 39: Global coca bush cultivation (hectares), 1990 to 2006
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Fig. 40: Global cocaine production (metric tons), 1990 to 2006
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Note: Colombian cocaine production estimates for 2004 and later are not directly comparable with previous years.
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Fig. 41: Annual coca bush cultivation and cocaine production in main producing countries, 1990 - 2006
COLOMBIA - COCA BUSH CULTIVATION, 1990 - 2006 (hectares) COLOMBIA - POTENTIAL COCAINE PRODUCTION, 1990 - 2006 (metric tons)
PERU - COCA BUSH CULTIVATION, 1990 - 2006 (hectares) PERU - POTENTIAL COCAINE PRODUCTION, 1990 - 2006 (metric tons)
BOLIVIA - COCA BUSH CULTIVATION, 1990 - 2006 (hectares) BOLIVIA - POTENTIAL COCAINE PRODUCTION, 1990 - 2006 (metric tons)
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Estimates for Colombia for 1999 and subsequent years come from the national monitoring system established by the Colombian government with 
the support of UNODC.  Due to the change of methodology, figures for 1999 and after cannot be directly compared with data from previous years.
Production data for 2004 to 2006 is based on new field research in Colombia.
1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Bolivia 1,100 5,493 7,512 7,000 11,620 15,353 7,653 9,395 11,839 10,089 8,437 6,073 5,070
Colombia 4,904 25,402 22,576 44,123 69,155 44,158 61,568 95,897 153,126 137,033 142,786 170,752 213,371
Peru - - 1,259 3,462 7,834 14,733 6,208 6,436 7,134 11,312 10,399 12,237 12,688
Ecuador - - - - - - - - - - - 17 -
Venezuela - - - - - - - - - - 118 40 0
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Fig. 42: Coca bush cultivation (in per cent of global total)
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Fig. 43: Potential cocaine production
Table 6: Reported cumulative eradication of coca bush (ha), 1994 - 2006
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Global seizures of cocaine rose to another record high
in 2005… 
In 2005, cocaine seizures increased to 756 mt (street
purity), which is the highest figure ever recorded, and a
30 per cent increase on the previous year. The increase
is largely the result of better cooperation among law
enforcement services and improved sharing of intelli-
gence, frequently enabling seizures prior to the drugs
arriving in the final destination countries.
… leading to a new record  in global cocaine intercep-
tion…
As a result, the global cocaine interception rate rose
from 34 per cent in 2004 to 42 per cent in 20051, a sig-
nificant increase from 20 per cent in 1995.  However,
yields and laboratory efficiency appear to have increased
over the last few years and this may not yet be fully
reflected in the current global cocaine production esti-
mates.  The result could be an overestimated global
cocaine interception rate. While some adjustments in
production figures may be  expected in the future, there
is little doubt that cocaine interception rates grew
strongly in recent years.   
… while cocaine trafficking continues to spread in
geographical terms 
At the same time, there has been a geographical spread
of cocaine trafficking.  In 2005, 131 countries reported
seizures of cocaine from 69 countries two decades ear-
lier; now nearly 80 per cent of all countries reporting
drug seizures report some seizures of cocaine. This sug-
gests that trafficking in cocaine is developing into a
global phenomenon, affecting all regions. 
Cocaine seizures remain concentrated in the Americas … 
There is still a strong concentration of cocaine seizures
in the Americas (85 per cent). South America, where all
of the coca leaf originates and most of the cocaine is
produced, accounted for 51 per cent of global seizures,
with North America, the world’s largest cocaine market,
accounting for 27 per cent. Central America and the
Caribbean, which are major transit regions, accounted
for 7 per cent of global seizures. The only large market
outside of the Americas is Europe, where 14 per cent of
global cocaine seizures were made, 99 per cent of which
were made in West and Central Europe. The rest of the
world was responsible for less than 1 per cent of global
seizures, mostly reported by countries in Africa. 
Seizures are rising in South America…
Over the last few years, the increase of global cocaine
seizures was particularly pronounced in South America,
where a rise was noted not only in absolute, but also in
relative terms. The proportion of cocaine seizures made
in South America (excluding the Caribbean and Central
America) rose from 38 per cent in 1990, to 44 per cent
in 2000 and 51 per cent in 2005. This clearly reflects
the growing efforts by producing countries and their
neighbours to step up interdiction at, and close to, the
source. 
Fig. 44: Spread of cocaine trafficking: Number of 
countries reporting cocaine seizures
Source: UNODC, Annual Reports Questionnaire Data /
DELTA.
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1 The global interception rate was calculated on the basis of a global cocaine production of 980 mt in 2005 and global seizures of 756  mt at street
purity, which, given a global average cocaine purity of 55 per cent in 2005 (as reported by Member States to UNODC in the Annual Reports
Questionnaires), would be equivalent to pure cocaine seizures of some 416  mt.  
1.3.3 Trafficking
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… as well as in Europe
Europe’s share in global cocaine seizures rose strongly
from less than 3 per cent in 1980, to 8 per cent in 2000
and 14 per cent in 2005. This reflects the rapidly grow-
ing trafficking flows and the spread of cocaine use in
Europe. 
The North American share of global seizures is declin-
ing …
In contrast, the proportion of seizures made in North
America declined, from 46 per cent in 1990, to 36 per
cent in 2000 and 27 per cent in 2005. This reflected a
stabilization or decline in the domestic market, as well
as efforts to strengthen interdiction capacities in the
source and transit countries. 
… and is reflected in student surveys on cocaine avail-
ability in the USA 
Increased interdiction efforts in the main drug transit
countries and in North America, have had an impact on
cocaine availability within the USA. The availability of
cocaine, as perceived by students, declined between
1998 and 2006, as 38 per cent of the students had
found it ‘easy’ or ‘fairly easy’ to obtain cocaine in 1998,
but only 33 per cent in 2006.  Over the last few years,
perceived availability fluctuated but basically remained
Fig. 45: Distribution of global cocaine seizures in 2005 (N = 756 mt) 
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Fig. 46: Global cocaine seizuresa, regional
breakdown, 1985-2005
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stable. In Europe, however, all indicators point to
increasing cocaine availability.  
The largest seizures remain concentrated in a few
countries 
While an increasing number of countries report on
cocaine seizures, the largest amounts are still seized in a
limited number of countries. Only five countries
accounted for 72 per cent of the global cocaine seizures
in 2005.
For the fourth year in a row, Colombia topped the rank-
ing of the world’s largest cocaine seizures. It seized 217
mt of cocaine hydrochloride (HCl) and cocaine base in
2005, equivalent to 29 per cent of the world total and
an increase from 19 per cent in 1995.  Seizures in
Colombia increased by 16 per cent from a year earlier,
representing the highest cocaine seizures ever reported
by a country. In 2005, the interception rate 2 of cocaine
produced in Colombia rose to 29 per cent, up from 25
per cent in 2004 and 13 per cent in 2000, clearly reflect-
ing continued enforcement efforts in the country.
The USA recorded the world’s second largest cocaine
seizures with 175 mt.  Over the last two decades, the
USA has ranked second six times, but has been in the
first place fourteen times.  US cocaine seizures rose by 5
per cent in 2005.  However, the US share in global
cocaine seizures has been declining steadily from 46 per
cent in 1985 to 23 per cent in 2005. 
The third largest cocaine seizures were reported by
Venezuela (59 mt or 8 per cent), up 88 per cent from
the previous year, ranking Venezuela third globally for
the second time. These seizures are a consequence of the
long common border with Colombia as well as intensi-
fied efforts in both countries.   
The fourth largest seizures were carried out by Spain, 48
mt or 6.5 per cent, which is a 46 per cent increase since
2004. Spain has recorded either the world’s third or
fourth largest annual cocaine seizures since 2001.  It has
also consistently recorded Europe’s largest cocaine
seizures for the last two decades. 
For the first time, the world’s fifth largest cocaine
seizures in 2005 were reported by Ecuador, Colombia’s
southern neighbour, with 43 mt (or 6 per cent of global
seizures), representing a nine-fold increase in a year.
This remarkable increase can be linked to first results of
an international container control project, supported by
UNODC and WCO, in which Ecuador participated.
Indications that Ecuador could be a major trans-ship-
ment country thus received some confirmation.
Fig. 47: Proportion of global seizures made in North 
America and in West and Central Europe
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Source: UNODC, Annual Reports Questionnaire Data / DELTA. 
Fig. 48: Perceived availability of cocaine among US
high school students, 1998-2006
(unweighted average of 8th, 10th and 12th 
grade students reporting that it is ‘fairly 
easy’ or ‘very easy’ to obtain cocaine 
powder)
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2 The interception rate of the cocaine seized in Colombia was calculated on the basis of domestic cocaine production and an average purity level of
cocaine of around 85 per cent. 
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Seizures in sixth place onwards were reported by:
Mexico (30 mt), the main direct transit country for
cocaine entering the USA; Peru (22 mt), the second
largest cocaine producer worldwide; Panama (18 mt),
the third main outlet of cocaine produced in Colombia;
Portugal (18 mt); Brazil (16 mt); the Netherlands (14
mt); Bolivia (12 mt), the world’s third largest cocaine
producer; and, Belgium (9 mt).
The main trafficking route still runs from the Andean
region to North America
Frequently quoted estimates among enforcement agen-
cies suggest that currently some 450 mt of cocaine (at
street purity) are destined for the markets in North
America and 250 mt of cocaine (at street purity) for the
markets in Europe.3 Far smaller amounts actually arrive
in these markets and are sold to the final cocaine con-
sumers, as almost half is seized or lost in transit. 
The world’s main cocaine trafficking routes continue to
run from the Andean region, notably Colombia, to the
USA. More than half of Colombia’s seizures take place
in the ports or at sea (56 per cent in 2005); 63 per cent
of the maritime seizures on the Pacific coast and 37 per
cent on the Atlantic coast4. In 2005, increasing amounts
appear to have left Colombia via Venezuela and
Ecuador. According to the US Interagency Assessment
of Cocaine Movement, half of the cocaine trafficked
towards the USA in 2005 transited the eastern Pacific,
whereas 38 per cent was trafficked through the western
Caribbean vector (i.e. along the coast of Central Amer-
ican countries). 
The main intermediate country of cocaine shipments to
North America is Mexico. The Mexican authorities have
intensified their interdiction efforts, resulting in cocaine
seizures more than doubling, from 13 mt in 2002 to 30
mt in 2005.5 However, drug-related violence has also
increased, with some 2000-2500 drug-related homi-
cides in 20066.
According to Mexican sources, about 60 per cent of the
cocaine is trafficked to Mexico by sea, with another 28
per cent by land from Central America (Guatemala and
Belize) and 12 per cent by air.  Important entry points
of cocaine into Mexico are the Pacific region and the
Yukatan peninsula on the Atlantic coast from where it is
usually transported north by land. While the most volu-
minous cocaine shipments are transported by sea, most
seizures in terms of cases, are on land.7 About 90 per
cent of the cocaine is destined for the USA, though close
to 10 per cent is apparently destined for Europe, which
is a new development.8
The US authorities estimate that between 74 per cent9
and 90 per cent10 of the cocaine which enters the coun-
Arrival Zone Area 2000 2001 2002 2003 2004 2005
Southwest Border
(in metric mt)
23 20 23 15 20 23
Southwest Border
(in per cent)
53 % 54% 68% 47% 57% 74%
U.S. East Coast 33% 30% 26% 28% 14% 13%
Puerto Rico/U.S.
Virgin Islands
14% 16% 6% 25% 20% 13%
Other 0% 0% 0% 0% 9% 0%
3
Direction Centrale de la Police Judiciaire / Police Nationale, ‘The Traffic of Cocaine through the Maritime Channel in 2006’, presentation given
by the French delegation to the Commission on Narcotic Drugs,  12-16 March 2007.  A 250 mt figure of cocaine destined for Europe has also
been repeatedly quoted by Europol as an estimate. The actual amounts available for consumption are, however, substantially lower. For 2000, the
Office of National Drug Control Policy estimated that the cocaine available for consumption in the USA amounted to only 259 mt. (Office of
National Drug Control Policy, National Drug Control Strategy, Data Supplement, Feb. 2003). As there are no indications that the market has
expanded since, a figure of around 250 mt would seem to be a reasonable estimate of the size of the US market in terms of actual consumption. 
4
UNODC, Andean Survey, Coca Cultivation in the Andean Region in 2005 (Part IV, Colombia Coca Cultivation Survey), June 2006. 
5
UNODC, Annual Reports Questionnaire Data. 
6 US Department of State, 2007 International Narcotics Control Strategy Report, March 2007.
7 UNODC/HONLAC, Informe nacional – México, Situación del tráfico de drogas en México, Oct. 2005. 
8 UNODC, Annual Reports Questionnaire (Mexico), for the year 2005.
Table 7: Cocaine Seizures in the US Arrival Zones, 2000-2005
Source: Interagency Assessment of Cocaine Movement, quoted in National Drug Intelligence Center, National Drug Threat Assessment
2007
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try transited Mexico, a proportion believed to have
increased over the last few years. The main entry point
into the USA over the common border with Mexico,
was through southern Texas, followed by southern
California, Arizona and western Texas.11
Criminal organizations of ethnic Mexican background,
at times holding US passports, have largely replaced the
Colombian criminal groups as the predominant whole-
sale cocaine distributors in several parts of the USA,
notably in the southern and mid-western regions over
the last 15 years.12 However, over the last few years, Mex-
ican drug trafficking organizations (DTOs) have also
developed cocaine distribution hubs in some eastern
states, slowly supplanting Colombian and Dominican
DTOs. In the USA, Atlanta emerged as the leading stag-
ing and distribution hub for cocaine to the east coast
drug markets, including those in Florida and New
York.13
Colombian organizations still handle cultivation, pro-
duction and initial offshore movement and some direct
shipments to the eastern parts of the United States,
while Mexican organizations increasingly coordinate the
remaining transportation and distribution segments
required for the cocaine to reach US streets.14 Despite
the encroachment of Mexican DTOs, Colombian and
Dominican DTOs remain the primary wholesale dis-
tributors of cocaine in many large east coast drug mar-
kets, including Boston, Miami, New York City, and
Philadelphia. However, the Colombian and Dominican
organizations’ control in these cities is diminishing.
While they continue to transport cocaine through the
Caribbean, including to Puerto Rico, for subsequent
transport to the east coast, they are also increasingly
employing Mexican DTOs to smuggle cocaine into the
USA on their behalf.15
While in the past (until the mid-1990s), coca paste and
coca base exports from Peru used to be in the hands of
the Colombian drug cartels, a significant proportion of
the Peruvian cocaine exports is now organized by crim-
inal groups from Mexico and leaves the country by sea.
About 70 per cent of the cocaine HCl leaving Peru is
now hidden in legitimate maritime cargo16.
The Caribbean is declining as a transhipment zone  
In the past, 30-50 per cent of the cocaine entered the
USA directly via the Caribbean. However, for 2005, the
United States Interagency Assessment of Cocaine Move-
ment concluded that this proportion had fallen to below
10 per cent.19 The main smuggling vectors via the
Caribbean in 2005 were Haiti and the Dominican
Republic (4 per cent), Jamaica (2 per cent) and Puerto
Rico (1 per cent).17
In contrast to the 1980s, direct shipments by air from
Colombia to the USA are diminishing and accounted
for less than 1 per cent of all cocaine shipments to the
USA in 2005.18 In total, about 11 per cent of all cocaine
destined for the USA entered the country by air in
2005.19
Europe is the second most important destination of
cocaine…
The second most important destination of cocaine pro-
duced in the Andean region is Europe. In addition to
Colombia as the main source country, Peru and Bolivia
are frequently mentioned among European countries as
sources of the cocaine found on their markets. The most
frequently mentioned transit country in 2005 was
Venezuela, followed by Ecuador and Brazil. In addition,
the Dominican Republic, Mexico and Argentina appear
to be gaining importance as transit countries. At the
street level, West African groups involved in cocaine
trafficking are becoming increasingly visible in a
number of European countries and West Africa is also
gaining importance as a transhipment zone.  
In 2005, European cocaine seizures amounted to nearly
107 mt, an increase of 48 per cent compared to 2004
and the highest ever reported. Over the 1995-2005
period, cocaine seizures in Europe increased by 17 per
cent per year, on average. Despite the rapidly growing
9 Intelligence Center, National Drug Threat Assessment 007.xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
10 US Department of State, 2007 International Narcotics Control Strategy Report, March 2007.
11 National Drug Intelligence Center, National Drug Threat Assessment 2007.
12 National Drug Intelligence Center, National Drug Threat Assessment 2006, Jan. 2006. 
13 National Drug Intelligence Center, National Drug Threat Assessment 2007.
14 Office of National Drug Control Policy, National Drug Control Strategy, Feb. 2006. 
15 National Drug Intelligence Center, National Drug Threat Assessment 2007.
16 US Dept. of State, International Narcotics Control Strategy Report 2006. 
17 National Drug Intelligence Center, National Drug Threat Assessment 2007, Oct.  2006. 
18 Interagency Assessment of Cocaine Movement, Midyear CY 2006 Update, quoted in National Drug Intelligence Center, National Drug Threat 
Assessment 2007. 
19 UNODC, Annual Reports Questionnaire (USA), for the year 2005. 
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seizures, cocaine prices have neither risen, nor has the
purity of cocaine deteriorated significantly. Thus, the
increase in European seizures does not only reflect
improved interdiction efforts, but unfortunately also an
increased availability of cocaine on the European
market.
… with Spain as the main entry point 
The main entry point of cocaine into Europe continues
to be Spain. Traffickers exploit Spain’s historic and lin-
guistic ties with Latin America, as well as its long coast-
line. Spain has reported Europe’s largest cocaine seizures
for the last twenty years. In 2005, Spain’s seizures of 48
mt of cocaine accounted for 45 per cent of all cocaine
seizures made in Europe, and rose by almost half from
2004 to 2005, which was also the result of greater effort
by the Spanish enforcement agencies. 
In 2006, 66 per cent of Spanish seizures were made
while the cocaine was still at sea, 11 per cent were made
in containers, and 6 per cent at airports.20 Traditionally,
most cocaine was seized along the northern Atlantic
coast, notably in Galicia. However, over the last three
years, cocaine increasingly entered the country via
southern Spain (Andalucia), Madrid (by air) and
Barcelona. 
Shipments to Spain are frequently reported to have tran-
sited Venezuela, Brazil and a number of other countries,
including Ecuador, the Dominican Republic, Argentina
and, as a new trend, Mexico. However, the main new
trend over the last two to three years has been the ship-
ment of cocaine to West Africa, typically off the coast of
Cape Verde, Guinea Bissau and the Canary Islands, as
well as to various countries along the Gulf of Guinea,
including Ghana, Côte d’Ivoire, Togo, Nigeria, and fur-
ther west to Guinea, Sierra Leone and Liberia for sub-
sequent deliveries to Europe. In 2005, Spain also
reported the dismantling of 11 cocaine laboratories on
its territory (up from 6 in 2004), which could indicate
that some coca products are also being imported from
Bolivia and Peru in semi-processed form.21
In 2005, 25 per cent of the foreigners arrested in Spain
in connection with the cocaine trade22 were Colombian
citizens, followed by Moroccan citizens (15 per cent),
citizens of the Dominican Republic (6 per cent) and
Italians (3 per cent). While the arrests of Colombians
always used to be high, more Moroccan arrestees point
to the increasing role of trafficking of cocaine from West
and North Africa.    
Portugal emerges as the second most important Euro-
pean point of entry 
Large increases in cocaine seizures have also been
reported by Portugal and with 18 mt it has Europe’s
second largest cocaine seizures in 2005, equivalent to 17
per cent of all European seizures.  Portugal’s cocaine
seizures more than doubled in 2005 (from 7 mt in
2004) and almost doubled again in 2006 to 35 mt,
thereby becoming another major European gateway for
cocaine. The huge seizures made by the authorities in
Portugal are mainly linked to the rising importance of
West Africa, including some of the Portuguese speaking
countries (such as Cape Verde or Guinea Bissau) for
smuggling cocaine from the Andean region, often via
Brazil and West Africa to Europe.
Cocaine continues to transit the Caribbean on its way
to Europe
One of the main cocaine trafficking routes to Europe
continues to go via the Caribbean, where the Nether-
lands Antilles, notably Aruba, are at the centre for ship-
ment of cocaine to the Netherlands. The Dutch
Fig. 49: Cocaine seizures in Europe (street purity)
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20 Ministerio del interior, presentation on cocaine trafficking by sea routes to CND, 12 - 16 March 2007.xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
21 UNODC, Annual Reports Questionnaire data (Spain), for 2005. x
22 The total number of foreigners arrested in Spain for cocaine-related violations of the narcotics law amounted to 2523 persons in 2005. The
number of offenders with Spanish passports amounted to 4988 persons; for 190 cases, no nationality was given. 
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authorities made more than 40 per cent of their total
seizures in the waters around the Netherlands Antilles in
200423 and in 2005, the second largest cocaine seizures
in the Caribbean region (more than 5 mt) were made in
the island of Aruba.  The largest cocaine seizures in the
Caribbean in 2005 were reported from St. Kitts and
Nevis, with slightly more than 5 mt; the second largest
were reported from Aruba and the third largest from the
Dominican Republic with slightly more than 2 mt. In
total, the countries in the Caribbean made seizures of 16
mt of cocaine in 2005, slightly more than a year earlier
(15 mt). 
Cocaine enters the Netherlands from the Caribbean
either by sea, typically via Rotterdam, or by air, mainly
via Schiphol airport in Amsterdam. However, the
importance of Amsterdam has declined drastically in
recent years following the introduction of strict controls
(100 per cent checks on direct flights from the Nether-
lands Antilles to Amsterdam) and greater cooperation
with the Netherlands Antilles and Suriname. As a con-
sequence, drug couriers choose other Caribbean coun-
tries, such as the Dominican Republic, to avoid
detection, and  are more reluctant to fly directly to Ams-
terdam. A number of European countries now report
the Netherlands as the destination country of the
cocaine seized on their territory, indicating that traf-
fickers are changing their routes and are increasingly
sending cocaine to Amsterdam via other European air-
ports.      
The Caribbean, notably Jamaica24, also continues to
play an important role for cocaine shipments to the UK.
Although the largest quantities are trafficked via Spain
and the Netherlands into the UK, small but rapidly
rising quantities arrive via countries in West Africa. A
significant number of the traffickers involved in the
smuggling of cocaine from the Caribbean into the UK
are British-born West Indians.25
The Caribbean region is also an important tranship-
ment location for cocaine entering France, although sig-
nificant amounts enter France via Spain, the
Netherlands and increasingly West Africa. In the
Caribbean, Martinique had the fourth highest drug-
related arrest figures per capita among all 100 French
departments in 2004, thereby exceeding the correspon-
ding rates for Paris.26 In 2005, significant seizures were
also made on private sailboats close to Guadeloupe,
which are used to smuggle cocaine from the Caribbean
to France and other European countries. Most of the
cocaine shipments from the Caribbean to France (as
well as from West Africa to France) are by air, frequently
going to the airports of Charles de Gaulle and Orly.27
France itself is not only a destination country but also a
significant transit country.  The French authorities, like
those of most other European countries, reported most
cocaine seized in 2005 as being in transit, primarily des-
tined for Spain (45 per cent), the Netherlands (10 per
cent) and only 17 per cent for domestic consumption.28
This shows at first sight a rather surprising two-way flow
of cocaine with both Spain and the Netherlands. Fur-
thermore, France was the only other European country,
apart from Spain, to report the dismantling of a cocaine
laboratory on its territory in 2005.  
Countries neighbouring the Andean producers are
growing as transhipment zones   
Other important transit countries from the Andean
region to Europe are Venezuela, Ecuador and Brazil, and
less frequently, the Netherlands Antilles, Suriname,
Argentina, Panama and Costa Rica.29 Some of these
countries also reported dismantling cocaine laboratories
(notably Venezuela and Argentina), which could indi-
cate that they are not only transit, but also cocaine
manufacturing countries. 
Italy, for instance, reported that 41 per cent of its
cocaine deliveries could be backtracked to Venezuela
(up from 22 per cent a year earlier) and 14 per cent to
Spain in 2005. The organized criminal groups of Naples
increasingly control the cocaine market in Italy,
although West African groups play an important role in
northern Italy as well. Most of the cocaine entering Italy
is for the domestic market (82 per cent). While the main
European transit countries for the cocaine entering Italy
are Spain, France and the Netherlands, there have also
been cocaine exports from Italy, mostly directed towards
the Netherlands (5 per cent of total seizures in 2005),
23 Seizures made in the waters around the Netherlands Antilles (13.7 mt) have subsequently been excluded from the total of seizures made by the 
Netherlands (21.4 mt) in order to gain a more accurate picture of their geographical location.  
24 Foreign and Commonwealth Office, Major cocaine producing and trafficking regions, May 2006.  
25 Serious Organized Crime Agency (SOCA), The United Kingdom Threat Assessment of Serious Organized Crime, 2006/07. 
26 Direction centrale de la police judiciare, Aspects de la criminalité et de la délinquence constatées en France en 2004 – Tome 2, Paris, 2005
27 UNODC, Annual Reports Questionnaire data (France), for 2005.  
28 UNODC, Annual Reports Questionnaire (France), for 2005.
29 UNODC, Annual Reports Questionnaire data. 
30 UNODC, Annual Reports Questionnaire data (Italy), for 2005. 
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another example of two-way flows of cocaine in
Europe.30
Concerns about cocaine along the Balkan route 
While most cocaine shipments from South America
continue to be directed towards western Europe (more
than 99 per cent of European cocaine seizures), some
shipments to East Europe and the Balkan countries have
been noticed by enforcement agencies. This raises con-
cerns about the development of new trafficking routes
and/or the incorporation of cocaine into the range of
products offered by traditional heroin trafficking groups
operating along the Balkan route. Some cases of cocaine
shipments via the Black Sea to Romania and via the
Adriatic Sea to Montenegro often organized by Alban-
ian criminal groups, have already been observed.  
Cocaine trafficking through West Africa emerges as a
serious problem… 
The rising importance of Africa, primarily West and
Central Africa, as a transit zone for cocaine shipments
destined for European markets is becoming increasingly
evident. However, seizures made in Africa (0.3 per cent
of global cocaine seizures in 2005) remain very modest
in comparison to the continent’s potential scale of traf-
ficking flows.  The low seizure rates mainly reflect eco-
nomic and institutional weakness in the region. 
In 2005, cocaine seizures reported by African countries
amounted to 2.5 mt; 52 per cent of these seizures were
in West and Central Africa, 33 per cent in North Africa
and 14 per cent in southern Africa. In 2005, African
cocaine seizures were higher than in 2003 or 2002, but
lower than in 2004. Nonetheless, there can be no doubt
that cocaine trafficking via Africa is on the rise.
UNODC’s database for individual seizures shows that 9
per cent of all cocaine seizure cases made in Europe in
2005, where the ‘origin’ was established, were smuggled
via Africa; in 2006, this proportion rose to 12 per cent.
Cocaine is frequently shipped to the countries along the
Gulf of Guinea, from where it is usually trafficked by
body packers to various destinations in Europe, with the
main African re-distribution centres being Ghana and
Nigeria. In addition, large quantities of cocaine are
shipped to the waters around Cape Verde and off the
coasts of Guinea and Guinea Bissau, most of which is
destined for Spain and Portugal 
The most frequently mentioned transit country of
cocaine shipments to Africa is Brazil, ahead of Colom-
bia, Peru and Venezuela. The authorities in Guinea esti-
mate that 60 per cent of the cocaine comes into their
waters via Brazil, and 40 per cent directly from Colom-
bia31.
The largest African cocaine seizures in 2005 were
reported by Morocco (0.8 mt), followed by Ghana (0.7
mt), Nigeria (0.4 mt), South Africa (0.3 mt) and Cape
Verde (0.2 mt). One cocaine laboratory was dismantled
in South Africa in 2005. Out of 40 African countries
reporting seizure statistics in 2005, 31 countries (78 per
cent) reported seizures of cocaine, an increase from 34
per cent in 1990.
… while cocaine trafficking in Asia and Oceania is still
limited
Although cocaine seizures in Asia almost doubled in
2005, they still remained at very low levels, 0.5 mt,
when compared to other regions. Seizures in Oceania
amounted to 0.1 mt in 2005. The largest seizures in Asia
were made by China (256 kg), followed by Israel (164
kg), the Islamic Republic of Iran (27 kg), Lebanon (26
kg), Hong Kong SAR of China (17 kg), Syria (14 kg),
Thailand (6 kg), Malaysia (5 kg), India (4 kg), Indone-
sia (1 kg), Cambodia (1 kg), Jordan (0.5 kg) and Saudi
Arabia (0.3 kg). Out of 41 Asian countries reporting
seizures, 18 countries (43 per cent) reported seizures of
cocaine in 2005. 
While cocaine manufacture in Asia is still the exception,
four clandestine cocaine-manufacturing laboratories
were dismantled in Hong Kong SAR of China in 2004.
In March 2006, authorities in mainland China, in
cooperation with the US DEA, made their largest ever
cocaine seizure (135 kg), close to the Hong Kong
border, and dismantled one laboratory. The people
arrested included Chinese and Colombian nationals.
31 UNODC, Annual Reports Questionnaire Data (Guinea), for 2005. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Fig. 50: Global Illicit supply of cocaine 1995 - 2005
(a) Converted to 100% purity. 
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Fig. 51: Global seizures of cocaine, 1995 - 2005
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Fig. 52: USA: Cocaine retail and whole sale prices, 
1990-2005 (US$/gram)
Fig. 53: EUROPE: Cocaine retail and wholesale 
prices, 1990-2006 (US$/gram)
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Fig. 54: Wholesale cocaine prices in Europe and the USA, 1990-2006 (US$/gram)
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Consumption continues to be concentrated in North
America, followed by Western Europe and South
America 
UNODC estimates that 14 million people worldwide
or 0.3 per cent of the population aged 15-64 use
cocaine. Annual prevalence rates are highest in North
America (2.2%), followed by West and Central Europe
(1.2%), South America (incl. the Caribbean and Cen-
tral America: 0.8%) and Oceania (0.8%). 
The largest numbers of cocaine users are found in North
America (6.4 million people), followed by West & Cen-
tral Europe (3.9 million) and South America (including
Central America and the Caribbean: 2.2 million).
Based on data from rapid assessments 1.1 million people
in Africa and 0.3 million people in Asia use cocaine.
No. of users in % of population 15-64 years
EUROPE 4,056,000 0.75
West & Central Europe 3,944,000 1.24
South-East Europe 66,000 0.08
Eastern Europe 46,000 0.03
AMERICAS 8,610,000 1.48
North America 6,363,000 2.19
South America 2,247,000 0.77
ASIA 329,000 0.01
OCEANIA 178,000 0.83
AFRICA 1,084,000 0.22
GLOBAL 14,257,000 0.34
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1.3.4 Abuse
Fig. 55: Annual prevalence of cocaine use (2005): 
distribution by region (N=14.3 million)
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Sources: UNODC, Annual Reports Questionnaire Data, UNODC
Field Offices,  UNODC’s Drug Abuse Information Network for
Asia and the Pacific (DAINAP), UNODC, Global Assessment Pro-
gramme on Drug Abuse (GAP), Govt. reports, EMCDDA, CICAD,
HONLEA reports, local studies,UNODC estimates.
Sources: UNODC, Annual Reports Questionnaire Data, UNODC Field Offices,  UNODC’s Drug Abuse Information Network for Asia and
the Pacific (DAINAP), UNODC, Global Assessment Programme on Drug Abuse (GAP), Govt. reports, EMCDDA, CICAD, HONLEA reports,
local studies, UNODC estimates.
Table 9: Annual prevalence of cocaine use, 2005 or latest year available
Above global average                             Around global average                           Below global average
Global cocaine use remained largely stable ... 
Year on year, the global prevalence rate for cocaine 0.3%
has remained the same though the estimated number of
cocaine users (14.3 million) has increased slightly.1
Increases of cocaine use in Europe, South America,
Africa and Asia have been largely offset by declines in
North America.2 The higher cocaine use at the global
level was due to higher estimates of cocaine use for West
and Central Europe (from 3.5 to 3.9 million ) and for
South America (from less than 2 million to 2.25 mil-
lion).  Cocaine use increased significantly in Western
Europe in 2005. 
The higher estimate for cocaine use in South America in
2005 resulted primarily from one new national house-
hold survey conducted in Brazil (which contains 40% of
the continent’s population.) The survey found substan-
tially higher cocaine prevalence rates than the previous
survey from 2001.3 UNODC also re-adjusted its preva-
lence estimates for a number of other countries in South
America, according to the results of new school surveys
done jointly with CICAD, UNODC and the countries
concerned.4 In most cases, this resulted only in minor
adjustments of previous estimates. In short, most of the
‘increase’ in South American prevalence rates in 2005
has been due to adjustments, trying to make the esti-
mates more realistic. Excluding such adjustments,
cocaine use in South America would have increased at a
much lower rate. The same is also true for estimates con-
cerning Africa (from 1 to 1.1 million) and Asia (from
0.26 to 0.33 million). Excluding such adjustments,
estimates for cocaine use in these regions, and at the
global level, would have remained largely stable.   
… even declining slightly according to experts opinion   
Trend estimates provided by national experts (weighted
by the number of cocaine users in each country) suggest
that global cocaine use has declined slightly in 2004 and
2005, following ongoing increases over the previous
decade.
The stabilization in expert perception reports in 2004
and 2005 was due to lower cocaine use level reported
from countries in North America (USA, Canada), off-
setting increases reported from South America: cocaine
producing countries Peru and Bolivia, their neighbours,
and most Central American countries, which are
increasingly being used as transhipment locations.
Cocaine use in the Caribbean was reported to have
remained largely stable (in line with reports of declining
use of the Caribbean for shipments to North America).
Cocaine use in Oceania was also reported to have been
basically stable, following some decline over the previ-
ous years.  
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Fig. 56: Cocaine use trends* as perceived by experts:
1992-2005
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Sources: UNODC, Annual Reports Questionnaire Data, UNODC
Field Offices,  UNODC’s Drug Abuse Information Network for
Asia and the Pacific (DAINAP), UNODC, Global Assessment Pro-
gramme on Drug Abuse (GAP), Govt. reports, EMCDDA, CICAD,
HONLEA reports and local studies. 
1 In the World Drug Report 2006, UNODC published an estimate of 13.4 million people or 0.3% of the population age 15-64. xxxxxxxxxxxxxxxx
2 One problem here is that there is regular reporting of the drug situation in North America (and thus only small declines are reported each year)
while reporting in other regions is far more sporadic, i.e. new estimates are only provided after intervals of several years (i.e. after new surveys have
been released). This has significant implications. It means that the global estimate is rather conservative. It also means that the reported trends are
potentially misleading. If a number of new surveys are released in countries where the trend has been increasing, the reported increase  has, in gen-
eral, not only occurred in the year of reporting but over a longer period. This can make year on year comparisons of global drug use levels poten-
tially misleading. 
3 There are some indications that the first national household survey, conducted in  Brazil in 2001, may have resulted in some under-reporting. The
2001 household survey showed annual cocaine use levels of  0.4%. The second household survey, conducted in 2005, found an annual prevalence
rate of cocaine use of 0.7%. This is in line with  current  results of student surveys in Brazil and the student surveys / national household survey
ratios in neighbouring countries, while this was not the case for the first survey, conducted in 2001.  In short, despite higher prevalence rates of
the 2005 national household survey, available data do not exclude the possibility that no significant increase of cocaine use may have taken place in
Brazil. School surveys failed to show any increase over the last few years. National school surveys conducted in 2004 showed a stabilization of life-
time prevalence rate at around  2%, about the same level as found in 1997 (2.1%). (Source: CEBRID, Levantamento Nacional Sobre o Uso de
Drogas Psicotropicas entre Estudantes do Ensino Fundamental e Medio da RedePublica de Ensino nas 27 Capitais Brasileiras, 2004).   
4 UNODC and CICAD – Sistema Subregional de Información e Investigación sobre Drogas en Argentina, Bolivia, Chile, Ecuador, Perú y Uruguay,
Primer estudio comparativo sobre uso de drogas en poblaciónescolar secundaria de Argentina, Bolivia, Brasil, Colombia, Chile, Ecuador, Paraguay,
Perú y Uruguay, Lima, Sept. 2006.   
Cocaine use in Europe, in contrast, continued to
increase unabated. Increases were reported from most of
Western Europe and South-Eastern Europe.  In fact,
most of the global increase of cocaine use over the last
decade can be attributed to rapidly rising cocaine con-
sumption in Europe. Only in Central Europe and in
East Europe were cocaine use levels reported to have
remained stable in 2005.  
Cocaine use in Africa increased, notably in western
Africa and in southern Africa as well as along the
Atlantic coast of north Africa. This is linked to the
increasing importance of Africa as a transhipment zone
for cocaine from South America to Europe. 
Cocaine use in Asia increased slightly, mainly due to
higher levels of use reported from India. The increase is,
however, from very low levels. Supply of cocaine to
India - though still very modest - seems to be mainly
organized by West African traffickers, exchanging
South-American cocaine with South-West Asian heroin
for final shipments to Europe or North America. In
most other parts of Asia, cocaine use levels remained
stable and at very low levels. 
… mainly reflecting falling cocaine use in North
America ... 
Indications of a decline of cocaine use are found in the
US National Household Survey on Drug Use and
Health as well as in student surveys (from both the US
and Canada) and in data from drug treatment admis-
sions.
The number of admissions for cocaine related treatment
in the USA fell over the last decade from 278,000 in
1995 to 256,000 in 2005. Expressed as a percentage of
all drug related treatment5, cocaine treatment fell from
23.5% in 1995 to 20.4 per cent in 1998 and 17.7 per
cent in 20056. Average annual prevalence of cocaine use
among 8th-12th graders fell from 4.6 per cent in 1999
to 3.6 per cent in 2006, equivalent to a decline of more
than 20 per cent. As compared to the peak in 1985,
cocaine use among 12th graders was even more than 50
per cent lower in 2006 (5.7 per cent in 2006 as com-
pared to 13.1 per cent in 1985).  Use of crack-cocaine,
which is responsible for much of problem drug use in
the USA, also declined. The annual prevalence of
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Fig. 57: Cocaine use trends as perceived by experts: 
regional contribution to global change: 
1992-2005
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Asia and the Pacific (DAINAP), UNODC, Global Assessment Pro-
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Fig. 58: Cocaine use trends as perceived by experts –
changes in regions, 1992-2005
(baseline: 1992=100)
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cocaine use among  the general population of the USA
also declined, from 2.5 per cent of the population age
12 and above in 2003 to 2.3 per cent in 2005, and is
more than 50 per cent lower than two decades ago.  
School surveys conducted in Ontario, Canada, also
showed a decline, from an annual prevalence rate of 5.1
per cent among 7th to 12th graders in 2003 to 4.2 per
cent in 2005, equivalent to a decline of 18 per cent
within a two-year period. Cocaine use in Canada is now
slightly below the levels reported two decades earlier.7
School survey data from Ontario suggest that cocaine
use levels among students are higher than those in the
United States.  If the general population is considered,
however, both annual prevalence of cocaine use (1.9 %
in Canada as a whole in 2004) as well as life-time use
(10.6 %)8 are significantly lower than the rates reported
from the USA (2.4 per cent and 14.2 per cent, respec-
tively, for 2004 or 2.3 % and 13.8 %, respectively for
2005).   
The highest levels of cocaine use in Canada are found
along the Pacific coast in the province of British Colom-
bia (16.7% life-time prevalence in 2004). The four
Canadian provinces along the Atlantic show rates of
cocaine use that are just half or less (3.7%-7.1%) the
levels reported from British Colombia. Life-time preva-
lence rates of cocaine use in British Colombia are also
higher than those reported for the USA as a whole.
British Colombia is also faced with the highest levels of
annual prevalence rates of cocaine use (2.6%) in
Canada, marginally ahead of Quebec (2.5%) and
Alberta (2.4%). 
Though very high by Canadian standards, a number of
states across the border in the USA show still signifi-
cantly higher levels of cocaine use than British Colom-
bia. Clearly higher levels (based on 2003 & 2004 data)9
are found in Rhode Island (3.5%), Colorado (3.4%),
Arizona (3.3%), New Mexico (3.1%) and the District of
Colombia (2.9%).
The data show that overall 4 states in the USA have
cocaine use levels of more than 3 per cent, 40 states have
between 2 per cent and 3 per cent and 7 states have
cocaine use levels of less than 2 per cent. These data also
suggest that differences between the lowest and highest
cocaine using states in the USA are less pronounced
than the differences among the provinces in neighbour-
ing Canada (or in Europe). 
Data for 2005 on the regional distribution of cocaine
use among youth (age 12-17) in the USA reveal wide-
spread cocaine consumption in the states bordering
Mexico (Texas, Arizona and New Mexico), reflecting,
inter alia,  increasing levels of cocaine trafficking via this
border.  Another area of concentration remains the New
England states along the East Coast. A comparison with
data for the older age groups (26+) suggests that the
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* Note: due to changes in methodology, household survey
results prior to 2002 are not directly comparable to those after
2002, and are thus not shown. 
Sources: SAMHSA, National Survey on Drug Use and Health and
NIDA, Monitoring the Future. 
Fig. 59: Cocaine use among the general population*
and among students (8th-12th grades), USA,
1998-2006
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Fig. 60: Ontario (Canada): Cocaine use among high-
school students (7th-11th grade)
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Source: CAMH, Drug Use Among  Ontario Students, 2005.
7 CAMH, Drug Use Among  Ontario Students, 2005.xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
8 Canadian Centre on Substance Abuse,  Canadian Addiction Survey 2004,  Ottawa 2005. 
9 SAMHSA, State Estimates of Substance Use from the 2003–2004 National Surveys on Drug Use and Health, Rockville MD  2006. 
high prevalence rates close to the Mexican border are a
relatively new phenomenon. Among the ‘older’ genera-
tion, cocaine use is more concentrated in the New Eng-
land states and in Florida. In fact, much of the initial
trafficking of cocaine from Colombia to the USA, either
directly by air or by boat via the Caribbean, targeted
these areas in particular. 
The latest data for 2006, based on results of drug test-
ing among the general workforce, show high levels of
cocaine use in the border regions of Texas with Mexico
and in the counties along the border between Texas and
New Mexico. In addition, high levels are found along
the East coast, from Florida to Washington D.C.  
Cocaine use levels across the border in Mexico are still
substantially lower than in the USA. The last national
household survey, conducted in 2002, found  an annual
prevalence rate of 0.35 per cent for the population aged
12-65 - which is in line with the global average but far
below the use levels reported from Canada or the USA10.
However, the survey also revealed that regional differ-
ences within Mexico are quite strong. The highest
prevalence rates of cocaine use were found in the north-
ern provinces (life-time prevalence of 3.1%), notably in
provinces bordering the United States. Prevalence rates
in central Mexico (0.7%) and in southern Mexico
(0.5%)  were still low. Overall, Mexico reported a stable
situation in 2005.   
… and rising cocaine use in South America 
Six countries in South America, including the
Caribbean and Central America, reported rising levels
of cocaine use  and four reported that levels of use were
stable.
Survey data from Colombia show that life-time preva-
lence of cocaine use increased over the 1992-2004
period, from 1.5 per cent in 199211 to 3.7 per cent in
2004,12 with  indications that the increase took place in
the late 1990s. Life-time prevalence of cocaine use
among youth, aged 10-24, was more than 5 times
higher in 2001 than in 1996. This increase may have
been associated with the rapid expansion of coca culti-
vation in Colombia in the late 1990s. A comparison of
annual prevalence estimates derived from these studies,
with actual annual prevalence data from the new
national survey, suggests that cocaine use prevalence
(including basuco) may have declined over the 2001-
2004 period in parallel with the decline of coca cultiva-
tion.13 Annual prevalence of cocaine use amounted to
0.8 per cent of the population age 18-65  in 2004.
Cocaine use in Bolivia rose over the 2000-2005 period
after declining in the late 1990s parallel to a decline in
domestic coca leaf production. Similarly, the increase in
the first years of the new millennium went in parallel
with rising levels of coca cultivation and cocaine pro-
duction.
Increases in cocaine use, from 0.4 per cent (annual
prevalence) in 2001 to 0.7 per cent in 2005, have been
reported in household surveys conducted in Brazil.
School surveys conducted in Brazil pointed to stable
cocaine use over  the 1997 - 2004 period.14 At the same
time, there are reports of increasing activities of cocaine
peddling gangs in the south-eastern states of the coun-
try and of the increasing exploitation of Brazil by inter-
national organized crime groups as a transit point for
cocaine shipments from Colombia, Bolivia and Peru to
Europe, often via Africa. This may have led to some
increase of local cocaine consumption . 
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Fig. 61: Bolivia: annual prevalence of cocaine use  
(age 12-50), 1992-2005 
Source: CELIN, Investigacion: Estudio Comparative Consumo de
Alcohol, Tabaco, Cocaina, y otras Drogas en Bolivia, 1992-1996-
1998-2000-2005, Bolivia 2005. 
10 Consejo Nacional Contra las Adicciones (CONADIC), Encuesta Nacional de Adicciones 2002, Mexico 2003.
11 Direccion Nacional de Estupefacientes, Estudio Nacional sobre Consumo de Sustancias Psicoactivas 1992.  
12 Direccion Nacional de Estupefacientes , Observatoria de Drogas de Colombia 2005, Acciones y Resultados, Bogota 2005. 
13 This type of direct comparison is methodolgically problematic and should be treated with caution.
14 CEBRID, Levantamento Nacional Sobre o Uso de Drogas Psicotropicas entre Estudantes do Ensino Fundamental e Medio da Rede Publica de
Ensino nas 27 Capitais Brasileiras, 2004. 
Analysis of the regional distribution of cocaine use in
Brazil shows that the South-East and the South are most
heavily affected while use in the North-East and North
is more moderate. 
School surveys conducted in 2003 and 2005/2006
showed strong increases of cocaine use in Ecuador. This
may be linked to the rapid increase of cocaine availabil-
ity as the country is increasingly used as a transshipment
zone for Colombian cocaine. Some increases – though
less significant - were also found in school surveys con-
ducted in Paraguay. Cocaine use levels in Paraguay
remained, nonetheless, low. School surveys conducted
in Uruguay suggest that cocaine use – starting from high
levels – has stabilized or even declined over the last few
years. 
Cocaine use also appears to have stabilized in Chile. Fol-
lowing increases in the 1990s, small declines in overall
cocaine use have been reported in annual household sur-
veys over the 2000-2004 period.  Annual prevalence of
cocaine use among the general population fell  from 1.9
per cent in 2000 to 1.7 per cent in 2004. If only cocaine
HCL is considered, the decline was from 1.5 per cent in
2000 to 1.3 per cent in 2004.   School survey results also
reveal a basically stable level of cocaine use over the
2001-2005 period. 
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Fig. 62: Brazil: annual prevalence of cocaine use in
2001 and 2005
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Fig. 63: Life-time prevalence of cocaine HCl use
among 15-16 year old students  in Uruguay, Ecuador
and Paraguay
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Sources:  UNODC and OAS/CICAD (Sistema Subregional de
Información e Investigación sobre Drogas en Argentina, Bolivia,
Chile, Ecuador, Perú y Uruguay with  participation of
SEDRONAR, CONACE, CONALTID, CONSEP, DEVIDA and JND),
Jóvenes y Drogas en Países Sudamericanos: un Desafío para las
Políticas Públicas - Primer Estudio Comparativo sobre Use de
Drogas en Población Escolar Secundaria, 2006 and OAS/CICAD,
Estudio Comparativo del Consumo de Drogas en Paises Ameri-
canos – Basado en Encuestas SIDUC a Estudiantes den
enseñanza Media, Washington 2003. 
Fig. 64: Chile: cocaine use among the general popu-
lation (age 12–64), 1996-2004
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New school survey data for South America show inter-
esting north-south patterns 
UNODC participated, together with the national
authorities and OAS/CICAD,  in the first  continent-
wide school survey among secondary students in South
America. This exercise facilitates direct comparison of
the drug use levels among students in different countries
across the continent, as well as with the results of school
surveys undertaken in North America and Europe. The
results15 have shown rather high levels of cocaine HCl
use in Argentina (life-time prevalence of 4.6% among
15-16 year old students) and in Chile (4.3%), followed
by Uruguay and Ecuador. The lowest levels were
reported by Paraguay (1.1%). Among the three Andean
countries, cocaine use levels among secondary students
turned out to be very similar (1.9%-2%), with only
marginally higher levels reported by Colombia. Levels of
cocaine paste/base consumption are highest in
Argentina, Chile and Bolivia.
The results of student surveys, when used for the pur-
poses of ranking, generally track those of general popu-
lation surveys. However, there do exist important
exceptions to this which could indicate an under-report-
ing in some of the household surveys.16 Also, in this par-
ticular case, the proportion of youths attending schools
differs significantly among South American countries.
This means that, for some countries, drug use levels
among young people in schools may not necessarily be
representative of drug use levels among youth in gen-
eral. Data  seem to indicate that the richest countries in
South America are faced with the highest levels of
cocaine use among students. One possible explanation
could be that the proportion of street children is larger
in less developed countries. Because these children can
fall outside school based surveys it could lead to an
under-representation of the youth substance abuse
problem in school surveys. 
Cocaine use levels in South America  could  be higher
than in Central America ...
The new results for South America suggest that cocaine
use levels could be higher than in Central America.  If
the data of  the individual South American countries are
aggregated, the average life-time use of cocaine HCl use
among 15-16 year olds amounts to 2.6 per cent
(unweighted). 
Previous comparative school surveys, undertaken under
the auspices of OAS/CICAD in Central America in
2001/02 found an (unweighted) average life-time preva-
lence rate among 15-16 year old students of 1.5 per
cent. Only Guatemala reported above average cocaine
use levels (2.3%).17 The perception of lower levels of
cocaine use in Central America could, however, be mis-
leading as one cannot exclude the possibility that
cocaine use increased substantially over the last few years
in this region. 
This might also apply to Venezuela, one of the few
South American countries that did not participate in the
latest UNODC/OAS/CICAD surveys. Venezuela used
to have very low levels of cocaine use among students in
2001/02 (life-time prevalence of 0.4% among 15-16
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15 Only the life-time prevalence rate among 15-16 year old students is discussed here because it forms the best internationally comparable data set.
This data set  is least biased given differences in school systems across countries. 
16 This is notably the case for Argentina, which reports both, one of the lowest cocaine use levels in its general population household survey (0.3%
in 2004), and the highest level cocaine use among secondary school students. In the 1999 general population household survey, Argentina reported
the highest level of cocaine use in South America.  Another case is Uruguay which also has a high prevalence rate of cocaine use among students,
but reports low cocaine use levels among the general population.   
17 OAS/CICAD, Estudio Comparativo del Consumo de Drogas en Paises Americanos – Basado en Encuestas SIDUC a Estudiantes den enseñanza
Media, Washington 2003. 
Fig. 65: Life-time prevalencea of cocaine use among 
high-school students in South America, age 
15-16,  2004-2006
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Población Escolar Secundaria, 2006. 
a/ results sorted by use of cocaine HCl; 
year old students).18 There is a high probability, how-
ever, that cocaine use may have increased substantially
over the last few years. 
.. and  new South American school surveys show levels
similar to Europe, though lower than North America 
If the data of the individual South American countries
are aggregated and weighted by the size of the youth
population of each country19, the average life-time
prevalence of cocaine HCl use among 15-16 year olds
amounts to 2.35 per cent in South America. This com-
pares with cocaine use levels of 4.8 per cent reported
among the same age group (10th graders) in the USA.
Cocaine use thus remains twice as high among students
in the USA. Cocaine use levels among students in South
America are close to those found in Europe. Europe has
an unweighted average of life-time cocaine use among
15-16 year old students of 1.8 per cent (average of 35
countries) and a weighted average20 of 2.4 per cent. 
Cocaine use continues to show an upward  trend in
Africa ...
The increasing use of African countries for cocaine
transshipment could be contributing to rising levels of
cocaine use. In 2005, ten African countries reported an
increase in cocaine use, up from 8 and 7 in 2004 and
2003 respectively. The number of African countries
reporting stable cocaine markets remained unchanged
in 2004 and 2005 (9 countries).  Not a single African
country reported a decline of  cocaine use in 2004 or in
2005.
The best documented increases of cocaine abuse are
found in South Africa, where the South African Com-
munity Epidemiology Network on Drug Use
(SACENDU) has been collecting data for the last 10
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18 OAS/CICAD, Estudio Comparativo del Consumo de Drogas en Paises Americanos – Basado en Encuestas SIDUC a Estudiantes den enseñanza
Media, Washington 2003. 
19 The weighting was done based on the size of the population age 15-19 in each country.  
20 These calculations are based on the 35 countries participating in the ESPAD School surveys in 2003 as well as Spain. The weighting was done
based on the size of the population age 15-19 in each country. (Sources: Council of Europe, The ESPAD Report 2003 – Alcohol and Other Drug
Use among Students in 35 European Countries), Stockholm 2004 and UNODC, Annual Reports Questionnaire for Spain, 2005). 
21 Cape Town, Gauteng (which includes the capital Pretoria and Johannesburg), Durban, Port Elisabeth,  East London and Mpulanga (the province
bordering Swaziland and Mozambique) 
Fig. 66: Life-time prevalence of cocaine HCl use 
among 15-16 year old students in South
America (2004-06), Europe (2003-04), and 
the USA (2006)
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Sources: UNODC and CICAD (Sistema Subregional de Informa-
ción e Investigación sobre Drogas en Argentina, Bolivia, Chile,
Ecuador, Perú y Uruguay with  participation of SEDRONAR,
CONACE, CONALTID, CONSEP, DEVIDA and JND),  Jóvenes y
Drogas en Países Sudamericanos: un Desafío para las Políticas
Públicas - Primer Estudio Comparativo sobre Use de Drogas en
Población Escolar Secundaria, 2006,  Council of Europe, The
ESPAD Report 2003 – Alcohol and Other Drug Use among Stu-
dents in 35 European Countries), Stockholm 2004 and UNODC,
Annual Reports Questionnaire for Spain, 2005) and NIDA, Moni-
toring the Future.  
Fig. 67: South Africa:  cocaine as primary drug of 
abuse in treatment demand*
* unweighted average of treatment (incl. alcohol) in 6 provinces.
Source: SACENDU, Research Brief, Vol. 9 (2), 2006. 
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years. Data from treatment centers in six locations21
indicate that cocaine abuse is increasing rapidly across
the country.  Cocaine related treatment demand as a
percentage of all treatment including alcohol - expressed
as an unweighted average of the six sites - rose from less
than 2 per cent in 1996 to more than 10 per cent in
2006.
The highest proportions related to cocaine abuse over
the first two quarters of 2006 (excluding alcohol) were
reported for people in treatment in Port Elisabeth
(36%) and in East London (28%), followed by Gauteng
(21%). Cape Town was the first city to develop a
cocaine epidemic in South Africa in the 1990s. In this
city, however, methamphetamine has largely replaced
cocaine as the drug of choice in recent years so that
cocaine now accounts for 9 per cent of treatment
demand.  Data for the third and fourth quarters of 2006
show that the overall upward trend for cocaine contin-
ued.
... a clear upward trend in Europe ... 
The most alarming trend with regard to cocaine has
been its rapid rise in Europe over the last few years. For
the year 2005, 16 countries reported rising levels of
cocaine use, 24 a stabilization and only four countries
reported a  decline. 
The highest prevalence rates of cocaine use in Europe
are found in Spain, which has long been the main entry
point of cocaine into Europe. More than one fifth of all
European cocaine users are in Spain, where cocaine is
the second most widely consumed drug after cannabis.
Despite large-scale prevention efforts and a very active
law enforcement sector, cocaine use doubled among the
general population (age 15-64) from 1.6% in 1999 to
3.0% in 2005.22 Cocaine use levels in Spain are more
than twice the West European average (1.2%) and four
times the overall European average (0.75%). For the
first time cocaine use levels exceed those reported from
the USA.
Estimates of cocaine related problem drug use in Spain
remain lower than those reported from the USA (1.4%
of the population age 15-64)23 but they are showing
upward trends: 0.2 per cent in 1999,  0.5 per cent in
200224 and it is very likely that the rates have continued
rising since. School surveys conducted in Spain have
already shown slightly higher use levels since 2002, and
they continue to show upward trends. 
In parallel, cocaine related treatment demand is increas-
ing. It accounted for 40.5 per cent of all treatment
demand in Spain in 2004 – by far the highest such pro-
portion in Europe -  up from 25.4 per cent in 2002. In
contrast to the rest of Europe, cocaine related treatment
in Spain is now only slightly less than opiate related
treatment (44.5% in 2004). In absolute numbers,
cocaine related treatment demand doubled, from
11,900 in 2002 to 21,400 in 2004.25 In Catalonia and
in Valencia, cocaine related treatment already exceeds
heroin related treatment26 which is unique for Europe. 
Cocaine use has also increased in the United Kingdom
which has Europe’s second highest cocaine prevalence
rates. In absolute numbers, estimates suggest that the
UK’s cocaine market (some 910,000 people)  is even
marginally larger than the market in Spain (some
890,000 people). Annual prevalence rates of cocaine use
increased  - according to British Crime survey data –
90
World Drug Report 2007
22 UNODC, Annual Reports Questionnaire Data.xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
23 ONDCP, 2003 National Drug Control Strategy,  Data Supplement.  
24 EMCDDA – Reitox National Focal Point ‘Spain’,  2005 National Report to the EMCDDA - New Development, Trends and in-depth Informa
tion on Selected Issues, Madrid 2006.  
25 UNODC, Annual Reports Questionnaire Data. 
26 EMCDDA – Reitox National Focal Point ‘Spain’,  2005 National Report to the EMCDDA - New Development, Trends and in-depth Informa
tion on Selected Issues, Madrid 2006. 
Fig. 68: Annual prevalence of cocaine use in Spain
among the general population and among 
high-school students, 1994-2005
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four-fold over the last decade, from 0.6% in 1996 to
2.4% of the population age 16-59 in 2006.27 Most of
the increase, however, took place in the second half of
the 1990s.  The highest cocaine use levels are reported
from London (4.1%) and the lowest from Wales (1.6%)
and Yorkshire (1.8%).28 Scotland – which is not
included in the survey mentioned above – had a lower
prevalence rate (1.5% in 2004) as did Northern Ireland
(1.1% in 2004).  If these data are aggregated, the annual
cocaine prevalence rate for the United Kingdom
amounts to 2.3 per cent of the population age 16-59.
Cocaine is now the second most widely used illegal drug
in the UK after cannabis.   
Italy is the third largest cocaine market in Europe. The
country has seen some of the strongest increases of
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Fig. 69: England & Wales: annual prevalence of 
cocaine use among the general population
(age 16-59)
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27 The survey was conducted over the period April 2005 to March 2006.xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
28 Home Office,  Home Office Statistical Bulletin, Drug Misuse Declared: findings from the 2005/06 British Crime Survey, October 2006. 
Fig. 71: Italy: annual prevalence among the general 
population*
1.1% 1.2%
2.1%
0.0%
0.5%
1.0%
1.5%
2.0%
2.5%
3.0%
2001 2003 2005
A
n
n
u
al
 p
re
va
le
n
ce
* 2001: age group: 15-45; 2003: age group 15-54: 2005 age
group: 15-64
Source: UNODC, Annual Reports Questionnaire Data.
Fig. 70: Incidence of cocaine use in Italy, 1975-2005 
Source: Istitute de Fisiologia Clinica, Concisglio Nazionale delle Ricerche.
cocaine use in recent years, with the annual prevalence
of cocaine use rising from 1.1% in 2001 to 2.1% of the
general population in 2005. Cocaine is the second most
widely used drug among the general population after
cannabis.
The incidence of cocaine use (i.e. the number of persons
using it for the first time) increased from levels around
1,000 persons/year in the first half of the 1990s to 9000
persons in 2005. The increase of cocaine use in Italy
went hand in hand with strongly falling cocaine prices
–a clear indication that a rise in trafficking of cocaine
into Italy played a role in the expansion of the market.
The involvement of organized crime in Naples (known
as the ‘Camorra’  or ‘the system’), is thought to have
actively worked towards the expansion of the cocaine
market in Italy, thus offsetting the prevention efforts
undertaken by the authorities. With some 800,000 per-
sons, Italy accounts for almost a fifth of the total Euro-
pean cocaine market.  Cocaine abuse is particularly
widespread in north-western Italy (Lombardia) as well
as in the central provinces along the coast from Naples
to Genova.  
No new prevalence data is available from Germany, the
fourth largest cocaine market in Europe (approximately
240,000 persons). According to the last household
survey, conducted in 2003,  the prevalence rate was 1%
of the population age 18-59. Cocaine is the second most
widespread drug among the general population after
cannabis. The German authorities, in contrast to many
other European countries, perceived cocaine consump-
tion levels to have remained stable over the last few years
following strong growth rates in the 1990s (starting
from 0.2% in 1990). 
Clear increases in cocaine use - though  starting from far
lower levels - have been also reported by France,
Europe’s fifth largest cocaine market (some 240,000
people). Between 2000 and 2005, the annual prevalence
of cocaine use tripled from 0.2% to 0.6% of the popu-
lation age 15-64.
… and a clear persistent East-West divide in Europe 
In terms of cocaine use among the general population,
there is still a strong east-west divide in Europe.  Ninety-
five per cent of all cocaine users are found in the coun-
tries of Western Europe (EU-15 and EFTA countries). 
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Cannabis is the largest illicit drug market by far and its
size is one of its most important characteristics. Its con-
sumer market is large, roughly 160 million people; its
production centres are widely dispersed, existing in
almost every country in the world and its factors of pro-
duction can be both flexible, rudimentary and small
scale and permanent, highly technical and large scale.
The widespread nature of production and consumption
make it very difficult to define and quantify. The con-
sumer market for cannabis is also different. The size of
the consumer market for cannabis could imply that con-
sumers are more varied.
Production is pervasive. A total of  82 countries explic-
itly reported the illicit cultivation of cannabis on their
territory over the 1995-2005 period. In addition,
Member States identified 134 source countries for the
production of cannabis. Moreover, 146 countries
reported seizing cannabis plants over the 1995-2005
period, which is an indirect indicator for the existence
of cannabis plant production in a country, as cannabis
plants are usually not trafficked across borders (only the
end-products; cannabis herb, cannabis resin or cannabis
oil).  Combining these data suggests that cannabis pro-
duction is taking place in at least 172 countries and ter-
ritories.
Although the insidiousness of cannabis renders effective
monitoring of the supply side difficult, it is probable
that the expansion of cannabis production ceased in
2005.  Indications of an overall stabilisation in the
market are extremely encouraging but whether this is
sustainable or not will  need to be confirmed with data
from the next few years.  
Some aspects of this market are evolving. Indoor culti-
vation is expanding in general and as this occurs several
‘consumer countries’  have emerged as important
cannabis producing countries – supplying their local
markets (at least to a limited extent). As this happens,
the overall potency of cannabis (i.e. the THC content as
engineered through horticultural innovations)  has been
rising in several countries. 
The production of cannabis resin, also known as hashish
is concentrated in North Africa (Morocco) and in the
South-West-Asia / Middle East region, particularly in
Afghanistan and Pakistan.
In Morocco, UNODC surveys, conducted in collabora-
tion with the authorities, revealed a fall in the area of
cannabis resin cultivation from a peak of 134,000 ha in
2003 to 76,400 ha in 2005. Moroccan cannabis resin
production, for years the main source of hashish for
Western Europe, declined even more strongly, from
3,070 mt in 2003 to 1,070 mt by 2005.  
Cannabis herb seizures continue to be mainly concen-
trated in North America (66% of global seizures in
2005), followed by Africa (16%). Global seizures of
cannabis herb showed a strong increase over the 2000-
2004 period, a probable reflection of rising cannabis
herb production, trafficking and consumption. How-
ever, in 2005, cannabis herb seizures declined substan-
tially to the levels reported back in 2000.  The decline
was reported across all continents.  The factors which
provoked this decline are not fully known; but eradica-
tion seems to have played a critical role.
Global cannabis resin seizures also declined in 2005 due
to lower production of cannabis resin in Morocco. The
world’s largest cannabis resin seizures continued to be
reported by Spain (52% of global hashish seizures in
2005), followed by Pakistan (7%) and Morocco (7%).  
The consumer markets in North America appear to
have contracted, but there has been an increase of
cannabis use in Africa and in most countries of South
America. The situation in Europe is mixed.  A decline
of cannabis use was  found in the Oceania region, which
has the world’s highest levels of prevalence rates for
cannabis. Countries of East & South-East Asia showed
stable or declining cannabis consumption trends while
in South-Asia, South-West Asia and Central Asia the
reported trends suggest an increase. 
The number of countries reporting increases in cannabis
use fell from 56 per cent in 2000 to 49 per cent in 2005,
while the number of countries reporting declines
increased from 11 per cent in 2000 to 18 per cent in
2005.
1.4 Cannabis Market
1.4.1 Summary trend overview
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Cannabis cultivation remains pervasive throughout the
globe
The pervasiveness of cannabis persists. Between 1995-
2005, 82 countries provided UNODC with cannabis
cultivation or production estimates. Unfortunately,
reporting on cannabis cultivation is complex and
resource intensive for a number of reasons and many
countries do not have the capacity or resources ot make
estimations. Consequently, UNODC also analyses
seizure reports which sometimes identify the source of
cannabis trafficked in a country. On this basis, 134 pro-
ducer countries were identified over the 1995-2005
period. A third list of producer countries was generated
by singling out those that reported the seizure of
cannabis plants. The inefficiency of transporting whole
plants internationally (as only some parts are useable as
a drug) means that when whole plants are seized, it is
very likely that they were locally produced. Seizures of
whole cannabis plants were reported in 146 countries
over the 1995-2005 period. 
Combining the three lists of estimates, 172 countries
and territories can be identified where cannabis is pro-
1
In some parts of North America, for instance, the following combinations are found: 'Candy sticks: cannabis herb cigarettes laced with cocaine;
'Buddha': cannabis herb spiked with opium; 'Ace' or ' Zoom' : cannabis herb mixed with PCP, etc.; use of cannabis in food items (e.g. in North
Africa'); 'Marijuana brownies' (e.g. in North America); as well as frequent use of both cannabis and alcohol (often reported from Europe and Aus-
tralia).
1.4.2 Production
Cannabis continues to be the most widely produced, trafficked and consumed drug worldwide. It is produced
for basically three different end products:
• Cannabis herb is comprised of the flowering tops and leaves of the plant, which are smoked like tobacco
using a variety of techniques. Depending on the region, cannabis herb is known under many different
names, including 'marijuana' (Americas; also referred to as 'grass', 'weed', 'ditch' or 'dope'), 'ganja'
(South-Asia / Jamaica), 'dagga' (South Africa), 'dimba' (West Africa) or 'chira' (North Africa; usually
cannabis resin powder). A very potent form of cannabis herb is sinsemilla, the flowerinng tops the unpol-
linated female plant. Cannabis herb accounted for 77 per cent of global cannabis seizures in 2005.
• Cannabis resin consists of the secretions of the plant emitted in the flowering phase of its development.
Depending on the region, cannabis resin is known as 'hashish' (North Africa / Europe) or as 'charas'
(South-Asia). It accounted for close to 23 per cent of global cannabis seizures in 2005. 
• Cannabis oil (hashish oil) is an oily mixture resulting from extraction or distillation of THC rich parts of
the cannabis plant. It is less widely used, accounting for 0.01 per cent of all cannabis seizures in 2005. 
In addition, a number of cannabis combinations are found on the markets, such as: 
• 'Kif' (North-Africa), often understood to mean the chopped flowering tops of the female cannabis plant,
mixed with tobacco, or 'Bhang' (South-Asia), often understood as a beverage prepared by grinding
cannabis leaves in milk and boiling it with spices and other ingredients; or 'White pipe' (South Africa),
the smoking of cannabis herb in combination with tobacco and Mandrax (consisting of methaqualone as
the active ingredient and antihistamines). Various combinations of cannabis with other drugs such as
cannabis/cocaine and cannabis/amphetamine, are reported inter alia from Eastern Africa. The combina-
tions usually carry region/country specific or local names. 1
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duced, equivalent to close to 90 per cent of the coun-
tries & territories which receive UNODC’s Annual
Reports Questionnaire (190-195).2
The analysis of the reported source countries (ARQ,
2002-2006 period) suggests that cannabis resin produc-
tion takes place in some 58 countries while cannabis
herb (marijuana) production occurs in at least 116
countries. The caveat here is that cannabis herb is
thought to be “produced” even in countries where the
main supply concentrates on resin. Cannabis herb pro-
duction is globally far more dispersed than global
cannabis resin production. 
1.4.2 Cannabis herb production 
Global production of cannabis herb is estimated to
have declined to 42,000 mt in 2005
Based on information collected from Member States,
UNODC estimates global cannabis herb production at
42,000 metric mt in 2005, dwarfing global heroin pro-
duction (472 mt in 2005) or global cocaine production
(980 mt in 2005). This represents a decline of almost
3,000 mt (-7%) over 2004. While these data must be
interpreted with caution, they seem to signal, that the
upward trend in herb production observed since the
early 1990s, may be coming to a halt. The cannabis herb
estimate suggests that 10.6 per cent of cannabis herb
production was seized in 2005. 
The area under cannabis cultivation is estimated to have
amounted to 530,000 ha in 2005, which was again far
more than the area under poppy cultivation (151,500
ha) or the area under coca cultivation (159,600 ha in
2006).3
The yields reported by Member States varied substan-
tially, from as low as 5 kg/ha to 17,500 kg/ha. This is a
reflection of the wide ranges of cannabis yields, e.g.
from wild  cannabis to hydroponically grown cannabis.
Within reported estimates the median cannabis yield
was 730 kg/ha and the (unweighted) average yield was
2,070 kg/ha. Despite the large difference, such yield fig-
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2 Cannabis production estimates must be viewed with caution: Although, production estimates for cannabis are systematically collected by UNODC
from Member States as part of the replies to the annual reports questionnaire (ARQ), the lack of clear geographical concentrations of cannabis pro-
duction (as with opium poppy or coca bush) makes it impracticable to introduce scientifically reliable crop monitoring systems. The fact that
cannabis is a plant that grows in virtually every inhabited region of the world, that it can be cultivated with little maintenance on small plots, and
that it can be also grown indoors, complicates matters. Resulting variations in cannabis yields are also huge. The majority of individual country
estimates are thus still based on expert opinion, rather than on the results of scientific crop monitoring systems. Nonetheless, given a number of
innovative approaches introduced by UNODC in recent years to arrive at estimates for countries that did not provide any estimates (see section on
methodology), the resulting global estimates should provide, at least, reasonable orders of magnitude of the problem. As the methodology used to
arrive at the estimates has remained basically the same in recent years, and as one should not under-rate the expertise of the authorities to come up
with reasonable estimates (even without detailed surveys), one may assume that resulting changes in the global production estimates basically reflect
underlying changes in cultivation and production. The fact that global cannabis production estimates largely mimic global seizures tends to support
this view.  
3 The estimate of area under cultivation for cannabis herb includes some, but not all, wild cannabis. Were there any practical way to measure wild
cannabis this figure would be much higher.
Fig.71: Number of countries/territories identified as
cannabis producers  (1995-2005): N = 172
A: 82 countries/territories providing cultivation/production esti-
mates
B: 134 countries/territories identified as source countries for 
cannabis that was trafficked
C: 146 countries reporting the seizure of whole cannabis plants 
Fig. 72: Estimates of global cannabis herb 
production, 1988-2005 
Sources: UNODC, Annual Reports Questionnaire Data and Govt.
reports. 
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ures are consistent with those reported in UNODC’s
last extensive survey of the global cannabis market4.
That study suggested that typical yields for cultivated
outdoor cannabis range from 470 kg/ha in non-irrigated
areas to 5,000 kg/ha in well tended gardens, with figures
around 2,000 kg/ha typical for the situation in the
USA5, and levels around 1,000 kg/ha typical for the sit-
uation in developing countries. In contrast, the yields of
hydroponically grown cannabis ranged from 15,000 to
30,000 kg per hectare. 
In 2005 the bulk of cannabis herb was produced in the
Americas (46%) and in Africa (26%), followed by coun-
tries in Asia and in Europe. Internationally, most
cannabis herb was produced for the domestic market
and/or for exports to neighbouring countries. Countries
in which cannabis is produced for extra regional export
are limited. They include a number of West, South and
North African countries (including South Africa, Nige-
ria and Morocco) and few East, West and Central Asian
countries (including Thailand, Pakistan and Kaza-
khstan). Most of these exports are destined for Europe. 
Production by region
The largest producers in North America continue to be
Mexico and the United States of America followed by
Canada. Estimates made available to UNODC suggest
that Mexico and the USA may be the world’s largest
cannabis herb producers. Production in Mexico is
mainly concentrated in states along the Pacific coast
(Sinaloa, Miachoacán, Guerrero, Jalisco, Oaxana and
Nayarit) which account for about 53 per cent of total
cannabis eradication, and in the Center/North region
(Chihuahua, and Baja California), where 42 per cent of
cannabis eradication took place in 2005. Cannabis pro-
duction in the USA is particularly widespread in the
states of California, Kentucky, Tennessee, Hawaii, and
Washington.6 Cannabis production in Canada is mainly
concentrated in British Colombia (40%), Ontario
(25%) and Quebec (25%). 
Cannabis production takes place in practically all coun-
tries in South America and the Caribbean. The largest
producers in South America are Paraguay, followed
(now) at far lower levels, by Colombia, Brazil and the
Caribbean region. Declines of cannabis production in
Colombia in recent years appear to have been offset by
increases in other parts of South America, notably in
Paraguay. Though Brazil is an important cannabis pro-
ducer, it is not ‘self-sufficient’ so that large quantities are
trafficked from Paraguay into that country. Frequently
mentioned source countries in the Caribbean region are
St. Vincent & the Grenadines as well as Jamaica.
Guatemala is frequently cited as a source country for
cannabis from Central America. 
Cannabis is grown in almost all of the countries of
Africa. The largest cannabis herb producers in Africa
include South Africa (as well as a number of other coun-
tries in the region, including Malawi, Zambia and
Swaziland), Nigeria, Ghana & several other West-
African countries (including Benin and Togo), the
Democractic Republic of the Congo in central Africa,
Tanzania in eastern Africa as well as Morocco in north-
ern Africa (though the latter country is mainly known
as a cannabis resin producer). 
Despite growing levels of domestic production, Europe
remains a region which still relies, to a significant extent,
on the importation of cannabis. The largest cannabis
producers in Europe are Albania and the Netherlands,
though significant amounts are also being produced in
most other European countries, including Germany,
Switzerland and the UK. 
The largest cannabis producers among the C.I.S coun-
tries are Kazakhstan, the Russian Federation and Kyr-
gyzstan. The Russian Federation and Kazakhstan
contain the world’s largest areas of wild cannabis. 
The largest producers in the Near East & South-West
Asia region are Afghanistan, followed by Lebanon and
Central / South 
America and the 
Caribbean
23%
Asia
22%
Oceania
1%
North America
23%
Africa
26%
Europe
5%
Fig. 73: Breakdown of global cannabis herb produc
tion in 2005 (N = 42,000 metric tons)
Sources: UNODC, Annual Reports Questionnaire Data and Govt.
reports. 
4
UNODC, 2006 World Drug Report, Vol. 1, pp. 193-195.UNODC, 2006 World Drug Report, Vol. 1, pp. 193-195.
5
As identified through the analysis of data from court cases
6 National Drug Intelligence Center, National Drug Threat Assessment 2007, October 2006
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Pakistan (in all of these countries, however, cannabis
herb production is far less important than the produc-
tion of cannabis resin). Important producers in South-
Asia are India, Nepal and Sri Lanka; and important
producers in South & South-East Asia include the
Philippines and Indonesia, followed, at lower levels, by
Thailand. The largest cannabis producer in the Oceania
region is Australia. 
Changes in the regional breakdown suggest that
cannabis production increased in Asia, Europe and
South America (including Central America and the Car-
ribean) but declined in North America and in Africa. 
The decline of cannabis production in North America
was mainly due to lower cannabis production levels in
Mexico, which reflect the strong eradication efforts
made in that country. Mexico has been extremely effi-
cient in eradicating cannabis, having eradicated some 85
per cent of the area under cultivation. The net area
under cultivation thus declined by 23 per cent in 2005
(from 7,500 to 5,800 ha) with a further decline reported
for the year 2006 (to 5,600 ha). Given differences in
yield estimates, production estimates for Mexico range
from 4,480 mt to 10,100  mt7 (for 2005). 
In parallel, cannabis eradication efforts in the USA were
significantly stepped up in recent years. According to
data of the Domestic Cannabis Eradication/Suppression
Program the number of eradicated cannabis plants in
the USA rose from 3.2 million in 2004 to 4.2 million
in 2005 (+31%) and 4.9 million plants (+17%) in 2006.
Including eradication efforts made by other government
agencies, total eradication amounted to 6.3 million
plants in the USA in 2006. Applying the DEA estimate
of, on average, 1 pound of cannabis herb per plant8,
eradication may have removed some 2,825  mt from the
US market in 2006, i.e. more than is produced in most
other countries of the world. Law enforcement reports
indicate that between 30 and 50 per cent of all cannabis
grown in the USA is now being eradicated. 
45,000
42,000
-
10,000
20,000
30,000
40,000
50,000
2004 2005
M
et
ric
 t
on
s
Africa
North America
South America (incl. Central America & Caribbean)
Oceania
Europe
Asia
7,500 5,800 5600
30,845
30,886 29,928
0
10,000
20,000
30,000
40,000
2004 2005 2006
H
ec
ta
re
s
Net area under cultivation Eradication
Fig. 75: Area under cannabis cultivation in Mexico, 
2004-2006
Sources: US State Dept., 2007 International Narcotics Control
Strategy Report and UNODC, Annual Reports Questionnaire
Data.
Fig. 74: Regional breakdown of global cannabis 
herb production in 2004 and in 2005
Sources: UNODC, Annual Reports Questionnaire Data and Govt.
reports
7 No official Mexican cannabis production estimates exist. The first estimate is based on INCSR cultivation estimates and a yield figure of 800
kg/ha, provided to UNODC by the Mexican authorities; the second figure reflects the US INCSR estimate for cannabis production in the year
2005. (US State Department, International Narcotics Control Strategy Report, March 2007). 
8 The DEA (US Drug Enforcement Agency) ratio of 1 pound (448 grams) per plant has been widely used in the USA. In contrast, the United States
Sentencing Commission has identified a 100 grams a plant figure to be more appropriate when looking at mixed gender crops. “The one plant =
100 grams of marijuana equivalency used by the Commission for offenses involving fewer than 50 marihuana plants was selected as a reasonable
approximation of the actual yield of marihuana plants taking into account (1) studies reporting the actual yield of marijuana plants ... (2) that all
plants regardless of size are counted for guideline purposes (while, in actuality, not all plants will produce useable marijuana) ...; and (3) that male
plants, which are counted for guideline purposes, are frequently culled because they do not produce the same quality of marijuana as do female
plants.” Federal Register 60 (May 10, 1995): 25078. This figure was extended to all crops, including those involving more than 50 plants. See also
United States Sentencing Commission, 1995 Annual Report, p. 148. USSG SS 1B1.10, 2D1.1(c)(E) (Nov. 1995). DEA and the National Drug
Intelligence Center of the US Department of Justice, however, continue using a yield figure of 1 pound per plant. (U.S. Department of Justice,
National Drug Intelligence Center, Domestic Cannabis Cultivation Assessment 2007.)
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Rising levels of eradication in the USA have been inter-
preted by some analysts as an indication of growing
levels of cannabis cultivation9. There has been an
increase in indoor cultivation, with the proportion of
eradicated indoor cannabis rising from 4.7 per cent in
2005 to 6.4 per cent of all eradicated cannabis in 2006.
Taking only the data from the DEA’s Domestic
Cannabis Eradication/Suppression (DCE/SP) Program,
the proportion of indoor cultivation rose from 6.4 per
cent in 2005 to 9 per cent in 2006. Moreover, the actual
identified locations where cannabis is grown (and erad-
icated) suggest that cannabis cultivation has been
spreading to more remote areas, including national
parks. In fact, the DEA’s DCE/SP program has forced
many traffickers to abandon large outdoor marijuana
plots in favour of smaller, better concealed illicit gar-
dens10. Rapidly rising levels of eradication thus may
have contributed to a stabilization, or even a reduction,
in overall US cannabis production. While US seizure
data for the 2002-2005 period point to a stabilization,
US demand data indicate a reduction. Published US
cannabis production estimates also point to a stabiliza-
tion or reduction. Estimates for the year 2002 suggested
that cannabis herb production ranged from 5,580 to
16,730 mt11 with a mid-range estimate of 11,150 mt.
After deducting eradication, this would leave net pro-
duction of close to 10,000 mt. The 2006 estimates
ranged from 5,650 to 9,420 mt with a mid range esti-
mate of some 7,530 mt. Estimates of net production
(after eradication) ranged from 2,830 to 6,590 mt12
with a mid-range estimate of 4,710 mt. 
In 2005, following several years of strong increases, the
US authorities also reported slightly less trafficking of
cannabis via Canada into the USA.13 This could indi-
cate that cannabis production stabilized, or even
declined slightly, in Canada, following large production
increases in previous years: between 2000 and 2004 pro-
duction in Canada more than doubled14. The Royal
Canadian Mounted Police estimate a marijuana produc-
tion of 800 to 2,000 mt15. Other estimates see the level
of cannabis herb production at between 960 and 2,400
mt in Canada.16 All of these estimates suggest that while
Table. 10: Number of cannabis plants eradicated in the USA, 2000 -2006
9 U.S. Department of Justice, National Drug Intelligence Center, Domestic Cannabis Cultivation Assessment 2007.
10
ONDCP, National Drug Control Strategy, Feb. 2007. 
11
Drug Availability Steering Committee, Drug Availability Estimates in the United States, December 2002 and Office on National Drug Control 
Policy, National Drug Control Strategy, Feb. 2003. 
12
U.S. Department of Justice, National Drug Intelligence Center, Domestic Cannabis Cultivation Assessment 2007.
13
The total marijuana seizures in the northern border states of the USA increased from 13.6  mt in 2002 to 31.4  mt in 2004 but then declined 
again to 26.4 mt in 2005. See National Drug Intelligence Centre, 2007 National Drug Threat Assessment, Oct. 2006
14
According to Government of Canada estimates, cited by the US Drug Intelligence Centre, production in Canada more than doubled from 2000 
through 2004 (National Drug Intelligence Centre, 2007 National Drug Threat Assessment, Oct. 2006).
15
There estimates were, inter alia, based on seizures of, on average, 1.1 million cannabis plants per year; see Royal Canadian Mounted Police, Drug
Situation in Canada in 2003, Ottawa, July 2004; see also National Drug Intelligence Centre, National Drug Threat Assessment 2005, Feb. 
2005.
16
Public Safety Canada, Canada-United States Border Drug Threat Assessment, Oct. 2004. 
2000 2001 2002 2003 2004 2005 2006
Outdoora 2,597,798 3,068,632 3,128,800 3,427,923 2,996,225 3,938,151 4,083,433
Indoora 217,105 236,128 213,040 223,183 203,896 270,935 403,322
Total
a 2,814,903 3,304,740 3,341,840 3,651,106 3,200,121 4,209,086 4,486,755
Outdoorb - - - - - 5,546,509 5,901,800
Indoorb - - - - - 270,935 403,322
Total
b
- - - - - 5,817,444 6,305,202
Source: aDomestic Cannabis Eradication/Suppression Program.
Source: bDomestic Cannabis Eradication/Suppression Program & U.S. Department of the Interior & U.S. Department of Agriculture and
Forest Service.
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cannabis production in Canada is important it remains
significantly lower than in the USA or in Mexico.
Canada is, however, an important source country for
high THC cannabis consumed and trafficked into the
USA. Such cannabis production in Canada is controlled
by Asian crime groups (often ethnic Chinese and Viet-
namese). Some of these groups are thought to have re-
located their indoor activities into the US17Pacific
Northwest and to California18, in order to avoid tight-
ened border controls. 
Despite some increase of cannabis herb production in
South America (including Central America and the
Caribbean), the overall proportion of cannabis herb
production in the Americas declined from 54 per cent
to 47 per cent of global production in 2005. This pat-
tern of growing production in South America and
declining production in North America is inconsistent
with the long-term trend which shows strong increases
in the North American proportion of global produc-
tion.
Cannabis production in Africa appears to have declined
slightly in 2005. This is also in contrast to a long-term
trend which showed strong increases of cannabis pro-
duction in that continent. The current estimate suggests
that Africa accounts for 25 per cent of global cannabis
herb production in 2005, slightly down from 26 per
cent in 2004. The decline of cannabis cultivation in
Africa has been mainly due to reductions reported from
Morocco (though most of this cannabis is used for
cannabis resin production). The area under cannabis
cultivation in Morocco, as identified in joint UNODC
and Government of Morocco surveys (based on remote
sensing techniques), declined by 37 per cent on a year
earlier in 2005. This followed a decline of 10 per cent
in 2004. In addition, eradication efforts in Nigeria, one
of the main cannabis producing countries in Western
Africa, dramatically increased. After having eradicated
255 ha of cannabis in 2004, the Nigerian authorities
reported the eradication of 14,316 ha in 2005 - which
is close to half the size of the eradications reported from
Mexico. This downward trend is not uniform in Africa
with several other countries reporting increases. Overall
cannabis production in Africa is expected to resume its
expansionary trend shortly.
Cannabis production reported from Asia is increasing.
The proportion of Asia in global cannabis production
increased from 15 per cent in 2004 to 22 per cent in
2005, with a significant increase reported from
Afghanistan, where the area under cannabis cultivation
is partially surveyed as a part of UNODC’s annual
opium surveys. Results are based on farmers’ reports of
the areas cultivated. Most of the cannabis cultivation in
Afghanistan is produced as cannabis resin. 
Cannabis herb production also increased in Europe,
with Europe’s share in global cannabis herb production
rising from 3 per cent in 2004 to 5 per cent in 2006.
The increase in domestic production of cannabis herb in
Europe seems to have offset some of the decline of
cannabis resin imports from Morocco. Understanding
how this happened could yield some interesting and
important information on the cannabis market.
4.2.2 Cannabis resin production 
Geographically, the production of cannabis resin is far
more concentrated than production of cannabis herb.
The world’s largest cannabis resin producer continues to
be Morocco, supplying the illicit markets of North
Africa and Western Europe. Western Europe is the
world’s largest market for cannabis resin, accounting for
some 70  per cent of global resin seizures in 2005; North
Africa accounts for another 8 per cent. 
The importance of Morocco as a source country for
cannabis resin is, however, declining. In 2003, the year
of the first UNODC/Government of Morocco survey
total resin production amounted to 3,060 mt, cultivated
on 134,000 ha of land in the Rif region of northern
Morocco by some 96,600 families. The 2004 survey
showed a 10 per cent decline in land under cannabis
cultivation (120,500 ha), with an estimated production
of 2,760 mt.19 In 2005 cultivation declined further to
72,500 ha, and production fell to 1,066 mt20, reflecting
the intensified efforts of the Moroccan authorities to
eliminate cannabis production from their territory.
Cannabis resin production in Morocco is concentrated
in the provinces of Chefchaouen (56 % of total in
2005), Taunate (17 %) and Al Hoceima (16 %). 
17 U.S. Department of Justice, National Drug Intelligence Center, Domestic Cannabis Cultivation Assessment 2007, Oct. 2006 and ONDCP, 
National Drug Control Strategy, Feb. 2007. 
18 U.S. State Department, 2007 International Narcotics Control Strategy Report, March 2007.
19 Some of the decline appears to have been a consequence of an earthquake, resulting in increased attention being given by the national authorities
and the international community to the region concerned.
20 UNODC, Morocco Cannabis Survey 2005, Executive Summary 2005, June 2005. 
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The decline of the importance of Morocco is also
reflected in the number of countries citing Morocco as
the source country of the cannabis resin found on their
markets. Over the 1999-200321 period 31 per cent of
countries reporting the origin of cannabis resin cited
Morocco as the origin of the hashish found on their
markets. By 2005, the proportion of Morocco (includ-
ing the subsequent transit countries, Spain and Portu-
gal) fell to 20 per cent, reflecting the massive decline of
Moroccan cannabis resin production in recent years. 
Reports of country of origin are based on the informa-
tion from 40 countries responding to this part of the
Annual Reports Questionnaire in 2005. In order to
expand the information base for the analysis of the
importance of less frequently mentioned producer
countries, the time period was increased to the 2003-05
period. This raised the information base to a sample of
61 countries (equivalent to almost a third of all coun-
tries). Considering the broader 2003-2005 period, 27
per cent22 of countries cited Morocco as the main source
country of the cannabis resin encountered on their
domestic market. 
The next most frequently mentioned countries were
Afghanistan/Pakistan, accounting for 8 per cent of such
mentions. Overwhelmingly, cannabis cultivation in
these countries is for the production of cannabis resin.
UNODC’s estimates suggest that the area under
cannabis cultivation in Afghanistan increased from
30,000 ha in 2004/05 to 50,000 ha in 2005/06 - equiv-
alent to 30 per cent the area under opium poppy culti-
vation.23
The next most frequently mentioned source countries
for cannabis resin are Nepal/India (mentioned by 7 per
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Fig. 77: Area under cannabis cultivation in 
Afghanistan* and Morocco, 2004-2005
* data for Afghanistan refer to 2004/05 and 2005/06
Sources: UNODC, 2006 Afghanistan Opium Survey (and previous
years) and UNODC/Government of Morocco, Maroc, Cannabis
Survey 2005, Jan. 2007. 
Fig. 76: Morocco – cannabis cultivation and production, 2003-2005
cultivation
134000
120,500
72,500
0
20,000
40,000
60,000
80,000
100,000
120,000
140,000
2003 2004 2005
H
ec
ta
re
s
21 UNODC, 2005 World Drug Report, Volume I. 
22
Over the 2003-05 period, Morocco was mentioned 48 times as a source country for cannabis resin in replies by member states to UNODC’s 
ARQ. Including Spain and Portugal, which are mainly transit countries of Moroccan hashish, the number of mentions 
increases to 70. The total number of all mentions of source countries (by the 61 reporting countries) amounted to 257. (Countries can mention 
more than one country as a source country). The proportion of Morocco (including the mentions of Spain and Portugal) was thus 27.2 per cent 
in all mentions.
23 UNODC, Afghanistan Opium Survey 2006, October 2006. 
Source: UNODC/Government of Morocco, Maroc, Cannabis Survey 2005, Jan. 2007 and previous years.
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cent of the countries) and the Central Asian and other
C.I.S. countries (5%), reflecting large areas of cannabis
in Kazakhstan (mainly wild cannabis) and Kyrgyzstan.
Significant levels cannabis production exist in the Chuy
valley and around the Lake Issyk-Kul in Kyrgyzystan
and in Zhambyl province of Kazakhstan bordering Kyr-
gyzstan. Both cannabis herb and resin are produced in
these areas. 
The Netherlands is also frequently mentioned as a
country of origin (5% of global mentions). It is, how-
ever, not clear to what extent the cannabis resin actually
originates in the Netherlands and to what extent it is
smuggled into the country (from Morocco and other
countries) for subsequent re-export. Though the
Netherlands is an important producer of cannabis herb,
other information suggests that resin production is lim-
ited. Similarly, the situation for Albania is not straight-
forward. This country is also frequently mentioned as a
cannabis resin source country (5% of all mentions,
mainly from neighbouring countries). What seems to be
clear, however, is that Albania’s role as a cannabis herb
producer clearly exceeds its role as cannabis resin pro-
ducer. 
The most important cannabis resin producer in the
Americas continues to be Jamaica (3% of global men-
tions), followed by Paraguay. Overall, production (and
consumption) of cannabis resin in the Americas remains
limited.
The most important cannabis resin producer in the
Near East remains Lebanon (2% of global mentions).
Following successful eradication campaigns, production
in Lebanon is drastically down as compared to the early
1990s.  Production of cannabis resin in Lebanon is con-
centrated in the Bekaa valley. 
Global cannabis resin production estimated at around
6,600 mt 
Tentative estimates24 suggest that some 6,600 mt of
cannabis resin were produced in 2005 (range: 3,800-
9,500). The previous year’s estimate, based on the same
methodology, resulted in an estimate of some 7,500 mt
(range: 4,200-10,700), indicating that, following years
of increases, global cannabis resin production actually
declined in 2005. The decline was largely due to the
lower cannabis resin production reported from
Morocco. A production of some 6,600 mt of cannabis
resin results in a calculated cannabis resin interception
rate of close to 20 per cent. 
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Fig. 78: Main source countries of cannabis resin, 
2003-2005 (based on information from 61 
countries)
number of times countries were identified as source countries as
a proportion of countries reporting
Source: UNODC, Annual Reports Questionnaire Data. 
24 Which are based on extrapolating the results from Moroccan cannabis resin production data and extrapolating global resin production from herb 
production estimates with the help of seizure statistics
Fig. 79: Global cannabis resin production estimates,
2002/03 – 2005
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Table 11: Tentative estimates of global cannabis resin production, 2005
1. Estimate based on Moroccan cannabis resin production 2005 and seizures 
Seizures in tons
(2005)
Estimated pro-
portion of
seizures related
to cannabis resin
originating in
Morocco
Estimated pro-
portion from
2005 harvest
Potential seizures
in tons related to
Moroccan
cannabis resin
production in
2005
Cannabis resin
production esti-
mates
West & Central Europe 912.8 70% 50% 319.5 -
North Africa 109.1 90% 50% 49.1 -
Seizures related to Moroccan
cannabis resin
- - - 368.6 -
Other seizures - - - 930.5 -
Global seizures - - - 1,299.1 -
in % - - - 28% -
Cannabis resin production in Morocco (2005) in tons 1,070
Global cannabis resin production estimate I 3,771
2. Estimate based on cannabis herb production estimates and seizures
Cannabis herb Cannabis resin Proportion
Cannabis resin
production esti-
mates
Seizures in tons (2005) 4,472 1,299 23%
Global cannabis production
estimate II
42,000 23% 9,455
3. Combined estimate 6,613
Rounded 6,600    
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Seizures of both cannabis herb and resin decline in
2005
Cannabis products remained the most widely trafficked
drugs worldwide in 2005, accounting for 57 per cent of
all global seizure cases (856,000 out of 1.5 million).
Practically all countries in the world are affected by
cannabis trafficking. Out of 165 countries and territo-
ries which reported seizures to UNODC, 99 per cent
reported seizures of cannabis.  
Cannabis herb seizures amounted to 4,600 mt and
cannabis resin seizures to 1,300 mt in 2005.  Small
quantities of cannabis oil (700 litres) were also seized.
Seizures of all three products declined in 2005 as com-
pared to a year earlier, thus reversing the upward trend
observed until 2004.  Herb seizures dropped by 35 per
cent, resin seizures by 11 per cent and cannabis oil
seizures by 15 per cent.   While changes in law enforce-
ment priorities in some countries may have played a
role, for the majority of countries lower seizures meant
less trafficking as compared to the previous year. Taken
together, cannabis herb and resin seizures are now back
to the levels reported over the 2000-2002 period. 
Most cannabis herb seizures in 2005 were reported from
Mexico (38% of the world total), followed by the
United States (24%), South Africa (6%), Brazil (3%),
Tanzania (3%) and India (3%). 
Most seizures of cannabis resin were made by Spain
(51%), followed by Pakistan and Morocco (7% each),
France (6%), Iran (5%), the UK (5% in 2004) and
Afghanistan (3%).
Most cannabis oil seizures were made in the Russian
Federation (34%) and the Ukraine (10%), followed by
Canada (7%) and Morocco ( 5%).  
Cannabis herb remains by far the most widely traf-
ficked drug
Despite of the strong decline in global seizures (-35%),
cannabis herb remains the most widely trafficked sub-
stance in terms of volume and geographic spread.
Ninety per cent of all countries reporting seizures (148
out of 165 countries) seized some cannabis herb.  In
contrast to other drugs, trafficking in cannabis herb is
primarily intra-regional, not inter-regional. Exceptions
to this are cannabis herb exports: from Africa (mainly
western and southern Africa) to West and Central
Europe; from South-East Asia (mainly Thailand) and
South-West Asia (mainly Pakistan) to Europe (mainly
the Netherlands);  from Central Asia to East Europe
(notably the Russian Federation); and from South
America (mostly Colombia) to North America (mainly
the USA).     
Close to two thirds of global cannabis herb seizures were
made in North America (64%) in 2005, notably by the
authorities of Mexico (1,781 mt) and the United States
(1,112 mt). This reflects the magnitude of the North
American cannabis market, both in terms size and of
enforcement effort.   
The next largest cannabis herb seizures were made in
Africa, accounting for 18 per cent of global seizures. The
largest seizures here were reported by South Africa (292
mt), Tanzania (150 mt) and Nigeria (126 mt).
South America, including the Caribbean and Central
America, accounted for 11 per cent of global cannabis
herb seizures. The main seizures in this region were
reported by Brazil (152 mt), Colombia (129 mt) and
Paraguay (67 mt).  
Cannabis herb seizures made in Asia accounted for 5 per
1.4.3 Trafficking
Fig. 80: Cannabis seizures, 1985-2005
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cent of the world total. The largest seizures here were
reported by India (147 mt), Indonesia (23 mt) and
Kazakhstan (22 mt). 
Europe’s cannabis herb seizures were equivalent to 2 per
cent of the world total. The largest seizures were made
by the Russian Federation (30 mt) and the UK (21 mt)1.
Europe is the only region which also ‘imports’ signifi-
cant amounts of cannabis from other regions. 
The overall decline of cannabis herb seizures in 2005 (-
35%) meant that they were at their lowest level since
1999.  A decline in cannabis herb seizures was reported
from several regions: Oceania (-6%), North America (-
11%), Europe (-39%) and Africa (-71%).  Seizures were
reported to be increasing, however, by countries of
South America (+4%) and Asia (+9%).  
Trafficking in cannabis resin 
Global cannabis resin seizures decline, notably in West
and Central Europe 
In terms of quantities seized (1300 mt in 2005),
cannabis resin is the second most widely trafficked drug
worldwide, after cannabis herb. Resin seizures were
reported in 104 countries in 2005, which is 63 per cent
of all countries reporting seizures to UNODC.  The
geographical scope of cannabis resin trafficking is thus
more limited than for herb trafficking. 
In contrast to herb, trafficking in resin is not intra-
regional but, significantly inter-regional. This applies, in
particular, to trafficking of resin from North Africa
(Morocco) to West and Central Europe, from Central
Asia to East Europe (notably the Russian Federation)
and from the Caribbean (notably Jamaica) to North
America (notably Canada).   
Global cannabis resin seizures declined by 11 per cent
in 2005. Most of the decline, in absolute terms, was due
to lower seizures reported by countries of West & Cen-
tral Europe (-15%). This was linked to the decline of
cannabis resin production in Morocco in 2004 and
2005. Data on individual seizures collected by the
World Customs Organization (WCO)2 in West Europe
show that resin seizures declined by a further 30 per cent
in 2006.  Most of the decline, in both 2005 and 2006,
was reported from Spain and France. 
In 2005 Cannabis resin seizures made in North Africa
increased slightly on a year earlier (+6%), but were still
5 per cent lower than in 2003 and 25 per cent lower
than in 2000. For 2006, WCO data on individual
seizures3 suggest that resin seizures declined by 18 per
cent.
Fig. 81: Distribution of global cannabis herb seizures
in 2005 (N=4,644 metric tons)
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Fig. 82: Regional breakdown of cannabis herb 
seizures, 1985-2005
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1 Data for 2004; no UK seizure data for the year 2005 are available as yet.xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
2 World Customs Organization, Individual Drug Seizure Database, 27 April 2007.  
3 World Customs Organization, Individual Drug Seizure Database, 27 April 2007.  
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Fig. 83: Global seizures of cannabis herb, 1995 - 2005
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Fig. 84: Global seizures of cannabis herb, 1995 - 2005
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Seizures also declined in the Near & Middle East /
South-West Asia sub-region (-16% in 2005). In con-
trast, there was an almost tenfold increase of cannabis
resin seizures in the Americas (notably in the
Caribbean). But, as a whole, the Americas still account
for less than 1 per cent of world resin seizures. 
… but West and Central Europe remains the largest
cannabis resin market
The world’s largest cannabis resin market continues to
be West and Central Europe, with the bulk of global
seizures (71%) made there. Spain accounts for 73 per
cent of all European cannabis resin seizures, ahead of
France (9%), the UK (7% in 2004),  Portugal (3%) and
Italy (2½ %). Spain plays a key role in limiting the
supply of cannabis resin for the European market.   
The next largest resin seizures were made in the Near &
Middle East / South-West Asia region (18% of the
world total). The largest seizures here were reported by
Pakistan (40% of all Asian cannabis resin seizures), fol-
lowed by Iran (30%) and Afghanistan (18%). The Near
East (defined as the Arabian peninsula, Lebanon, Syria,
Jordan, Israel and Iraq) accounted for 10 per cent of
cannabis resin seizures made in Asia; the remaining 2
per cent were made in other parts of Asia.   
North Africa accounted for 8 per cent of global seizures.
Including other parts of Africa, total cannabis resin
seizures in Africa add up to 10 per cent of the world
total. The largest seizures here were reported by
Morocco, accounting for 67 per cent of all African
cannabis resin seizures or 85 per cent of all cannabis
resin seizures made in North Africa in 2005.   
Fig. 87: Regional breakdown of cannabis resin 
seizures, 1985-2005
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Fig. 86: Distribution of global cannabis resin seizures  in 2005 (N = 1,302 metric tons)
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Fig. 88: Global seizures of cannabis resin, 1995 - 2005
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Fig. 89: Global seizures of cannabis resin, 1995 - 2005
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Cannabis remains the most widely used drug world-
wide ...
Cannabis remains by far the most commonly used drug
in the world. Almost 160 million people used cannabis
in 2005, equivalent to 3.8 per cent of the global popu-
lation aged 15 to 64. 
In relative terms, cannabis use is most prevalent in
Oceania (15.8%), followed by North America (10.7%),
Africa (7.7%) and West and Central Europe (7.4%).
The highest rates within Africa are found in West and
Central Africa (13%) and in southern Africa (8.5%).
Asia has the lowest prevalence rates (1.9%), reflecting
low levels reported from East and South-East Asia
(0.9%). For South Asia, estimates show an average
prevalence rate of 3.2 per cent; for the Near and Middle
East region 3.5 per cent and for Central Asia 4.2 per
cent, i.e. all regions in Asia, except for East-South-East
Asia, are close to the global average.  
No. of users in % of population 15-64 years 
EUROPE 30,500,000 5.6
West & Central Europe 23,400,000 7.4
South-East Europe 1,700,000 2.0
Eastern Europe 5,400,000 3.8
AMERICAS 37,600,000 6.5
North America 30,900,000 10.7
South America 6,700,000 2.3
ASIA 49,100,000 1.9
OCEANIA 3,400,000 15.8
AFRICA 38,200,000 7.7
GLOBAL 158,800,000 3.8
1.4.4 Abuse
Fig. 90: Cannabis consumption in 2005 – regional 
breakdown (N = 158.8 million)
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24%
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Sources: UNODC, Annual Reports Questionnaire Data, UNODC
Field Offices,  UNODC Drug Abuse Information Network for Asia
and the Pacific (DAINAP), UNODC Global Assessment
Programme on Drug Abuse (GAP), Govt. reports, EMCDDA,
CICAD, HONLEA reports, local studies, UNODC estimates.
Fig. 12: Annual prevalence of cannabis use, 2005 or latest year available   
Sources: UNODC, Annual Reports Questionnaire Data, UNODC Field Offices, UNODC Drug Abuse Information Network for Asia and the
Pacific (DAINAP), UNODC Global Assessment Programme on Drug Abuse (GAP), Govt. reports, EMCDDA, CICAD, HONLEA reports,
local studies,  UNODC estimates.
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In absolute terms, 49 million cannabis users, almost a
third of the estimated total, live in Asia.  Africa, with 38
million and the Americas, also with 38 million, each
account for a about a quarter of global cannabis use.
Europe, with about 30 million users, accounts for a fifth
of global cannabis use and Oceania for 2 per cent.  
… but the recent trend is difficult to measure
After years of increases, this year’s cannabis use estimates
of 159 million people are slightly lower than those pub-
lished in last year’s World Drug Report (162 million). It
would be premature, however, to categorize this as a
downward trend.  Some of the lower figures come from
a few new household surveys.  They replace previous
UNODC estimates which were slightly higher.  At the
same time, the new survey results did not, in general,
show a further growth in cannabis use. There thus
appears to be a general stabilization in cannabis use. 
In contrast to this, the trend indicator, which shows the
perceptions of experts and officials in Member States,
suggests that cannabis use continued to grow in 2005.
It is difficult to evaluate the accuracy of these percep-
tions.  It can be argued that it is harder to report against
a long-standing and generally accepted trend – in this
case the trend of virtually universal increases in cannabis
use over the last decade.  Such perceptions do not
change easily, even when new data, for instance from
household surveys, would appear to indicate an improv-
ing situation.  There could be thus some bias towards
reporting an ongoing increase in cannabis use, and this
has to be taken into account when interpreting the per-
ception trend indicator for cannabis.  
The general rise in the cannabis trend indicator was due
to increasing cannabis use perceived by the authorities
in most of Africa, several parts of Asia  (South-Asia,
South-West Asia and Central Asia) and most of South
America.  This more than offset declines perceived in
North America and some European countries, as well as
the stabilization or declines perceived in several coun-
tries of East and South-East Asia.  Trend data for Ocea-
nia suggest stabilization at lower levels, after cannabis
use had fallen for several years, though there are some
indications that the downward trend in the region actu-
ally continued. Cannabis use trends in Europe showed
a mixed picture, with increases perceived in East and
South-East Europe and stabilization or decline reported
from several West European countries. 
Over the 1992 to 2005 period, the cannabis trend indi-
cator shows that the rates of increase were similar in the
Americas, in Europe and in Africa.  Over time, however,
the patterns differed. Following increases in the Ameri-
cas in the 1990s, the trend stabilized and a net decline
Fig. 91: Cannabis use trends as perceived by 
experts: regional contribution to global 
change, 1992 - 2005
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Fig. 92: Cannabis use trends as perceived by experts
-  regional changes, 1992-2005
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was reported for 2005. Europe and Africa showed an
upward trend throughout the period with Africa show-
ing higher growth rates in recent years. For Asia, the
indicator shows, in contrast, lower than average
increases. This was due to an apparent decline in the
popularity of cannabis in the late 1990s. In the new mil-
lennium this changed and Asia, together with Africa,
showed some of the strongest increases in recent years.
Starting from high levels, Oceania showed higher than
average increases in the 1990s, but a clear downward
trend thereafter. Oceania is thus the only region in the
world where the cannabis consumption fell back to
levels reported in the early 1990s. 
Cannabis use continues declining in North America 
Cannabis use among 12th graders in the USA declined
by 18 per cent between 1997 and 2006 and is signifi-
cantly lower than three decades ago  (-29%).  As com-
pared to the peak in 1979, annual prevalence data for
12th graders show a decline of 38 per cent.  
A strong decline in cannabis use was also reported
among high-school students in Ontario (-19% over the
2003-2005 period). The previous upward trend was
thus reversed. 
A decline was also noticed for cannabis use among the
general population. General population household
survey data show that cannabis use in the USA declined
from 11 per cent in 2002 to 10.4 per cent in 20051.  As
compared to the peak in 1979 (16.6%)2, cannabis use is
37 per cent lower. 
Declines in cannabis use were also reported from
Mexico for the year 2005. 
… but increases in South America 
A clear increase in cannabis use was reported from coun-
tries in South America. Seven countries reported rising
use in 2005 and only one country reported a decline.
Nine countries described the situation as stable.  The
rate of increase thus appears to have declined: a year ear-
lier 11 countries reported rising levels of cannabis use.  
The most important increase – though starting from
very low levels – was reported from the continent’s
largest country, Brazil.  This probably reflects increased
availability of cannabis products from neighbouring
Paraguay. The annual prevalence of cannabis use
increased from 1 per cent in 2001 to 2.6 per cent in
20053.
… and shows a mixed picture in Europe with stabiliza-
tion/decline in the main  West European markets 
The majority of countries of West and Central Europe
(14) reported cannabis use has stabilized. Nonetheless,
1 SAMHSA, 2005 National Survey on Drug Use & Health,  Rockville MD, Sept. 2006. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
2 Data quoted in SAMHSA, Preliminary Results from the 1996 Household Survey on Drug Abuse, August 1997. 
3 CEBRID,  Il Levantamento Domiciliar sobre o Use de Drogas Psicotrópicas no Basil: Estudo Envolvendo as 107 Maiores Cidades do País, Sao
Paolo 2002; CEBRID, Il Levantamento Domiciliar sobre o Uso de Drogas Psicotrópicas no Basil: Estudo Envolvendo as 108 Maiores Cidades do
Pais,  Sao Paolo 2006. 
Fig. 93: Annual prevalence among high-school students in the USA and in Ontario, Canada, 1975-2006
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the number of countries reporting increases (11) was
still nearly double those reporting declines (6). 
In Europe’s main cannabis markets, however, cannabis
has now either stabilized or started to decline. Growing
awareness of the negative effects of the high THC
cannabis found in many European markets seems to
have contributed to this stabilization/decline. 
The authorities in Spain, one of Europe’s largest
cannabis markets, still reported some increase in
cannabis use for the year 20054. This perception, how-
ever, may be too pessimistic. Household survey data
actually indicate stabilization of the market from 2003
to 2005 (11.3% in 2003 and 11.2% in 2005), follow-
ing strong growth over the 1999-2003 period.  The sta-
bilization went in parallel with a growing awareness of
the dangers of cannabis use among young people in
Spain.5
Authorities in France reported a stabilization of
cannabis use. Analysis of national household surveys in
4 UNODC, Annual Reports Questionnaire Data for the year 2005 for Spain. XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
5 A study done by Eurobarometer among 15-24 year olds in Spain found the perception that occasional use of cannabis was harmless falling from 44
per cent in 2002 to 31 per in cent in 2004. European Commission, Eurobarometer, Young people and drugs, Brussels, June 2004). 
Fig. 94: Spain: annual prevalence of cannabis use 
among the general population (age 15-64), 
1995-2005
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Fig. 96: France: annual prevalence of cannabis use 
among the general population (age 15-64), 
1992-2005
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Fig. 95: England & Wales: annual prevalence of cannabis use among the general population (age 16-59) and
among youth (16-24), 1996 - 2006
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the country suggests, however, that cannabis use
declined. Annual prevalence fell from 9.8 per cent in
2002 to 8.6 per cent in 2005 and is almost back to the
levels reported at the beginning of the new millennium.
The decline in France also went in parallel with a grow-
ing awareness of the dangers of cannabis use among
young people.6
For the United Kingdom, which was Europe’s largest
cannabis market for many years, cannabis use is now
showing a downward trend.  Use among the general
population (age 16-59) declined in England and Wales
from 10.8 per cent in 2003/04 to 8.7 per cent in
2005/06.  Including data from Scotland and Northern
Ireland, the UK has now a prevalence rate of 8.4 per
cent and thus ranks behind Spain and France. 
The downward trend among young people in England
and Wales appears to have started shortly after 1998, as
the UK drug prevention budget was expanded and a
number of new activities targeting youth became oper-
ational. The trend then became more pronounced in the
new millennium, probably because extensive discussion
about re-scheduling cannabis brought new scientific
findings on the potential harm of cannabis into the
limelight.  Growing awareness of the dangers of
cannabis use among young people7 went in parallel with
declining cannabis use.   
Most of the stabilization or decline in Europe was in the
mature and saturated cannabis markets.  There have also
been some positive exceptions, notably among the
Nordic countries.  Data for Finland show stabilization
of cannabis use among the general population at a level
of 2.9 per cent between 2002 and 2004.  Similarly, in
Norway cannabis use remained de-facto unchanged in
recent years (4.5% in 1999, 4.6% in 2004).  Even
though Sweden already has among the lowest levels of
cannabis use in Europe, data show some declines. Life-
time prevalence of cannabis use among military recruits
(typically age 18), declined from 16.7 per cent in 2002
to 12.6 per cent in 2005. Annual prevalence of cannabis
use among the general population declined from 2.2 per
cent in 2004 to 2.0 per cent in 2005. 
Cannabis use shows an upward trend in Africa ... 
A total of 17 African countries reported rising levels of
cannabis use in 2005, and only 4 countries saw a
decline; a further 4 countries described the cannabis sit-
uation as stable. As compared to a year earlier, the
upward trend appears to have lost at least some of its
momentum. For 2004, 20 countries saw cannabis use
rising, only 3 reported a decline and 4 reported stabiliza-
tion.
…while the situation in Asia is more complex 
The cannabis trend indicator, weighted by the cannabis
using population, showed a clear upward trend for Asia
in 2005. In terms of the number of countries reporting
changes in cannabis use, however, the picture is more
complex. In fact, only 8 countries reported rising
cannabis use for 2005, while 12 reported a decline and
a further 12 saw their cannabis markets as stable. Data
from Thailand, one of the few countries in the region
which conducts regular household surveys, show that
the annual prevalence of cannabis use among the gen-
eral population (age 12-65) declined from 1.5 per cent
in 2001 to 0.9 per cent in 20068.  Several other coun-
tries in East and South-East Asia may well have similar
patterns.    
Fig. 97: Sweden: life-time prevalence of cannabis 
use among military recruits 
6 A study done by Eurobarometer among 15-24 year olds in France found the perception that occasional use of cannabis was harmless falling from
48 per cent in 2002 to 30 per in cent in 2004, the strongest decline observed in Europe.  (European Commission, Eurobarometer, Young people
and drugs, Brussels, June 2004.) 
7 While 47 per cent of youth (age 15-24) in the UK considered the occasional use of cannabis to be harmless in 2002, this proportion declined to
40 per cent by 2004. (European Commission, Eurobarometer, Young people and drugs, Brussels, June 2004.) 
8 UNODC (Regional Centre for East Asia and the Pacific), Amphetamine-type Stimulants in East Asia and the Pacific: Analysis of 2003 Regional ATS
Questionnaire, Bangkok 2004 and UNODC (Regional Centre for East Asia and the Pacific), Drug Abuse Information Network for Asia and the
Pacific (DAINAP), 2007. 
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… and a clear downward trend is observed in Oceania 
The Australian Household Survey data show that
cannabis use declined by some 37 per cent between
1998 and 2004 and use levels are now below those in
1993. Though changes in the methodology may, to
some extent, hinder direct comparison between 1998
and 2001, there is hardly any doubt that a significant
decline has occurred since the late 1990s. Student sur-
veys, conducted in regular intervals between 1996 and
2005, show an even stronger decline, from a monthly
prevalence rate of 18 per cent in 1996 to 7 per cent in
2005, which would indicate that school prevention pro-
grammes  have been working. While general population
data show that cannabis use is still marginally higher in
Australia than in the USA (10.6% in 2004), Australian
school survey data9 show that cannabis prevalence
among high-school students is lower than in the USA
(31.8% life-time and 13.9% monthly prevalence among
8-12th graders in the USA, 2005; 18% life-time and
7% monthly prevalence among secondary school stu-
dents aged 12-17 in Australia, 2005).  The opposite was
true a decade earlier. Though there are no definitive
explanations for the decline, it appears that, as in other
parts of the world, cannabis is beginning to loose some
of its benign image among young people.  
9 The Cancer Council Victoria, Report for Drug Strategy Branch, Dept of Health and Ageing, Government of Australia, Australian secondary
school students’ use of over-the-counter and illicit substances in 2005, June 2006
Fig. 98: Australia: annual prevalence of cannabis use
among the general population (age 14+), 
1998-2004
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There has been an overall stabilisation of the ATS market
with notable contractions seen on both the supply and the
demand sides. The market remains highly diversified (geo-
graphically and product-wise). It continues to be charac-
terised by youthful consumers, a comparatively inexpensive
final product, and low-overhead production which is fairly
close to the consumer. Some of these characteristics differ-
entiate it from the markets for opiates, cocaine and
cannabis. The ATS market’s heavy reliance on regulated
precursor chemicals also define its characteristics, as well as
its control. In the past this has been a vibrant, highly adap-
tive market. However, it appears that supply control and
demand reduction measures have been effective in sup-
pressing expansion.
The alarming increases in the production of ATS through-
out the 1990s seem to have levelled off over the last few
years. This is likely a result of recent efforts to monitor and
improve precursor control. 
The largest production areas for methamphetamine con-
tinue to be in South-East Asia, including Myanmar, China
and the Philippines, and in North America. Traditionally,
the majority of methamphetamine was produced in the
USA, with the precursor chemicals smuggled into this
country via Canada or Mexico. Improved controls in
Canada and further tightening of controls in the USA has
led to a decline in the number of clandestine laboratories
operating within the United States and a shift of produc-
tion across the border to Mexico. However, Mexico has
now also improved its precursor control regime, prompting
drug trafficking organizations to exploit other areas such as
Central America and possibly Africa. In the Republic of
South Africa, where methamphetamine is produced for the
domestic market, both production and consumption have
increased. The Oceania region, notably Australia and New
Zealand, continue to be important producers and con-
sumers of methamphetamine, but there are no indications
that these drugs are exported.
Amphetamine production continues to be primarily
located in Europe, notably in the Netherlands and Poland,
followed by the Baltic region and Belgium. Amphetamine
production also takes place in North America (notably in
the USA) and in South-East Asia. Ecstasy production also
continues to be largely concentrated in Europe, though the
expansion of ecstasy production, in recent years, has
mainly taken place outside Europe, notably in North
America and in East and South-East Asia. 
Global seizures of ATS are dominated by seizures of
methamphetamine. Over the 2000-2005 period, 49 per
cent of ATS seizures were in the form of methamphetamine,
15 per cent in the form of amphetamine, and 14 per cent
in the form of ecstasy; the rest (23 per cent) was not prop-
erly defined. The trend in recent years, however, has been
towards rising proportions of amphetamine and falling pro-
portions of methamphetamine, reflecting improved control
over the two main methamphetamine precursors, ephedrine
and pseudo-ephedrine. Taking amphetamine and metham-
phetamine together, about half of global seizures took place
in East & South-East Asia in 2005, about a fifth took place
in North America and another fifth in West and Central
Europe. This distribution is consistent with that of previous
years. In the case of ecstasy, 38 per cent of global seizures in
2005 took place in West and Central Europe, 27 per cent
in the Oceania region, 20 per cent in North America and 9
per cent in East and South-East Asia.
Global demand for amphetamines (methamphetamine and
amphetamine), which increased strongly in most parts of
the world in the 1990’s, is now showing signs of an overall
stabilisation. With close to 25 million people, the global
amphetamines consumer market is larger than the markets
for cocaine or heroin. Between 15-16 million of these per-
sons are thought to consume methamphetamine. Follow-
ing the expansion of the consumer market throughout the
1990’s, fuelled by rising demand in East and South-East
Asia, Europe and North America, there have been consis-
tent signs of slow down and stabilisation over the last few
years. 
A key element of this slowdown has been the downward
trend in amphetamines use in North America. Metham-
phetamine consumption among high school students in
the USA fell by more than 37 per cent over the 2002-2006
period. The rate was closer to 20 per cent for the rest of the
population. There has also been a clear stabilisation of
demand within Europe and Asia. Overall, 44 per cent of
reporting countries recorded a stabilization of ATS con-
sumption in 2005, up from 33 per cent in 2000, while the
proportion of countries experiencing an increase fell from
55 per cent in 2000 to 45 per cent in 2005; 11 per cent of
countries reported a decline in ATS use. 
1.5 Amphetamine-type stimulants
1.5.1 Summary trend / overview
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Global ATS production stabilizes at less than 500 mt
World ATS production appears to have stabilized at
some 480 mt in 20051. Total ATS production in 2005
(rounded figures) was composed of 110 mt of ecstasy
and 370 mt of ‘amphetamines’ (including 290 mt of
methamphetamine and 80 mt of amphetamine). The
2005 estimates for both methamphetamine and ecstasy
are slightly lower than those for 2004 while the amphet-
amine estimate is higher. 
The ATS production estimates are based on three sub-
components: (i) seizures of ATS end products, (ii) seizures
of ATS precursors and (iii) estimates of ATS users. Using
the lowest and the highest estimates, actual ATS produc-
tion could have amounted to any value between 360 and
880 mt in 2005. Propagation of error calculations nar-
rows the range to between 410 and 560 mt.
Though the average production estimates for the years
2004 and 2005 are similar to those of previous years, the
potential margins of error have widened, notably for the
production of the amphetamines. This is a consequence
of the fact that precursor seizures increased drastically
while end-product seizures declined in 2004. The oppo-
site was true for 2005.
The wide margins of error associated with estimating
ATS production make trend analysis difficult. It is clear,
however, that following a strong increase of ATS pro-
duction in the 1990s, the situation appears to have sta-
bilized in the last few years. 
ATS production is concentrated in North America,
East & South-East Asia, Europe, Oceania and south-
ern Africa 
In recent years ATS production has been spreading in
geographical terms. Existing concentrations of produc-
tion have not been dispersed but new locations of pro-
duction have been identified. Production continues to
be concentrated in North America, East & South-East
Asia, Europe, Oceania as well as – and this is a recent
phenomenon - in South Africa. Most methampheta-
mine production continues to occur in North America
and in East & South-East Asia. Concentration patterns
have not changed for amphetamine, the production of
which mainly takes place in Europe. Similarly, most
ecstasy production takes place in Europe and in North
America, though production has increasingly also been
found in East and South-East Asia. 
Based on ‘Amphetamines’(methamphetamine, amphetamine) Ecstasy Total
Estimate Range Estimate Range Estimate Range
Consumption 308 246 – 369 125 112 – 139 433 358 – 508
Drug seizures 307 282 – 332 80 66 – 94 387 348 – 426
Precursor seizures 483 322 – 690 132 88 – 189 615 410 – 879
Average of all estimates 366 308 – 438* 113 95 – 132* 478 417 – 553*
Rounded estimates 370 310 – 440* 110 90 – 130* 480 410 – 560*
Table 13: Production estimates of amphetamine-type stimulants, 2005
* Ranges calculated on the basis of ‘propagation of error’ statistics. 
Maximum range of all results: 358 – 879 metric tons
Sources: UNODC estimates based on UNODC, Annual Reports Questionnaire Data / DELTA and INCB, 2006 Precursors, March 2007.
1.5.2 Production
1 Production of amphetamine-type stimulants (ATS) can only be estimated indirectly. A methodology to arrive at such estimates was first developed
in UNODC’s report Ecstasy and Amphetamines - A Global Survey 2003 and is described in more detail in the Methodology Section.
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Seizures of both laboratories and 
ATS precursors decline 
The seizure and dismantling of laboratories is one of the
key elements in the interdiction of ATS supply. In 2005,
over 95 percent of ATS laboratories dismantled world-
wide were producing methamphetamine. Labs produc-
ing amphetamine and ecstasy were negligible in
comparison. Methamphetamine production is highly
dispersed and it can be produced in sophisticated super-
labs as well as in kitchen-labs. These small, easily impro-
vised kitchen labs form the overwhelming proportion of
dismantled methamphetamine labs. The global number
of dismantled labs grew strongly, from some 550 in
1990 to a record high of 18,500 in 2004, and then fell
to 13,400 in 2005. In line with ATS production esti-
mates, the proportion of labs producing amphetamine
rose while the proportion of labs producing ecstasy and
methamphetamine fell. 
A similar pattern can be observed for seizures of ATS
precursors, which is another key element in curtailing
supply.2 Expressed in ATS weight equivalents, ATS pre-
cursor seizures rose from 5 mt in 1990 to a record high
of 323 mt in 2004. In 2005, they fell back to 54 mt.
About half of the seized ATS precursors could have been
used for the production of methamphetamine and a quar-
ter each for the production of amphetamine and ecstasy.
Global seizures of ATS precursors in 2005 included: 
• Ephedrine and pseudo-ephedrine, sufficient to
produce some 28 mt of methamphetamine;
• P-2-P sufficient to produce around 1.5 mt of
amphetamine, and phenyl acetic acid3 sufficient to
produce some 12 mt of amphetamine; 
• 3,4-MDP-2-P (also known as PMK) sufficient to
produce 10 mt of MDMA (ecstasy), piperonal
sufficient to produce 2 mt of MDMA; and small
quantities of safrole and isosafrole sufficient to
produce some 11 kg of MDMA.4
The strong decline of ATS precursor seizures in 2005 is
linked to successes in precursor control, which works by
preventing the diversion of chemicals into illicit manu-
facture. If suspicious precursor shipments are actually
suspended or stopped, the amount of seizures will obvi-
ously go down. For instance, as a part of project PRISM
(Precursors Required In Synthetic drug Manufacture), a
task force involving several countries and international
organizations, the International Narcotics Control
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Fig. 100: Production estimates of amphetamine-type stimulants
Sources: UNODC estimates based on UNODC, Annual Reports Questionnaire Data/DELTA, INCB, 2006 Precursors, March 2007, UNODC,
World Drug Report 2006 (and previous years) and UNODC, Ecstasy and Amphetamines – Global Survey 2003.
2 Precursor seizure data, unless cited otherwise, have been taken from International Narcotics Control Board (INCB), 2006 Precursors and chemicals
frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, New York 2007 (and previous years); hereafter cited as INCB,
2006 Precursors. 
3 P-2-P or 1-phenyl-2-propanone, also known as BMK, is typically used for the manufacture of amphetamine, but can be also used for
methamphetamine; phenyl acetic acid is a precursor for the production of P-2-P and thus a ‘pre-precursor’ for the manufacture of amphetamine.
4 Pipersonal, safrole and isosafrole are all ‘precursors’ for the production of 3,4-MDP-2-P and thus ‘pre-precursors’ for the manufacture of MDMA.
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Board (INCB), was informed of some 1,900 shipments
involving ephedrine and pseudo-ephedrine between
November 2004 and October 20055. Between Novem-
ber 2005 and October 2006, over 2,200 shipments of
ATS precursors were monitored. This resulted in 99
detailed investigations, including 40 cases involving 165
mt of ephedrine and pseudo-ephedrine that were inter-
dicted or suspended. 6
Precursor control is beginning to show results in
squeezing the supply of raw material to illicit ATS labs.
As a consequence, pre-precursors (such as ephedra-
extracts) are increasingly being trafficked. In addition,
new and rather unusual trafficking routes for precursor
chemicals have developed in order to circumvent
improved controls. The traffic in pseudo-ephedrine
from Asia via the Democratic Republic of the Congo to
North America7 is thought to be one such route.
Methamphetamine production goes down in the USA 
There are strong indications that domestic metham-
phetamine production in the USA has been falling.8
This is reflected in the declining number of seized
methamphetamine labs, from 17,199 in 2004 to 12,144
in 2005. Precursor control has also had a positive
impact. Pseudo-ephedrine seizures in North America
fell dramatically from a record 174.4 mt in 2004 to 0.6
mt in 2005. Ephedrine seizures also declined from 2.1
to 1.4 mt 9. Expressed in ATS equivalents, the precur-
sors seized in 2004 would have been sufficient to pro-
duce 118 mt of methamphetamine; those seized in 2005
would have been sufficient to produce only 1.3 mt.10
The USA also reduced the availability of over-the-
counter (OTC) pharmaceutical preparations containing
ATS precursors, notably pseudo-ephedrine. Similar con-
trols in Canada (since 2003) reduced the flow of OTC
preparations containing pseudo-ephedrine across the
border. These efforts squeezed out large numbers of
kitchen labs, and thus led to less US laboratory seizures
in 2005 - a trend which appears to have continued in
2006.
Nonetheless, labs in the USA still accounted for 95 per
cent of all dismantled methamphetamine labs world-
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Source: UNODC, Annual Reports Questionnaire Data / DELTA. 
5 INCB, 2006 Precursors.CB, 2006 Precursors, March 2007.CB, 2006 Precursors, March 2007.
6 ‘Role of Project PRISM in countering synthetic drugs and their precursors’, INCB presentation to the Conference “Europe-Asia Cooperation on
Synthetic Drugs and their Precursors”, Paris, 6-7 March 2007. These are substantial amounts. By comparison, total licit trade in ephedrine and
pseudo-ephedrine is estimated at around 530 mt and 1,200 mt respectively. [Source: INCB, 2005 Precursors]. The 165 mt of interdicted/suspended
shipments could have been used to produce 110 mt of methamphetamine. Were this to have ended up on the illicit market, it would have increased
global methamphetamine production by some 40 per cent. 
7 INCB, 2006 Precursors.
8 Office of National Drug Control Policy, Drug Facts – Methamphetamine; 
http://www.whitehousedrugpolicy.gov/drugfact/methamphetamine/index.html
9 INCB, 2006 Precursors.
10 Applying the higher production ratios used by the US authorities, reflecting higher levels of know-how and equipment than in many other parts of
the world, the decline would be from a potential production capacity of 159 mt of methamphetamine in 2004 to 1.8 mt in 2005.
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wide in 2005. Similarly, from 2004 to 2005, seizures of
ephedrine and pseudo-ephedrine in the USA accounted
for 76 per cent of global methamphetamine precursor
seizures. 
Methamphetamine production, which used to be con-
centrated in the west and the southwest, has now spread
across the USA, with clandestine methamphetamine
labs dismantled in all 50 states in 2005. The number of
super-labs11 dismantled has, however, been falling, from
244 in 2001 to 35 in 2005. A further decline is expected
for 2006. Most of the super-labs (30 out of 35) were
operating in California.12
Taking North America as a whole, the declines in the
USA were partly offset by rising production in a few
super-labs in Mexico. The number of methampheta-
mine laboratories dismantled in Mexico rose from 10 in
2002 to 18 in 2004 and 34 in 2005. Until recently
pseudo-ephedrine and ephedrine were fairly readily
available in the country. The Mexican authorities, how-
ever, have recently taken measures to counter the diver-
sion of the two chemicals. These efforts reduced the
import of ephedrine and pseudo-ephedrine by 40 per
cent in 2005 (to 133 mt), with a further reduction of
almost 50 per cent (to about 70 mt) expected for 2006.13
… remains a problem in East and South-East Asia …
Although the number of methamphetamine labs dis-
mantled in East and South-East Asia increased in 2005
to 49, it remains lower than the levels reached in 2001
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Fig. 102: Global seizures of ATS precursors, expressed in kilograms of ATS equivalents 
Source: UNODC calculations based on INCB, 2006 Precursors, March 2007. 
11 A super-lab is defined as a clandestine laboratory that is able to produce more than 5 kg of the substance in 24 hours (INCB, 2005 Precursors). 
12 National Drug Intelligence Centre, National Drug Threat Assessment 2007, Oct. 2006.
13 National Drug Intelligence Centre, National Drug Threat Assessment 2007, Oct. 2006; According to data collected by the INCB, the decline was
from 177.8 mt of pseudo-ephedrine in 2004 to 107.7 mt in 2005 and from 118 kg ephedrine in 2004 to 64 kg in 2005, which is also equivalent
to an overall decline of about 40 per cent.
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14 Presentation by Hiroto Yoshimura, Deputy Commissioner General of the National Police Agency of Japan, to the 50th Commission on Narcotic
Drugs, Vienna, March 12-16, 2007. 
15 This information was obtained from 10 reporting Asian countries over the 2003-2005 period.
16 Office of China National Narcotics Control Commission (NNCCC), The Current ATS Problem and Control Situation in the PRC, Sept. 20, 2006.
17 Zhao Wanpeng (Deputy Director of International Cooperation Division, Narcotics Control Bureau, Ministry of Public Security, People’s Republic
of China) “Measures Implemented in China for the prevention of Illicit Production of Synthetic Drugs and their Precursors”, Presentation at Con-
ference “Europe-Asia Cooperation on Synthetic Drugs and their Precursors”, Paris, 6-7 March 2007.
18 ibid.
(63) or in 1999 (64). Over the last decade, metham-
phetamine lab seizures have been reported in many coun-
tries throughout East and South East Asia. In order of
importance these are: China, Thailand, the Philippines,
Myanmar, Taiwan Province of China, the Republic of
Korea, Cambodia, Hong Kong SAR of China, Indone-
sia, Vietnam, and Malaysia. For the year 2005, the high-
est numbers of dismantled labs were reported from China
(37), the Philippines (7), and Myanmar (2), followed by
Indonesia, Hong Kong SAR of China and Vietnam
(tabletting machine).
The Democratic Republic of Korea also seems to man-
ufacture methamphetamine. The Japanese authorities
reported the dismantling of a North Korean trafficking
syndicate, in May 2006, which was apparently working
in close cooperation with Japanese criminal groups.
Over the 1997-2002 period, approximately 40 per cent
of all methamphetamine confiscated in large volume
seizures in Japan, was believed to have originated in
North Korea. This proportion has since declined signif-
icantly. According to Japanese authorities, since 2002,
more than half of seized methamphetamine may have
originated in China.14
One indirect measure of methamphetamine production
is to analyze the number of times a country is identified,
by the country making the seizure, as the origin of the
seized drug. This information is normally furnished in
the Annual Reports Questionnaire. Based on this
method,15 over the 2003-05 period the three largest
methamphetamine producers in the region seem to be
China, followed by Myanmar, the Philippines and ‘other
Asia’. This includes countries such as Indonesia, the Lao
PDR and India, mainly producing for the local market.
China reported dismantling 37 methamphetamine labs
in 2005, and 51 labs in the first half of 2006. A third of
the latter were in Guangdong province.16 Indeed, most
methamphetamine production in China seems to be
taking place in the two southeastern provinces of
Guangdong and Fujian. However, as controls in these
provinces tighten, clandestine production is now
spreading to many inland locations in provinces of cen-
tral, southern and northern China.17
Methamphetamine production in Myanmar is mostly
concentrated in the Shan State, which borders China
and Thailand, and is produced mainly for export to
those countries. Thailand reports that most of the
methamphetamine on its markets originates in Myan-
mar, and is trafficked across the border or via the Lao
PDR and Cambodia. This trafficking route is thought
to be growing. The strongest growth, however, is cur-
rently in methamphetamine destined for the Chinese
market. For 2006 the Chinese authorities reported that
55 per cent (up from a third in 2005) of all of their
methamphetamine seizures took place in Yunnan
province. This suggests that methamphetamine pro-
duced in Myanmar is increasingly penetrating the Chi-
nese market and partly offsetting the successes in
dismantling illicit labs.18
Methamphetamine produced in the Philippines sup-
plies both the domestic market and neighbouring coun-
tries. It has been concentrated for some time in the
Metro Manila area. Determined efforts to dismantle
clandestine labs led to a shortage of the drug and caused
* Number of times a country was identified by other Asian countries
as a source country for methamphetamine production over the
2003-05 period, expressed as a proportion of all such reports
obtained (N = 35) ‘Origin’ refers to the countries to which drug
shipments could be traced back.
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
20.0%
22.9%
31.4%
8.6%
17.1%
0% 10% 20% 30% 40%
Others
Other Asia
Philippines
Myanmar*
China
Fig. 104: Origina of methamphetamine as reported 
by Asian countries, 2003-2005
129
1. Trends in world drug markets Amphetamine-type stimulants market
prices to more than double in Manila in 2006.
Methamphetamine production is now increasingly
found in other provinces, including in the region of
Mindanao, which has been suffering from a local insur-
gency for years.19
A further, indirect indication of methamphetamine pro-
duction can be derived from the geographical location
of ephedrine and pseudo-ephedrine seizures. The largest
such seizures in Asia over the 2004-2005 period were
reported from China (which is also one of the main licit
producers of ephedrine and pseudo-ephedrine), fol-
lowed by the Philippines, Myanmar, Indonesia and
India (another major licit producer of ephedrine and
pseudo-ephedrine), and at far lower levels, Hong Kong
SAR of China and Thailand. Taken together, the Asian
countries accounted for 89 per cent of the world’s
ephedrine and pseudo-ephedrine seizures in 2005.20
… shows signs of stabilization in Oceania … 
Following several years of massive increase, there are
now the signs that domestic methamphetamine pro-
duction in Oceania could be stabilizing. Several indica-
tors from Australia point in this direction. A large
majority of Australian methamphetamine users
reported that availability had stabilized in 2005. For
2004/05, the Australian authorities dismantled 381
ATS labs, most of which were producing methamphet-
amine, up from 199 labs in 2000/01. Seizures of
ephedrine, pseudo-ephedrine and P-2-P all rose in
2005. Methamphetamine prices increased by some 70
per cent between 2000 and 2005.21 In 2006, monitor-
ing and control of the sale of pharmaceutical prepara-
tions containing pseudo-ephedrine were improved.
Amongst other measures, a computer system which per-
mits pharmacists to track the purchases of pseudo-
ephedrine products by their clients is now being
implemented across the country. First evaluations of
this system seem to suggest that it has contributed to a
reduction in domestic methamphetamine production.
Against this backdrop of stabilizing of domestic pro-
duction, it appears that attempts are being made to
import methamphetamine, including crystal-ice, from
South-East Asia, notably from China.22
… remains limited in Europe … 
Methamphetamine production in Europe continues to
be limited to a few countries. For 2005 only the Czech
Republic and the Republic of Moldova reported dis-
mantling methamphetamine labs. Over the last decade,
the Czech Republic, the Republic of Moldova and Slo-
vakia have reported lab seizures consistently. Occasional
lab seizures have been made in the Ukraine, Germany,
the UK, Lithuania and Bulgaria. There are some indi-
cations that methamphetamine production might be
taking place in the Russian Federation, though no lab
seizure has been reported.23
The total number of dismantled labs in Europe shows,
nonetheless, a clear upward trend, increasing from less
than 20 in 1995 to 127 in 2000 and 310 in 2005.
Because the majority of these are small kitchen labs, the
actual production of methamphetamine is still limited.
Although still tiny compared to amphetamine, the
amount of methamphetamine seized in Europe rose
more than four-fold between 2000 and 2005. 
Europe as a whole accounted for about 6 per cent of
global ephedrine seizures over the 2004-2005 period.
Listed in order of importance, the following European
countries reported seizures of methamphetamine pre-
cursors over the same period: the Czech Republic,
Greece, the Russian Federation, the UK, Bulgaria, Ger-
many, Iceland, Romania, Hungary, Slovakia, the
Ukraine, France, Norway and Latvia. In 2006,
EUROPOL noted increased export, transshipment and
diversion of ephedrine and pseudo-ephedrine to the
European Union.24
… and is developing into a problem in southern Africa 
Methamphetamine production is becoming a problem
in South Africa. This is also reflected in demand indica-
tors, notably in Cape Town. The number of dismantled
methamphetamine labs has been rising steadily, from
only 1 in 2002 to 4 in 2004 and 11 in 2005. Both
ephedrine and pseudo-ephedrine, mainly originating in
China, are now being seized in the country. Thus far
there are no indications that methamphetamine is pro-
duced for export. 
19 U.S. Department of State, 2007 International Narcotics Control Strategy Report, March 2007.
20 INCB, 2006 Precusors.
21 UNODC calculation, based on NDARC, Australian Drug Trend 2005, Findings from the Illicit Drug Reporting System (IDRS), NDARC Monograph
No. 59, Sydney 2006. Prices weighted by reported methamphetamine offences.
22 Australian Crime Commission (ACC), Illicit Drug Data Report 2004-2005, May 2006. 
23 The Russian Federation has only reported the seizure of amphetamine labs; many of these labs may, however, have produced methamphetamine.
The main ATS precursors seized in Russia is ephedrine. This would point towards the production of methamphetamine (or methcathinone, locally
known as ephedrone). In contrast, no seizures of P-2-P or of phenyl acetic acid, which could confirm the production of amphetamine in the coun-
try, were reported in recent years.
24 EUROPOL, “Production and Trafficking of Synthetic Drugs and Precursors”, The Hague, 1 March 2007.
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Global amphetamine production shows 
an upward trend 
Global amphetamine production appears to be rising.
The number of labs dismantled rose from 336 in 2000
to 499 in 2004 and 569 in 2005.25 Amphetamine
seizures rose four-fold between 2000 and 2005 and
more than doubled from 2004 to 2005. 
Most illicit amphetamine production continues to take
place in Europe, which had 80 per cent of the 187 labs
seized worldwide. Similarly, of a total of 24 countries
reporting the dismantling of amphetamine labs between
2000 and 2005 period, 18 were in Europe. In 2005, the
largest number of labs seized in Europe was reported
from the Russian Federation (108),26 followed by Poland
(20), the Netherlands (8), Belgium (6), Germany (6),
Lithuania (1) and Belarus (1). A year earlier, Bulgaria
(7), Spain (2), Estonia (1) and Norway (1) had also
reported the dismantling of amphetamine labs. 
In the Russian Federation, seizures of ephedrine sug-
gested that methamphetamine was the main ATS being
produced. According to EUROPOL, however, the pre-
cursor BMK (or P-2-P, normally used to produce
amphetamine) originating in Russia was identified in
the European Union in 2004. These precursors were
marked with 4-Tert-Butyl (the so-called TB-Factor) and
their origin could thus be identified. They were traf-
ficked from Russia via Latvia or Belarus, Lithuania,
Poland and Germany to amphetamine production facil-
ities in Belgium, the Netherlands and Poland. They
appear to have increasingly replaced BMK from
China.27 Given the apparent availability of BMK in
Russia, a significant number of the dismantled labs
could indeed have produced amphetamine for the
domestic market. There are no indications that amphet-
amine produced in Russia was exported. 
Apart from the Russian Federation, the largest numbers
of amphetamine labs dismantled over the 2000-2005
period were in Poland (91) and the Netherlands (60),
followed by Germany (18), Bulgaria (15), Belgium (14)
and the UK (12).
Outside Europe, the largest numbers of amphetamine
labs seized in 2005 were reported from South Africa
(28) and the USA (9). In previous years, lab seizures
were also reported from Canada (22 in 2000), Indone-
sia (6 in 2003), Mexico (1 in 2003) and Chile (1 in
2002). In addition, a number of amphetamine labs are
dismantled each year in Australia.   
As discussed above in the case of methamphetamine,
another indirect measure of production is the origin of
amphetamine seizures, as identified (“mentioned”) and
reported by Member States. Europe as a whole accounts
for 83 per cent of such mentions. On this basis, the
largest amphetamine production seems to take place in
25 These figures include reports from countries which were not in a position to differentiate types of ATS labs
26 As noted above, there are some indications that at least some of these laboratories may have actually produced methamphetamine.
27 EUROPOL, “Production and Trafficking of Synthetic Drugs and Precursors”, The Hague, 1 March 2007.
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the Netherlands (24% of mentions), followed by Poland
(15%) and Belgium (9%), followed by the Baltic region
(Lithuania and Estonia), the Balkan region (Serbia &
Montenegro, Bulgaria, Bosnia & Herzegovina) and
Germany. Comparing these results with those of previ-
ous years, it looks as though the importance of the
Netherlands, Belgium and Germany as amphetamine
producers has been declining, and production has been
shifting towards Eastern Europe.  
Seizures of amphetamine precursor parallel the pattern
mentioned above. Over the 2004-05 period most
amphetamine precursor seizures (P-2-P) took place in
the Netherlands (6,620 litres) and Poland (4,996 litres).
The next largest seizures were reported by Germany
(1,310 litres). Smaller quantities have been reported
from Estonia (27 litres), Ireland (26 litres), Lithuania
(24 litres), Belarus (18 litres) and Bulgaria (16 litres).
If the period under investigation is extended, impor-
tant P-2-P seizures were also reported from Belgium
(4000 litres in 2001) and the UK (120 litres in 2002).
Over the last five years the Netherlands reported the
largest P-2-P seizures in Europe annually; but these
seizures have been falling (from 18,238 litres in 2001
to 340 in 2005).
Global ecstasy production falls – reflecting declines in
Europe, the main production area  
The number of ecstasy labs dismantled fell by 40 per
cent in 2005 to just 52 labs, 20 per cent less than in
2000. Seizures of ecstasy precursors also fell by 40 per
cent in 2005. In parallel, global ecstasy seizures fell by
one third in 2005. All of this suggests that global ecstasy
production, after strong increases in the 1990s, is now
shrinking, primarily because of production falling in
Europe.28 Production in several other parts of the world,
in contrast, continues expanding. 
Over the 2000-2005 period (n = 379), 42 per cent of all
ecstasy labs were dismantled in Europe, 41 per cent in
the Americas, 8 per cent in Asia, 7 per cent in Oceania
and 2 per cent in Africa. Since 2003, more labs have
been dismantled in the Americas than in Europe, and
ecstasy for domestic consumption in North America is
increasingly being produced locally. Most US ecstasy
seizures now take place along the Canadian border. The
proportion of ecstasy smuggled out of Europe (tradi-
tionally from the Netherlands) to the USA, has declined
in recent years. In parallel, there are also reports of
increasing production of ecstasy in South-East Asia.  
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28 The falling trend in Europe has been also identified by EUROPOL, “Production and Trafficking of Synthetic Drugs and Precursors”, The Hague,
1 March 2007. 
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The largest numbers of ecstasy labs dismantled in 2005
were reported from Canada (19) and the USA (18), fol-
lowed by the Netherlands (8) and Belgium (5). In addi-
tion, some ecstasy labs were dismantled in Australia, but
were included under the category of ATS laboratories,
with no detailed breakdown provided. Ecstasy labs were
also seized in Indonesia and India in 2005. 
Over the 2000-2005 period, the largest numbers of
ecstasy labs were dismantled in the Netherlands (111),
followed by the USA (83), Canada (71) and Belgium
(26). Double-digit numbers of seized labs were reported
from Australia, Indonesia and China. Five or more lab-
oratories were dismantled in the UK, South Africa,
Hong Kong SAR of China and Estonia. Non-European
seizures of labs included New Zealand, Mexico,
Argentina, Egypt, India and Malaysia. 
In terms of the origin of ecstasy seizures reported (“men-
tioned”) by Member States, more than a third of the
reporting countries (35%) continue to mention the
Netherlands as the main source country (2003-05
period), followed by Belgium (9%). Europe as a whole
accounts for 81 per cent of such mentions. There may
be a statistical bias, however, as 60 per cent of the coun-
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tries29 reporting on the origin of ecstasy were actually
European countries (34 out 57), which are more likely
to cite other European countries as the source of ecstasy
found on their markets. Country origin mentions sug-
gest that the role of the Netherlands as the key produc-
tion centre for ecstasy is declining in importance. While
over the 2002-04 period, 39 per cent of all mentions
referred to the Netherlands, this proportion fell to 32
per cent by 2005. Countries outside Europe which are
frequently mentioned as sources of ecstasy include
Canada, China, South Africa, USA as well as Hong
Kong SAR of China. 
European seizures of ecstasy precursors (expressed in
potential ecstasy equivalents) accounted for 60 per cent
of global ecstasy precursor seizures over the 2001-2005
period. By 2005, this proportion fell to 32 per cent,
another indication that ecstasy production is falling.
The largest ecstasy precursor seizures in Europe, mainly
(3,4-MDP-2-P or PMK), have been reported from the
Netherlands over the 2001-2005 period. However, this
is declining, from almost 11,000 litres in 2001 to 1,762
litres in 2005. Dutch ecstasy production may therefore
be going down. PMK is seized in other European coun-
tries, but seizures tend to be sporadic. The largest PMK
seizures in 2004 were reported from Belgium (3,840
litres), and in 2005 from France (3,960 litres). The
largest PMK seizures outside Europe have been reported
from China (5,331 litres in 2004) and from Hong Kong
SAR of China (3,356 litres in 2005). 
Up until late 2004, large quantities of PMK were smug-
gled into major European Union ports such as Antwerp,
Hamburg and Rotterdam. Greater cooperation between
Chinese and European authorities appears to have
reduced this flow. According to EUROPOL, illicit
PMK prices rose in the European Union in 2005 and
2006, indicating an emerging shortage on the market.
Ecstasy production at significant levels nonetheless con-
tinued. This has raised questions about the origin of
ecstasy precursors in Europe. Some of them still appear
to come from China, but a great variety of new routes
have been identified, including overland by rail via Cen-
tral & West Asia and East Europe, and by sea via Asia
and Africa.30
ATS markets in Africa and South America are mainly
supplied by diversions from licit trade
ATS production continues to be limited in South Amer-
ica and in Africa. The main exception here is South
Africa where ATS production, notably methampheta-
mine and methcathinone, has increased substantially in
recent years. Between 1995 and 1999, South Africa used
to report, on average, the dismantling of one lab per
year. This figure increased to 27 labs in 2004 and 39 in
2005.
Though domestic production of ATS is limited in Africa
and South America, drug use surveys conducted in the
two regions show that ATS consumption is far from
negligible. This means that the markets are supplied by
ATS diverted from legitimate pharmaceutical trade. In
fact, the defined daily dose per 1000 inhabitants for
legally produced ATS in the Americas amounts to more
than 10, as compared to rates between 1 and 2 in
Europe and Asia.31
Countries in North Africa and the Near and Middle
East are also affected by ATS that are apparently pro-
duced in the illicit sector, although the actual location
of this production is not known. The best examples here
are ‘Maxiton Forte’ and ‘Captagon’. The former used to
be a pharmaceutical preparation of dexafetamine, pro-
duced in France, but its production has long ceased.
There are some indications that the ‘Maxiton Forte’
being sold on illicit markets in Egypt today could actu-
ally be methamphetamine, selling under the old brand
name. However, the source of production is not known.
In Saudi Arabia and its neighbouring countries, there is
another ATS market for ‘Captagon’ (originally the trade
name for fenetylline). ‘Captagon’, which nowadays is
mainly amphetamine, is smuggled to the Near and
Middle East usually via Bulgaria, Turkey, Syria and
Jordan. The Turkish authorities reported increasing
seizures of this substance in 2006.32
29 The total number of countries providing information to UNODC over the 2000-2005 period was 190, of which 43 or 23 per cent were countries
located in Europe. The total number of countries providing data on ecstasy seizures over the 2000-2005 period was 103, of which 42 were located
in Europe (41%). A proportion of 60 per cent of countries reporting on the origin of ecstasy, being located in Europe, thus signals over-sampling.  
30 EUROPOL, Production and Trafficking of Synthetic Drugs and Precursors, The Hague, 1 March 2007. 
31 This refers to ‘S-DDD’ (defined daily doses for statistical purposes) per 1000 inhabitants for legally produced Schedule-IV stimulants; see INCB,
2006 Psychotropic Substances.
32 Ministry of Interior / Turkish National Police, Turkish Report on Drugs and Organized Crime 2006, March 2007. 
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1.5.3 Trafficking
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* Note: Seizures reported in kilograms, litres and units, where a unit (pill) of ecstasy was assumed to contain on average 100 mg of MDMA; a unit
of amphetamine/ methamphetamine was assumed to contain 30 mg of amphetamine/methamphetamine; a litre was assumed to equal a kilogram.
Until 1999 ‘other hallucinogens’ are included in data for ecstasy, but the proportion of ‘ecstasy’ in the total seems to have exceeded 90 per cent in
most years (2000-2005: 90 per cent-95 per cent) 
Source: UNODC, Annual Report Questionnaire Data/DELTA.
1 The category of ‘not-defined ATS’, ‘non-defined amphetamines’ or ‘non-specified amphetamines’ comprises stimulants where the authorities were not
in a position to make the appropriate distinction or identification as well as seizures of substances such as Methcathinone (ephedrone), ‘Captagon’
(originally fenetylline, today probably amphetamine) and ‘Maxiton Forte’ (originally dexamfetamine, today likely to be identified as methamphetamine).
Fig. 109: Seizures* of amphetamine-type stimulants (ATS), 1985-2005
ATS seizures are higher than a decade ago, but still
lower than at the beginning of the new millennium 
Trafficking in ATS end-products is still mainly intra-
regional, while trafficking in the ATS precursors con-
tinues to be predominantly inter-regional.
Global ATS seizures increased again in 2005 to 43.4 mt
but remained 11 per cent lower than in 2000, indicat-
ing a stabilisation of trafficking at the global level. A
total of 104 countries and territories reported seizures of
ATS to UNODC in 2005, a number similar to reports
received in 2000 (99), although more than in 1995 (61)
and 1985 (40). 
Methamphetamine continues to account for 
the bulk of global ATS seizures
In 2005, as in previous years, most ATS seizures con-
tained methamphetamine. Out of all ATS seizures
(N=43.4 mt), methamphetamine accounted for 40 per
cent, amphetamine for 30 per cent and ‘non-specified
amphetamines’1 for 18 per cent. The ‘amphetamines’ as
a group, constituted 88 per cent of all ATS seizures, with
ecstasy accounting for the remaining 12 per cent. 
If the period examined were expanded to 2000-2005,
the share of methamphetamine would account for 49
per cent, clearly ahead of ‘non-defined amphetamines’
(23 per cent), amphetamine (15 per cent) and ecstasy
(14 per cent). (The category ‘ecstasy seizures’ comprises
the whole ecstasy group, i.e. seizures of MDMA, MDA
and MDME, though the bulk, more than 90 per cent
of ecstacy seizures, comprise MDMA.) 
While methamphetamine seizures increased in 2005,
they still only reached half the level reported in 2000.
Ecstasy seizures declined in 2005 and are now back to
levels reported in 2000/01. In contrast, amphetamine
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seizures have shown a clear upward trend from the late
1990s to 2005. The decline of ‘non-identified amphet-
amines’ between 2001 and 2005 reflects the lower
seizures of ‘Maxiton Forte’ reported by Egypt. The
increase in 2005 is due to higher ‘Captagon’ seizures
reported by Saudi Arabia.
During the period 2004-05, the world’s largest ATS
seizures took place in East and South-East Asia (32 per
cent), followed by West and Central Europe (25 per
cent), and North America (18 per cent). Seizures in
North Africa (6 per cent), mainly reflect ‘Maxiton Forte’
in Egypt. Similarly seizures in the Near and Middle East
Region (6 per cent), are ‘Captagon’ tablets seized in
Saudi Arabia and neighbouring countries. 
If the 2005 data were considered in isolation, East and
South-East Asia accounted for 38 per cent of global ATS
seizures, West and Central Europe for 18 per cent,
North America for 17 per cent and the Oceania region
as well South-East Europe, North Africa and Sub-Saha-
ran Africa for 4 per cent each. 
The year on year increase of ATS seizures in 2005 was
particularly pronounced in East and South-East Asia
where they doubled and returned to levels reported in
2003. However, they still remained below the levels
reported in 1999 and 2000. Stronger increases, albeit
from lower levels, were reported from the Near and
Middle-East region were ATS seizures showed a 9-fold
increase in 2005, mainly reflecting large increases in
‘Captagon’ seizures in Saudi Arabia during 2005. In
southern Africa and in West and Central Africa, ATS
seizures rose 5-fold in 2005. The overall ATS seizure
levels in Africa are still lower than levels reported in
2001/2002 due to Egypt’s decrease in ‘Maxiton Forte’
seizures. ATS seizures in West and Central Europe
declined in 2005. 
The largest national ATS seizures in 2005 were reported
from China (23 per cent), followed by the United States
of America (14 per cent) and Saudi Arabia (8 per cent).
China and the USA seized primarily methampheta-
mine, both produced locally or smuggled into the coun-
try from a direct neighbour (Myanmar and Mexico,
respectively). Saudi Arabia seized primarily ‘Captagon’
tablets which had been shipped across several borders
from South-East Europe. Other large ATS seizures in
2005 were reported by Taiwan province of China (7 per
cent), the Netherlands (6 per cent), Thailand (5 per
Fig. 110: Breakdown of ATS seizures, by substance, 
2000-2005 (N=34 tons p.a.)
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Fig. 111: Seizures of ATS – by substance, 2000-2005 
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cent), the UK2 (4 per cent), Australia (4 per cent), Egypt
(3 per cent), Bulgaria (3 per cent), South Africa (2 per
cent), Burkina Faso (2 per cent), Mexico (2 per cent)
and Germany (2 per cent). 
Trafficking in methamphetamine
Although the trade appears to be spreading, the main
methamphetamine trafficking destinations remain
East and South-East Asia and North America. 
Although the overall amounts of methamphetamine
seized in 2005 were substantially lower than in 2000,
there is still an ongoing geographical spread of metham-
phetamine trafficking that warrants attention. In total,
51 countries reported methamphetamine seizures to
UNODC in 2005, an increase from 43 countries in
2004 and 32 in 2000. 
Sixty three per cent or 17 mt of global methampheta-
mine seizures continue to be reported from countries in
East and South-East Asia; 36 per cent are seized by
North American countries. In comparison to 2004, the
proportion of East and South-East Asia in the global
methamphetamine seizures increased from 58 per cent
to 69 per cent, while North America declined from 38
per cent to 36 per cent. In 2005, methamphetamine
seizures in the regions of Oceania and Europe,
accounted for 0.8 per cent of global methamphetamine
seizures respectively. While methamphetamine seizures
in Europe remain very low, reflecting the limited avail-
ability of methamphetamine on the European market,
an upward trend has become discernable. European
Fig. 112: Global ATS seizures, in metric ton equivalents, 1985-2005
Source: UNODC, Annual Report Questionnaire Data/DELTA.
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Fig. 113: Distribution of global ATS seizures in 
metric ton equivalents, 2004-2005
Source: UNODC, Annual Reports Questionnaire Data/DELTA.
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seizures of methamphetamine rose more than 4-fold
over the 2000-05 period. 
According to reports to UNODC, the rest of the world
accounted for a mere 0.02 per cent of the global
methamphetamine seizures. However, if the ‘Maxiton
Forte’ seized in Egypt were to be identified as metham-
phetamine and the ATS seized in South Africa were to
constitute largely methamphetamine overall seizures
would increase significantly. The North African propor-
tion in global methamphetamine seizures would rise to
7 per cent, and South Africa to 5 per cent. Under these
assumptions around 12 per cent of the global metham-
phetamine seizures could have taken place in Africa.
Between 2005 and 2006 several shipments of ephedrine
and pseudo-ephedrine were intercepted between Asia
and Africa. While it is possible that they were destined
for North America several of them could have equally
been headed for Africa. In South Africa, ATS seizures
have clearly shown an upward trend over the last few
years. In contrast, in Egypt ‘Maxiton Forte’ seizures fell
by more than 90 per cent over the 2001-2005 period,
even though they increased again in 2006. 
The largest methamphetamine seizures at the global
level in 2005 were reported by China (6.8 mt, or 39 per
cent), followed by the USA (5.1 mt, or 30 per cent) and
Thailand (2.3 mt, or 14 per cent). The shift in the top
seizure rankings over recent years reflects both the
nature of the drug problem as well as national authori-
ties’ reaction to it. For example, China’s reported dou-
bling of its methamphetamine seizures in 2005, and
subsequent maintenance of this level in 2006 indicates
the Chinese authorities are taking the methampheta-
mine production, trafficking and abuse very seriously.
In 2004 the world’s largest methamphetamine seizures
were reported by the USA, followed by China and
Thailand. Previous to that, during most of the 1990s as
well as in 2002 and 2003, Thailand had the world’s
highest methamphetamine seizures. Domestic produc-
tion and large-scale trafficking of methamphetamine
from neighbouring Myanmar had left the country with
a large scale problem. Concerted government interven-
tion in 2003 led to a shrinking of the market that has
been substained.
The next largest of methamphetamine in 2005 were
reported from Mexico (5 per cent), Taiwan Province of
China (3 per cent), Indonesia (2.1 per cent), Myanmar
(1.6 per cent), Hong-Kong SAR of China (1.5 per cent),
Japan (0.7 per cent), Australia (0.7 per cent), the Philip-
pines (0.7 per cent) and Canada (0.5 per cent). If the
‘Maxiton Forte’ seizures of Egypt and the ATS seizures
of South Africa were added, the seizures in the latter two
countries would have exceeded seizures made by Mexico.
Methamphetamine trafficking remains predominantly
intra-regional in East and South-East Asia
Throughout the world, trafficking of methampheta-
mine remains largely intra-regional, with labs producing
only for the domestic market or for neighbouring coun-
tries. While this also applies to South-East Asia, a few
trends have surfaced in recent years which link South-
East Asia with the Oceania region and North America. 
Important trafficking routes in South-East Asia are: 
• From Myanmar to China: trafficking along this
route has increased. In 2006, the Chinese author-
ities reported some 55 per cent of their total
methamphetamine seizures as having taken place
in Yunnan province bordering Myanmar, a signif-
icant increase from 18 per cent in 2002. 
• From Myanmar to Thailand: either directly (26
per cent in 2005) or indirectly via the Lao PDR
(65 per cent) or Cambodia. Although traditionally
only ‘yaba’ (methamphetamine tablets) originated
in Myanmar, over the last few years ‘ice’ (crystal
methamphetamine) has been reported as originat-
ing in Myanmar.
• From Myanmar to the north-eastern provinces of
India and Bangladesh; 
• From Myanmar via Thailand to Malaysia and
Brunei Darussalam as final destinations. 
• From China to Hong Kong SAR of China, the
Philippines, Malaysia, Republic of Korea, Taiwan
province of China and/or Japan.
• From Hong Kong SAR of China to Japan, Aus-
tralia, New Zealand, Guam (USA), and Thailand. 
Fig. 114: Regional breakdown of methamphetamine
seizures in 2005 (N = 17.2 metric tons)
Source: UNODC, Annual Reports Questionnaire Data/DELTA
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• From the Philippines to the Republic of Korea,
Malaysia, Brunei Darussalam, Taiwan province of
China, Japan, Australia, New Zealand, the USA
(including Guam), Canada and Spain (small
quantities).
• From Thailand to Malaysia, Taiwan province of
China, the Republic of Korea as well as to various
other international markets, including the United
Kingdom (small quantities). 
In 2005, the authorities of the Republic of Korea
reported that 70 per cent of the trafficked and seized
methamphetamine originated from China, 22 per cent
from the Philippines and 4 per cent from Canada. In
addition, the USA was identified as a source country in
both 2003 and 2004.3
Japan remains the most lucrative methamphetamine
market in East and South-East Asia. Methamphetamine
continues to be smuggled into Japan primarily from the
People’s Republic of China (more than 50 per cent of the
identified seizures since 2002) as well as from a number
of other countries in the region, including the Philip-
pines, Taiwan province of China and Thailand (Myan-
mar). There have also been reports of methamphetamine
shipments from Canada to Japan and occasionally even
from the USA. In Japan, more than half of the drug traf-
ficking importation and dealing is undertaken through
the Japanese organized crime groups, called Boryokudan.
In May 2006, the Japanese authorities dismantled a
major North Korean drug trafficking syndicate which
cooperated with the Boryokudan. This provided evi-
dence that the Democratic People’s Republic of Korea is
another important source country for the methamphet-
amine found on the Japanese market. Immediately after
the dismantling of this “network”, methamphetamine
retail prices increased markedly in Japan responding to
the interruption in supply.4
Interregional trafficking of methamphetamine persists
in North America 
The bulk of methamphetamine-related trafficking in
North America takes place within the USA and from
Mexico to the USA. The export of methamphetamine
produced in North America to other regions remains
marginal (mostly linked to some trafficking of metham-
phetamine from Canada to Japan). 
However, cross-national trafficking within the North
American region is gaining importance. While there is
some smuggling of methamphetamine from Canada to
the USA, the most significant development of the
methamphetamine trade in North America over the last
few years has been intensified smuggling to the United
States from Mexico. Methamphetamine is thought to be
increasingly produced in super labs5 in Mexico. Accord-
ing to the Mexican authorities, 99 per cent of the
methamphetamine produced in Mexico is for subse-
quent export to the USA. 
Between 2001 and 2004, the amounts of methamphet-
amine seized by the US authorities along the common
south-west border with Mexico increased from 1.2 mt
to 2.3 mt6, equivalent to 75 per cent of all reported US
seizures in 2004, up from 41 per cent 2001. The
increase followed successes in Canada and in the USA
in tightening the control of precursor chemicals, leading
to a decline in methamphetamine production within
the USA. However, organized criminal groups in
Mexico have partly filled this gap, notably in the mid-
western states of the USA, where Mexican groups have
taken over much of the methamphetamine business pre-
viously controlled by local independent traffickers.
Mexican criminal groups have also introduced crystal
methamphetamine into these regions.7
As previously mentioned, the Mexican authorities have
taken decisive steps to reduce methamphetamine pro-
duction and trafficking by drastically reducing the
import of methamphetamine precursor chemicals. 
The number of countries reporting seizures of
methamphetamine increases
The number of countries outside the two main
methamphetamine producing and trafficking regions
(South-East Asia and North America) reporting
seizures of methamphetamine increased from 15 in
2000, to 27 in 2004 and 34 in 2005, suggesting that
methamphetamine trafficking is spreading in geo-
graphical terms. The European region reported a 4-fold
increase in the number of methamphetamine seizures
over the period 2000-2005, though the amounts seized
in 2005 were lower than in 2004. The methampheta-
mine seizures reported from the Oceania region
declined in 2004 and 2005. Demand data from Aus-
3 UNODC, Annual Reports Questionnaire Data.UNODC, Annual Reports Questionnaire Data.UNODC, Annual Reports Questionnaire Data.
4 National Police Agency, Oral Presentation by the Deputy Commissioner General, Hiroto Yoshimura, of the National Police Agency, to the 50th
Session of the Commission on Narcotic Drugs, Vienna, 12-16 March 2007. 
5 A ‘super lab’ is defined by the US authorities as a clandestine laboratory which can produce more than 10 pounds (i.e. more than 5 kg) of
methamphetamine over a production cycle (ONDPC, 2007 National Drug Control Strategy, Feb. 2007). 
6 ONDCP, Synthetic Drug Control Strategy, June 2006. 
7 National Drug Intelligence Centre, National Drug Threat Assessment, 2007, October 2006. 
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tralia also point to a stabilization of the market.
Methamphetamine trafficking in Southern Africa con-
tinues to increase.
Amphetamine trafficking continues to be concentrated
in Europe – but seizures are rising sharply in East and
South-East Asia
Amphetamine seizures increased in 2005 (from 5.8 mt
in 2004 and 3.2 mt in 2000), to 12.9 mt. Most of this
increase was due to a sharp rise in seizures in East and
South-East Asia. 
During the 2000-2005 period, some 80 per cent of
global amphetamine seizures took place in Europe,
mostly in West and Central Europe (68 per cent) and in
South-East Europe (11 per cent). East and South-East
Asia accounted for 15 per cent of global amphetamine
seizures and the Near and Middle East for 2 per cent
(excluding ‘Captagon’ seizures, which could also fall
under the amphetamine category). 
If data for 2005 were considered alone, the proportion
of West and Central Europe falls to 45 per cent leaving
40 per cent of all amphetamine seizures as have been
reported from countries in East and South-East Asia.
While the latter region is known for methamphetamine
production and trafficking, this large scale production
and trafficking of amphetamine is more or less unprece-
dented. In 2005, the world’s largest amphetamine
seizures were reported from China (2.8 mt) and from
Taiwan province of China (2.4 mt). Amphetamine was
also seized in the Netherlands (2 mt), the UK (1.4 mt
in 2004), Bulgaria (1.1 mt), Germany (0.7 mt) and
Poland (0.5 mt). It remains to be seen whether these
huge amphetamine seizures in East Asia reflect a one
time event in 2005 or whether they indicate the begin-
ning of a more fundamental trend toward ATS product
diversification taking advantage of the availability of dif-
ferent kinds of precursor chemicals. Reports of seizures
of 258 kg of semi-processed amphetamine in Taiwan
province of China over the first nine months of 20068,
would support this theory. 
The proportion of West and Central Europe would fall
further if the ATS tablet seizures of Saudi Arabia (111.5
million tablets reported by ICPO/INTERPOL) were
included on the basis that such tablets typically contain
amphetamine.9
Assuming that such a tablet had an average ampheta-
mine content of 30 mg10, the reported seizures would be
equivalent to an amount equivalent to some 3.3 mt,
higher than the amphetamine seizures reported from
China. ‘Captagon’ tablets are typically produced in
South East Europe (Bulgaria and, according to the Bul-
garian authorities, also in Turkey) and are then traf-
ficked by various Middle East groups to Syria, Jordan
and Saudi Arabia. 
Fig. 115: Global amphetamine seizures, 2000-2005 
Source: UNODC, Annual Reports Questionnaire Data. 
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Fig. 116: Distribution of amphetamine seizures, 
2000-2005 (6 metric tons per year)
Source: UNODC, Annual Reports Questionnaire Data / DELTA. 
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8 U.S. Department of State, International Narcotics Control Strategy Report 2007, March 2007. 
9 While ‘Captagon’ tablets analyzed by UNODC in the early 1990s still contained fenethyline, ‘Captagon’ tablets in later years contained typically
amphetamine and caffeine, but not fenethyline. However, a number of other substances were found in some of the tablets, including quinine and
theophyline. The Interpol data suggest that out of the total of 111.5 million tablets seized in 2006, 36 million were ‘Captagon’ tablets and the rest
were amphetamine tablets. 
10 This is UNODCs generally applied transformation ratio for all amphetamines, unless more precise information has been made available by
member states. 
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Because amphetamine production and trafficking has
been traditionally concentrated in Europe, Europe’s
amphetamine seizures (with the exception of data for
2005) serve as a good proxy for global amphetamine
seizures. Europe’s amphetamine seizures increased
between 1980 and 1997, before falling temporarily
towards the end of the 1990s. Between 2000 and 2005,
European amphetamine seizures picked up again and
more than doubled. Overall trafficking of amphetamine
in Europe (and, thus, indirectly of amphetamine traf-
ficking at the global level) has increased over the last two
decades, including over the 2000-2005 period. 
If the ‘non-identified amphetamines’ are included in the
analysis - in the case of Europe it can be assumed that the
bulk of the substance registered under this heading were
actually amphetamine - the overall increase over the last
two decades as well as over the 2000-2005 period is even
larger. However, such statistics also suggest that seizures
of amphetamine are likely to have declined in 2005 as
compared to 2004. This would be consistent with infor-
mation on shortages of P-2-P, the main precursor for
amphetamine production following the improvment in
controls by the Chinese authorities. The limited avail-
ability of these precursor chemicals on the European
market was reflected in rising prices and falling P-2-P
seizures in 2005. P-2-P diverted from the Russian
market11 partly offset this and prevented any large-scale
decline in European amphetamine production.
One remarkable trend within Europe has been the shift
of production and trafficking in amphetamine from the
old to the new EU member states, as well as to non-EU
member states. Back in 1995, the EU-15 countries
accounted for 95 per cent of all European amphetamine
seizures, a share that declined to 85 per cent by the year
2000 and to 70 per cent by the year 2005. 
Fig. 117: Amphetamine seizures in Europe, 1985-2005
* in kilogram equivalents, assuming a dose/unit to be equivalent to 30 milligrams
Source: UNODC, Annual Reports Questionnaire Data.
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Fig. 118: Proportion of amphetamine seizures in 
EU-15 countries among all European 
amphetamine seizures
* in kilogram equivalents, assuming a dose/unit to be equivalent to 30
milligrams
Source: UNODC, Annual Reports Questionnaire Data.
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TREND - amphetamines
Overall ‘amphetamines’ seizures remain concentrated
in South-East Asia, North America and Europe
Because some countries are still having problems with
the exact identification of the substances concerned, it
is helpful to look at overall trends in sub-markets
together, i.e. methamphetamine, amphetamine and
non-identified amphetamines. 
In this context, all available indicators, including seizure
statistics, suggest that global trafficking in ampheta-
mines increased strongly in the second half of the 1990s
but remained relatively stable thereafter. Overall seizures
fell over the 2000-2004 period, rose in 2005, but remain
below the peak levels reported in 2000 and 2001.
South-East Asia continues to be the main market for
such stimulants, accounting for 42 per cent of total
seizures in 2005, followed by North America (17 %)
and West and Central Europe (16 %). Other important
regions include the Near and Middle East (11 %) and
Africa (9 %). The proportion of seizures made in East
and South-East Asia in 2005 was clearly higher than in
2004 (28 %), but remained below the average of the
2000-2005 period (49 %). 
In comparison to the year 2000, amphetamines seizures
declined in East and South-East Asia as well as in the
Oceania region, South Asia, East Africa and in the
Caribbean. Seizures increased in all other regions. When
compared to 2004, amphetamines seizures declined in
West and Central Europe, South-East Europe, North
Africa, South-Asia and Central America, and rose in all
other regions. The net result was an increase in global
seizures in 2005 as compared to 2004, although global
seizures remained some 13 per cent below the record
levels of 2000. 
Fig. 119: Global seizures* of amphetamines – breakdown by region, 1980-2005
* in metric ton equivalents, assuming a dose/unit to be equivalent to 30 milligrams; 1 litre to be equivalent to 1 kilogram.
Source: UNODC, Annual Reports Questionnaire Data.
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Year 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Metric ton 
Equivalents 7          10        15        14        33        44        43        32        34        24        38         
(a) amphetamine, methamphetamine and related stimulants
(b) 1 unit is assumed to be equal to 30 mg; 1 litre is assumed to be equal to 1 kg
(c) data refer to 2004
(d) total seizures reported by national as well as state & territory law enforcement agencies which may result in double counting. 
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(b) 1 unit is assumed to be equivalent to 30 mg
Fig. 120: Global seizures of amphetamines(a), 1995  - 2005
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(a)
Increase in 2001 due to huge seizures of Maxiton Forte in Egypt
(reported in litres); conversion rate used: 1 litre = 1 kg
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Trafficking in Ecstasy 
Ecstasy seizures drop in 2005 and the share of Europe
in global ecstasy trafficking declines
After increasing over the last decade, reported ecstasy
seizures, which declined 33 per cent in 2005, are now
back to the levels reported at the beginning of the mil-
lennium.
The largest seizures over the 2000-2005 period have
been reported from the countries of West and Central
Europe (54 %), followed by North America (21 %),
the Oceania region (15 %) and East and South-East
Asia (6 %).
Although it has not affected the overall dominance of
West and Central Europe in the ecstasy trade, the gen-
eral trend has been towards an increase in ecstasy pro-
duction, trafficking and abuse outside West and Central
Europe. The share of West and Central Europe in global
ecstasy seizures fell from 78 per cent in 1995, to 56 per
cent in 2000 and 38 per cent in 2005. The next largest
seizures in 2005 were registered by countries in the
Oceania region (27 %), North America (20 %) and East
and South-East Asia (9 %). For the second time, ecstasy
seizures in the Oceania region exceeded those of North
America.
While ecstasy trafficking decreased in West and Central
Europe, it increased in East and South-East Europe.
Nonetheless, ecstasy seizures for Europe as whole fell by
25 per cent over the 2000-2005 period. During the
same period, even stronger declines of ecstasy seizures
were reported from North America (minus 35 per cent),
reflecting successful efforts to curtail the ecstasy trade
and reduce consumption over the last few years. The
strongest increases were registered by countries in the
Oceania region and, to a lesser extent and from lower
levels, by countries in South America and in East and
South-East Asia. 
Although trafficking in ecstasy is both inter- and intra-
regional, the latter is gaining in importance with pro-
duction shifting to new markets 
Trafficking in ecstasy used to be intra-regional in
Europe and inter-regional outside Europe, as Europe
has been, and still is, where the main production for the
illicit manufacture of MDMA is located. The main
source countries identified for ecstasy production are
still the Netherlands followed by Belgium. However, the
importance of these and other European countries as
source countries is declining. In parallel, ecstasy pro-
duction outside Europe is increasing with the USA,
Canada, Australia, China, Indonesia, Hong Kong SAR
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Fig. 122: Global ecstasy seizures, 1995-2005
* Note: a pill of ecstasy was assumed to contain on average 100 mg of MDMA. 
Source: UNODC, Annual Reports Questionnaire Data / DELTA.
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of China, South-Africa, New Zealand, Mexico,
Argentina, Egypt, India and Malaysia having been iden-
tified as ecstasy producing countries outside Europe. 
The production of ecstasy in Europe is becoming ever
more sophisticated, characterized by increased profes-
sionalism and efficiency in production. Trends such as
the participation of more specialized staff, companies
and facilitators12, have been identified. The subsequent
distribution of ecstasy end products however, may be
more ad hoc. It is thought to be undertaken by a large
number of rather small drug trafficking groups of vari-
ous nationalities. They typically purchase the ecstasy in
the Netherlands, Belgium or other producing countries
(the Baltic countries, Poland, Balkan region etc.) and
then traffic the drugs to their respective home coun-
tries.13
Trafficking of ecstasy from Europe to North America
and some other regions was controlled for many years
by criminal groups of Israeli origin, sometimes with
links to Russia, other European countries and the USA.
Israeli citizens have been part of international ecstasy
trafficking networks in source, transit and distribution
countries, and were found in locations in France, Spain,
Germany, Denmark, Holland and Belgium, serving as
brokers and transporters of ecstasy to the USA.14 These
trafficking groups operated mainly outside Israel,
though in some instances, they were also involved in
trafficking ecstasy from the Netherlands and Belgium to
Israel. However, the importance of these trafficking
rings was significantly reduced following the successful
disruption of several of them over the last few years.
This is now also reflected in US seizure statistics, as
Israeli groups used to smuggle MDMA via east coast
cities (such as New York, Newark or Miami) into the
USA. Ecstasy seizures along the east coast have declined,
while they clearly increased along the Canadian border.
Such ecstasy is mainly distributed by Asian criminal
groups (often ethnic Chinese or Vietnamese persons
holding Canadian passports), who increasingly produce
the ecstasy in Canada and smuggle the necessary chem-
icals into Canada from various Asian countries (typically
China).15 The Canadian authorities reported that as of
2005 already 85 per cent of the ecstasy seized was
12 Europol, Synthetic Drugs and Precursors, presentation given by the Europol Drug Unit to the Europe-Asia Conference, Paris, 6-7 March 2007. 
13 Germany, for instance, reported that organized crime groups of non-German citizens account for 65 per cent of all organized crime activities in the
narcotics trade; however, when it comes to synthetic drugs, notably ecstasy, local German groups dominate the scene (See Bundeskriminalamt,
Bundeslagebild Organisierte Kriminalität 2005, Wiesbaden, June 2006). Similarly, Austria reports a strong concentration of foreign groups in drug
trafficking, but when it come to ecstasy, the situation is different. Most of it is bought by domestic Austrian groups in the Netherlands and then
trafficked into the country (see Bundesministerium für Inneres, Bundeskriminalamt, Suchtmittelkriminalität Jahresbericht 2006, Wien 2007). 
14 US State Department, International Narcotics Control Strategy Report, March 2006.
15 National Drug Intelligence Centre, 2007 National Drug Threat Assessment, October 2006. 
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Fig. 123: Regional breakdown of ecstasy seizures, 2000-2005 (average annual seizures: 5.6 metric tons)
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domestically produced and only 15 per cent came from
Europe. At the same time, the Republic of Korea
reported that a third of the ecstasy found on its market
originated from Canada and two thirds from China.16
Criminal groups from the Dominican Republic have
been involved in shipping ecstasy in significant quanti-
ties from Europe, often via Spain and the Caribbean, to
the USA.17 Some groups were also organized by Euro-
pean expatriates who lived in the Dominican Republi-
can and hired European couriers to buy the drugs in the
Netherlands and then traffic them to final destinations
in the USA.18 Nonetheless, the overall importance of
these groups from the Dominican Republic appears to
have declined following the dismantling of several such
networks. 
As the North American market has become more risky
and competition from Asian groups more fierce, some
Israeli criminal groups seem to have shifted their activi-
ties to smuggling ecstasy to the Oceania region.19 Crim-
inal British and Dutch groups have also been involved
in these activities for many years. The main ‘embarka-
tion’ countries in 2004/05 for shipments of ecstasy to
Australia were mostly located in West and Central
Europe (Italy, Poland, Belgium and the Netherlands),
South-East Asia (Indonesia and Malaysia) and North
America (Canada).20 The importance of all of these tran-
shipments may decline as domestic ecstasy production
within the Oceania region increases. 
The largest ecstasy seizures in 2005 were reported by
Australia (27 %), followed by the USA (14 %), the
Netherlands (12 %), the UK21 (9 %), Canada (6 %),
Belgium (5 %) and China (4 %). 
16 UNODC, Annual Reports Questionnaire. UNODC, Annual Reports Questionnaire.UNODC, Annual Reports Questionnaire.
17 UNODC, World Drug Report 2006, June 2006. 
18 US Drug Enforcement Agency (DEA), Press Release, ‘Federal Jury Convicts Dominican Republic-Based Ecstasy Trafficker of Conspiracies to Dis-
tribute and Import Millions of Dollars of Ecstasy Pills’, June 5, 2006.
19 In April 2007, one such ecstasy trafficking ring, organized by an Israeli group, was dismantled in Australia (see ABC, ‘AFP says $37m ecstasy haul
will reduce supply’, April 23, 2007; Jerusalem Post, ‘Israeli suspected in Ecstasy smuggling’, April 23, 2007). 
20 Australian Crime Commission, Illicit Drug Data Report 2004/05, Canberra 2006. 
21 Data for the UK refer to 2004; 2004 data are used as proxy for 2005 seizures. 
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* total seizures reported by national as well as State & Territory law enforcement agencies which may result in double counting.
** data refer to 2003.
(b) total seizures reported by national as well as state & territory law enforcement agencies which may result in double counting.
 (c) data refer to 2004.
(a) Seizures as reported (street purity); units converted into weight equivalents (100mg / unit)
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Amphetamines and related 
synthetic stimulants 
Methamphetamine consumption dominates ATS
abuse at the global level 
For 2005, UNODC estimates suggest that close to 25
million people in the world, or an equivalent of 0.6 per
cent of the population aged 15-64, consume ampheta-
mines. This is a higher number than those consuming
cocaine or heroin. The total estimates have not changed
much in comparison to 2004 or the beginning of the
new millennium. 
In terms of the actual substances used, only a tentative
breakdown is possible as most countries do not differ-
entiate in detail whether drug users take methampheta-
mine, amphetamine or other stimulants. However,
Member States have repeatedly reported distinct
regional characteristics to UNODC, which help estab-
lish reasonable orders of magnitude at the regional level.
As an example, the information available suggests that
amphetamines users in East and South-East Asia con-
sume primarily methamphetamine while users in
Europe take primarily amphetamine (with a few excep-
tions, notably the Czech Republic where methamphet-
amine is the preferred substance). Household surveys
show that about half of the stimulant users in North
America use methamphetamine. ‘Captagon’ use, which
is widespread in the Near East, basically reflects the use
of amphetamine (often in combination with caffeine).
In contrast, users of amphetamines in South Africa and
in North Africa, seem to lean more towards metham-
phetamine. In addition, information available indicates
that in most parts of South America, Central America,
the Caribbean, in western, central and eastern Africa as
well as in some parts of southern Africa and Asia, the
amphetamines markets consist primarily of various
diverted pharmaceutical preparations. 
UNODC statistics take all of this information into con-
sideration and suggest that there are between 15 and 16
million methamphetamine users worldwide, i.e. a simi-
lar number as heroin or cocaine users at the global level.
The number of amphetamine users is estimated to be
lower, at around 4 million people. A further 5 million
people are estimated to consume various diverted phar-
maceutical preparations or other illegal stimulants, such
as methcathinone. Again, it is important to recall that
these are only tentative estimates based on information
made available to UNODC by Member States. Fur-
thermore, one should be aware that the actual numbers
for the individual substances could be slightly higher as
poly-drug use is known to be common, and could well
extend to ATS consumption as well.1
South-East Asia continues to be the world’s largest
amphetamines market, followed by North America
and Europe 
Some 14 million people, or 55 per cent of the world’s
amphetamines users are estimated to live in Asia.2 While
1.5.4 Abuse
Amphetamine
16%
Methamphetamine
63%
Other amphetamines 
and diverted licit 
amphetamines
21%
1 For statistical reasons, this applies in particular to ‘amphetamine’ and to the category of ‘other amphetamines and diverted amphetamines’, but less
for methamphetamine. 
2 The figure for Asia is slightly lower as compared to the estimate published a year earlier (15.2 million). The difference was mainly due to results
from the national household survey from Indonesia, conducted in 2005 (See National Narcotics Board Indonesia, National Survey of Illicit Drug
Use and Trafficking among Household Groups in Indonesia, 2005). The estimate, showing an annual prevalence rate of 0.2 per cent of methampheta-
mine use among the general population aged 10-60, turned out to be lower than previous estimates (see UNODC, Patterns and Trends of Ampheta-
mine-type Stimulants (ATS), Bangkok 2006). 
Fig. 125: Users of ‘amphetamines’ – tentative 
breakdown by substance (N = 24.8 million)
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most are methamphetamine users in East and South-East
Asia, this sub-region alone accounts for 97 per cent of all
amphetamines use in Asia. The total number of amphet-
amines users in North America is estimated at around
3.8 million people3 and in Europe at 2.8 million people,
whereby North America would account for 15 per cent
and Europe for 11 per cent of the total global figure.
The number of amphetamines users in Africa is esti-
mated at 2.1 million and in South America (including
the Caribbean and Central America) at 1.9 million
people, each region accounting for some 8 per cent.
About 0.6 million people use amphetamines in Ocea-
nia, which is 3 per cent of the world total. 
For years, Thailand used to have the world’s highest
methamphetamine prevalence figures, but this changed
following the market crack-down in 2003. Based on
survey results in 2005, the highest prevalence rates
worldwide are now found in the Philippines. This
prompted the authorities in 2005 and 2006 to take
severe measures against domestic methamphetamine
production and intensify prevention and treatment
efforts. Although falling, the second highest prevalence
rates have been reported from Australia. 
Number of users    
In per cent of population
15-64 years
EUROPE 2,750,000 0.5
West and Central Europe 2,220,000 0.7
South-East Europe 180,000 0.2
Eastern Europe 350,000 0.2
AMERICAS 5,710,000 1.0
North America 3,790,000 1.3
South America 1,920,000 0.7
ASIA 13,700,000 0.5
OCEANIA 620,000 2.9
AFRICA 2,100,000 0.4
GLOBAL 24,890,000 0.6
Table 14: Annual prevalence of amphetamines use, 2005 or latest year available 
Above global average Around global average Below global average
Sources: UNODC, Annual Reports Questionnaire data, Government reports, reports of regional bodies and UNODC estimates.
3 This figure of 3.8 million is higher than the figure quoted in last year’s World Drug Report (3.2 million). The difference is entirely due to method-
ological improvements. In fact, amphetamines use, including methamphetamine use, is showing a downward trend in the USA and thus in North
America as a whole. A review of the accuracy of results obtained via the US household surveys found that questions of people’s methamphetamine
use under the heading of ‘prescription drugs’ (as had been done to date) leads to under-reporting. Many people, even when taking methampheta-
mine, do not associate their methamphetamine consumption with the use of a prescription drug, as the question dated back to the time when
methamphetamine was still a prescription drug in the USA. However, over the years it ceased to be a diverted prescription drug and is now only
produced in clandestine laboratories, the reason why the question has become misleading. In order to improve the accuracy of the results, people
who had not replied positively to the use of methamphetamine as a prescription drug, were asked for a second time, and outside the context of
prescription drugs, whether they had taken methamphetamine. Furthermore, some typical street names were added to the definition in the ques-
tion: “Methamphetamine, also known as crank, ice, crystal meth, speed, glass, and many other names, is a stimulant that usually comes in crystal or
powder forms. It can be smoked, “snorted,” swallowed or injected. Have you ever, even once, used methamphetamine?” This second question (which had
not existed in the past) raised the annual prevalence rate of methamphetamine use among those aged12 and above quite substantially, from 0.5 per
cent (before the second question was added in 2005) to 0.8 per cent (after the second question was added in 2005). Hence, the total stimulants
use increased from 1.1 per cent to 1.4 per cent in 2005. (See Substance Abuse and Mental Health Services Administration (SAMHSA). Results
from the 2005 National Survey on Drug Use and Health: National Findings (Office of Applied Studies, NSDUH Series H-30, DHHS Publication
No. SMA 06-4194). Rockville, MD, Sept. 2006; http://www.oas.samhsa.gov/nsduh/2k5nsduh/AppB.htm#TabB-6). UNODC now uses these
higher figures for methamphetamine and stimulants use for the USA, which consequently also raised the figures for North America as a whole. 
Asia
55%
Europe
11%
North 
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8%
Oceania
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South 
America
8%
Fig. 126: Breakdown of amphetamines users 
by region (N = 24.8 million)
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At the sub-regional level, the highest annual prevalence
rates of amphetamines use are reported by the countries
in the Oceania region (2.9 per cent), followed by North
America (1.3 per cent), East and South-East Asia (0.9
per cent) and West and Central Europe (0.7 per cent).
The average annual prevalence rate in Africa is estimated
at 0.4 per cent. The highest prevalence rates in the
Oceania region are reported by Australia, in Europe by
the UK, Denmark and Estonia, in North America by
the USA, in Central America by El Salvador, in South
America by Brazil, and in Africa, at lower levels, by
Nigeria (and some other West African countries), South
Africa and Egypt. 
Following increases in the 1990s, amphetamines use is
now stabilizing at the global level… 
Both the estimates of the total number of ampheta-
mines users, as well as trend data provided by experts,
suggest that amphetamines use has started to stabilize in
recent years, following a strong increase in the 1990s. 
Most of the increase in the 1990s was due to rapidly
rising use of amphetamines in Asia, notably in East and
South-East Asia. Increases in Europe and North Amer-
ica also contributed to the global rise of the 1990s, albeit
to a lesser extent. The stabilization over the last few years
is therefore a global phenomenon. 
When analyzing changes in the individual regions
during the period 1992-2005, trend data show that
growth rates were highest in the Asia region and below
average in all other regions. However, following strong
increases in the 1990s, growth in the Asia region has
come to a halt and the Oceania region and the Ameri-
cas even experienced some declines in recent years. In
Europe, while the amphetamines use grew above aver-
age in the 1990s, over the last years it has followed the
global average and in fact always remained slightly
below it. However, in Africa amphetamines use has
grown in recent years, albeit from relatively low levels,
and the overall increases during the 1992-2005 period
have been clearly below the global average. 
Amphetamines use is falling in North America
The most significant shift has been the downward trend
of amphetamines use in North America, reflecting
reports from the USA. This downward trend follows
many years of continued spread of methamphetamine
abuse in the USA, from the Pacific towards the rest of
the country. 
The downward trend among US students started
around 1997 and became more pronounced after 2002.
While the annual prevalence of amphetamines use (cov-
ering both methamphetamine and amphetamine use)
among high school students declined over the 1997-
2006 period by a third, the decline between 2002 and
2006 amounted to almost 30 per cent. Lower levels of
use went hand in hand with reports of lower availability
and a higher risk perception linked to the use of such
substances.
Sources: UNODC, Annual Reports Questionnaire Data, UNODC
Field Offices, UNODC’s Drug Abuse Information Network for
Asia and the Pacific (DAINAP), UNODC, Global Assessment Pro-
gramme on Drug Abuse (GAP), Government reports, EMCDDA,
CICAD, HONLEA reports and local studies. 
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Asia and the Pacific (DAINAP), UNODC, Global Assessment Pro-
gramme on Drug Abuse (GAP), Government reports, EMCDDA,
CICAD, HONLEA reports and local studies.
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The decline in methamphetamine consumption was
even more pronounced among high school students in
the USA, and fell by more than 37 per cent over the
2002-2006 period, or by 60 per cent between 1999 and
2006. Similar declines were also reported by high school
students in Ontario, Canada (down 56 per cent between
1999 and 2005), clearly showing that raising risk aware-
ness in combination with policies to reduce supply
(mainly due to improved precursor controls) have had a
positive impact.  
The downward trend among the general population in
the USA, as reflected in household survey data, began
after 2002. Between 2002 and 2005 amphetamines use
fell by more than 20 per cent, from an annual preva-
lence rate of 1.4 per cent in 2002 to 1.1 per cent among
those aged 12 and above in 2005.
Meanwhile, workplace testing results had indicated an
upward trend until 20044, but a clear downward trend
has been observed here as well since mid-2005. This was
observed notably in the Pacific and in central western
states where abuse levels were normally the highest. The
overall proportion of those testing positive for amphet-
amines use among the US workforce declined by almost
20 per cent between 2004 and 2006, from 0.52 per cent
in 2004 to 0.48 per cent in 2005 and 0.42 per cent in
2006.
Nevertheless, the positive trends reported from the USA
and Canada have been partly offset by reports of rising
methamphetamine abuse in Mexico. This seems to
reflect growing methamphetamine production there
and, although the bulk of the methamphetamine pro-
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Fig. 129: Amphetamines use trends* as perceived by experts – changes in regions, 1992-2005 
(baseline: 1992=100)
Sources: UNODC, Annual Reports Questionnaire Data, UNODC Field Offices, UNODC’s Drug Abuse Information Network for Asia and
the Pacific (DAINAP), UNODC, Global Assessment Programme on Drug Abuse (GAP), Government reports, EMCDDA, CICAD, HONLEA
reports and local studies. 
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Fig. 130: Annual prevalence of amphetamines 
(methamphetamine/amphetamine) use 
among high-school students in the USA
Source: NIDA, Monitoring the Future, Overview of Key Findings
in 2006, Bethesda Maryland, May 2007. 
4 The following reasons may have been responsible for why trends according to household survey data and drug testing data at the workplace dif-
fered for few years: 
- there has been a clear expansion of drug testing across the USA which helped to improve the national coverage; 
- the quality and reliability of drug tests has improved; 
- a growing demand for labour, related to a strong growth of the US economy, enabled many people (including drug users) to join the workforce 
who in previous years may have remained unemployed. 
- While this has improved the accuracy and reliability of current results, it may have made direct comparisons more difficult.  
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duced in Mexico is destined for the US market, the
small proportion remaining in the country has been suf-
ficient to increase local availability, thereby fuelling
domestic demand. 
… and has stabilized in Europe 
Following many years of significant increases, ampheta-
mine use in Europe has now stabilized. In 2005, 19
European countries reported a stabilization of amphet-
amine use, 6 reported an increase and 6 reported a
decrease in amphetamine use. Increases in amphetamine
use are now concentrated in South-Eastern Europe,
while most of Western Europe shows stable or falling
levels of amphetamine use. 
The most significant downward trend, starting in the
mid-1990s, was reported from Europe’s largest amphet-
amine market, the United Kingdom. The annual preva-
lence of amphetamine use in England and Wales fell
from 3.2 per cent in 1996 to 1.4 per cent in 2005 and
1.3 per cent in 2006, a decline equivalent to about 60
per cent for the population aged 16-59. The increased
prevention efforts as well as measures to limit supply
seem to have been behind this success. According to a
study by the EMCDDA, this was also made possible by
the UK allocating the third largest expenditures per
capita and percentage of GDP to fighting drug abuse
among the countries of the European Union (after the
Netherlands and Sweden)5. While this significant avail-
ability of funds to fight the drug problem showed posi-
tive results, some of the progress made in reducing
amphetamines use in the UK was offset by rising levels
of cocaine use. Nonetheless, the overall decline in
amphetamine use over the last decade turned out to be
stronger than the increase in cocaine. 
Significant successes have been also achieved in Sweden,
Europe’s first ATS market which developed between the
1940s and the 1960s.6 Life-time prevalence rates among
Fig. 131: Annual prevalence of methamphetamine 
use among high school students in the 
USA and in Ontario (Canada), 1999-2006
Source: SAMHSA, 2005 National Survey on Drug Use and
Health, 2006 and previous years
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Fig. 132: Annual prevalence of stimulants/
methamphetamine use in the USA 
among the population age 12 and above
5 This includes expenditure on both the supply and the demand side. Drug related expenditure amounted to 68 in the UK or 0.35 per cent of GDP,
more than twice the EU average (0.15 per cent). Higher levels have been only reported by the Netherlands ( 139 per capita or 0.66 per cent of
GDP) and Sweden ( 107 per capita or 0.47 per cent of GDP. (See EMCDDA, Public Expenditure on Drugs in the European Union, 2000-2004).
6 UNODC, Sweden’s successful Drug Policy: A Review of the Evidence, (February 2007). 
Sources: CAMH, Drug Use among Ontario Students, 1997-2005,
Toronto 2005 and NIDA, Monitoring the Future, Overview of Key
Findings in 2006, Bethesda Maryland, May 2007.
Fig. 133: England and Wales: annual prevalence of 
amphetamine use among the general 
population, aged 16-59
Source: Home Office, Drug Misuse Declared: Findings from the
2005/06 British Crime Survey, London, Oct. 2006. 
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military recruits declined by more than 50 per cent
between 2000 and 2005 and Sweden’s amphetamine
prevalence rates among the general population, which
used to be some of the highest, are now among the
lowest in Europe. 
A trend towards stabilization is reported from Asia 
In 2005, the number of Asian countries reporting an
increase in amphetamines use declined to 15, while the
number of countries reporting stable or declining
amphetamines use increased to 16. A year earlier, 20
Asian countries had reported an increase and only 12
countries saw a stable or declining trend. Once the
reported trends are weighted by the amphetamines
using population, the net result shows a (marginal)
decline. This stabilization followed years of uninter-
rupted growth over the last decade in the Asia region. 
Increases in amphetamines use are mainly reported by
countries of western and southern Asia. In contrast,
countries of East and South-East Asia, which account
for the bulk of all amphetamines use in Asia, report a
stabilization or even a marginal decline.7
Following strong increases in the 1970s, early 1980s and
late 1990s, all data for Japan, Asia’s most lucrative
methamphetamine market, suggest that methampheta-
mine abuse stabilized or even declined slightly in recent
years. The life-time prevalence rate of methampheta-
mine was reported to have amounted to 0.4 per cent of
the population aged 15 and above in 2003, but fell to
0.3 per cent by 2005. 
In 2005, a continued decline in methamphetamine
abuse (methamphetamine pills or ‘yaba’) was reported
by Thailand. This followed a forceful intervention by
the Thai authorities in the market in 2003, which
resulted in a decline in methamphetamine abuse, but
unfortunately also in a significant number of casualties.
The 2001 household survey showed that Thailand had
a prevalence rate of 2.4 per cent of the population aged
12-65 and thus the world’s most serious methampheta-
mine problem at the time, despite also having reported
the world’s largest ATS seizures for many years. In 2003,
a subsequent household survey found far lower preva-
lence rates (0.2 per cent)8. However, these data may have
been influenced by police operations, resulting in a
likely underestimate as respondents were influenced by
13,456
19,156
15,267
24,022
19,937
 15,332 
-
5,000
10,000
15,000
20,000
25,000
1
9
5
0
1
9
5
5
1
9
6
5
1
9
7
1
1
9
7
3
1
9
7
5
1
9
7
7
1
9
7
9
1
9
8
1
1
9
8
3
1
9
8
5
1
9
8
7
1
9
8
9
1
9
9
1
1
9
9
3
1
9
9
5
1
9
9
7
1
9
9
9
2
0
0
1
2
0
0
3
2
0
0
5
55,664 32,14
Fig. 134: Reported violations against the Stimulants Law in Japan, 1950-2005
Sources: Ministry of Health and Social Welfare, National Police Agency of Japan and UNODC, Annual Reports Questionnaire Data. 
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7 However, there are some differences in sources and in reporting to UNODC and this issue will be examined further in the future.
8 UNODC (Regional Centre for East Asia and the Pacific), Patterns and Trends of Amphetamine-type Stimulants (ATS) and Other Drugs of Abuse in
East Asia and the Pacific 2005, Bangkok 2006. 
9 This could be seen by a massive decline in reported life-time prevalence rates of methamphetamine use, from 7.8 per cent in 2001 to 2.4 per cent
in 2003, which is not likely to reflect the reality as many people were afraid to admit that they were methamphetamine users at the time. 
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the then ongoing ‘war on drugs’.9 Taking all available
information into account, UNODC estimated that the
actual values were probably closer to 0.7 per cent,10
which would still represent a significantly lower rate
than what was reported in 2001. The upper limit of the
UNODC estimate for 2003 was around 1.3 per cent
(based on rapid assessment findings of changes in drug
abuse in the first few months of the ‘war on drugs’). A
new household survey conducted in 2006 found an
annual prevalence of 0.75 per cent, which appears more
realistic.
There is no doubt that the methamphetamine situation
in Thailand is far better today than it was at the peak of
the methamphetamine epidemic in 2001. Whether the
situation will continue to improve or not is less certain.
Seizures of methamphetamine pills (‘yaba’) point to an
ongoing reduction of trafficking, which could indirectly
lead to an ongoing reduction of abuse. However,
seizures of crystal methamphetamine are rising, albeit
from low levels. The information derived from the
demand for methamphetamine-related treatment is
even more complex. In 2003, following the authorities’
intervention on the methamphetamine market, there
was a massive increase in demand for treatment which
helped eliminate a large number of potential consumers
from the market. The methamphetamine treatment
demand then dropped to below average levels in 2004,
as was to be expected, but increased again in 2005
before stabilizing in 2006. In the meantime, there is no
other Asian country that devotes as many resources as
Thailand does to the treatment of methamphetamine
dependent persons. 
Simultaneously, reports suggest that increased traffick-
ing via the Lao PDR and Cambodia may have started
to partly offset the declines in direct trafficking of
methamphetamine from Myanmar into Thailand. Both
the Lao PDR and Cambodia are already reporting
rising levels of methamphetamine abuse as a conse-
quence of increasing trafficking activities through their
territories. Increases have also been reported from Viet-
nam.
In the Philippines, the latest national household surveys
conducted between September 2004 and January 2005,
of 12,000 people between ages of 10 and 44, are still
being reviewed by the authorities and their results have
yet to be officially released. However, preliminary
results have been made available11 to UNODC and
would indicate that the Philippines could be facing an
annual prevalence rate of methamphetamine use of
around 6 per cent of the population age 15-64.12 These
estimates suggest that the Philippines has currently the
world’s highest methamphetamine prevalence rate.
Given the likely extent of the problem, as highlighted
in the World Drug Report 2006, the Philippine author-
ities have intensified their fight against methampheta-
mine production, trafficking and abuse. For 2005, the
Philippine authorities have reported methamphetamine
abuse levels as stable.
A stable trend was also reported by Malaysia, Singapore
and China. China appears as one of the world’s largest
methamphetamine markets, despite the methampheta-
mine prevalence rates of China being lower than in sev-
eral of the other South-East Asian countries. The
number of registered ATS users exceeded 50,000 in
2005 (6.7 per cent of all registered drug users in 2005)13,
but this number is likely to constitute only a fraction of
the total number of ATS users in that country. Although
China has not undertaken any national drug-related
household survey to date, it has an elaborate system of
registering drug users which helps identify abuse pat-
terns. As an example, the system revealed that ATS
abuse differs quite substantially across China, with the
highest percentage of registered drug abusers reported
from the provinces of Heilongjian (80 per cent), Jilin
(62 per cent) and Liaoning (30 per cent), i.e. provinces
10 UNODC, World Drug Report 2006, June 2006. UNODC, 2006 World Drug Report, June 2006.
11 UNODC, Patterns and Trends of Amphetamine-Type stimulants (ATS) and Other Drugs of Abuse in East Asia and the Pacific 2005.
12 UNODC, World Drug Report 2006, June 2006, Vol. II.
Fig. 135: Thailand: annual prevalence of 
methamphetamine abuse, 2001-2006
Sources: UNODC, Annual Reports Questionnaire Data; UNODC,
Patterns and Trends of Amphetamine-type Stimulants (ATS) and
Other Drug of Abuse in East Asia and the Pacific 2005, June
2006 and UNODC, Drug Abuse Information Network for Asia
and the Pacific (DAINAP).
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of north-eastern China, close to the Democratic Repub-
lic of Korea. The proportion of ATS in north-eastern
China accounted for 52 per cent of registered drug users
in 2005 and thereby proportionally exceeds the levels of
opiate users. Other provinces of importance for ATS
abuse are Hunan province in south-eastern China (8 per
cent), located next to Guandong province (where the
largest numbers of clandestine laboratories were found
in recent years) as well as the provinces close to Shang-
hai along the East Chinese sea, Jiangsu province (7 per
cent) and Zhejiang province (5 per cent).14 The latter
province borders Fujian province, another location of
clandestine methamphetamine manufacture in China.
However, in 2005, in contrast to previous years which
had been characterized by rapidly growing ATS abuse,
the Chinese authorities reported a stabilization of
amphetamines use.
Authorities of Indonesia reported some decline of
methamphetamine abuse to UNODC in their replies to
the Annual Reports Questionnaire. This was in line
with the results of the first national survey15 conducted
in Indonesia in 2005, which revealed a methampheta-
mine prevalence rate of 0.2 per cent among the popula-
tion aged 15-64, which was lower than previous
estimates had suggested. 
Ongoing stabilization/decline in the Oceania region 
In Australia, household surveys have shown a gradual
decline of methamphetamine use from an annual preva-
lence rate of 3.7 per cent of the population age 14 and
above in 1998, to 3.4 per cent in 200116 and 3.2 per
cent in 2004. Data collected through Australia’s DUMA
(Drug Use Monitoring in Australia) system, where
arrestees in selected sites across the country are regularly
tested (urine-analysis) for drug consumption within 48
hours after having entered custody, suggest that the
trend towards a stabilization/moderate decline of
methamphetamine use also continued in subsequent
years. The proportion of the arrestees testing positive for
methamphetamine declined slightly from 28.4 per cent
in 2003 and 28.1 per cent in 2004 to 25.9 per cent in
2006. The decline has been most pronounced in
Queensland (which traditionally has been the location
of most dismantled methamphetamine laboratories),
followed by sites in Western Australia and Southern
Fig. 136: Australia: annual prevalence of 
amphetamines use among the population 
aged 14 and above
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13 Zhao Wanpeng (Deputy Director of International Cooperation Division, Narcotics Control Bureau, Ministry of Public Security) ‘Measures Imple-
mented in China for the prevention of Illicit Production of Synthetic Drugs and their Precursors’, presentation to the Conference on Cooperation
between Europe and Asia in the field of Synthetic Drugs and their Precursors, Paris 6-7 March 2007. 
14 National Surveillance Centre on Drug Abuse, National Institute on Drug Dependence, Peking University, 2005 Annual Report on Drug Abuse in
China, Beijing 2006. 
15 National Narcotics Control Board, National Survey of Illicit Drug Use and Trafficking among Household Groups in Indonesia, 2005, Jakarta 2007.
16 It must be noted though that a direct comparison of the 1998 and the 2001 household survey data in Australia could be potentially misleading as
the underlying methodology for the surveys changed quite substantially during this period. 
Source: Australian Institute for Health and Welfare (AIHW), 2004
National Drug Strategy - Household Survey 2004, Canberra
2005.
Fig. 137: Australia: Methamphetamine - drug use 
testing among arrestees in selected sites*, 
2003-06
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Australia. While the overall methamphetamine abuse
appears to have stabilized, some data point to an
increase in the use of ‘crystal ice’ as well as an increase
in injecting methamphetamine.17
The stabilization of methamphetamine abuse in Aus-
tralia, the largest country in the region, meant that the
situation also stabilized de facto for the Oceania region
as a whole. Nonetheless, individual countries showed
opposing trends. For example New Zealand reported a
continued rise in methamphetamine abuse in 2005,
albeit from lower levels. 
Rising levels of abuse in southern Africa …
Although amphetamines use in Africa remained stable,
abuse of methamphetamine is rapidly increasing in
South Africa. In Cape Town, methamphetamine
accounted for less than 1 per cent of all substance
related treatment demand by the end of 2002, but this
has risen since and over the first two quarters of 2006,
the proportion amounted to 37 per cent. In other parts
of the country, while abuse remains far lower, small
increases could still be noted. For all the locations cov-
ered by SACENDU (Cape Town, Gauteng, Port Elisa-
beth, Durban, Mpulanga, and East London), the pro-
portion of methamphetamine in total treatment
demand reached 13.5 per cent over the first two quar-
ters of 2006, an increase from less than 1 per cent in
2002.
… and from South America 
Rising levels have also been reported from several coun-
tries of South America. Although 5 countries reported
rising levels, and another 5 countries saw consumption
levels stable, not a single country reported a decline in
South America (including the Caribbean and Central
America). Such rising levels of ATS use in South Amer-
ica are in line with reports of rising levels of legal ATS
consumption over the last few years, which has facili-
tated diversion. The defined daily doses per 1000 inhab-
itants for legally produced Schedule-IV stimulants in
the Americas amounted to more than 10 over the 2003-
2005 period, up from levels around 7 over the 2000-
2002 period, or rates between 1 and 2 currently in
Europe or Asia.18
17 National Alcohol and Drugs Research Centre, University of New South Wales - presentation to UNODC, ‘Australian Drug Monitoring Systems: 
Overview of IDRS and EDRS’, May 2007.
18 INCB, 2006 Psychotropic Substances, New York 2007. CB, 2006 Psychotropic Substances, New York 2007.
Fig. 138: Cape Town (South Africa): proportion of methamphetamine as primary substance of abuse 
in treatment, 2000-2006
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Ecstasy
Ecstasy continues to be concentrated in Western
Europe and North America 
Global ecstasy use is estimated to affect some 9 million
people or 0.2 per cent of the population aged 15-64.
There are more than 3 million ecstasy users in Europe,
accounting for some 36 per cent of ecstasy users world-
wide. About 90 per cent of them are located in West and
Central Europe. The annual prevalence rate of ecstasy
use is estimated at 0.9 per cent of the population aged
15-64 in West and Central Europe, exceeding the levels
reported from North America (0.8 per cent). The lower
levels of ecstasy use in North America reflect a decline
in ecstasy use there over the last few years. While drug
use trends of Western Europe are largely stable, ecstasy
use in several East and South-East European countries
continues to grow. 
The prevalence rates are still higher in the Oceania
region (3 per cent) and the ecstasy use in the Oceania
region is reported to be continuing to increase. The
ecstasy prevalence in Asia is still low (0.1 per cent), but
notably East and South-East Asia have emerged as sig-
nificant ecstasy markets over the last few years. In addi-
tion, some countries in South America have reported
rising levels of ecstasy use. 
Global ecstasy consumption remains stable or declines
slightly … 
Following years of massive increases in the 1990s, data
suggest that ecstasy consumption has stabilized at the
global level over the last few years, or perhaps even mar-
ginally declined. This stabilization or slight decline is
largely due to the significant decline reported from
countries in North America.
… reflecting a significant decline in North America … 
Following strong increases in the late 1990s, both school
surveys and household surveys in Ontario, Canada, as
well as in the USA, showed significant declines in the
levels of ecstasy use since the beginning of the new mil-
Number of users    
In per cent of population
15-64 years
EUROPE 3,105,000 0.6
West and Central Europe 2,788,000 0.9
South-East Europe 201,000 0.2
Eastern Europe 116,000 0.1
AMERICAS 2,696,000 0.5
North America 2,214,000 0.8
South America 482,000 0.2
ASIA 1,940,000 0.1
OCEANIA 627,000 3.0
AFRICA 193,000 0.04
GLOBAL 8,561,000 0.2
Table 15: Annual prevalence of ecstasy use, 2005 or latest year available
Above global average Around global average Below global average
Sources: Annual Reports Questionnaire data, various Government reports, reports of regional Bodies and UNODC estimates.
Africa
2%Oceania
7%
Asia
23%
South 
America
6%
Europe
36%
North 
America
26%
Fig. 139: Global distribution of ecstasy use in 2005 
(total: 8.6 million people)
Sources: Annual Reports Questionnaire data, Government
reports, reports of regional bodies and UNODC estimates.
162
World Drug Report 2007
lennium. General population surveys in the USA found
a decline in the use of ecstasy from 1.3 per cent of the
population aged 12 and above in 2002, to 0.8 per cent
in 2005. 
Ecstasy use data among high school students in the
province of Ontario, Canada, showed a fall in annual
prevalence levels by around one third between 2001 and
2005. In 2006, ecstasy use among US high school stu-
dents was 55 per cent below the peak levels reported in
2001.
In 2006, this falling trend continued for 8th graders in
the USA, though among 10th and 12th graders a small
increase was again noted. Also in 2006, while availabil-
ity was still perceived to be marginally declining, the risk
perceptions, which had become ever more pronounced
during the period 2001-2005, started to weaken again
in 2006 but remained significantly higher (and avail-
ability far lower) than in 2001. Ecstasy use among US
students also remained lower than a decade earlier. 
… and stabilization/decline in large parts of Europe
While in the 1990s, most surveys conducted in Europe
showed ever higher levels of ecstasy use, this has now
changed to a general trend towards stabilization at the
higher levels that were reached since. In all of Western
Europe and several countries of Central Europe, preva-
lence data show a stabilization or even a decline in
ecstasy use. This stabilization/decline can be linked to
more prevention efforts and campaigns across Europe,
which informed youth and young adults of the poten-
tial dangers of ecstasy consumption. Other contributing
factors include a diminished popularity of the ‘rave’ cul-
ture as well as some successes in limiting the supply of
ecstasy by making it more difficult for the operators of
clandestine laboratories to obtain the necessary precur-
sor chemicals. 
* Note: Trends as reported by national experts in response to UNODC’s
Annual Reports Questionnaire. Points allocated for trend data: ‘strong
increase’ 2; ‘some increase’: 1; stable: 0; ‘some decline’ -1; ‘strong
decline’ -2. Reported drug use trends were weighted by the proportion
of ecstasy users in a country expressed as a per centage of global
amphetamine use. If all countries had reported ‘some increase’, the
global trend line would have increased by one point each year and
would have reached 113 by 2005. Ecstasy trend data were collected
systematically only as of 2000. As there are indications from a number
of countries that ecstasy trends in the 1990s showed similar growth
rates as ATS in general, the latter trends are shown in the graph for the
period 1992-1999 and are thus used as a proxy for the likely ecstasy
trends.
Sources: UNODC, Annual Reports Questionnaire Data, UNODC
Field Offices, UNODC’s Drug Abuse Information Network for
Asia and the Pacific (DAINAP), UNODC, Global Assessment Pro-
gramme on Drug Abuse (GAP), Government reports, EMCDDA,
CICAD, HONLEA reports and local studies.
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Fig. 140: ATS/Ecstasy use trends* as perceived 
by experts: 1992-2005
Fig. 142: Annual prevalence of ecstasy use in 
England and Wales, 1998-2006
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Some of the most impressive examples in this context
are Spain, Europe’s first ecstasy market that started to
develop in the late 1980s, and the United Kingdom,
which was for many years Europe’s largest ecstasy
market. Following massive increases in the 1990s (from
just 1 per cent of the population aged 16-59 of England
and Wales in 1994, to 2.2 per cent in 2002) annual
prevalence rates of ecstasy use had again fallen to 1.6 per
cent by 2006, i.e. by more than a quarter to approxi-
mately the same level as in 1998 (1.5 per cent).
Similarly, household survey data for Spain showed
increases in the 1990s and a decline by more than a
third, from 1.9 per cent of the population aged 15-64
in 2001, to 1.2 per cent in 2005. 
In contrast, in South-East Europe as well as Eastern
Europe, ecstasy use rates were reported as continuing to
rise (albeit rising from far lower levels). In 2005, all of
the countries in Eastern and South-East Europe report-
ing to UNODC saw rising levels of ecstasy use. 
… and in Asia …
In 2005, following many years of continuing increases
in ecstasy use, 8 Asian countries reported a stabilization
and 5 saw a decline; only 4 countries reported an
increase. In 2004, 10 countries reported an increase and
only 2 a decline in ecstasy use. While these changes may
be related to lowered imports from Europe, local pro-
duction offset much of the import reduction.  
… while significant increases in ecstasy use were
reported from Oceania until 2005, first signs of
stabilization emerged in 2006 …
In Australia ecstasy use continued to rise in 2005.
According to household survey data, ecstasy use rose in
Australia from 0.9 per cent to 3.4 per cent of the general
population by 2004, the world’s highest level. This
increase was in contrast to a general decline of drug use
in that country over the last few years. Australia also
reported the world’s largest ecstasy seizures in 2005.
Data collected through Australia’s DUMA19 (Drug Use
Monitoring in Australia) system, suggest that the upward
trend continued in 2005. The proportion of arrestees
who tested positive for ecstasy increased from 0.5 per
cent in 2000 to 2 per cent in 2004 and 2.5 per cent in
2005. However, data among arrestees for 2006 show first
signs of a stabilization at the higher levels.
The Australian Ecstasy and Related Drugs reporting
system (ERDS), which is based on interviews with reg-
ular ecstasy users, seems to confirm these results. The
proportion of regular ecstasy users consuming more
than a tablet per event declined in 2006 in New South
Wales (from 84 per cent in 2004 to 70 per cent in 2006)
and in Queensland (from 76 per cent in 2005 to 63 per
cent in 2006), the two main ecstasy markets of the
country. In Western Australia, South Australia, North-
ern Territory and Tasmania the opposite trends were
observed. Therefore, in 2006, ecstasy use trends, among
regular ecstasy users, appear to have stabilized for Aus-
tralia on the whole. The median number of days ecstasy
19 Under this system, arrestees in selected sites across the country are regularly tested (urine-analysis) for drug consumption within 48 hours of
having entered custody.
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Fig. 144: Annual prevalence of ecstasy use
in Australia, 1995-2004
Source: AIHW, 2004 National Drug Strategy Household Survey,
Canberra 2005.
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2. INVISIBLE EMPIRE OR INVISIBLE HAND? 
Organized crime and transnational drug trafficking
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2. Invisible empire or invisible hand?
Transnational drug interdiction is an evolving technol-
ogy. Decades of experience, of successes and failures,
inform the way anti-trafficking operations are con-
ducted today.  While the traffickers have also learned
from experience, there have been clear gains in the share
of the global drug outputs seized by law enforcement.
Between 1994 and 2005, the share of global heroin pro-
duction that was seized more than doubled, from 10 per
cent to 26 per cent, while the share of global cocaine
production seized increased from 23 per cent to 42 per
cent. This chapter argues that documenting this success,
particularly by capturing and analysing the details of
each seizure, is key to ensuring that it continues.
Attaching firm numbers to the transnational drug trade
is important, because markets can be deceptive. What
may appear to be highly coordinated enterprises are
often the independent actions of a large number of
people dancing to the same economic tune. In clandes-
tine activities like transnational drug trafficking, it can
be even more difficult to distinguish centralised control
from common motivation, or to know the rules that
govern market activity. The process of transporting
drugs like cocaine and heroin across multiple borders,
often by convoluted routes, is an operation of consider-
able complexity, which would seem to call for large, spe-
cialised organizations. But it remains unclear whether
highly organized crime groups do, in fact, dominate the
global drugs market.
Admittedly, quantifying a clandestine phenomenon like
organized crime is a complex undertaking, and most
indicators will, of necessity, be indirect. But these diffi-
culties must be overcome, because having an accurate
picture of illicit activity is vital to formulating sound
policy. To tackle transnational drug trafficking, it is
important to understand how it is organized, and by
whom. If large organizations were driving the trade,
then targeting these organizations would be essential to
stopping the flow of drugs. If, on the other hand, the
organizations are merely participants in a freestanding
market, then the market itself must be addressed. For
example, the classic strategy for combating organized
crime involves pressuring low-level functionaries to
inform against high-ranking crime bosses, with the aim
of “decapitating” the criminal organization. This tech-
nique is useful where top-down command structures
mean that the important information for directing the
criminal activity is concentrated at the top. But this
approach is far less effective when the criminal activity
is not reliant on such a hierarchy.
Similarly, crime networks can be disrupted by identify-
ing the weak links in a criminal commodity chain, or by
targeting those actors whose skills are in relatively short
supply. For example, in 2000/2001, Australian law
enforcement was able to significantly disrupt local
heroin trafficking networks by focusing on the relatively
small number of brokers who brought together suppli-
ers, financiers, skilled traffickers, and street distributors.
This tack would be less successful where the skills
needed to conduct the criminal activity, as well as the
incentives to do so, are widespread. 
Thus, a key question for international drug law enforce-
ment is: how important are large criminal organizations
to the drug trade? This brief chapter suggests some ways
Fig. 1: Share of global drug supply seized, 1994-
2005*
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2. Invisible empire or invisible hand?
Organized crime and transnational drug trafficking
2.1 Introduction
in which this question might be answered.
Drug trafficking is of interest to transnational organized
crime groups because drugs generate more profits than
any other form of trafficking. Placing a value on illicit
markets is difficult, but the estimates generated by spe-
cialist organiations show that the drugs trade is greater
in value than most other criminal commodities by at
least an order of magnitude. In the 2005 World Drug
Report, UNODC valued the world narcotics trade at
some US$320 billion, a figure in keeping with previous
estimates from a variety of sources. Estimates for other
major illicit flows are considerably less. For example, in
2005 the International Labour Organization estimated
the value of global human trafficking to be US$32 bil-
lion.1 Estimates of the value of the trade in conflict dia-
monds range from  1.5 - 2 per cent to 3 -15 per cent of
the overall trade in rough diamonds.2 Small Arms
Survey puts the value of the illicit firearms trade at no
more than US$1billion.3 The relatively high value
assigned to the drug trade is understandable because,
unlike human beings, diamonds or firearms, the drug
supply is consumed each year and in need of continu-
ous renewal. As a result, drug trafficking remains the
single most profitable sector of transnational criminal-
ity.
These profits accrue to a wide range of actors, from poor
rural farmers to affluent urban dealers. But, in many
instances, the single most profitable sector of the market
is the process of transporting the drugs internationally.
The funds raised by trafficking groups can be used to
underwrite other criminal activity and even political
insurgency. It is thus vital for international security that
firm tabs be kept on the identity and nature of the
groups that benefit from the drug trade.
What share of this lucrative market is controlled by
organized crime groups? It is true that most known
organized crime groups engage in drug dealing, but this
is rarely the only form of criminal activity in which they
are involved.5 It is also true that, under the broad defi-
nition of the United Nations Convention against
Transnational Organized Crime, nearly all transnational
drug trafficking is conducted by organized crime
groups. Under the Convention:
[an] organized criminal group [is] a structured group of
three or more persons, existing for a period of time and
acting in concert with the aim of committing one or more
serious crimes … in order to obtain, directly or indirectly,
a financial or other material benefit.6
Transnational drug trafficking generally requires the
involvement of at least three people, it requires some
time, and is profit-motivated, so most drug trafficking
groups would be considered organized crime groups
under this schema. But the Convention definition was
cast broadly, in the interest of capturing the wide range
of international experience. For the purposes of analy-
sis, it is important to distinguish between degrees of
organization.
Drug trafficking groups today appear to lie along a spec-
trum. On the one hand, there are the groups that pop-
ularly spring to mind when “organized crime” is
mentioned: large, highly-structured, longstanding
groups, the criminal equivalent of a transnational cor-
poration, perhaps best typified by the Sicilian Cosa
Nostra in its heyday. On the other hand, there are the
small, flexible and impermanent associations of entre-
preneurs and criminal service-providers commonly
labelled “criminal networks”, of which West African
organized crime groups are often used as exemplars.
Even less organized are those groups which, while they
may fit the Convention definition, involve a large
number of people who would not consider themselves
professional criminals, organized mainly by market
forces. While all of these likely play a role in global drug
trafficking today, it remains unclear what shares of any
given drug flow each group commands.
Many national and regional organizations provide
annual assessments of organized crime and its involve-
ment in drug trafficking.  These are based on criminal
intelligence, including much field experience.  However,
they typically focus on a single country or region, and
they are largely qualitative assessments. These reports
could be greatly enhanced by a set of standard indica-
tors that could be tracked over time, globally. The fol-
lowing section suggests some possible candidates for this
purpose.
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Fig. 2: Estimated global value of illicit markets
Source: UNODC, 2005; ILO, 2005; US GAO, 2002; Small Arms
Survey, 2002iv
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2. Invisible empire or invisible hand?
2.2 Assessing the degree of 
organization
The Convention definition supports the idea that the
size and longevity of the groups involved are essential
components of organization.  But how can the size and
permanence of the groups involved in any given drug
flow be determined? This chapter suggests that at least
five currently available indicators could be useful for this
purpose:
• The share of total seizures that are large seizures.
• The diversity of techniques and routes used.
• The nationality of those arrested in connection
with seizures.
• Regional price differentials and volatility in drug
producing countries.
• The levels of drug use in transit countries.
This is not an exhaustive list, of course. Many other
variables could be useful if the data available were suffi-
ciently robust.  For example, although UNODC gath-
ers drug price data from countries around the world,
Has organized crime become less organized?
Crime experts appear to agree that the traditional image of organized crime groups as highly structured, hier-
archical entities has become outdated. Increasing emphasis is being placed on more flexible structures involv-
ing networks of skilled individuals.  For example, Europol has recently argued that, “Organised crime groups
are becoming increasingly heterogeneous and dynamically organised in structural terms, moving toward loose
networks rather than pyramidal monoliths …While there are criminal groups organised along the homogeneous
and hierarchical lines, many groups are in practice loose networks of relatively independent members that coa-
lesce around one or more prominent criminals. These networks take up tasks of varying structure, length and
complexity according to the demand and concrete profits.”7
The consensus among experts seems to be that the global drug trafficking situation has also become more com-
plex in recent years, with many groups emerging that are smaller, more flexible and more temporary than they
were in the past. As one Rand study points out, “The old [mid-1980s] images of highly centralized and con-
trolled drug distribution systems have largely disappeared in [the] face of growing evidence of competitive vio-
lence and the failure of individual organizations to endure in dominant positions.”8 This decentralisation has
allegedly manifested itself in several new features:
• Diversification of activities – Criminal activities are increasingly diversified,9 with drug traffickers moving
other forms of contraband as well, and simultaneously engaging in legitimate business. In some regions,
such as Europe, poly-drug trafficking has become common.10 Of the European drug seizures captured in
the UNODC Individual Seizures Database in 2003, 39 per cent involved more than one drug, a trend
not reflected in data from the Americas. In some user countries, poly-drug brokers have emerged, link-
ing what are often single-drug importers to street distribution networks.11
• Diversification of personnel – While ethnic links remain important, many groups involve people of mul-
tiple ethnicities and nationalities.  If expertise is needed which lies outside the group, alliances may be
made with other organized crime groups or individuals may be contracted to do the work. These service
providers may be otherwise uninvolved in criminal activity and maintain an image of legitimacy.12 Indi-
viduals from non-criminal backgrounds may also be recruited for specific tasks, including murder.13 Gangs
from ethnic minority communities may also be contracted to do the “dirty work” of majority organized
crime groups.14 Transnational organizations may make alliances with indigenous crime groups to access a
new territory as a destination or a transit zone.15
It is difficult to determine to what extent these perceived changes are real and to what extent they are a mani-
festation of a growing understanding of what constitutes organized criminal activity. In the past, many may
have regarded the classic mafia-type hierarchy as the only true manifestation of organized crime, but research
and legislative changes, including the use of the Convention definition, have expanded the scope of the dis-
cussion. For example, based on commissioned research, the European Union has begun to shift its focus from
“criminal groups” to “criminal activities and the individuals involved in those activities”.16 In other words, it
has been recognised that the past focus on criminal organizations may have been misplaced, as many relevant
individuals and activities fall outside these structures. This change in perspective may lead to the recognition
of complexities that were previously overlooked. 
these data are provided by local law enforcement agen-
cies, which may use a range of methodologies in making
estimations. As a result, these data are not easily com-
parable and there are many gaps in the information
base. Further, any one of these indicators is subject to
multiple interpretations and could be misleading if
viewed in isolation. Looking at a range of indicators and
combining this information with qualitative intelligence
can generate a more accurate picture of these hidden
enterprises.  Where apparent contradictions emerge,
exploring these can lead to even greater insights into the
world of drug trafficking.
Among available data, some sense of the size of the
organizations can be gained by reviewing law enforce-
ment records of major seizures. While small seizures do
not preclude the involvement of large organizations,
large seizures are indicative of well-resourced actors.
Groups that can afford to invest in individual drug ship-
ments worth hundreds of millions of dollars are likely to
be large and professional. In contrast, anyone with a
small amount of operating capital and the right con-
nections can attempt to transport drugs concealed on
their person on a commercial air flight.  It is possible
that a temporary consortium of independent actors
could pool resources to import, for example, a one-off
multi-ton maritime consignment of cocaine from South
America via the Caribbean and West Africa into Europe,
but it is far more likely that such activity is directed by
large and sophisticated organizations with some
longevity. 
A large number of smaller seizures does not preclude
organization, however. For example, until recently, the
Netherlands Antilles was a major transit country for
body couriers bringing cocaine to Europe in their intes-
tines. Between 1 January 2004 and 1 April 2006, 6,147
couriers were identified arriving at Schiphol Airport
from the Dutch Caribbean, and 7.5 mt of cocaine were
seized.17 It is believed that between 80 and 100 couriers
per day were passing through the Hato International
Airport in 2003, with tens arriving on a single flight.18
This “shotgun” method of couriering is highly associ-
ated with West African crime networks and other simi-
lar groups, which employ small armies of couriers
carrying around a kilogram of cocaine apiece. But while
such trafficking organizations are highly flexible and
endeavor to stay one step ahead of law enforcement pro-
files, they tend to utilize a single channel and technique
of trafficking until it is no longer profitable. Where it is
clear that a wide range of trafficking techniques and
routes are being employed, this is probably indicative of
a wide range of independent actors, rather than a few
puppet-masters coordinating thousands of individual
strings.
However, a caveat must be registered here. In general,
the smaller the share of the total drug flow reflected in
the seizure figures, the less certainty these figures pro-
vide. The resolution of our image of drug trafficking is
proportionate to the number of pixels available. For
example, the absence of large seizures does not preclude
the existence of large syndicates if seizures comprise a
small share of the total flow. Under these circumstances,
it is possible that large shipments are protected by cor-
ruption, and that the small seizures only reflect the
removal of petty competition. Where seizure rates are
low, the other indicators, as well as police intelligence,
become more important.
UNODC maintains two databases on seizures: the
national seizure totals as reported by Member States in
the Annual Reports Questionnaire (ARQ)19 and the
Individual Drug Seizures database.20 The latter includes
detail on seizures above a threshold amount, including
seizures of above 100 grams for cocaine and heroin. This
amount is too large for personal use or even for most
dealers to hold in stock at any given time: 100 grams of
cocaine or heroin retails for about US$10,000 in West-
ern Europe. The intent is to focus on drugs held by traf-
fickers, rather than the small amounts encountered
when domestic users are arrested. Additional details are
provided in these reports that allow a comprehensive
picture of seizure patterns to be formed, including the
exact geographic location of the seizures, trafficking
method, and nationalities of those arrested. Unfortu-
nately, a relatively small number of countries provide
this information and when they do, it is not always
complete. The dynamics of global drug markets would
be much clearer if every country endeavoured to con-
tribute their information to the international data pool.
Where sufficient data are available, it is possible to com-
pare the individual large seizures with national seizure
totals. If the bulk of the seizures in a particular transit
stream comes in the form of very large shipments, this
suggests that the groups involved are large and well
resourced, because smaller groups simply could not
afford shipments of this size.  Similarly, seizure of large
amounts of cash or expensive property could be used as
an indicator of large organizations. If, on the other
hand, most of the drugs are seized in a large number of
small seizures, this indicates smaller trafficking groups,
especially if these seizures involve diverse trafficking
techniques.
A further indicator of the degree of organization is the
nationality of the arrestees when a seizure is made, par-
ticularly in destination countries. If the arrestees origi-
nate from the drug producing countries, this would
suggest that the groups involved could have a hand in
all aspects of the trade, from cultivation to distribution,
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Nationality/ethnicity and organized crime
Describing organized crime groups is problematic, not only due to their clandestine nature. Organized crime
groups are often described by the dominant nationality of their members. However, some researchers argue that
although “….culture, language and set of values can sometimes (but not always) increase trust, communica-
tion and, ultimately, competitive advantage for some groups, it is inaccurate to adopt ethnicity as the only, or
main, dimension for classification of organized crime groups.”21
Clearly, speaking about the relationship between criminality and ethnicity/nationality is dangerous. In addition
to fuelling xenophobia and reinforcing stereotypes, it is politically problematic because the language used sug-
gests the involvement of national governments or impugns national character.  Often, no distinction is made
between foreign nationals and citizens of foreign descent.   But while there certainly exist multinational and
multiethnic organized crime and drug trafficking organizations, there remains a strong relationship between
ethnicity/nationality organized crime.
Due to the transnational nature of the crime, a significant share of the traffickers who are arrested each year are
not nationals of the country where this arrest took place. For example, of the 11,787 people arrested for cocaine
trafficking by the federal authorities in the USA in 2004, 2,373 were foreign nationals (25%), including 1,410
Mexican nationals (12%). This does not include those US citizens of Mexican descent who are involved in
domestic drug markets. Past research has indicated that just under half of all federal drug arrestees were His-
panic,22 and people of Mexican descent comprise by far the largest Hispanic group in the USA. Similarly, in
Ecuador, of the 915 people arrested for cocaine trafficking in 2004, 227 were foreign (25%), including 117
Colombians (13%).  In Spain, 34 per cent of cocaine trafficking arrests in 2004 involved foreigners, as did 32
per cent of drug trafficking arrests overall. Looking just at major seizures, of the 40 people who were arrested
with more than 100 grams of cocaine in Nicaragua in 2004  and whose nationality was known, 14 were for-
eign nationals (35%), including eight Guatemalans and five Hondurans. 
Many non-criminal transnational business activities are commonly discussed in terms of nationality, because
diaspora communities are a recognised basis for much international commerce.  Cultural norms can explain
behaviour that appears irrational in terms of simple market logic and can help in predicting how groups will
behave. There are clear cases where relationships in the home country (including national political as well as
neighbourhood/kinship relations) affect transnational operations – that is, the criminal behaviour has less to
do with the country where it is manifest than the country from which the traffickers originate. Without refer-
ence to the origin country, this behaviour would be inexplicable. Finally, for simple operational purposes, the
association between certain national groups and trafficking provides invaluable clues as to where fugitives may
flee, likely transit countries, and favoured money laundering and investment sites. As a result, the dominance
of certain national groups remains a key issue in many drug markets.
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Fig.3 : Nationalities of individuals arrested for drug trafficking in Spain in 2004
Source: UNODC ARQ
indicating a high degree of sophistication. High levels of
participation by citizens of transit countries, on the
other hand, suggest that the drug has been re-sold in
transit. While there may be other explanations, this sug-
gests the groups involved at the outset did not have the
capacity to deliver the drugs all the way to their final
destination. If arrests in transit countries involve prima-
rily the nationals of these countries, this also indicates
that the international drug flow is, in fact, merely the
sum of national drug flows, percolating slowly toward
higher value markets.  Of course, when the user coun-
try and the destination country are the same, or imme-
diately adjacent to one another, no such conclusion can
be reached.
Provincial drug price data in drug producing countries
can be useful in evaluating the degree of organization at
the start of the market chain. Large regional price dif-
ferentials which cannot be explained by geographic or
law enforcement barriers suggest strong local controls
over the supply. If the supply were not well controlled
by regionally based interests, national price equilibrium
would quickly be achieved by competition between
these local markets. In other words, stark price differ-
ences in drug producing countries indicate an unseen
barrier to competition, likely a regional monopoly held
by a powerful organization. Of course, nationally
homogeneous prices could be indicative of a single, all-
powerful cartel. Price stability is likewise an indicator of
large organisations, resistant to the vagaries of changes
in production and interdiction rates, possibly holding
drug stockpiles. High levels of volatility in prices, on the
other hand, are indicative of competition or vulnerabil-
ity to shocks, both of which could be indications of con-
tested markets and thus possibly less organized criminal
groups.
Another indicator of poor transnational delivery capac-
ity is the presence of drug users in transit countries.
The goal of drug trafficking organizations is to gain
profits, and this is best achieved by delivering the drugs
to the markets where they command the highest prices.
Any “spillage” of drugs before reaching their highest-
value destination represents the kind of inefficiency typ-
ical of under-resourced groups, who may pay couriers in
drugs rather than cash. This manifests itself in drug use
problems in transit countries with lower value markets.
As a result, low levels of drug usage in these transit
countries indicate that the drug flow is either highly
organized or relatively new.
While all of these indicators – the size of seizures, the
techniques and routes involved, the nationality of the
traffickers, local prices in production countries, and the
levels of drug use in transit countries – can be deceptive
in some cases, their use in combination can provide an
important supplement to qualitative criminal intelli-
gence. In order to explore the potential of using seizure,
price, and drug use figures to get a sense of the extent of
organisation in contemporary drug trafficking, two of
the most important drug flows in the world are dis-
cussed and compared in the remainder of this chapter: 
• the traffic of cocaine from Colombia via Central
America to the USA; and,
• the traffic of heroin from Afghanistan via Central
Asia to the Russian Federation.
These two examples were chosen to contrast a well
established drug flow involving a number of large drug
trafficking organizations (cocaine via Central America)
with a relatively recent pattern of trafficking where the
groups involved appear more diffuse (heroin via Central
Asia). These are also the two drug flows where govern-
ments have contributed comprehensive data for several
affected countries, including detailed information on a
large number of seizures in Colombia and the Russian
Federation.
This analysis is not intended to provide the final word
on the level of organization in either of these trafficking
areas, bur rather to “test drive” the indicators to see how
they might work in application to a real world situation.
Despite excellent data in some instances, there remain
great gaps in what we know about both trafficking pat-
terns. In the end, this analysis is less about providing
definitive answers than suggesting the kind of questions
that should be asked.
2.3 Cocaine via Central America to the 
USA
The organizations involved in trafficking of cocaine to
the USA have traditionally been highly organised.
During the 1980s, the groups involved were even
dubbed “cartels”.  A cartel is a consortium of businesses
whose combined domination of an industry is so com-
plete that they can collaborate to set prices and other-
wise manipulate the market to their mutual benefit.
While some dispute the applicability of this term to the
Colombian groups, at its peak the Cali cartel is said to
have been responsible for up to 80 per cent of cocaine
trafficking to the USA, then, as now, the world’s largest
consumer of the drug.23
The cartels were subjected to the full weight of interna-
tional law enforcement during the 1980s and 1990s:
their assets were seized and their leadership extradited
and imprisoned. Insofar as the organizations were con-
cerned, this strategy worked, and the Medellin and Cali
cartels were effectively eliminated. In their place sprung
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a large number of lower-profile groups, the so-called
“baby cartels”, said by some to number in the hun-
dreds.24 While some of these have achieved more promi-
nence than others, there are no organizations
comparable to the Cali and Medellin groups today. In
fact, Colombian groups have lost their monopoly over
cocaine trafficking altogether and currently most of the
drugs reportedly enter the USA in the hands of Mexi-
can organized crime groups. The respective roles of the
Colombian and Mexican syndicates are discussed fur-
ther below.
Most of the world’s cocaine still comes from or through
Colombia, and most of the world’s cocaine is still con-
sumed in the USA. UNODC estimated global cocaine
production to be 1,008 mt in 2004, of which 640 mt
was produced in Colombia, 270 mt in Peru, and 98 mt
in Bolivia. In 2004, Europol estimates about 200 mt
went to Europe25 and the US National Drug Intelligence
Agency estimates between 325 and 675 mt went to the
USA.26 Based on previous years’ estimates, this total is
probably in the order of 450 mt.27 If all of these 450 mt
were wholesaled in the USA, they would be worth just
under US$12 billion today, and three to five times that
at retail level.28 Some 80 per cent of this flow travelled
by private boats.29 The fact that so large a share is mar-
itime suggests high levels of organization,
as shipments are likely to be sizable and
sea craft are a relatively expensive means of
transport, given the risks of asset forfei-
ture.
According to US estimates, some 88 per
cent of the cocaine destined for the USA
transits the Central America/Mexico cor-
ridor, about 50 per cent along the Pacific
and 38 per cent along the Caribbean coast
of Central America.30 This is in keeping
with what the Colombian authorities
report: about 60 per cent of the seizures in
Colombia occurred at the ports, 60 per
cent on the Pacific and 40 per cent on the
Atlantic.31 In more concrete terms, this
would be equal to about 250 mt along the
Pacific and 200 mt along the Caribbean.
Of this flow, the US estimates 196 mt
were lost or seized in transit, and 34 mt
were seized at the US border, in 2004.32 In
other words, about half the cocaine des-
tined for the USA never arrived at its des-
tination. If these estimates are accurate,
data on seizures represent a very large
sample of the overall flow. 
Of the 2004 seizures of cocaine in the Western Hemi-
sphere, 62 mt (about 6 per cent of total annual produc-
tion) can be traced to just 26 seizures of more than 1 mt
documented in the Individual Seizures Database, most
of which occurred in Colombia. Today, 1 mt of cocaine
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Map 1: Central American countries affected by cocaine trafficking from Colombia to the United States
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wholesales for about US $1.9 million in Colombia, and
retails for over US$100 million in the USA.  According
to media reports, a seizure of 13 mt of cocaine, said to
be the property of the Norte de Valle cartel, was made
in early 2007 in Colombia.33 Seizures of this scale sug-
gest a substantial concentration of the market in the
hands of a limited number of organizations at the outset
of the trafficking chain.
The Colombian source
Coca is a plant, so the first link in the supply chain is
the farmers.  The cultivation of coca leaf is a highly
decentralised activity, due to the need to conceal the
crop from a continual campaign of aerial spraying and
manual eradication. The average plot size is small, about
one hectare, making coca growing a kind of family busi-
ness. In 2005, some 68,600 households were involved in
this activity, cultivating in 23 out of Colombia’s 32
provinces.34 No one believes that these tens of thousands
of households are directly in the employ of organized
crime, but neither are they simply freelance market play-
ers. Particularly in the areas controlled by insurgent or
paramilitary groups, a variety of mechanisms may be
used to encourage coca cultivation, and those who grow
the drug are not simply peasants cultivating a traditional
crop. The UNODC/Government of Colombia 2005
Coca cultivation Survey found that only one third of
the farmers were just cultivators – the balance were
involved in processing the plant into drugs, up to the
point of creating cocaine base.  
There is substantial regional variation in the price paid
for cocaine base and the refined cocaine.  While data are
sparse, it appears that cultivators in the Pacific region,
open to sea trafficking lanes, were paid substantially less
for base than those in the centre of the country. If base
were trafficked within the country, this would result in
a paradoxical loss of value as the drug is moved closer to
departure. Of course, the Pacific region is home of the-
Cali and its successor Norte de Valle cartels, and may
still be home to syndicates powerful enough to control
prices paid to farmers and resist local competition.
Cocaine prices comply more closely with market logic,
though regional variations of almost 25 per cent also
suggest that the market for cocaine may not be compet-
itive on a national level. Whether this is due to the
regional domination of certain crime groups, to law
enforcement pressure or to some other cause remains
uncertain.
Coca cultivators do not create the finished drug, how-
ever. The processing of cocaine base into cocaine
hydrochloride requires a laboratory of some sophistica-
tion, so these are generally operated by specialists, not
farmers. Each syndicate, including insurgent and para-
military groups, runs its own laboratories, so these are
directly in the control of organized crime. The Colom-
bian government destroyed 243 cocaine hydrochloride
laboratories in 21 provinces in 2004 and 163 in 19
provinces in 2005. According to the Colombian Direc-
ción de Antinarcóticos (DIRAN), an average laboratory
can produce between 300 kg and 500 kg per week, or,
in theory, up to 26 mt per year. If true, total cocaine
production could be handled in just 25 laboratories.
Given the wide dispersion of cultivation, however, the
proliferation of sites may be tied to logistic convenience,
and is not necessarily an indicator of a multiplicity of
independent actors.
Large amounts of cocaine are found virtually every-
where in the country, so it is remarkable that adult
annual cocaine use prevalence is only 0.8 per cent of the
population age 18-65, more than twice the global aver-
age, though less than a third of that in the USA. This
indicates high levels of control over the cocaine supply.
As is the case in many agriculture-exporting countries,
export stock is not widely consumed locally. 
In order to generate the multi-ton loads leaving the
country, a process of consolidation must occur before
trafficking, and this implies large organizations. As in
many other drug producing regions of the world, there
appears to be a symbiotic relationship between political
instability and the drug trade. There is strong evidence
to show how both the insurgency (principally the Rev-
olutionary Armed Forces of Colombia, the FARC) and
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Fig. 5: Regional prices of cocaine base and cocaine 
in September 2005
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the paramilitary forces (the United Self-Defence Forces
of Colombia, the AUC), progressed from simply
“taxing” the crop in the past to assuming a managerial
role over production in the regions they control.35 There
is also some evidence, principally concerning the AUC,
that these groups have been involved in transnational
trafficking, including trading drugs for arms.36 This is
not surprising, as many AUC units were founded with
drug trafficking money. But while these groups are key
in the cultivation, processing, and consolidation of the
drug loads, their concerns remain highly local. The bulk
of the trafficking appears to remain in the hands of a
larger number of smaller professional drug smuggling
groups – the so-called “baby cartels”.
Over the past two decades, Mexican groups, which had
previously been used instrumentally by the Colombians,
have increasingly taken control of the US market. This
transfer of responsibilities has not been complete, how-
ever, and Colombian groups, as well as their Dominican
associates, remain prominent in the wholesale and retail
trades in the northeast part of the USA. In addition, it
appears that Colombian trafficking organizations have
expanded operations in Mexico, taking advantage of the
disarray of the Mexican syndicates following law
enforcement successes and inter-syndicate warfare.37
Mexican groups have also extended their reach and have
expanded presence in producer countries, Peru in par-
ticular.38 Although only 20 Mexicans were arrested for
drug trafficking in Colombia in 2004, several were asso-
ciated with large seizures. 
While there is no clear delineation of function, there
has been a clear shift of roles over time, with the
Colombian nationals generally forming the first part
of the chain and Mexican nationals assuming respon-
sibility for getting the drug to its destination markets
in the USA. It is not clear at what point most of the
cocaine leaves the possession of Colombian groups
and becomes the property of Mexican groups, but
most of it leaves Colombia in Colombian hands and
crosses the US southern border in Mexican hands. 
Large seizures are also made in Venezuela, which might
be considered to be less a transit country than a sort of
proxy source country, given the permeability of the bor-
ders. Under growing pressure from the government,
both insurgent groups and traffickers appear to have
relocated across the border, and, increasingly, suspect air
and sea activity is originating in Venezuela.39 A total of
31 mt of cocaine were seized in Venezuela in 2004, the
fourth largest annual seizure total in the world. Individ-
ual seizures include one of 7.6 mt and at least three
other multi-ton seizures totalling over 15.5 mt, or about
half of the annual seizure total. This indicates that
cocaine trafficking though Venezuela, as in Colombia,
involves well-organized and well-resourced groups.  
The Central American link
Central America is comprised of seven small, under-
resourced countries that serve as re-fuelling stops or
transit zones for cocaine moving northward. It does not
appear that Central American groups assume ownership
of most of the large shipments transiting the region. The
US government asserts that Central American countries
are used as stockpiling locations, particularly
Guatemala.40 Guatemala has ports on both the Pacific
and the Gulf of Mexico, as well as large wilderness areas
bordering Mexico, making it an ideal spot to store
cocaine destined for Mexico while avoiding the scrutiny
of Mexican law enforcement. The role Guatemalan
organized crime groups play in transnational cocaine
traffic is unclear, however.
Lack of law enforcement capacity means that seizures,
or the lack thereof, do not necessarily reflect the flow of
drugs through the region. About 27 mt were seized by
the Central American countries in 2004.  Though com-
prising only 5 per cent of global cocaine seizures, this
amount is remarkable when considered on a per capita
basis.
UNODC individual seizure data for the region is
patchy, but both Nicaragua and Honduras submitted
complete reports for 2004. Along the Atlantic coast of
Central America, most of the drug traffic is shuttled by
go-fast boat, so re-fuelling stopovers can occur in rela-
tively isolated areas. Large parts of the Caribbean coast
of Nicaragua and the Mosquito Coast of Honduras are
sparsely populated. These two countries comprise the
longest stretch of coastline along the Caribbean route. In
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Fig. 6: Kilograms of cocaine seized per 100,000
citizens in 2004
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Honduras in 2004, police made 86 arrests for cocaine
and 42 for crack. Since crack is bulkier than cocaine and
is easy to manufacture on-site, it is rarely trafficked
internationally, so crack seizures are generally indicative
of local use levels, not transnational smuggling. Looking
just at the 86 cocaine arrests, 21 involved quantities of
more than 100 grams, comprising 62 per cent of all the
cocaine seized that year. One seizure, on Jutiapa Beach,
netted 1 mt of cocaine, more than 25 per cent of the
cocaine seized that year. All seizures of over 100 kg were
destined for the USA. Similarly, in Nicaragua in 2004,
some 42 per cent of the cocaine recovered that year was
seized in just two major seizures on the Atlantic coast.
The size of these individual seizures in comparison to
the small size of the lesser traffic suggests a high degree
of organization in the movement of cocaine through
this area.
The importance of large seizures to the national seizure
totals of the Central American countries is manifest in
the extreme volatility of total seizure levels from one
year to the next. For example, Belize seized 13 kg of
cocaine in 2000, 3.1 mt in 2001, and 10 kg in 2003.
Honduras seized 79 kg in 2002 and 5.6 mt the next
year, a year-on-year increase of 7100 per cent. El Sal-
vador went from 32 kg in 2001 to 2 or 3 mt from 2002
to 2004, before plunging back down to 32 kg in 2005.
Even Panama’s totals have ranged from about 2.5 mt in
2002 to 14 mt in 2005.  It is unlikely that these varia-
tions are reflective of changes in trafficking or enforce-
ment patterns.  Rather, those years in which the
large-scale traffic is untapped show that the small-scale
traffic is relatively insignificant. Thus, volatility in
seizure trends for small countries, in combination with
other indicators, may be an indicator of high degrees of
organization.
While minor in impact, there does appear to be a large
number of incidents of international movement of small
amounts of cocaine within Central America and/or
involving Central Americans travelling internationally.
Central Americans have been arrested numerous times
in recent years in the USA, Spain, Germany, and parts
of South America for involvement in cocaine traffick-
ing. The amounts involved are generally moderate and
the techniques involved run the gamut, from intestinal
couriers travelling on commercial flights to concealment
in luggage on transnational bus lines and custom fitted
freight vehicles travelling the Pan-American Highway.
This wide range of techniques and routes suggests
numerous smaller operations, as coordinating these
myriad ventures would be a logistic nightmare for a cen-
tralised organization. 
Given per capita seizure figures, it is remarkable that use
levels in the region are quite low. Less than 200,000
people use cocaine in the seven countries of Central
America every year, compared to a user population in
the USA of 5.5 million. In the 2005 World Drug Report,
the UNODC estimated that each Central American
cocaine user consumed, on average, about 20 grams a
year. This would result in a total demand for the region
of less than four mt of cocaine per annum. As a result,
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Fig. 7: Cocaine seizures in Honduras in 2004 
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Fig. 8: Metric tons of cocaine seized in Central 
American countries (rounded)
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Date Location Nationality Quantity Details
4 January 2004 El Salvador Guatemalan 1 kg In a residence
10 February 2004 Madrid Costa Rican 1 kg In baggage
21 February 2004 Nicaragua Guatemalan 116 kg With car parts
23 February 2004 Madrid Costa Rican 2 kg In baggage
23 February 2004 Nicaragua Guatemalan 6 kg With car parts
28 February 2004 Nicaragua Guatemalan 18 kg At business
3 March 2004 Nicaragua Guatemalan 39 kg ——-
6 April 2004 Venezuela Nicaraguan 11 kg In baggage
8 April 2004 El Salvador Honduran 2 kg
Procured in Honduras, bound for
United States
19 April 2004 Nicaragua Honduran 7 kg In bus
30 April 2004 Nicaragua Honduran 7 kg In bus
1 May 2004 Nicaragua Honduran 33 kg Two arrested
10 May 2004 El Salvador Guatemalan < 1 kg Procured in Colombia
12 May 2004 Nicaragua Honduran 3 kg With Nicaraguan
21 May 2004 Venezuela Costa Rican < 1 kg Swallowed
3 June 2004 Nicaragua Guatemalan 30 kg With Nicaraguan
19 August 2004 Managua Guatemalan 100 kg Commercial road vehicle
28 August 2004 Nicaragua Guatemalan 1.7 mt With one Colombian
9 September 2004 Barcelona Salvadoran 2 kg Sourced in Guatemala
4 October 2004 Madrid Salvadorian 1 kg Body carry
5 October 2004 Spain Salvadorian 3 kg Via Guatemala
10 December 2004 Madrid Guatemalan 3 kg From Guatemala
1 January 2005 Argentina Costa Rican 2 kg —-
15 January 2005 Honduras Salvadorian 1 kg With 2 Hondurans
17 January 2005 Madrid Salvadorian 2 kg Via Guatemala
2 March 2005 Portugal Panamanian 2.5 kg With 2 Portuguese
5 April 2005 Madrid Nicaraguan 1.5 kg From Nicaragua
13 April 2005 Madrid 2 Guatemalans 2 kg Destined for Netherlands
13 April 2005 Barcelona Salvadoran 1.5 kg Sourced in Panama
15 April 2005 Madrid Guatemala 1 kg Swallowed
3 June 2005 Madrid Guatemala 4 kg In baggage
12 June 2005 Barcelona Guatemala 2 kg ——
17 June 2005 Frankfurt Costa Rican 11 kg With 2 Germans
30 January 2006 Madrid Salvadoran 1 kg Sourced in Peru
2 Febuary 2006 Madrid Salvadoran 2 kg With Colombian and Spaniard
24 March 2006 Madrid Salvadoran 2.5 kg Sourced in Dominican Republic
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Table 1: Some recent transnational cocaine seizures involving Central Americans 
Source: UNODC Major Seizures Database
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Street gangs and international drug trafficking
While street gangs are universally associated with drug dealing, the relationship between these groups and the
traffickers is in need of more investigation. Much has been made of the possible connection between Central
America’s street gangs, or maras, and related groups resident in the USA. During the civil wars that long afflicted
the region, many Central Americans emigrated northward, settling in the slums of large cities like Los Angeles
and Washington, DC.  Here, youth became involved in street gangs (such as the 18th Street gang) and formed
some of their own (such as Mara Salvatrucha).  These groups spread to Central America after large numbers of
gang members were deported following criminal convictions under the broadened provisions of the 1996 Ille-
gal Immigration Reform and Immigrant Responsibility Act.  Street gang members are key in drug distribution
in the USA, and the presence of these youth in a drug transhipment zone raised the spectre of transnational
drug networks arranged along gang lines.
But it does not appear that this potential has been realised.  While mara members are certainly involved in dis-
tributing drugs to the small markets of their home countries, the gang members themselves appear to comprise
a large share of this market. Most of the areas where gang members dominate are situated inland, away from
the maritime channels that carry most of the drugs. Even if they were located on the coast, it is unclear what
role they would play, given that street gangsters are unlikely to have advanced nautical skills. It is highly likely
that mara members move small amounts of drugs through the post or via couriers, but they do not seem to
have the capacity to assert themselves as a new order of drug cartels.
This example highlights many common points of confusion around the relationship between drugs, gangs, and
organized crime. The term “drug gangs” is common parlance, but the relationship between street gangs and
drugs is highly controversial.  Research indicates that although drug dealing is common among street gang
members, it is not generally the primary purpose of the gang.  Since most gang members are drug users, they
may become involved in drug dealing in the same way other drug users do – in order to finance their habit.41
Street gangs are not simply profit-motivated organized crime operations.  For their members, they provide sur-
rogate families, a sense of identity, and a means of survival. They remain chiefly concerned with local matters
– defending turf and fighting for “respect”, often in ways that undercut the profits from their criminal activi-
ties. Most members are in their teens and early 20s, undereducated, and not too familiar with the world beyond
their immediate neighbourhoods. 
Another source of persistent confusion is the tendency to assume that groups bearing the same name respond
to a common command structure. While Mara Salvatrucha gangs exist in both the USA and El Salvador and
both trace their roots to the Rampart area of Los Angeles, there has been little evidence of coordinated activ-
ity. Indeed, even within a country, individual cliques of large umbrella gangs appear to operate with a great deal
of autonomy. The same may apply to other organized crime groupings bearing a common name.
Fig. 9: Share of adults (aged 15 - 64) using cocaine in the last year, 2005 or latest year available
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Source: UNODC Delta database estimations 
large seizures made in this region are almost exclusively
in transit, bound for the USA.  This suggests that well
organized groups control the bulk of the flow, and most
shipments pass through the region intact.
The Mexican link
Today, Mexico is the premier gateway for cocaine enter-
ing the USA. According to US government estimates,
roughly 90 per cent of the cocaine entering the country
transits Mexico,42 and three quarters of the cocaine
seized entering the USA is apprehended along the land
border with Mexico, particularly the border with
Texas.43 Making use of this gateway requires working
with the Mexican criminal syndicates that control it.
Inside Mexico, most of the drugs are controlled by one
of several well-recognised “cartels”, based in provinces
along the border and along the southeast coast. North-
ern groups have fought for “plazas”, or key border cross-
ing areas, with syndicates forming around Tijuana,
Juarez, Sinaloa, and the Gulf (Nuevo Laredo and Mata-
moros), for example. These battles have involved dedi-
cated combat wings, such as the Zetas, a group of
former Mexican army commandos employed by the
Gulf cartel to terrorise rival groups and to assassinate
prominent figures in law enforcement, government, and
the press. At least 1,400 drug-related murders occurred
in Mexico in 2006, most along the border with the
USA,44 with some sources placing the number as high as
2,500.45
Violence has recently spread to the southeast, where
groups have formed in the primary docking locations
for shipments entering the country. The size of the
organizations is indicated by the seizure of assets and
precursors. For example, in March 2007, a police raid
in Michoacan resulted in the seizure of US$206 million
in cash in a single location. In December 2006, just
under 20 mt of pseudoephedrine, a key precursor in
methamphetamine manufacture, was seized at Lazaro
Cardenas seaport in the same province. 
Given the highly competitive and violent nature of the
Mexican criminal syndicates, it is difficult for foreigners
to operate in this market, and 98 per cent of those
arrested for drug trafficking in 2004 were indeed Mex-
ican nationals.
Like the Colombian organizations, Mexican criminal
syndicates often have a dynastic character, involving
multiple family members at the top of the command
structure. For example, the Tijuana cartel was also
known as the Arellano-Felix organization, due to the
prominent role this family has played in the leadership
of the group.  But this should not obscure the fact that
these are large and well organized criminal enterprises,
not family businesses. These groups have proven
resilient in the face of “decapitation”, with deputies or
enforcers taking control when prominent figures are
arrested or killed. It has been argued that some Mexican
syndicates have evolved from traditional hierarchical
organizations to cell-based structures in response to
enforcement efforts, with the Zambada-Garcia organi-
zation being a case in point.46 Regardless, it appears that
large and well-organised groups dominate trafficking in
Mexico.
The presence of large groups is further demonstrated in
the seizure figures. In the first nine months of 2005, at
least five seizures of more than one mt of cocaine were
made, two in Mexican waters, one at a seaport, one at a
clandestine airstrip and one on the highway. There were
also another dozen of more than 100 kg, worth at least
a million US dollars in Mexico. These indicate highly
resourced organizations. On the other hand, there were
many lesser seizures, so smaller-scale trafficking also
occurs. Without more comprehensive seizure data, it
remains difficult to say with any precision what share of
the total market these minor players command, both in
Mexico and throughout the supply chain. 
Finally, the high level of organization is demonstrated in
the low levels of drug use in the country – only 0.4 per
cent of Mexican adults used cocaine in 2002, barely
above the global average of 0.3 per cent. Once in
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Fig. 10: Nationalities of those arrested for drug
trafficking in Mexico in 2004
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Mexico, the allure of greater profits over the border is
too strong for much cocaine to be left behind.
Destination USA
Unfortunately, the US government has so far not sub-
mitted the individual seizures information. Given the
decentralised nature of US law enforcement, there may
be administrative reasons for this omission.  The US
reports seizing 176 mt of cocaine in 2005, but the
details of these seizures are not available.  It is known
that only 31 mt of this total were seized at the US arrival
zones,47 so the balance must have been apprehended
internally or on international waters.
The USA does submit detailed information on the
nationality of federal drug trafficking arrestees however.
In 2004, there were 11,787 people arrested for cocaine
trafficking in the USA by the federal authorities. Of
these, 8,814 (75 %) were US citizens. Of the foreigners
whose nationality was known, 1,410 (56 %) were Mex-
ican nationals, 378 (15 %) were Colombian, and 286
(11 %) were from the Dominican Republic. Dominican
cocaine and heroin wholesalers and retailers have long
been an integral part of the distribution network of the
Colombian drug trafficking organizations, so these two
can arguably be combined. In essence, the two major
groups of rival syndicates (Colombian and Mexican)
comprise 82 per cent of the arrests of foreigners for
cocaine trafficking. Only five Venezuelans were arrested,
and the seven Central American countries combined
make up 96 arrests (4 %). 
If cocaine were sold and re-sold in transit countries,
Venezuelans and Central Americans would be expected
to play a greater role in delivering the drugs to their des-
tinations. While their direct role in US markets has been
diminished, the fact that Colombian nationals continue
to comprise a significant portion of drug trafficking
arrestees in the USA reinforces the idea that the flow of
cocaine is controlled by multi-national groups with the
capacity to source, transport, and market the drug. All
this supports the notion that the bulk of the cocaine
traffic to the USA is controlled by large organizations,
not small networks or the invisible hand of the market.
In summary, while cocaine trafficking to the USA is not
as centralised as it was in the days of the big cartels, it
appears that the bulk of the flow remains in the hands
of large and well-organized syndicates because:
• Multi-ton seizures, worth hundreds of millions of
dollars on arrival in the USA, are found at all
points in the trafficking chain, often comprising a
large share of national annual seizures.
• The trafficking chain appears to be divided
between Colombian and Mexican syndicates, with
an unknown share controlled entirely by Colom-
bian groups.
• While transit country nationals are arrested with
small amounts of drugs all over the world, they do
not appear to be taking control of a significant
share of the drug flow.
• Cocaine use prevalence is low in transit countries,
indicating that most of the drugs (less seizures) are
reaching their highest-value destination.
2.4 Heroin via Central Asia to the Russian 
Federation
In contrast to the trafficking of cocaine to the USA, the
flow of heroin from Afghanistan through Central Asia
to the Russian Federation appears to be less organised.
There are several possible reasons for this. The flow is
more recent, with the use of heroin in Russia only start-
ing in the 1980s and picking up after the collapse of the
former Soviet Union in 1991. The recurrent conflicts
and poverty in Afghanistan have provided an opportu-
nity for illicit production to become widespread.
Poverty and conflicts in Central Asia have also hindered
the development of defences against trafficking. But
these factors may also have retarded the consolidation of
the market – it is difficult to transport large shipments
of drugs when scores of feuding warlords block the way
and roads are in poor repair. As a result, it is only in
recent years that there has been sufficient order for
larger scale groups to coalesce.
Today, Afghanistan is the source of upwards of 90 per
cent of the world’s heroin, but most of this is produced
in the southern and eastern parts of the country. This is
known with some certainty because UNODC does
comprehensive opium crop surveys in each of the major
heroin producing countries. Although estimating traf-
ficking flows is more complicated, there is a strong basis
to believe that most of the heroin produced in
Afghanistan moves out via Iran and Pakistan toward
Europe on what is known as the Balkan Route. This is
based not only on drug seizures but also cultivation pat-
terns and interviews with drug market actors in
Afghanistan. But while the exact amounts are subject to
debate, about a fifth of the Afghan heroin produced,
estimated to be about 100 mt in 2005, leaves the county
to the North though Central Asia toward the Russian
Federation. It would appear that only a small share of
this flow is seized – around 10 per cent. If this were true,
the seizure figures would be a less reliable gauge of the
underlying undetected flows in this region than they are
in the Americas. In particular, this lower interdiction
ratio leaves open the possibility that large shipments are
occurring under the protection of corruption, and that
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seizures merely reflect the small-fry who attempt to
operate without this protection. However, there are
other indicators, such as local heroin use levels, that sug-
gest the trafficking of the drugs through Central Asia is
still highly disorganized.
The destination of most of these drugs is the Russian
Federation, which has one of the highest rates of opiate
use in the world. An estimated 2 per cent of the adult
population annually use either heroin or one of the
many homemade opiate concoctions. The best estimates
place the heroin user population in Russia at about 1.6
million, consuming up to 80 mt of heroin each year,48
worth some US$1.5 billion at wholesale level in Russia.
This is about a tenth of the wholesale value of the US
cocaine market.
The Afghan source
The internal market in Afghanistan appears to be com-
prised of at least four distinct levels:
• A market-driven population of 2.9 million farm-
ers in 2006;
• A semi-regulated stratum of about a quarter of a
million small-scale local traders.
• A small number of large-scale traders, moving
large shipments to the border and, in some cases,
beyond.
• A large number of small-scale cross-border traf-
fickers.
As in Colombia, the cultivation of drug crops in
Afghanistan is diffuse. Cultivation occurred in 28 of 34
provinces in 2006, involving 2.9 million of
Afghanistan’s 23 million people, or 13 per cent of the
entire population.49 It would be implausible to suggest
that 13 per cent of the Afghan population are employed
by, or even directed by, organized crime groups. Most
farmers are not involved in refining the drug, and do
not necessarily have direct contact with those who do.  
Rather, widespread cultivation of opium is largely a
product of the fact that fertile land is scarce in
Afghanistan and alternative livelihoods are in short
supply. A large share of the population subsists on small-
scale agriculture. While opium poppy is more labour-
intensive than other crops, labour is cheap in
Afghanistan, and poppy yields eight times the income of
a comparable area of wheat, the other main crop in the
region. Some 448,000 households farmed 165,000
hectares of poppy in 2006, or just over a third of a
hectare per household, producing an income of
US$1,700 a year per family.50 This is one-seventh the
income earned by coca cultivating households in
Colombia.51
As is the case everywhere, farmers require credit in order
to survive, and one of the primary sources of these
micro-loans appears to be opium traders. Landless farm-
ers must lease the land they wish to till, and are even
more credit dependent. Credit is extended by opium
traders – including shopkeepers, bazaar traders, and
itinerant traders – to be repaid in opium.  Opium has
become a kind of currency, with high value per weight,
a means of storing value. While credit is not the only or
even the dominant reason farmers cultivate opium, the
credit dynamic is a key mechanism by which the market
is ordered.
There are a lot of these creditors/opium traders, an esti-
mated one for every thirteen farmers, or perhaps
225,000 traders in the country.52 Research indicates that
this group is not directed by organized crime, and there
appears to be a lot of competition among them.53 This is
not to say the market is open to just anyone, however.
Regional warlords sanctioned and taxed opium dealings
in the past, and many of these men have assumed posi-
tions of local authority today. It is likely that only those
authorised to deal and willing to pay for the privilege are
allowed to operate.
The opium outputs consolidated by the small-scale
traders are sold at one of many well-known bazaars to
large-scale traders. These consolidated loads are moved
to the border areas, where the drugs are either smuggled
as opium or processed to become heroin in one of a
number of laboratories.54 In the first eight months of
2006, 248 heroin labs were dismantled in Afghanistan.55
The “cooks” who convert the opium to heroin are
largely Pashtun. In the north, they are often Shinwaris
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Fig. 11: Heroin seizures in Afghanistan/Russia
transit zone in 2005
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originating near the Pakistan border, who were among
the first to be exposed to the manufacture of heroin.
They sell their skills to the highest bidder and thus oper-
ate as independent contractors. Most traders appear to
leave the cross-border trafficking to specialist groups,
who may also be of distinct ethnic groups (e.g. Baluchis
in the South of Afghanistan; Uzbeks or Tajiks in the
North).
In the North, in 2006, heroin prices varied by 50 per
cent or more between the province of Balkh, located on
the border with Uzbekistan (US$2,194/kg in March
2007), and the province of Badakhshan, located on the
border with Tajikistan (US$3,500). This is despite the
fact that a major road connects the two regions and they
are a few hundred kilometres apart. It is unlikely that
the real costs of transport between these two locations
would justify a price differential of US$1,300/kg, par-
ticularly given that the quality of opium from
Badakhshan  is known to be better, and notwithstand-
ing the threat of law enforcement in Kunduz.56 This sug-
gests that different stretches of border comprise distinct
markets and that there is scant trading between them, or
prices would quickly approach equilibrium. The lack of
trading between nearby markets suggests high levels of
regional control of supply, likely due to the domination
of strong criminal actors.  On the other hand, it could
also be related to superior law enforcement in Balkh,
which is not known to contain heroin labs, and the
proximity of the higher value market of Iran.
It remains something of a puzzle that these large-scale
traders appear to sell their stocks off in relatively small
amounts to cross border traffickers. While some Afghan
nationals do carry the drug across the border to Tajik-
istan, they do not appear to be involved in trafficking
much further north than that. Afghanis of Tajik ethnic-
ity lack the Russian language skills of their co-ethnics
further north, which may inhibit their movement
toward higher value markets. It may well be that no
single organized crime group has sufficient international
connections to consistently navigate all the local power
structures that stand between Afghanistan and Russia,
but the rewards will be great for the first groups to
manage this feat. At present, however, it appears that
once the drug leaves Afghanistan, the trafficking net-
works are small and market driven.  
The Central Asian link
Seizures in Russia and Central Asia show that multi-
ethnic trafficking groups do exist. But at least at the ini-
tial stages, cross-border ethnicity is key. Tajik or Uzbek
Afghans smuggle the drugs almost exclusively to Tajik-
istan and Uzbekistan respectively. From there, the
heroin may change hands to Kyrgyz or Kazakh nation-
als until reaching Kazakhstan, and thereafter Kazakh or
Russian groups transport it to Russia.  Russian nation-
als have been arrested in connection with large seizures
as far south as Tajikistan, however. It would appear that
Kyrgyz and Kazakh nationals are reliant on the Tajik
and Uzbek groups to provide the drugs for further traf-
ficking. In general, transport through the transit zone
appears to be controlled by the nationals of the transit
zone, with border crossings involving groups of both
states.
In addition, it appears that heroin is bought and sold
multiple times before it reaches its destination in the
Russian Federation. In other words, the movement of
heroin toward Russia is largely a product of independ-
ent national agents pursuing the profits gained by trans-
porting the drugs over a series of borders, not the grand
design of a single organization orchestrating transport
from Afghanistan to Russia.
Exiting Afghanistan to the North, the trafficker is pre-
sented with three countries to choose from: Tajikistan,
Uzbekistan, and Turkmenistan. Based solely on seizure
figures, it would appear that only Tajikistan is heavily
utilized by traffickers, but there remains very little infor-
mation on the situation in Turkmenistan.
It is not surprising that Tajikistan would provide an
attractive target, due to the weakness of the state fol-
lowing its recent civil war (1992-1997) and the fact that
it suffers from the lowest levels of human development
in Central Asia, according to UNDP’s 2006 Human
Development Report. In addition, those who dominate
the heroin producing areas of northern Afghanistan are
primarily Tajik in ethnicity, and many Tajik villages in
other parts of Afghanistan grow poppy. In 2005, Tajik-
istan seized 78 per cent of the heroin among the three
border countries, and 60 per cent of that seized in Cen-
tral Asia as a whole. These figures are all the more
remarkable given that Tajikistan has only 6.5 million
people, about 12 per cent of the regional population, so
its per capita seizures are seven times higher than any
other Central Asian country. While this suggests that
the country is the preferred trafficking route, it also
reflects a substantial achievement of Tajik law enforce-
ment.
Further, Tajikistan still commands the bulk of regional
drug seizures after two years of precipitous drops in the
amount of drugs intercepted: in 2003, seizures were
twice as high. Declines in seizures in Tajikistan after
2003 can be partly attributed to declines in opium pro-
duction in northeastern Afghanistan: in neighbouring
Badakhshan, production declined by 53 per cent in
2005. But it is also tied to the withdrawal of the Russ-
ian border troops, resulting in decreased interdiction
efficiency. The Tajik Government cannot afford to fully
replace these troops, which cost the Russian Govern-
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ment some US$30 million per annum to maintain, and
this is likely to increase the attractiveness of the country
as a drug transhipment route even further. 
Turkmenistan offers a second likely routing, as it is the
only Central Asian country bordering both Afghanistan
and Iran. It lies just across the Caspian Sea, and it has
historically enjoyed political relations with both the Tal-
iban and the Northern Alliance. There have also been
recent increases in production in northwestern
Afghanistan, and it would be odd if production in
Faryab, for example, were headed anywhere but directly
over the border to Turkmenistan. Given these facts, it
was not surprising when 78 per cent of heroin seized in
Central Asia in 1997 was seized in Turkmenistan, or
that some 4.6 mt of opium were seized in 1999,57 or that
during 1995-2000, more than 198 mt of precursor
chemicals, mostly acetic anhydride,58 were also seized.
But in recent years, there has been little recorded activ-
ity, aside from sporadic opium seizures. 
Turkmenistan is perceived to suffer from high levels of
corruption,59 and this is one possible explanation for the
lack of seizures. But there is no reason to believe that
this alleged corruption is a recent development in the
country,60 so it does not explain why seizures suddenly
stopped. In addition, as will be discussed below, very
few Turkmen have been arrested by the Russian author-
ities for trafficking into Russia. In the absence of other
compelling data, it cannot be assumed that Turk-
menistan is a major conduit for northern-bound heroin.
Uzbekistan, in contrast, has a stronger state, and shares
a relatively short border with Afghanistan (137 km).
Instead of entering the country directly, the drugs that
do enter Uzbekistan seem to transit Tajikistan and Kyr-
gyzstan.61 Low seizure levels have been reported in
recent years, not much better than Turkmenistan, but
more Uzbeks have been arrested in Russia.
From Tajikistan it appears that a large share of the drugs
also transit Kyrgyzstan, a country almost as poor and
also encountering instability. From Kyrgyzstan, the
heroin must transit Kazakhstan, which also receives
some traffic from Uzbekistan and, presumably, Turk-
menistan.
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Fig. 12: Kilograms of heroin seized per 100,000
citizens in 2005
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Fig. 13: Breakdown of seizures among Central Asian
countries bordering Afghanistan in 2005
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Fig.14:  Heroin seizures in Tajikistan and 
Turkmenistan, 1997-2005
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Tajik/Kyrgyz/Kazakh corridor. Estimations of preva-
lence in Central Asia are based on the number of regis-
tered addicts or treatment patients.  Known drug users
are asked if they have been registered and this figure is
used as a multiplier. However, given the uncertainties
inherent in this technique, it is probably safest simply to
rely on the raw registration figures themselves for trend
analysis.
What registration data do show is a growing problem,
indicating that, despite its lower sales value, some of the
heroin headed toward the Russian Federation has been
diverted to local markets. The number of registered
users increased rapidly throughout the 1990s, though
growing at a slower rate in the first years of this cen-
tury.63 Such a rise is to be expected when trafficking is
conducted by a large number of independent actors util-
ising couriers who may be paid in kind rather than in
cash, and reinforces the contention that trafficking in
this region is relatively disorganized.
Destination Russia
The Russian government reported seizing 3,897 kg of
heroin in 2004, and 4,674 kg in 2005. Of this, almost
two-thirds (5.6 mt) were made in some 1,870 individ-
ual heroin seizures above 100 grams reported by the
government of the Russian Federation over the two
years. Only eight involved more than 100 kg. Almost 95
per cent involved amounts of less than 6 kg, the whole-
sale value of which was about US$10,000 in
Afghanistan. In other words, these consignments were
within the reach of relatively small criminal networks.
Similarly, most of the seizures made in the Central Asian
countries were minor.
The large (over 100 kg) seizures show no clear pattern,
and thus were probably not the product of a single
organization.  Three were made in Moscow, but some
were made in quite remote locations. The site of the
largest, Tynda district, is deep in Siberia, north of the
Chinese border – the town of Tynda has a population of
about 40,000. Very few large seizures have been
reported in the Central Asian countries in recent years.
Many of the traffickers arrested in the Russian Federa-
tion are citizens of Central Asian countries, particularly
Tajik nationals, who are not necessarily ethnically Tajik.
The Russian government reported 954 heroin seizures
of over 100 grams to the UNODC between 1999 and
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Fig. 16: Registered drug users in Kazakhstan, Kyrgyzstan, Tajikistan, and Uzbekistan
Source: UNODC Regional Office for Central Asia
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Fig. 17: Breakdown of quantities of heroin seized in 
1870 large (100 g +) seizures in the Russian 
Federation, 2004-2005
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2004 in which the nationalities of the traffickers were
specified. Of these, 586 cases (62 %) involved Russian
nationals exclusively. A remarkable 252 involved Tajik
nationals (26 %), operating either alone or in concert
with traffickers of other nationalities. Smaller numbers
of seizures involved nationals of Kazakhstan (16),
Uzbekistan (29), the Kyrgyz Republic (31), and other
national groups (40). No nationals of Turkmenistan
were arrested in these records. Of seizures involving for-
eigners, Tajik nationals were present in more than two
thirds of the cases.  However, recall that few Tajik
nationals were arrested in Kazakhstan.  So while Tajik
groups are important in both cross-border operations
with Afghanistan and trafficking within Russia, it is pos-
sible that they do not control the heroin during the
intermediate trafficking period.
Tajikistan is quite a distance from Russia, but a 2003
International Organization for Migration survey found
that over a quarter of Tajik households have a member
working abroad, an estimated 84 per cent of whom are
in Russia, representing perhaps half a million people.64
Many are employed as poorly paid labourers and some
of them may serve as couriers to supplement their
incomes. Though the poverty of ethnic Tajiks along the
border with Afghanistan and in Russia seems to favour
their involvement in drug trafficking, it does not appear
that large Tajik groups control the entire drug traffick-
ing chain, due the lack of Tajik nationals arrested in
Kazakhstan.
Of course, given the relatively small share of the total
drug flow seized (probably less than 10 %) and the small
size of the seizures, it is possible that these seizures and
arrests comprise only those portions of the market that
are not shielded by corruption. The prominence of Tajik
nationals in the arrest figures could be a product of the
targeting of this vulnerable group by law enforcement.
Past research on drug markets in the Russian Federation
has emphasised high levels of corruption, but has also
demonstrated the essential disorganization of this
market.65 The Russian Ministry of Internal Affairs esti-
mates that there are 450 criminal organizations in the
country with about 12,000 members.  This suggests an
average group size of 26 members, and a national rate of
eight organized crime members per 100,000 popula-
tion. Only nine of these groups are said to have inter-
national links.66 In 2005, the Russian Federal Drug
Control Service attributed 14,415 out of 110,310 drug
distribution cases to criminal groups (13 %), a share
unchanged from the previous two years.67 These esti-
mates by Russian law enforcement authorities also sup-
port the notion that most of the market remains
disorganized.
In summary, once heroin leaves Afghanistan for Russia,
the international trafficking of the drug appears to be
conducted by small groups, because:
• Most heroin seizures above 100 grams, both en
route and in Russia, are small (less than 6 kg),
Date Location Nationality Quantity Details
3 March 2004 Moscow Russian Fed 178 kg Sourced in Tajikistan
6 April 2004 Zubovo-Polyana
1 Russian Fed
2 Tajikistan
1 Ukraine
1 Uzbekistan
103 kg Sourced in Tajikistan
26 April 2004 Tynda District Czech Rep 536 kg Concealed in clothing
21 June 2004 Ekaterinburg —— 150 kg In freight from Uzbekistan
17 July 2004 Novosibirsk Region —— 237 kg In beverages on train from Tajikistan
26 August 2005 Moscow —— 165 kg ——
29 August 2005 Moscow —— 156 kg ——
14 October 2005 Orenburg —— 362 kg ——
188
World Drug Report 2007
Table 2: Eight seizures of above 100 kg of heroin in the Russian Federation 2004-2005
Source: UNODC Individual Seizures Database
Fig.18: Non-Russian involvement in large Russian 
heroin seizures, 1999-2004
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within the reach of small groups.
• The drugs appear to be sold and re-sold en route,
with national groups controlling each link of the
supply chain and very little Afghan presence in
Russian markets.
• Arrest figures do not exclude the possibility that
the drugs pass from Tajik hands to those of other
groups and back to Tajik groups again, with Tajik
nationals present in 26 per cent of major heroin
seizures in Russia in 2004/2005.
• Heroin use rose steeply in Central Asia in the
1990s, indicating much of the drugs did not reach
their highest value destination.
2.5 Tracking trafficking
The two examples discussed above highlight two
extremes of a spectrum: on the one hand, the highly
organized groups active in shipping multi-million dollar
consignments of cocaine from Colombia to the USA;
on the other, the many, uncoordinated players who,
responding to market incentives, move heroin from
Afghanistan to Russia.  It appears that the two regions
are vaguely converging, however – cocaine trafficking
has become less organized since the days of the Medellin
and Cali cartels, and the heroin trade, at least in the
North of Afghanistan, is growing increasingly and is get-
ting more organized. The potential for large organized
crime groups emerging in Central Asia appears to be
great, given the profits involved. 
Similar analyses could be done for the movement of
cocaine from Colombia to Europe, or the movement of
heroin via the Balkan route, or any of a number of other
trafficking patterns. The key limitation is the lack of
standardised data. UNODC needs greater input from
Member States to its individual seizures database,
including detailed information on the nationalities of
traffickers and the techniques employed. On this basis,
important analysis of the world drug trafficking situa-
tion could be completed for the benefit of all. 
Indeed, such an analysis need not be limited to drugs.
Similar databases can be developed for trafficked per-
sons, or firearms, or any other smuggled commodity to
produce a standardised and quantified barometer of
transnational criminal activity as a supplement to exist-
ing intelligence-based assessments. Issues for which
there are currently no accurate global figures, such as
human trafficking, are difficult to discuss without this
basic data.
Determining the degree of organization is important in
formulating policy. Despite the claim that there may be
as many as 400 “baby cartels” operating in Colombia
today, they are clearly not all of the same importance. If
all were equal, each would be responsible for moving
just 1.25 mt of cocaine every year, but individual
seizures are made that are more than ten times that
amount. There are clearly some major players running
the cocaine market, and their removal from the scene
could represent a pivotal setback for cocaine trafficking.
Further, the process of combining the produce of nearly
70,000 farm families distributed among 23 provinces is
highly reliant on the organization skills and field pres-
ence of the insurgent and paramilitary groups. If this
link in the supply chain were disrupted, it could also be
devastating for the cocaine market. 
On the other hand, it would be difficult to imagine a
similar scenario working in the de-centralised markets
of Afghanistan and Central Asia.  Here, the consolida-
tion process from farmers to traffickers works by a
sophisticated market network of traders and bazaars.
While the drugs appear to come under the control of a
limited number of players at the top of the Afghan
market, this concentration does not appear to be fully
exploited today, and consolidated loads appear to be
broken down again in order to accommodate the reali-
ties of disorganized trafficking.  Even removing the top
Afghan drug lords may not prevent the decentralised
traders from carrying on the cross-border trade with
their equally decentralised trafficker counterparts.
Drugs percolate through Central Asia, changing hands
several times, indicating the flow is not centrally
planned. There is no “head” of Central Asian trafficking
to decapitate. Rather, detailed information is required
about the market mechanisms that siphon heroin from
Afghanistan to Russia. The incentives and deterrents
informing this market must be studied and interven-
tions created on this basis.
Much more could be done with this data if it were more
complete. As with any international undertaking of this
scale, the international efforts to combat drug traffick-
ing need to be monitored in an objective, standardised
way if lessons are to be learned from successes and fail-
ures. The myriad individual interdiction experiences of
law enforcement agencies around the world need to be
pooled for centralised analysis.  This can be teamed with
data on issues like prices and drug usage, existing but
under-developed data sources, to create powerful
models for probing the world of illicit markets. 
One example of transnational information sharing and
a coordinated approach to drug issues is the efforts
being undertaken under the aegis of the “Paris Pact”.68
West and Central Asian and European countries
affected by heroin trafficking from Afghanistan are now
working together, with the support of UNODC, to
coordinate their efforts to improve the quality of data
and information, standardize data collection methods,
and strengthen their respective analytical capacities in
the field of counternarcotics. Efforts of this sort are
essential to ensure a better understanding of drug traf-
ficking flows, as well as to develop effective responses to
transnational drug markets.
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3. STATISTICAL ANNEX

2005
Variation on 
2005
2006
Net opium poppy cultivation 104,000 ha +59% 165,000 ha
In per cent of agricultural land 2.30% 3.65%
In per cent of global cultivation 62% 82%
Number of provinces affected (total: 34) 26 28
Eradication 5,000 ha +210% 15,300 ha
Weighted average opium yield 39.3 kg/ha -6% 37.0 kg/ha
Potential production of opium 4,100 mt +49% 6,100 mt
In per cent of global production 87% 92%
Number of households involved in opium cultivation 309,000 +45% 448,000
Number of persons involved in opium cultivation 2.0 million 2.9 million
In per cent of total population (23 million) 8.7% 12.6%
Average farm-gate price of dry opium at harvest time US$ 138/kg -9% US$ 125/kg
Afghanistan GDP2 US$ 5.2 billion +29% US$ 6.7 billion
Total farm-gate value of opium production US$ 0.56 billion +36% US$ 0.76 billion
in per cent of GDP 11% 11%
Total export value of opium to neighbouring countries US$ 2.7 billion +15% US$ 3.1 billion
In per cent of GDP 52% 46%
Gross trafficking profits to Afghan traffickers US$ 2.14 billion +9% US$ 2.34 billion
Household average yearly gross income from opium 
of opium growing families
US$ 1,800 -5% US$ 1,700
Per capita gross income of opium growing farmers US$ 280 -7% US$ 260
Afghanistan’s GDP per capita US$ 226 +28% US$ 290
Indicative gross income from opium per ha US$ 5,400 -15% US$ 4,600
Indicative gross income from wheat per ha US$ 550 -4% US$ 530
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3.1.1 Afghanistan
Fact Sheet - Afghanistan Opium Survey 20061
Cultivation and eradication
The area under opium poppy cultivation in Afghanistan
increased by 59 per cent from 104,000 hectares in 2005
to 165,000 hectares in 2006. This is the largest area
under opium poppy cultivation ever found in
Afghanistan. As a result of this upsurge, the share of
Afghanistan in global opium poppy cultivation
increased from 65 per cent in 2005 to 82 per cent in
2006. Most of the opium poppy cultivation took place
in the southern region of Afghanistan, which accounted
for 62 per cent of the total cultivation. Only six out of
1 The information in this section comes from the report on the Afghanistan Opium Survey 2006 (UNODC/Ministry of Counter Narcotics,
Afghanistan, October 2006), and can also be found on the internet (http://www.unodc.org/unodc/en/crop_monitoring.html). 
2 Source : Afghan Government, Central Statistics Office, preliminary estimate.
Production
In 2006, the average opium yield per hectare was
slightly lower than in 2005. The increase in potential
opium production by 49 per cent was therefore less
pronounced than the increase for cultivation. In 2006,
6,100 metric tons of opium were produced, out of
which 62 per cent were produced in the southern
region of the country. Opium production in
Afghanistan accounted for 92 per cent of the global
opium production.
Region 2005 (ha) 2006 (ha) Change 2005-2006 2006 as % of total
Southern 46,147 101,900 +121% 62%
Northern 28,282 22,574 -20% 14%
Western 16,543 16,615 0% 10%
North-Eastern 8,734 15,234 +74% 9%
Eastern 4,095 8,312 +103% 5%
Central 106 337 +218% 0%
Rounded Total 104,000 165,000 +59% 100%
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Afghanistan’s 34 provinces were free of opium poppy
cultivation in 2006. In the 12 years since the start of the
UNODC opium surveys in 1994, opium cultivation
increased in eight years, and decreased in only four. 
UNODC does not conduct a cannabis cultivation survey
in Afghanistan. However, based on observations made
during the annual opium survey, the area under cannabis
cultivation in 2005/2006 was estimated at about 50,000
hectares compared to 30,000 hectares in 2004.
In 2006, a total of 15,300 hectares of opium poppy
fields were eradicated by Afghan authorities. This is
roughly 8 per cent of the area under opium poppy cul-
tivation, up from 5 per cent in 2005. Overall, two thirds
of cultivated opium poppy in each village was left stand-
ing after the eradication teams had carried out their
activities.
Southern
 62%
Northern
16%
Eastern
5%
North-
Eastern
10%
Western
9%
Afghanistan, potential opium production by region
(mt), 2006
Prices
Despite the strong increase in production, farm gate
prices at harvest time in 2006 were only slightly lower
than in 2005. On average, farmers fetched US$ 94/kg
for fresh opium and US$ 138/kg for dry opium. During
2006, trader prices for dry opium were relatively stable. 
The strong regional price differences observed at the
beginning of 2006, with low prices in the northern and
southern regions and high prices in the eastern region,
became less pronounced towards the end of the year.
The overall trend was downward. 
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3. Statistical Annex Production
Farm gate value
The farm gate value of the opium harvest amounted to
US$ 0.76 billion, or 11 per cent of licit GDP,  in 2006.
The total potential value of Afghanistan’s 2006 opium
harvest accruing to farmers, laboratory owners and
Afghan traffickers reached about US$ 3.1 billion. This
is almost half the size of the country’s licit GDP of US$
6.7 billion, or 32 per cent of the overall economy
(including the opium sector).
Households involved 
An estimated 448,000 households, or 2.9 million per-
sons, were involved in opium poppy cultivation in
2006. This is equivalent to 12.6 per cent of
Afghanistan’s total population of 23 million. 
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3.1.2 Bolivia
FACT SHEET - Bolivia Survey 20063
2005
Variation
on 2005
2006
Coca cultivation 
Of which in the Yungas of La Paz
in Chapare
in Apolo
Of which permitted by Bolivian law 1008
25,400 ha
18,100 ha
7,000 ha
300 ha
12,000 ha
+8%
+4%
+19%
0%
27,500 ha
18,900 ha
8,300 ha
300 ha
12,000 ha
Average annual sun-dried coca leaf yield
in Chapare
in the Yungas of La Paz4
in Apolo
2,764 kg/ha
1,317 kg/ha
820 kg/ha
2,764 kg/ha
1,317 kg/ha
820 kg/ha
Production of sun-dried coca leaf 43,000 mt +12% 48,000 mt
Potential production of cocaine HCl
In per cent of the global cocaine production
80 mt
8%
+18% 94 mt
10%
National weighted average farm-gate price of sun-dried
coca leaf (outside state market)
US$ 4.3/kg -9% US$ 3.9/kg
Average farm-gate price of sun-dried coca leaf 
in Chapare
US$ 4.1/kg -22% US$ 3.2/kg
Total farm-gate value of sun-dried coca leaf production US$180 million 0% US$ 180 million
GDP5
Farm-gate value of coca leaf production 
in per cent of GDP
US$ 8.4 billion
2.1%
US$ 8.7 billion
2.0%
Value of agricultural sector
Farm-gate value of coca leaf production 
in percent of value of 2003 agricultural sector
US$ 1.5 billion
12%
US$ 1.37 billion
13%
Reported eradication of coca bush 6,073 ha -17% 5,070 ha
Reported seizure of coca leaves 900 mt +52% 1,364 mt
Reported seizure of cocaine base 10,152 kg +26% 12,779 kg
Reported seizure of cocaine hydrochloride 1,309 kg 0% 1,309 kg
3 The information in this section comes from the report on Coca Cultivation in the Andean Region (UNODC/Governments of Bolivia, Colombia
and Peru, 2007), and can also be found on the internet (http://www.unodc.org/en/crop_monitoring.html). 
4 Figures for 2005 were updated based a new UNODC study on coca leaf yield in the Yungas of La Paz.
5 Source: INE 2006. 
202
World Drug Report 2007
0
10,000
20,000
30,000
40,000
50,000
H
ec
ta
re
s
Cultivation 50,300 47,900 45,300 47,200 48,100 48,600 48,100 45,800 38,000 21,800 14,600 19,900 24,400 23,600 27,700 25,400 27,500 
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Bolivia, coca cultivation (hectares), 1990 to 2006
Cultivation and eradication
Although Bolivia is the third largest producer of coca
leaf in the world, it still trails far behind the world’s
largest producer, Colombia. In 2006, Bolivia accounted
for 18 per cent of global coca cultivation. The area
under coca cultivation increased by 8 per cent compared
to 2005, and reached 27,500 hectares in 2006. This
increase offsets the decrease achieved between 2004 and
2005, when the coca cultivation area declined by 8 per
cent from 27,700 hectares to only 25,400 hectares.
Overall, the area cultivated with coca bush in Bolivia
remained much lower than in the early and mid-1990s,
when coca was grown on over 45,000 hectares.
As in previous years, the Yungas of La Paz constituted the
largest coca cultivating region in Bolivia with over two
thirds of the total area under coca bush, followed by Cha-
pare, with just under one third of the area. Still, most of
the total coca area increase of 2,100 hectares took place
in Chapare, where the coca cultivated area increased by
19 per cent, or 1,300 hectares, whereas the Yungas of La
Paz accounted for only 800 hectares of the total increase. 
The Government of Bolivia reported a decrease of the
area eradicated by 17 per cent to 5,070 hectares in 2006.
Practically all the eradication took place in the region of
Chapare. 
Chapare
30%
(8,300 ha)
Yungas of La Paz
69%
(18,900 ha)
Apolo
1% (300 ha)
Bolivia, coca cultivation by region, 2006 Production
Based on new field research on the coca leaf yield in the
Yungas of La Paz, the potential production of cocaine
HCl in Bolivia in 2006 was 94 metric tons, an increase
by 18 per cent compared to the revised production esti-
mate of 80 metric tons in 2005. The increase in cocaine
production is much more pronounced than the coca
cultivation increase due to the fact that most of the area
increase took place in Chapare, where coca leaf yields
are more than twice the amount recorded in the Yungas
of La Paz. 
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Prices
In Bolivia, farm-gate prices for sun-dried coca leaf fell
by 9 per cent to a national average of only US$3.9/kg,
which is well below the price level reached during the
period 2000 to 2004. 
The even sharper decrease in price of 22 per cent in
Chapare can be attributed to the greater availability of
coca leaf on the illicit market due to higher production,
despite government efforts to prevent coca leaf trading
outside the market authorized by the Government.
Prices for coca leaf in Bolivia continued to be consider-
ably higher than in neighbouring Peru. 
Bolivia, potential cocaine production (metric tons), 1990 to 2006
Bolivia, farm-gate prices for sun-dried coca leaf in Chapare region (US$/kg), 1990 to 2006
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Figures for 2004 and 2005 were updated based a new UNODC study on coca leaf yield in the Yungas of La Paz.
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3.1.3 Colombia
FACT SHEET - Colombia Survey 20066
6 The information in this section comes from the report on Coca Cultivation in the Andean Region (UNODC/Governments of Bolivia, Colombia
and Peru, 2007), and can also be found on the internet (http://www.unodc.org/en/crop_monitoring.html). 
7 Includes laboratories processing coca paste/base, cocaine HCl, heroin, morphine, potassium permanganate, and non-specified.
2005
Variation on
2005
2006
Net coca cultivation (rounded total) 
Of which Meta-Guaviare region
Pacific region
Putumayo-Caqueta region
Central region 
Elsewhere
86,000 ha
25,970 ha
17,650 ha
13,950 ha
15,630 ha
12,570 ha
-9%
-21%
+7%
+23%
-22%
-27%
78,000 ha
20,540 ha
18,810 ha
17,220 ha 
12,130 ha
9,170 ha
Reported cumulative aerial spraying of coca bush 138,775 ha +24% 172,025 ha
Reported manual eradication of coca bush 31,285 ha +32% 41,346 ha
Average farm-gate price of coca paste
US$ 910/kg
COP 2,109,000/kg
-3%
-2%
US$ 879/kg
COP 2,070,000/kg
Potential production of cocaine
In % of world cocaine production 
640 mt
65%
-5% 610 mt
62%
Average cocaine price (wholesale)
US$ 1,860/kg
COP 4,315,000/kg
-5%
-4%
US$ 1,762/kg
COP 4,155,000/kg
Reported opium poppy cultivation 1,950 ha -48% 1,023 ha
Potential opium latex production 59 mt -48% 31 mt
Potential heroin production 2.5 mt -48% 1.3 mt
Average farm-gate price of opium latex US$ 230/kg +3% US$ 237/kg
Average heroin price (wholesale) US$ 9,050/kg +12% US$ 10,103/kg
Reported seizures of cocaine 173,265 kg -27% 127,326 kg
Reported seizures of heroin 745 kg -41% 442 kg
Reported number of clandestine laboratories7 destructed 1,953 +16% 2,270
Cultivation and eradication of coca
In 2006, Colombia remained the country with the
world’s largest coca growing area, which represented one
half of the global area under coca bush. Coca cultivation
in Colombia declined by 9 per cent from 86,000
hectares in 2005 to only 78,000 hectares in 2006. Over-
all, despite the increases and decreases observed in recent
years, coca cultivation in Colombia has proven to be rel-
atively stable at around 80,000 hectares since 2003.
Meta-Guaviare remains the largest cultivation region
with almost 21,000 hectares of coca bush, or just over a
quarter of the total coca cultivation area, closely fol-
lowed by the Pacific and Putumayo-Caqueta regions.
Considerable decreases in the Meta-Guaviare, Central
and Orinoco regions in 2006 were partly offset by
strong increases in the Putumayo-Caqueta region, once
the largest cultivation region. 
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In 2006, the Colombian authorities further intensified
their eradication efforts, especially in higher yielding
regions such as Meta-Guaviare, Orinoco and Putu-
mayo-Caqueta. The area of coca bush eradicated
reached a record level of over 213,000 hectares, which
includes about 172,000 hectares of spraying and 41,346
hectares of manual eradication. The cumulative area
eradicated in 2006 was 2.7 times larger than the net cul-
tivation area, which indicates an intensity of eradication
activities never reached before. 
Cultivation and eradication of opium poppy
Colombia is one of the smaller opium cultivating coun-
tries and its contribution the world opium production
is declining. Opium poppy in Colombia is mainly being
cultivated on mountain sides in the south-west of the
country. According to Government reports, the area cul-
tivated with opium poppy continued to decline in 2006
and reached just over 1,000 hectares, a reduction by
almost half compared to 2005. Eradication efforts of
opium poppy remained intensive in comparison to the
level of cultivation. 
Production
In 2006, the potential production of cocaine HCl in
Colombia amounted to 610 metric tons, a decrease by
5 per cent or 30 metric tons compared to 2005. As a
consequence of this decrease and simultaneous produc-
tion increases in Bolivia and Peru, Colombia’s share of
the world cocaine production fell from 65 per cent in
2005 to 62 per cent in 2006. 
Prices for coca paste, cocaine, and opium
Overall, prices for coca-related products have been
remarkably stable over the last five years in the case of
coca paste and for an even longer period in the case of
cocaine HCl. 
The annual average of the farm-gate prices for coca
paste, the first derivate in the cocaine production chain,
changed little compared to 2005. However, the annual
average hides a price increase by 38 per cent from a five-
year low of 1,714,000 Colombian pesos in January
2006 to 2,360,000 Colombian pesos in December
2006, which is the highest monthly average observed
since the start of price monitoring in 2000. The
monthly fluctuations in the price of coca paste can
partly be attributed to the eradication campaigns.
Colombia, coca cultivation (hectares), 1990 to 2006
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2002 2003 2004 2005 2006
‘000
COP
US$
‘000
COP
US$
‘000
COP
US$
‘000
COP
US$
‘000
COP
US$
Opium latex (farm-gate) 529 211 444 154 433 164 534 230 560 237
Heroin (wholesale) 21,370 8,520 16,561 5,740 20,067 7,635 21,051 9,050 23,822 10,103
Colombia, prices for opium latex and heroin (COP/kg and US$/kg), 2002 to 2006
Colombia, monthly farm-gate prices for coca paste (‘000 COP/kg), 2000 to 2006
Colombia, annual wholesale prices for cocaine HCl (US$ and ‘000 COP), 1991 to 2006
In 2006, prices for opium latex and heroin continued to increase slightly for the second consecutive year. The price
increases are thought to reflect the reduction in opium poppy cultivation in Colombia. 
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While wholesale prices for cocaine HCl in Colombian pesos fell for the second consecutive year, it was the first time
in three years that it fell in US dollars. It is noteworthy that over the last 16 years, the national average cocaine HCl
prices in US dollar terms have remained in a relatively narrow range between US$ 1,350 and US$ 1,860 per kg. As
most of the cocaine HCl from Colombia is meant for export, US dollar prices for cocaine HCl may give a good
insight into the dynamics of the international illicit drug market, as far as prices are concerned.
  
Cultivation and eradication
In early 2006, Lao PDR declared that it was virtually
opium poppy-free. Opium poppy cultivation has
declined by over 90 per cent since 1998, when cultiva-
tion culminated at 26,800 hectares. 
In 2006, the area under opium poppy cultivation in Lao
PDR was estimated at 2,500 hectares. This is an increase
of 39 per cent compared to 2005 (1,800 hectares). How-
ever, in absolute terms, the level of opium poppy culti-
vation remained at a very low level. Cultivation is mainly
concentrated in seven northern provinces of Lao PDR.
The Government of Lao PDR reported intense eradica-
tion activities in the cultivation areas, including after the
annual opium survey, on which the cultivation estimate
is based. 
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2005
Variation on
2005
2006
Opium poppy cultivation 1,800 ha +40% 2,500 ha
Average opium yield 8 kg 0% 8 kg
Potential production of opium 14.4 mt +40% 20 mt
Number of villages growing opium poppy 270 n/a
Number of households cultivating opium poppy 6200 -6% 58009
Average farm gate price of opium US$ 521/kg +6% US$ 550/kg
Total potential value of opium production US$ 7.4 million +49% US$ 11 million
Average annual cash income of opium growing households
1,457,000 kip
(US$ 139)
n/a
Opium growing households with rice deficit 57% n/a
Average annual cash income of households not 
cultivating opium poppy
2,418,000 kip
(US$ 231)
n/a
Eradication10 2,575 ha -41% 1,518 ha
Number of opium addicts11 20,160 11,200
Average drug prevalence rate 
(based on 8 northern provinces in 2005 and 6 in 2006)11
1% 0.58%
3.1.4 Lao PDR
FACT SHEET - Laos Opium Survey 20068
8 The information in this section comes from the report on Opium Poppy Cultivation in the Golden Triangle (UNODC/Governments of Lao PDR,
Myanmar, and Thailand, October 2006), and can also be found on the internet (http://www.unodc.org/unodc/en/crop_monitoring.html).
9 Source: Lao Commission for Drug Control and Supervision (LCDC), provincial authorities survey. 
10 Source: LCDC.
11 Source: LCDC. Survey areas of 2005 and 2006 are not comparable.
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Production
The potential production of dry opium for the year 2006 was 20 metric tons, which is an increase of about 40 per
cent compared to 2005. As in 2005, weather conditions were favourable for opium poppy cultivation, and the opium
yield was estimated at 8 kg/ha. 
Lao PDR, potential opium production (metric tons), 1990 to 2006
Lao PDR, opium poppy cultivation (hectares), 1990 to 2006
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Prices
In Lao PDR, opium is mainly bought and consumed by
local addicts. In 2006, opium prices remained high with
US$ 550 per kg, an increase of 5 per cent compared to
2005.
Laos, opium prices at farm gate (US$/kg), 
2002 to 2006
Households
The number of opium poppy cultivation households in
2006 was 5,800, as reported by the Government. It
seems that only a few households abandoned opium
poppy cultivation in 2006 compared to previous years.
The lack of viable alternative income strategies in
remote rural areas and the high opium prices might have
contributed to this situation. The high price level was
also responsible for a disproportionate increase of the
total value of the opium production by 49 per cent,
while the area under cultivation only increased by 40
per cent.
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Year 2005
Variation 
on 2005
Year 2006
Opium poppy cultivation in Myanmar13 32,800 ha -34% 21,500 ha
Opium poppy cultivation in Shan State 30,800 ha -33% 20,500 ha
Opium yield (weighted by area) 9.5 kg/ha +54% 14.6 kg/ha
Potential production of opium in Myanmar 
(including the Shan State)
312 mt +1% 315 mt
Opium poppy eradication in the Union of Myanmar14 3,907 ha + 2% 3,970 ha
Average farm-gate price of opium15 US$ 187/kg +23% US$ 230/kg
Total potential farm-gate value of opium production US$ 58 million +25% US$ 72 million
Estimated number of households involved in opium poppy
cultivation in Myanmar
193,000 -34% 126,500
Number of persons involved in opium poppy cultivation in
Myanmar
965,000 -34% 632,500
Estimated number of households involved in opium poppy
cultivation in the Shan State
181,000 -34% 120,000
Household average yearly income in opium producing 
households (Shan State)
Of which from opium sale
Per capita income in opium producing households 
(Shan State)
US$ 292
US$ 152
(or 52%)
US$ 58
+50%
+ 43%
+50%
US$ 437
US$ 217
(or 50 %)
US$ 87
Household average yearly income in non-opium poppy 
producing household (Shan State)
Per capita income in non-opium producing households 
(Shan State)
US$ 364
US$ 73
-12%
US$ 318
US$ 64
Addiction rate in Shan State and Kachin 
(Population aged 15 and above) 
0.57%
(including Wa)
n.a.
0.60%
(excluding Wa)
3.1.5 Myanmar
Fact Sheet - Myanmar Opium Survey 200612
12 The information in this section comes from the report on Opium Poppy Cultivation in the Golden Triangle (UNODC/Governments of Lao
PDR, Myanmar, and Thailand, October 2006), and can also be found on the internet: (http://www.unodc.org/unodc/en/crop_monitoring.html).
13 In 2006, an additional four townships in Kachin State and two in Kayah State were included into the survey.
14 Source: Central Committee for Drug Abuse Control (CCDAC), Government of Myanmar.
15 For 2006: price at harvest time.
Cultivation and eradication
In 2006, the total area under opium poppy cultivation
was estimated at 21,500 hectares, representing a
decrease of 34 per cent compared to 2005 (32,800
hectares). The largest cultivation areas were found in
South Shan State, where 72 per cent of the national cul-
tivation took place. While other cultivation areas such
as Kachin, North Shan and Wa were on the decline, the
area under opium poppy increased sharply in South and
East Shan. Opium poppy cultivation practices seemed
to change in South Shan, where farmers prolonged the
cultivation season by using multi-stage cropping, or
planting outside the typical opium poppy season. Signs
of intensification such as irrigation and application of
fertilizer were also observed. 
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Myanmar, opium poppy cultivation (hectares), 1990 to 2006
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Opium poppy eradication as reported by the Government of the Union of Myanmar (hectares), 2002 to 2006
Administrative Unit 2002 2003 2004 2005 2006
North Shan State 6,223 235 172 1,211 76
South Shan State 511 182 2,170 1,203 3,175
East Shan State 14 91 195 124 32
S. R. 2 (Wa) 94 55 0 0 0
Shan State 6,842 563 2,537 2,538 3,283
Kachin State 97 56 126 1,341 678
Kayah State 527 9 83 8 0
Other States 3 8 74 20 9
Total 7,469 638 2,820 3,907 3,970
Myanmar, distribution of opium poppy cultivation by state, 2006
Official reports from the Government indicated that the
level of opium poppy eradication in 2006 (3,970
hectares) was similar to 2005 levels. The Government
increased its eradication activities specifically in South
Shan, where an upsurge of cultivation was observed,
while eradication decreased in the other regions. Over-
all, the decrease in cultivation can be largely attributed
to the observance of the opium ban in Wa and North
Shan, and not to an increase in eradication. 
Opium cultivation in Myanmar continues to decline.
Since 2002, the year of the first joint GoUM/UNODC
survey, opium poppy cultivation has fallen 73 per cent.
Remarkably, no opium cultivation was observed in the
Wa region in 2006.  In 2005, this region contributed to
30 per cent of the national opium poppy cultivation.
The decline in cultivation poses serious challenges for
the rural population in the remote areas of this region,
who do not have viable alternative income strategies. 
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Region
2005 2006
Non-growing
villages
Growing villages
Non-growing
villages
Growing villages
East Shan 327 205 464 217
North Shan 276 309 447 383
South Shan 188 169 230 210
Kachin 366 256 715 258
Weighted National Average 187 230
Myanmar, average opium poppy prices at harvest time (US$/kg), 2005 to 2006
Production
In 2006, weather conditions were favourable for opium
poppy cultivation. In addition, improved cultivation
practices in the main cultivation area led to higher
yields, which increased to 14.6 kg/ha in 2006 as
opposed to only 9.5 kg/ha in 2005. With 315 metric
tons of dry opium, the level of opium production in
2006 remained therefore at about the 2005 level,
despite the cultivation decreases. 
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Prices
The average farm gate price of opium at harvest time
was estimated at US$ 230 per kg. This represents an
increase of 23 per cent compared to 2005. Regional
price differences were pronounced with the highest
prices in low cultivation areas of Kachin and North
Shan and the lowest prices in the main cultivation areas
South and East Shan. The regional price differences
seem to reflect well the scarcity or availability of opium
in different regions, as well as the fragmentation of the
opium market caused by opium bans in some regions. 
Myanmar, potential opium production (metric tons), 1990 to 2006
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Household income and strategies
In 2006, a much smaller number of households (minus
34 per cent) produced the same amount of opium due
to higher yields and sold it for a much higher price com-
pared to 2005. As a consequence, the total value of the
national opium production, which increased consider-
ably, was distributed among fewer households. This
concentration led to an unusually high average house-
hold cash income of US$ 437 in opium cultivating
households in 2006, an increase by 50 per cent com-
pared to 2005. 
In 2006, the cash income of households in villages that
never grew opium poppy was higher than in villages that
stopped cultivation, as these villages could not find ade-
quate ways of substituting the lost income from opium.
The most common strategy for farmers who had
stopped opium poppy cultivation was to grow more
(upland) rice or maize and sell livestock. Villages with
access to paddy land were less likely to cultivate opium
poppy as households generally achieved a higher degree
of food self-sufficiency. 
Addiction
In the Shan State (excluding Wa region), opium addic-
tion affected 0.60 per cent of the rural adult population
in 2006. Within the survey area, the average level of
addiction was 2.16 per cent in villages with opium
poppy cultivation, which is significantly higher than in
villages where opium poppy was not cultivated (0.25
per cent). 
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Wholesale prices for dry opium at Mong Pawk, Wa Special Region 2, Eastern Shan State (US$/kg), 1999 to 2007
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3.1.6 Peru
FACT SHEET - Peru Survey 200616
16 The information in this section comes from the report on Opium Poppy Cultivation in the Golden Triangle (UNODC/Governments of Lao PDR,
Myanmar, and Thailand, October 2006), and can also be found on the internet (http://www.unodc.org/unodc/en/crop_monitoring.html).
17 Figure for 2005 was revised based on updated information available on the amount of coca leaf necessary to produce one kilogramme of cocaine
HCl.
2005
Variation
on 2005
2006
Coca cultivation
Of which in Alto Huallaga
Apurímac-Ene
La Convención-Lares
Elsewhere
48,200 ha
16,000 ha
15,000 ha
12,500 ha 
4,200 ha
+7%
+7%
+2%
+2%
+38%
51,400 ha
17,100 ha
15,800 ha
12,700 ha
5,800 ha
Weighted average sun-dried coca leaf yield 2,200 kg/ha 2,200 kg/ha
Potential production of sun-dried coca leaf 106,000 mt +8% 114,100 mt
Potential production of cocaine HCl17
In per cent of global production
260 mt
27%
+8% 280 mt
28%
Average farm-gate price of sun-dried coca leaf US$ 2.87/kg -12% US$ 2.52/kg
Potential farm-gate value of sun-dried coca leaf US$ 307 million -7% US$ 285 million
Average price of coca paste US$ 638/kg -14% US$ 550/kg
Average price of cocaine HCl US$ 897/kg -8% US$ 823/kg
Reported eradication of coca cultivation 12,237 ha +4% 12,688 ha
Reported seizure of coca paste 4,583 kg +10% 5,044 kg
Reported seizure of cocaine HCl 17,815 kg -17% 14,749 kg
Reported seizure of opium latex 505 kg -78% 109 kg
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Production
Based on updated information on the amount of coca
leaf necessary to produce one kilogram of cocaine HCl,
the total potential cocaine production in 2006
amounted to 280 metric tons, which is an increase of 8
per cent compared to 2005. While this is the highest
production figure since 1998, it is still only about half
the amount registered during the cocaine production
peak in Peru in 1992. In 2006, Peru accounted for 28
per cent of the global cocaine production. 
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Peru, coca cultivation by region, 2006
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Cultivation and eradication
In 2006, coca cultivation in Peru increased by 7 per cent
and amounted to 51,400 hectares. Despite this increase,
coca cultivation remained well below the levels registered
in the mid 1990s, when Peru was the world’s largest cul-
tivator of coca bush. However, Peru remains the second
largest coca cultivating country behind Colombia, and
accounts for one third of the global cultivation.
Although there was only a moderate increase in the coca
cultivation in the three major cultivating regions, Alto
Huallaga, Apurimac and La Convencion-Lares, they
were still the largest contributors to the overall increase
of 3,200 hectares in absolute terms. Furthermore, sev-
eral of the smaller cultivation areas grew rapidly and a
new cultivation area was discovered in the Brazil-
Colombia-Peru border triangle. 
Eradication of coca bush, which in Peru is done manu-
ally, was slightly higher than in 2005 and reached
12,688 hectares, the second highest eradication figure
reported by the Government. 
Seizures of a small amount of opium latex indicate that
opium poppy cultivation in Peru continues to exist.
There are no indications that the level of opium culti-
vation has changed significantly since 2004, when the
last estimate of about 1,400 hectares was released by the
Government. 
Peru, coca cultivation and eradication (hectares), 1990 to 2006
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Prices
By and large, monthly average prices for sun-dried coca
leaf at the farm-gate in 2006 remained in the US$ 2/kg
to US$ 3/kg price range observed since 2001. Farm-gate
prices for sun-dried coca leaf declined from a national
average of US$ 2.9/kg in 2005, to only US$ 2.5/kg in
2006. This decline was observed in all cultivation
regions. However, regional and seasonal price differ-
ences continued to be present.
In 2006, wholesale prices for coca paste and cocaine HCl
fell by 14 per cent and 8 per cent respectively compared
to 2005, similar to the prices for sun-dried coca leaf.
Peru, monthly farm-gate prices of sun-dried coca leaf (US$/kg), 1990 to 2006
Peru, potential cocaine production (metric tons), 1990 to 2006
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Figures from 2003 to 2005 were revised based on updated information on the amount of coca leaf necessary to produce one
kilogramme of cocaine HCl. 
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3.2 Seizures
A complete set of seizures tables can be found on the UNODC website at:
www.unodc.org/unodc/en/world_drug_report.html
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3.3 Seizures of illicit laboratories
A complete set of seizures of illicit laboratories tables can be found on the
UNODC website at: www.unodc.org/unodc/en/world_drug_report.html
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3.4 Prices
3.4.1 Opiates: Wholesale, street prices and purity levels
EUROPE 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006**
Austria  072  052  302  301 831 231  17 47 57 86 29 44 57 75 49 07 78
Belgium  09  501 501  23 13 92 72 73 14 14 73 65 57 57 77  13 19         
Denmark  782  151 562  221 621 111 611 571 741 881 751 191 822 931  001 321 49
Finland  008  077 696  881 121 702 052 452 752 414 554 606 427 195   591  521 281
France  541  051 351  111 911 311 651 071 441 531  23  43  76 96 86 75 74
Germany  501  69 57  64 84 94 64 83 83 93 54 34 15 47 09 19 47
Greece  021  36 571  57 13 15 56 54 35 55 55 55 08 77 88 501 44
Italy  761  041 841  511 14 55 92  021 89  76 86 96 36 95 86 17 59
Luxembourg  271  051 051  051  621 331 141 831 202 271  76 96  76  67 54  46 46
Netherlands  94  05  55  94  55 43 55 84 16  03  75 04 53 34 52  04 04
Norway  086,1  015 525  022 841 891 561 751 821 661 681 891 282 003 943 572 220       
Iceland  481  473 673  704  273 773 014 083  273 273 273  273 273 273 273 273 273
Portugal  38  27 28  94 25 25 45 14 54 54 73 47 55 86 97 56 36
Spain  571  081 581  621  211 021 231  87 08 18 57 16 75 95 57 28 88
Sweden*  522  591 012  561 081  531 643 733  031 126 113 129 133 128 119 92 92
Switzerland  213  842 122  611 091 461 621  761 69 18  93 54 35  84 84 84 84
United Kingdom  751  441  441  701 801 021 811 801 521 921 431  39 011 001 19 68 97         
Ireland  691  081 081  161 861  252 842 971 971 071 671 402 312 822 572 971 252       
Average unweighted in US$   092  012 222  421 821 131 761 971 971 861  501 801 801 501 001 39 99
inflation adjustment in US$  744  203 823 111 511 511 211 501 611 151 951 561 412 632 342 532  501
Weighted average in US$  371  741 941  811 911 811 701  17 27 57 07 26 95 46 78 49 39
Adjusted for inflation in US$  762  112 122  501 711 711 151 751 161 941  17 47 18 77 07 76 47
Weighted average in Euro  631  311 021  65 85 16 26 66 66 96 18 48 28 39 19 001 19
Adjusted for inflation in Euro  691  941 561  011 011 321 611  65 95 26 56 07 17 67 19 69 59
Sources: ARQ data and EUROPOL and in italic UNODC * Calculation for Sweden is based on brown heroin price (80%) and white heroin price (20%) ** Data available till November 2006
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
USA  182  862 972  011 621 731 261 151 071 691 402 862  591 251 611 88
Adjusted for inflation  334  583 314  521 841 561 102 091 912 952 772 473  102 261 721 89
Sources: ONDCP: 1990-2000 data, UNODC ARQ: 2001-2002 data, ONDCP, The Price & Purity of Illicit Drugs 1981-2003, for 2003 and CEWG  for 2004.
EUROPE 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006**
Austria 55,244 46,145 63,000 36,000 37,752 30,491 30,222 28,831 34,565 31,087 25,026 19,553 23,547 33,900 37,260 36,168 37,640
Belgium 30,000 30,000 28,500 26,600 29,586 32,580 24,307 21,761 20,847 18,557 18,360 20,292 22,229 20,960 23,040 23,336 23,336
Denmark 110,000 100,000 85,000 95,000 117,625 106,805 86,806 100,465 65,693 61,507 23,585 32,889 20,803 41,770 32,820 37,741 35,967
Finland 353,774 353,774 353,774 353,774 353,774 353,774 321,586 199,442 197,856 194,357 161,034 44,840 51,804 51,800 68,314 69,192 69,192
France 180,000 72,250 80,000 63,750 75,000 66,035 46,603 32,230 25,885 25,596 22,158 26,906 23,547 28,250 31,050 31,450 35,548
Germany 45,244 36,145 41,667 35,206 36,448 35,256 27,890 25,686 25,608 24,770 20,263 17,816 20,325 21,510 25,723 25,765 22,510
Greece 90,000 70,000 35,000 28,000 29,536 34,362 39,090 28,775 21,020 20,714 17,320 16,592 17,425 18,650 17,540 14,782 19,447
Italy 67,500 60,000 108,000 42,581 47,690 35,786 48,152 37,795 36,459 36,894 31,163 32,979 33,669 29,830 30,109 30,496 29,750
Luxembourg 86,000 75,000 75,000 49,500 86,000 57,079 59,852 54,786 52,630 50,368 48,000 50,369 50,369 24,700 43,473 31,450 31,450
Netherlands 23,850 25,000 26,550 23,850 23,850 24,384 20,572 13,810 14,056 16,985 14,703 15,757 29,199 17,730 17,730 18,240 18,240
Norway 220,000 200,000 212,500 151,099 101,744 85,000 72,520 62,209 64,918 49,872 44,561 35,874 37,676 48,234 52,790 53,490 53,490
Portugal 50,000 55,000 46,667 31,500 32,428 43,171 45,902 38,841 30,483 29,339 25,398 31,310 25,839 31,000 34,075 34,512 34,512
Spain 160,000 125,000 122,500 91,000 74,418 79,880 84,395 63,880 52,755 53,820 43,596 32,000 41,202 48,420 46,350 47,055 47,371
Sweden* 140,000 130,000 115,000 95,000 117,625 62,655 64,829 65,771 63,190 61,022 41,626 33,702 34,738 41,900 31,648 35,970 35,970
Switzerland 124,000 153,800 228,875 47,460 52,823 54,850 41,665 37,234 34,294 33,422 29,568 16,082 19,149 22,340 23,580 25,420 25,420
United Kingdom 53,940 43,940 43,500 43,210 42,500 42,004 34,846 39,491 41,667 29,126 26,718 25,926 30,620 34,340 39,041 33,249 27,920
Ireland 63,940 53,940 53,500 53,210 52,500 81,479 77,643 36,531 34,396 43,478 37,600 36,441 36,441 30,510 30,510 33,967 33,967
Sources: ARQ data and EUROPOL and in italic UNODC * Calculation for Sweden is based on brown heroin price (80%) and white heroin price (20%) ** Data available till November 2006
Average unweighted in US$ 109,029 95,882 101,120 74,514 77,135 72,094 66,287 52,208 48,019 45,936 37,099 28,784 30,505 32,108 34,415 34,252 34,219
infl.adj. in US$ 168,131 141,887 145,265 103,933 104,903 95,344 85,151 65,561 59,375 55,573 43,422 32,758 34,176 35,171 36,719 35,348 34,219
Weighted average in US$ 93,652 68,208   144,77 138,13 623,23 043,03 691,82 908,52 905,82 382,43 925,63 184,93 000,84 075,25 183,65 329,45   31,027
Inflation adj. (kg) in US$ 144,418 100,934 111,249 76,607 76,678 69,525 61,659 49,579 45,168 41,475 33,367 29,372 31,590 33,233 34,490 32,849 31,027
Inflation adj. (gram) in US$ 144 101 111 77 77 70 62 50 45 41 33 29 32 33 34 33 31
Weighted in Euro (g) 74 55 60 47 47 40 38 35 33 32 31 29 30 27 26 26 25
Inflation adjusted in Euro (g) 106 75 79 60 59 49 45 40 37 36 34 31 32 28 27 26 25
Sources: UNODC ARQ and EUROPOL. * Calculation for Sweden is based on brown heroin price (80%) and white heroin price (20%) ** Data available till November 2006
USA 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Average in US$ 162,500 155,000 150,000 146,000 142,500 146,000 141,875 129,375 125,000 107,000 81,200 59,500 50,750 000,56 008,86 005,56
Inflation adj. (kg) in US$ 250,588 229,370 215,484 203,642 193,798 193,086 182,249 162,464 154,563 129,447 95,040 67,714 56,857 71,747 73,407 67,080
Inflation adj. (gram) in US$ 235 215 202 191 182 181 171 152 145 121 89 63 53 72 73 67
Source: UNODC ARQ, CEWG for 2004.
Retail prices (street price), US$/gram
Wholesale, US$/kg
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Region / country or territory Typical Year Typical Year
Africa
North Africa
Egypt  8.81 6.02 -  3.22  0.052,35002 0.024,3- 0.080,3        2005
Sudan  4.0 2005
Southern Africa
Zambia  7.8 9.8 -  9.8 2004
Americas
North America
Canada  2.42 3.04 -  7.88  4.845,815002 8.522,82- 9.147,71      2005
United States  0.82 0.43 -  0.04  0.005,134002 0.000,53- 0.000,82      2005
South America
Colombia  4.982 2005
Asia
Central Asia  and Transcaucasia
Armenia  0.53  0.000,525002 0.07- 0.46 69.0 5002 0.08-
Georgia
Kazakhstan  0.2 0.5 -  0.7  0.554,44002 0.000,21- 0.005,1      2005
Kyrgyzstan  0.1 3.1 -  5.1  0.052,15002 0.005,1- 0.000,1        2005
Tajikistan  0.2 0.3 -  0.4  0.4865002 100.0          - 600.0          2005
Turkmenistan
Uzbekistan  0.057,4 0.000,7- 0.005,2        2005
East and South-East Asia
China  0.1 8.1 -  0.3  0.000,124002 0.000,08- 0.005,6      2005
Indonesia  9.62 8.92 -  6.23 2005
Japan  8.72 2004
Laos  0.812 200.0          - 400.0          2005
Malaysia  3.466,2 0.851,3- 0.250,1        2005
Myanmar  6.0 7.0 -  9.0  5.9325002 172.0          - 436.0          2005
Philippines  6.3  5.626,35002 2005
Republic of Korea  5.42 3.03 -  0.94  3.091,55002 2004
Thailand  1.2  0.000,16002 2005
Vietnam  0.053 320.0          - 380.0          2005
Near and Middle East /South-West Asia
Afghanistan  1.0  7.4515002 2005
Iran ( Islamic Republic of)  6.3  0.7085002 2005
Jordan 4.211 4.621 -  4.041  5.532,115002 9.936,21- 0.138,9      2005
Lebanon  0.000,71 0.000,52- 0.000,51      2005
Pakistan  4.0 5.0 -  7.0  9.4664002 236.5          - 446.6          2005
Syrian Arab Republic  5.4 0.6 -  0.000,44002 0.07- 0.03 5.7 0.000,5- 0.000,3        30.0 - 70.0  2005
United Arab Emirates  0.054,3 0.002,4- 0.007,2        2005
South Asia
Bangladesh  5.1 0.2 -  0.002,15002 0.04- 0.02 5.2 0.005,1- 0.000,1        2005
India  8.543 230.0          - 461.0          2005
Sri Lanka  1.4 6.5 -  2.7 2005
Europe
East Europe
Belarus  0.01  0.005,64002 2004
Russian Federation  7.4 5.32 -  5.87  3.938,35002 6.532,5- 0.344,2        2005
Southeast Europe
FYR of Macedonia  9.196 629.0          - 754.8          2005
Romania  3.6 0.22 -  6.21  6.717,45002 2005
Turkey  2.043,4 7.831,2- 3.167,1        2005
West and Central Europe
Austria  8.8 1.01 -  6.01  9.429,25002 1.541,3- 1.615,2        2005
Czech Rep.  2.4  0.045,25002 2005
France  9.81 2005
Latvia *  8.8 2005
Lithuania  8.1 0.3 -  6.3 2005
Norway  7.73  7.498,215002 4.690,51- 0.396,01      2005
Sweden  7.319,7  2.491,7 8,633.1       2005
United Kingdom  4.72 2005 8232.58 2005
* For 1cm3 of concentrate of poppy straw
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
Range Purity Range Purity
RETAIL PRICE (per gram) WHOLESALE PRICE (per kilogram)
 OPIUM
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
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Region / country or territory raeYlacipyTraeYlacipyT
Africa
East Africa
Kenya (Heroin no.3) 12.9      12.9      - 19.4 4.541,614002       12,916.6      - 19,374.8 4002
          (Heroin no.4) 15.5      15.5      - 23.3 0.406,224002       19,374.8      - 25,833.1 4002
Uganda (Heroin no.3) 12.5      10.0      - 15.0 0.000,035002       25,000.0      - 30,000.0 5002
            (Heroin no.4) 17.5      15.0      - 20.0 5002
North Africa
Egypt 36.0      34.3      - 37.7 0.586,525002       23,970.0      - 27,400.0 5002
Libya 39,370.1      23,622.1      - 55,118.1 5002
Southern Africa
Namibia (Heroin no.3 & 4.) 76.0      76.0      - 84.5 5002
South Africa 44.8 4002
Zimbabwe 49.3      43.8      - 54.8 4002
West and Central Africa
Burkina Faso 49.8      49.8      - 69.8 5002
Cameroon 29.9 5002
Congo 10.0      10.0      - 14.0 2.072,95002         9,270.2        - 11,124.3 4002
Gabon 92.7      55.6      - 111.2 4002
Ghana 16.2 0.000,915002       16,000.0      - 22,000.0 4002
Guinea 17.5      15.0      - 20.0 0.005,715002       15,000.0      - 20,000.0 5002
Nigeria (Heroin no.3) 17.1      15.2      - 19.0 5.877,815002       18,588.8      - 18,968.1 5002
           (Heroin no.4) 22,586.1 4002
Togo (Heroin no.1) 23.9      23.9      - 29.9 5002
Americas
Caribbean
Dominican R. 30.0 0.000,035002 5002
Trinidad Tobago 128.8 5002
Central America
El Salvador 69.0      65.0      - 70.0 0.000,575002       70,000.0      - 80,000.0 4002
Guatemala 11.6      11.6      - 12.9      80.0   - 85.0     2005
Honduras 5.3        2.6        - 7.9        2004 18,000.0      16,000.0      - 20,000.0      85.0     - 93.0   2005
Panama 10,000.0 5002
North America
Canada (Heroin no.3) 201.6    161.3    - 322.6    1.0     - 100.0   2005 64,516.1      64,516.1      - 88,709.7 5002
            (Heroin no.4) 282.3    282.3    - 645.2 9.216,675002       64,516.1      - 181,451.6 5002
Mexico  (Heroin no.4) 32,850.0 5002
United States  (Heroin no.4) 207.5    40.0      - 375.0    12.0   - 95.0     2005 65,000.0      40,000.0      - 90,000.0      90.0     2005
                     (Black Tar) 195.0    40.0      - 350.0    5.0     - 53.0     2005 28,000.0      16,000.0      - 40,000.0      39.0     2005
South America
Argentina 110,000.0    100,000.0    - 120,000.0 4002
Brazil 50.0      30.0      - 70.0 0.000,055002 5002
Colombia (Heroin no.4) 20.1 7.838,65002 5002
Ecuador 13,000.0      12,000.0      - 15,000.0 5002
Asia
Central Asia and Transcaucasia
Armenia 150.0 0.000,0215002 0.06      - 75.0   2005
Georgia 100.0    90.0      - 200.0 4002
Kazakhstan 17.0      11.0      - 22.0 3.187,514002       4,000.0        - 40,000.0 5002
Kyrgyzstan (Heroin no.4) 4.5        4.0        - 5.0        2005 1,500.0        1,000.0        - 2,000.0 5002
Tajikistan (Heroin no.3) 2.5        2.0        - 3.0        2005 1,800.0        1,200.0        - 2,500.0 5002
              (Heroin no.4) 5,500.0        4,000.0        - 7,000.0        10.0     - 80.0   2005
Uzbekistan 25,000.0      15,000.0      - 35,000.0 5002
East and South-East Asia
China 36.2      18.1      - 96.5 4002
Hong Kong SAR, China (no.4) 45.7      16.9      - 96.8 1.842,335002       23,225.8      - 48,000.0 5002
Indonesia 64.5      53.8      - 75.3 5002
Japan 339.8    291.3    - 388.4 0.000,245002       28,000.0      - 56,000.0 4002
Laos 12,000.0      10,000.0      - 14,000.0 4002
Macau SAR, China (Heroin no.3) 50.0      37.0      - 62.0 5002
Malaysia (Heroin no.3) 6,068.6        3,749.0        - 6,974.0 5002
              (Heroin no.4) 25,230.0      10,526.0      - 45,000.0 5002
Myanmar (Heroin no.4) 56.2      11.2      - 89.9 5002
Philippines 108.8 2.497,8015002 5002
Singapore (Heroin no.3) 138.0    122.7    - 153.4 0.588,95002         9,400.0        - 10,370.0 4002
Thailand 105.0    87.5      - 122.0 1.421,95002         7,820.7        - 10,427.5 5002
Vietnam 16,000.0      14,000.0      - 18,000.0 5002
75 (60-90)
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Region / country or territory raeYlacipyTraeYlacipyT ytiruPegnaRytiruP
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
)margolikrep(ECIRPELASELOHW)margrep(ECIRPLIATER
HEROIN
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
Range
Near and Middle East/ South- West Asia
Afghanistan 3.0        2.8        - 3.1        2005 3,016.5        2,830.0        - 3,203.0 5002
Bahrain (Heroin no.3) 265.2    212.2    - 318.2 2.688,8915002     159,109.0    - 212,145.3 5002
           (Heroin no.4) 318.2    265.2    - 397.8 7.181,5625002     212,145.3    - 318,218.0 5002
Iran ( Islamic Republic of) 12.7      5.1        20.3 0.172,35002 5002
Israel 45.0      20.0      - 50.0 0.000,025002       15,000.0      - 23,000.0 5002
Jordan 49.2      42.1      - 56.2 1.266,915002       18,257.7      - 21,066.5 5002
Lebanon (Heroin no.3) 35.0      30.0      - 40.0      40.0   - 60.0     2005 20,000.0      15,000.0      - 25,000.0      20.0     - 80.0   2005
             (Heroin no.4) 40.0      35.0      - 45.0 0.000,045002       35,000.0      - 45,000.0      80.0     2005
Oman 51.9 3.731,135002 5002
Pakistan (Heroin no.3) 2.7        2.3        - 3.1        2005 2,688.4        2,280.0        - 3,096.8 5002
              (Heroin no.4) 4.2        4.6        - 4.2        2005 4,158.8        3,733.5        - 4,584.1 5002
Syrian Arab Republic 20.0      17.0      - 23.0      75.0   - 95.0     2005 17,000.0      15,000.0      - 19,000.0      30.0     - 50.0   2005
United Arab Emirates (No.4) 142.5    135.0    - 150.0 0.000,414002       13,000.0      - 15,000.0 5002
South Asia
Bangladesh (Heroin no.3) 8.0        7.0        - 10.0      3.0     - 6.0       2005 6,000.0        5,000.0        - 7,000.0        3.0       - 6.0     2005
                 (Heroin no.4) 9.0        8.0        - 12.0      5.0     - 8.0       2005 8,000.0        7,000.0        - 9,000.0        5.0       - 8.0     2005
India 4,610.4        3,457.8        - 11,526.1 5002
Maldives 77.6      77.6      - 232.9 2.043,455002       38,814.5      - 77,628.9 5002
Sri Lanka (Heroin no.3) 20.6      18.5      - 22.6      23.0   - 56.0     2005
Europe
East Europe
Belarus (Heroin no.3) 45.0      30.0      - 90.0 0.000,425002       14,000.0      - 50,000.0 5002
Moldova R. 57.7      48.0      - 64.1 0.000,065002       55,000.0      - 65,000.0 5002
Russian Federation (Heroin no.3) 40.0 5.127,325002 5002
                           (Heroin no.4) 57.0      10.5      - 209.4    3.0     - 27.0     2005 32,809.0      8,027.9        - 17,452.0      64.0     - 95.0   2005
Ukraine 85.0      70.0      - 100.0 5002
Southeast Europe
Albania (Heroin no.3) 22.5      20.0      - 25.0 0.005,315002       12,000.0      - 15,000.0 5002
Bulgaria (Heroin no.3) 43.7      33.6      - 201.6    15.0   - 91.0     2005
Croatia 43.4      34.7      - 52.1      5.0     - 15.0     2005 19,531.3      18,229.2      - 20,833.3      30.0     - 50.0   2005
FYR of Macedonia 22.0      18.9      - 25.2 4.838,315002       12,580.4      - 15,096.4 5002
Romania (Heroin no.3) 50.3      31.5      - 50.3 6.683,125002       16,354.5      - 21,386.6 5002
Turkey 18.2      16.4      - 20.1 3.534,95002         9,749.8        - 10,693.3      35.0     - 80.0   2005
West and Central Europe
Andorra 56.6      50.3      - 62.9 5002
Austria (Heroin no.3) 72.3      56.6      - 88.1 0.695,435002       25,160.7      - 44,031.3      54.0     2005
           (Heroin no.4) 106.9    100.6    - 113.2 0.291,965002       62,901.8      - 75,482.1 5002
Belgium (Heroin no.3) 32.3 6.633,324002 5002
Cyprus (Heroin no.3) 129.1 0.582,235002 5002
           (Heroin no.4) 180.1 9.487,134002 4002
Czech Republic (Heroin no.3) 47.2      21.6      - 86.8      5.0     - 89.0     2005 33,828.6      17,360.9      - 52,044.9      20.0     2005
Denmark (Heroin no.3) 123.0    52.7      - 210.9 7.639,345002       17,574.7      - 61,511.4 5002
              (Heroin no.4) 210.9    105.5    - 351.5 3.466,835002       6,151.1        - 79,086.1 5002
Estonia (Heroin no.4) 94.4 9.970,235002 5002
Finland (Heroin no.4) 113.2    75.5      - 151.0 0.291,965002       62,901.8      - 75,482.1      6.0       - 63.0   2005
France (Heroin no.3) 50.3      37.7      - 69.2      2.0     - 10.0     2005 25,160.7      18,870.5      - 37,741.1      5.0       - 25.0   2005
           (Heroin no.4) 62.9      37.7      - 100.6    2.0     - 10.0     2005 44,031.3      25,160.7      - 50,321.4      5.0       - 25.0   2005
Germany (Heroin no.3) 47.6 8.567,525002 5002
Greece (Heroin no.3) 72.3      50.3      - 94.4 6.994,915002       12,580.4      - 26,418.8      100.0   2005
            (Heroin no.4) 78.6      56.6      - 100.6 7.987,525002       18,870.5      - 32,708.9 5002
Hungary (Heroin no.3) 49.2 5.389,615002 5002
           (Heroin no. 4) 65.6 3.938,655002 5002
Ireland (Heroin no. 3) 251.6 0.769,335002 5002
Italy (Heroin no. 3) 68.4      59.9      - 76.8 2.857,035002       27,103.5      - 34,412.9 5002
       (Heroin no. 4) 102.7    93.2      - 112.2 5.775,845002       44,399.6      - 52,755.5 5002
Latvia 179.9    132.6    - 227.3    2.0     - 87.0     2005 94,700.0      75,760.0      - 113,640.0 5002
Liechtenstein 33.9      29.7      - 42.4 5002
Lithuania (Heroin no.3) 36.4 1.396,025002 4002
Luxembourg (Heroin no.3) 102.7 0.5      - 58.0     2005 31,450.9 5002
Malta (Heroin no.3) 76.8 0.000,055002       45,000.0      - 53,000.0      27.0     - 41.0   2005
Netherlands 37.7      25.2      - 50.3 5.142,815002       16,354.5      - 20,128.6 5002
Norway 220.2    125.8    - 314.5    5.0     - 50.0     2005 53,466.5      31,450.9      - 75,482.1 5002
Poland 44.0      31.5      - 62.9 8.303,145002 5002
Portugal (Heroin no.3) 52.1 0.315,435002 5002
Slovakia 32.6      26.1      - 39.1      51.0   2005 16,284.5      13,027.6      - 19,541.4 5002
Slovenia (Heroin no.3) 50.3 8.373,915002 5002
Spain (Heroin no.3) 80.1 1.097,645002 0.74      2005
67 (50-85)
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Sweden (Heroin no.3) 91.6 2.179,535002       28,777.0      - 43,165.5 5002
            (Heroin no.4) 125.9 5.297,545002 5002
Switzerland 65.7      29.7      - 101.7    10.0   - 15.0     2005 25,423.7      16,949.2      - 67,796.6 5002
United Kingdom 101.9    37.7      - 566.0    1.0     - 87.0     2005 39,622.6      22,641.5      - 56,603.8      1.0       - 78.0   2005
Oceania
Australia 310.3    155.2    - 465.5 4.590,395002       62,063.6      - 124,127.2 5002
New Zealand (no.4 - Imported) 785.7    714.3    - 857.1 5002
                    ('homebake') 114.4    65.4      - 163.4 4002
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3.4.2 Cocaine: Wholesale, street prices and purity levels
EUROPE 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006**
Austria 198       180       167       120       126       156       138       118       113       93         94         78         71         90         103       101       88         
Belgium 80         90         68         95         82         93         90         57         55         60         55         51         50         51         51         51         62         
Denmark 144       135       111       90         150       176       169       108       119       165       106       120       91         122       82         82         92         
Finland 159       150       126       105       165       191       184       123       179       157       138       121       111       151       146       125       100       
France 99         119       140       153       151       174       125       87         84         82         50         87         75         90         99         94         82         
Germany 120       103       111       95         109       103       90         77         72         68         57         58         57         68         73         79         74         
Greece 150       120       105       54         116       111       144       91         54         82         69         72         75         96         93         79         110       
Iceland 167       203       207       200       211       228       226       238       149       134       121       109       150       207       156       156       156       
Italy 108       120       164       90         104       113       129       109       129       135       100       89         90         101       113       114       106       
Luxembourg 150       150       150       150       172       194       127       115       110       119       119       119       107       96         114       114       114       
Netherlands 66         70         74         66         60         79         52         64         38         33         33         33         33         50         59         59         59         
Norway 176       170       255       156       145       150       153       177       133       128       114       157       165       170       155       155       155       
Portugal 63         57         60         57         59         66         64         57         51         43         56         48         36         47         49         55         49         
Spain 110       100       100       63         78         91         72         68         68         63         52         52         56         70         76         76         76         
Sweden 160       152       183       123       148       118       118       98         88         97         77         79         87         99         93         92         92         
Switzerland 178       144       188       136       146       148       127       117       110       109       77         69         74         89         86         86         86         
United Kingdom 131       127       69         123       113       111       102       124       128       104       94         94         84         90         91         79         91         
Ireland 141       137       120       110       100       119       32         34         32         30         28         28         94         79         87         88         88         
Average unweighted in US$ 133       129       133       110       124       134       119       103       95         95         80         81         84         98         96         94         93         
Inflation adjusted in US$ 206       191       191       154       169       178       153       130       117       114       94         92         94         107       102       97         93         
Weighted average US$ 117       115       118       104       112       118       105       92         92         88         70         74         72         84         88         87         85         
Inflation adjusted in US$ 180       170       169       145       152       157       135       116       113       106       82         85         80         92         94         89         85         
Weighted average in Euro 92         93         91         89         94         91         83         81         82         82         76         83         76         74         71         70         67         
Inflation adjusted in Euro 132       127       120       113       117       109       98         94         94         93         84         90         81         77         73         71         67         
Sources: ARQ data and  EUROPOL and in italic UNODC; data for Europe for 2006: Europol ** Data available till November 2006
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
USA 184       177       170       147       137       131       126       127       124       118       129       98 86 75 87.3 103.7
Adjusted for inflation 284       262       245       205       186       174       162       159       154       142       151       111       96         82         93         107       
EUROPE 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006**
Austria 66,000 66,000 54,000 40,000 41,946 52,084 45,875 56,723 54,440 38,859 47,094 43,995 42,385 59,300 55,894 59,757 56,460
Belgium 25,000 24,000 38,250 28,000 26,920 30,560 21,927 17,025 19,167 23,859 22,376 26,771 28,111 29,610 32,480 32,480 32,480
Denmark 80,000 85,000 85,000 82,500 58,516 60,034 46,141 38,640 44,517 78,900 43,462 47,839 37,823 53,160 45,896 50,321 46,005
Finland 79,500 75,000 62,750 52,500 82,500 95,450 91,750 61,550 89,350 78,460 68,321 59,492 51,804 62,150 68,315 68,315 68,315
France 117,000 38,250 45,000 38,250 40,000 39,877 48,077 43,554 42,159 27,714 27,000 34,978 37,676 45,200 49,683 50,321 40,776
Germany 69,000 53,100 60,300 54,142 57,692 54,676 53,925 45,294 41,210 39,639 33,752 33,235 34,476 40,110 44,243 46,525 45,320
Greece 75,000 90,000 95,000 36,000 46,413 53,098 72,015 43,795 49,180 49,320 41,237 40,359 42,385 53,680 57,446 62,902 62,733
Italy 54,000 48,000 94,000 41,935 51,097 51,455 55,633 50,629 49,091 47,250 46,000 40,529 41,412 47,440 51,759 52,188 52,530
Luxembourg 93,919 95,939 113,521 50,847 157,593 141,343 47,625 43,103 41,072 47,718 47,718 47,718 47,718 47,718 31,052 31,450 31,450
Netherlands 26,500 28,000 29,500 26,500 24,680 33,232 23,894 29,698 22,355 27,500 27,500 27,500 27,500 27,400 33,775 33,775 33,775
Norway 120,000 120,000 127,500 110,000 39,971 50,000 41,670 60,028 81,699 57,545 51,417 51,569 54,159 56,500 65,209 65,209 65,209
Portugal 39,500 39,285 33,000 27,000 27,950 34,483 42,591 37,908 33,447 30,000 28,000 29,080 31,046 32,410 36,399 36,399 36,399
Spain 65,000 60,000 55,000 35,000 36,434 41,322 38,760 36,806 38,924 38,898 30,882 38,898 31,511 38,830 42,167 41,321 41,862
Sweden 80,000 85,000 91,375 61,450 73,825 55,556 59,255 45,573 50,484 48,508 38,394 34,693 35,763 43,130 39,560 40,068 40,068
Switzerland 63,900 94,250 116,250 50,847 72,012 75,949 51,587 40,780 41,152 41,000 35,482 23,392 19,274 37,230 44,008 44,008 44,008
United Kingdom 47,850 46,475 20,625 43,210 45,000 46,774 40,625 47,500 47,500 33,981 38,168 36,008 35,848 40,880 50,036 50,036 48,400
Ireland 45,000 45,000 40,000 50,000 45,000 42,000 31,646 33,733 31,530 29,891 29,891 29,891 29,891 30,510 30,510 30,510 30,510
Average unweighted in US$ 67,481 64,312 68,298 48,717 54,562 56,347 47,823 43,079 45,722 43,473 38,629 37,997 36,987 43,839 45,790 46,799 45,665
Inflation adjusted in US$ 104,060 95,169 98,115 67,950 74,203 74,519 61,433 54,097 56,535 52,593 45,213 43,242 41,438 48,020 48,856 48,297 45,665
Weighted average US$ 67,793  51,895  57,392  43,998  47,040  48,150  47,754  43,975  43,434  38,491  35,580  36,095  35,950  42,322  46,832  47,692  45,703
Adjusted for inflation (kg) 104,542 76,794 82,446 61,368 63,974 63,679 61,343 55,222 53,706 46,565 41,644 41,078 40,276 46,358 49,968 49,218 45,703
inflation adjusted (gram) 105 77 82 61 64 64 61 55 54 47 42 41 40 46 50 49 46
Weighted in Euro (g) 53 42 44 38 40 37 38 39 39 36 38 40 38 37 38 38 36
Inflation adjusted in Euro (g) 77 57 58 48 49 45 44 45 44 41 43 44 41 39 39 39 36
Sources: ARQ data and EUROPOL and in italic UNODC; data for Europe for 2006: Europol ** Data available till November 2006
1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
USA 45,430  48,300  48,100  44,730  42,180  38,640  35,700  34,320  31,960  30,870  29,580  21,500  23,000  21,500  22,066  20,500
Adjusted for inflation (kg) 70,057  71,475  69,099  62,390  57,364  51,102  45,859  43,098  39,519  37,346  34,622  24,468  25,768  23,551  23,544  21,156
Adjusted for inflation (gram) 70         71         69         62         57         51         46         43         40         37         35         24         26         24         24         21         
Sources: ONDCP 1990-2000 (prices for 10-100 gram, at street purity), UNODC ARQ 2001-2005 (mid-point of min/max prices).
Retail price (street price), US$/gram
Wholesale price, US$/kg
Sources: ONDCP 1990-2000 (prices for 1 gram or less, at street purity), ONDCP, ONDCP, The Price & Purity of Illicit Drugs 1981-2003 ( prices for < 2 grams) for 2001-03, Community Epidemiology Network - June 2005 (for 
2004) and UNODC, ARQ data for 2005.
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Africa
East Africa
Kenya 32.3     25.8    - 38.8 0.802,544002      38,749.7     - 51,666.2     40.0     - 50.0     2004
North Africa
Egypt 77.1     68.5    - 85.6 0.039,955002      51,370.0     - 68,490.0 5002
Southern Africa
Namibia 84.5     50.7    - 84.5     10.0      - 33.0     2005 68,119.9 4002
             (Crack) 16.9     15.2    - 16.9     9.0        - 19.0     2005 15,137.8 0.07      2004
South Africa 38.9 4002
             (Crack) 14.5 4002
Zambia 35.4 4.183,534002      33,898.3     - 37,076.3 4002
Zimbabwe 60.3     54.8    - 65.7 4002
West and Central Africa
Burkina Faso (Coca Base) 49.8 5002
Cameroon 29.9 5002
Congo R.(Coca Base) 6.0       6.0      - 10.0 1.807,35002        1,854.1       - 3,708.1 4002
Ghana 18.8 0.005,615002      15,000.0     - 18,000.0     70.0     - 96.0     2004
Guinea 20.0     18.0    - 22.0 0.338,025002      18,000.0     - 20,833.0 5002
Nigeria 14.4     13.7    - 15.2 8.514,415002      13,657.1     - 15,174.5 5002
Togo 29.9     29.9    - 33.9 5002
Americas
Caribbean
Anguilla 17.5     15.0    - 20.0 0.005,715002      15,000.0     - 20,000.0 5002
Bahamas 20.0     20.0    - 50.0 0.000,94002        9,000.0       - 15,000.0 4002
                  (Crack) 5.0       5.0      - 10.0 4002
Dominica 57.5     55.0    - 60.0 0.000,834002      35,000.0     - 50,000.0     80.0     - 98.0     2005
                  (Crack) 55.0 0.06       - 98.0     2005
Dominican R. 7.8 0.008,75002 5002
Grenada 36.9     33.2    - 44.3 4.322,95002        8,116.6       - 9,961.2 5002
                  (Crack) 33.2     29.5    - 36.9 5002
Haiti 10.0     8.0      - 12.0 0.005,64002        5,000.0       - 8,000.0 4002
Jamaica (Coca base) 9,250.0       9,000.0       - 9,500.0 4002
Montserrat (Coca Base) 59.0     55.9    - 62.1 9.088,84002        8,197.7       - 9,564.0 4002
St. Lucia 9.3       7.5      - 11.2 4.511,124002      24,841.6     - 31,052.0 4002
St. Vincent & Grenadines 5,534.0       5,534.0       - 7,378.7 5002
Trinidad Tobago 64.4 0.001,45002        3,500.0       - 4,700.0       1.0       - 95.0     2005
Turks and Caicos Islands 20.0 0.000,85002        7,000.0       - 9,000.0 5002
                  (Crack) 10.0 5002
Central America
Belize 7.5       7.5      - 12.5     90.0      - 96.0     2005 6,015.0       5,012.5       - 7,518.8       90.0     - 96.0     2004
                  (Crack) 5.0       5.0      - 10.0     90.0      - 96.0     2005 30,000.0     30,000.0     - 35,000.0 4002
Costa Rica 6.0       5.4      - 6.5 3.031,45002        3,912.9       - 4,347.6       53.0     - 90.0     2005
                  (Crack) 1.3       0.5      - 2.1 5002
El Salvador 24.0     23.0    - 25.0 0.000,425002      23,000.0     - 25,000.0 5002
                  (Crack) 24.0     23.0    - 25.0 0.000,425002      23,000.0     - 25,000.0 5002
Guatemala 6.4       6.4      - 7.7       65.0      - 70.0     2005 12,853.5     10,282.8     - 11,568.1     83.0     - 98.0     2005
                  (Crack) 3.9       3.9      - 6.4       50.0      - 55.0     2005 9,640.1       3,213.4       - 9,640.1       50.0     - 55.0     2005
Honduras 11.8     7.9      - 15.8     30.0      - 45.0     2005 10,473.0     8,950.0       - 15,000.0     90.0     - 96.0     2005
                  (Crack) 5.3       2.6      - 7.9       35.0      - 50.0     2005
Panama 2.0 0.1         - 100.0   2005 2,500.0 5002
                  (Crack) 1.0 0.1         - 100.0   2005 2,500.0 0.05      - 60.0     2005
North America
Canada 64.5     64.5    - 80.7     99.0      2005 32,258.1     28,225.8     - 48,387.1     99.0     2005
                  (Crack) 121.0   80.7    - 161.3   38.0      - 100.0   2005 25,806.5     24,193.6     - 32,258.1     39.0     - 100.0   2005
Mexico 7,880.0 5002
United States 110.0   20.0    - 200.0 0.005,025002      7,000.0       - 34,000.0 5002
                            (Crack) 110.0   20.0    - 200.0 0.000,425002      14,000.0     - 34,000.0 5002
90
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breakdown by drug, region and country or territory
South America
Argentina 5.9       3.5      - 8.3 0.008,44002        2,600.0       - 7,000.0 4002
Bolivia 9.0 0.09       2005 1,300.0 5002
Brazil 12.0     10.0    - 13.0     15.0      - 36.0     2005 3,000.0       2,000.0       - 7,000.0       80.0     - 98.0     2005
                  (Crack) 6.0       3.0      - 8.0 0.000,25002        1,500.0       - 3,000.0 5002
Chile 10.1     6.9      - 13.8 2.710,325002      2,931.0       - 43,103.5 5002
                  (Coca Base) 1.7       1.4      - 1.7 9.659,45002        1,293.1       - 8,620.7 5002
Colombia 2.0 1.280,25002 5002
                  (Coca Base) 810.0          711.0          - 949.0 4002
Ecuador 4,000.0       3,000.0       - 4,500.0 5002
                  (Coca Base) 2.0       1.0      - 3.0 0.009,15002        1,800.0       - 2,000.0 5002
Guyana 5.0 0.009,45002        4,600.0       - 5,000.0 5002
                  (Crack) 4.5 0.005,45002        4,400.0       - 4,600.0 5002
Paraguay 6,930.0 4002
Uruguay 13.2     10.1    - 16.2     15.0      - 25.0     2005 6,000.0       5,000.0       - 7,000.0 4002
Asia
East and South-East Asia
Hong Kong SAR, China 96.1     51.6    - 209.2 0.459,435002      25,673.9     - 46,213.1 4002
Indonesia 112.9   107.5 - 118.3 5002
Japan 242.7   194.2 - 291.3 0.083,645002 4002
Malaysia 20,000.0 5002
Philppines 90.7 8.166,095002 5002
Singapore 167.1   147.9 - 184.7 5002
Thailand 65.2     52.1    - 78.2 5002
Near and Middle East /South-West Asia
Bahrain 159.1   132.6 - 185.6 5002
Iran 126.3 5002
Israel 70.0     30.0    - 100.0 0.000,545002      36,000.0     - 56,000.0 5002
Jordan 77.2     84.3    - 98.3 5.800,665002      63,199.6     - 70,221.8 5002
Lebanon 70.0     50.0    - 90.0 0.000,565002      50,000.0     - 80,000.0 5002
Syrian Arab Republic (Coca Base) 100.0   80.0    - 120.0 0.000,065002      50,000.0     - 70,000.0 5002
Europe
East Europe
Belarus 123.0   110.0 - 135.0 0.000,065002 5002
Moldova R. 96.1     7.7      - 112.1 0.000,0015002    80,000.0     - 120,000.0 5002
Russian Federation 159.0   78.5    - 279.2   38.0      - 54.0     2005 107,309.1   61,082.0     - 244,328.1   62.0     - 81.0     2005
Southeast Europe
Albania 70.0     60.0    - 80.0 0.000,645002      43,000.0     - 49,000.0 5002
Bulgaria 84.0     53.8    - 235.2   15.0      - 91.0     2005 109,207.0   30,241.9     - 188,172.0   15.0     - 91.0     2005
Croatia 78.1     69.4    - 86.8     20.0      - 40.0     2005 39,062.5     34,722.2     - 43,402.8     60.0     - 80.0     2005
FYR of Macedonia 50.3     37.7    - 62.9 0.695,435002      31,450.9     - 37,741.1 5002
Romania 113.2 8.109,265002      44,031.3     - 62,901.8 5002
Serbia and Montenegro 74.5     62.1    - 87.0 3.386,944002      37,262.5     - 62,104.0 4002
Turkey 113.2   100.6 - 125.8 2.771,85002        84,917.4     - 94,352.7 5002
West and Central Europe
Andorra 69.2     62.9    - 75.5 5002
Austria 97.5     81.8    - 113.2 8.109,265002      50,321.4     - 75,482.1     1.0       - 94.0     2005
Belgium 32,480.4 4002
Cyprus 150.7 2.153,745002 5002
Czech Republic 98.2     65.0    - 130.1   12.0      - 100.0   2005 76,249.6     65,040.5     - 99,762.2     12.0     - 100.0   2005
                  (Coca Base) 85.7 0.392,154002 4002
Denmark 81.8 4.123,055002 5002
Estonia 75.5 4.878,925002 5002
Finland 100.6   75.5    - 125.8 6.116,655002      50,321.4     - 62,901.8     13.0     - 78.0     2005
France 88.1     75.5    - 100.6   10.0      - 40.0     2005 37,741.1     33,967.0     - 50,321.4     20.0     - 80.0     2005
                  (Crack) 72.3 5002
Germany 79.1 7.425,645002 5002
                  (Crack) 76.5 5002
70 (50-90)
50 (40-60)
36.0 (3-95) 
85 (80-90)
33
30 (25-35)
60 (60-80)
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3. Statistical Annex Prices
Region / country or territory raeYlacipyTraeYlacipyT
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
)margolikrep(ECIRPELASELOHW)margrep(ECIRPLIATER
ytiruPegnaRytiruPegnaR
COCAINE
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
Greece 110.1   94.4    - 125.8 8.109,265002      50,321.4     - 75,482.1     68.0     - 100.0   2005
Hungary 75.0 4.476,645002 5002
                  (Crack) 63.9     97.0    - 137.4 5002
Iceland 143.3 5002
Ireland 88.1 5002
Italy 109.3   96.8    - 121.9 2.782,255002      46,861.7     - 57,712.6 5002
Latvia 80.5     66.3    - 94.7     22.0      - 66.0     2005 66,046.9 5002
Lithuania 65.6     58.3    - 65.6     13.0      - 86.0     2005
Luxembourg 115.3   25.2    - 151.0   28.0      - 95.0     2004 31,450.9 5002
Malta 107.4 4.209,495002 5002
Netherlands 62.9     50.3    - 75.5 9.128,035002      28,934.8     - 32,708.9 5002
Norway 157.3   125.8 - 188.7   20.0      - 80.0     2005 66,046.9     44,031.3     - 88,062.5     20.0     - 80.0     2005
Poland 62.7 5.108,735002 5002
                  (Crack) 94.4     88.1    - 100.6 5002
Portugal 55.5 2.993,635002 4002
Slovakia 70.0     58.6    - 81.4 3.117,045002      24,426.8     - 48,853.6 5002
Slovenia 64.2 8.929,735002 5002
Spain 76.0 0.35       2005 41,210.7 5002
Sweden 100.7   71.9    - 129.5 7.953,055002      43,165.5     - 57,554.0 5002
Switzerland 93.2     29.7    - 169.5 6.754,745002      25,423.7     - 67,796.6 5002
United Kingdom 92.5     37.7    - 204.6   1.0        - 99.0     2005 46,226.4     26,415.1     - 66,037.7     7.0       - 94.0     2005
                (Crack) 35.9     9.4      - 150.9   6.0        - 99.0     2005 50,943.4     33,962.3     - 67,924.5     48.0     - 89.0     2005
OCEANIA
Australia 252.1   116.4 - 387.9 3.783,2615002    130,220.0   - 244,160.0 4002
New Zealand 714.3   500.0 - 857.1   60.0      - 80.0     2005
75
70 (40-99)
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3.4.3 Cannabis: Wholesale, street prices and purity levels
Region / country or territory Ty TraeYlacip y raeYlacip
Africa
East Africa
Eritrea 3.3      3..33 - 4.3       5.0 2005 400.0        400.0       - 466.7 5002
Kenya 0.2      0.1     - 0.3 9.694002           64.6         - 129.2 4002
Madagascar 0.02    0.02   - 0.1       2.0       - 10.0    2005 15.1          18.9         - 25.2            2.0        - 10.0     2005
Rwanda 0.13    0.1     - 0.2 4002
Seychelles
Uganda 0.06    0.09   - 0.1 0.0515002         100.0       - 200.0 5002
North Africa
Egypt 2.6      1.7     - 3.4 0.055002           40.0         - 60.0 5002
Southern Africa
Malawi 0.07    0.05   - 0.09     35.0     - 50.0    2005 3.8            4.7           - 6.6              70.0      - 90.0     2005
Namibia 0.5      0.3     - 0.8 4.545002           53.0         - 68.1 4002
South Africa 0.2      0.2     - 0.3 7.224002           15.1         - 30.3 4002
Swaziland
Zambia 0.2 4002
Zimbabwe 0.4      0.3     - 0.5 8.345002           32.9         - 54.8 4002
West and Central Africa
Burkina Faso 0.2      0.2     - 0.5       100.0   2005 12.0          15.9         - 19.9 5002
Cameroon 0.02 5002
Congo Rep. 0.2      0.2     - 0.4       100.0   2004 29.9          23.2         - 29.9 5002
Gabon 0.4      0.2     - 0.9 4.5814002 4002
Ghana 4.0      3.0     - 5.0 4002
Guinea 0.01 5.315002           12.0         - 15.0 5002
Nigeria 2.20    2.1     - 2.3       100.0   2005 12.1          11.4         - 12.9 5002
Togo 0.1      0.1     - 0.2 0.0415002 0.03       2004
Americas
Caribbean
Anguilla 12.5    10.0   - 15.0 0.005,215002    10,000.0 - 15,000.0 5002
Bahamas 5.0      5.0     - 10.0 0.008,14002      1,800.0    - 2,200.0 4002
Dominica 32.5    25.0   - 40.0 0.051,25002      1,800.0    - 2,500.0 5002
Dominican Rep. 0.6 0.0525002 5002
Grenada 1.8      1.1     - 3.0 2.5925002         221.4       - 442.7 5002
Haiti 0.6      0.5     - 0.6 0.554002           50.0         - 60.0 4002
Jamaica 99.0          33.0         - 165.0          60.0      - 80.0     2004
Montserrat 24.0    22.1   - 25.8 2.5925002         258.3       - 332.0 5002
St. Lucia 3.7      3.7     - 5.6 5.8924002         559.7       - 671.6 4002
St. Vincent & Grenadines 368.9        295.2       - 442.7 5002
Trinidad Tobago 1.6 0.5235002         300.0       - 350.0          100.0    2005
Turks & Caicos Islands 10.0 0.0075002         600.0       - 900.0 5002
Central America
Belize 0.5      0.5     - 2.5       90.0     - 98.0    2005 162.9        125.3       - 200.5          90.0      - 98.0     2005
Costa Rica 0.8      0.5     - 1.1 4.7125002         173.9       - 260.9 5002
El Salvador 1.0      1.0     - 1.1 0.0575002         700.0       - 800.0 5002
Guatemala 2.6      2.6     - 3.2       100.0   2005 104.8        109.3       - 115.7          100.0    2005
Honduras 0.3      0.3     - 0.4       90.0     - 95.0    2005 92.6          69.5         - 115.8 5002
Panama 10.0 0.001    2005 50.0 0.001     2005
North America
Canada 8.1      8.1     - 20.2     35.0     2005 3,225.8     2,419.4    - 4,838.7       53.0      2005
Mexico 79.0 0.001     2005
United States 15.0    10.0   - 25.0     2.0       - 13.0    2005 10,237.5   975.0       - 19,500.0     4.0        - 13.0     2005
South America
Argentina 1.3      1.0     - 1.6 0.0044002         300.0       - 500.0 5002
Bolivia 1.2 0.001    2005 145.0 0.001     2005
Brazil 0.3      0.3     - 0.8       80.0     - 90.0    2005 150.0        100.0       - 180.0          4.0        2005
Chile 5.2      1.7     - 8.6 7.9865002         517.2       - 862.1 5002
Colombia 0.4 3.045002 5002
Ecuador 1.0      1.0     - 2.0 0.0545002         400.0       - 500.0 5002
Guyana 0.5 0.0445002         435.0       - 445.0 5002
Paraguay 30.0 4002
Uruguay 1.0      0.8    - 1.2       10.0     - 20.0  2005
CANNABIS HERB
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
)margolikrep(ECIRPELASELOHW)margrep(ECIRPLIATER
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3. Statistical Annex Prices
Region / country or territory Ty TraeYlacip y raeYlacip
CANNABIS HERB
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
)margolikrep(ECIRPELASELOHW)margrep(ECIRPLIATER
ytiruPegnaRytiruPegnaR
Asia
Central Asia  and Transcaucasia
Armenia 2.5 0.07      - 80.0    2005 1,500.0 5002
Georgia 3.0      1.0     - 4.0 4002
Kazakhstan 2.5 5.4424002         30.0         - 1,000.0 5002
Kyrgyzstan 0.05    0.03   - 0.06 0.035002           20.0         - 40.0 5002
Tajikistan 2004 140.0        117.0       - 161.0 4002
Uzbekistan
East and South-East Asia
Brunei Darussalam 50.7 5002
China 0.8      0.6     - 1.2 4002
Hong Kong SAR, China 7.4      3.0     - 16.8 8.717,15002      967.7       - 2,322.6 5002
Indonesia 0.2      0.2     - 0.3 5002
Japan 58.3    19.4   - 116.5 6.541,55002      2,427.2    - 7,767.0 5002
Laos 14.0          14.0         - 16.0 4002
Macau SAR, China 12.0    10.0   - 15.0 0.053,25002      2,200.0    - 2,500.0 4002
Malaysia 585.1        315.0       - 631.0 5002
Myanmar 0.1 0.0215002         100.0       - 130.0 5002
Philippines 0.5      0.4     - 0.9 3.3545002         362.7       - 906.6          100.0    2005
Republic of Korea 6.1      2.0     - 11.8 4.0895002 5002
Singapore 20.5 6.420,25002      1,840.5    - 2,208.6 5002
Thailand 0.4      0.2     - 0.5 5002
Near and Middle East /South-West Asia
Israel 3.0 0.0815002         80.0         - 400.0 5002
South Asia
Bangladesh 0.3      0.2     - 0.3       6.0       - 8.0      2005 120.0        100.0       - 140.0          6.0        - 8.0       2005
India 46.1          34.6         - 115.3 5002
Sri Lanka 0.015  0.01   - 0.02 5002
Europe
East Europe
Belarus 3.0      1.0    - 7.5 0.004,15002    550.0 - 2,000.0 5002
Moldova R. 1.6      1.2     - 2.4 5002
Russian Federation 4.0      0.3     - 7.5       1.0       - 3.0      2005 1,940.0     3,490.4    - 8,586.4       1.0        - 3.0       2005
Southeast Europe
Albania 1.0      1.0     - 1.5 0.5115002         100.0       - 130.0 5002
Bulgaria 1.0      0.9    - 1.2 4002
Croatia 3.5      2.6     - 6.1 2.4655002         520.8       - 607.6 5002
FYR of Macedonia 1.6      1.3     - 1.9 8.1745002         314.5       - 629.0 5002
Romania 8.8      6.3     - 12.6 0.1885002 5002
Serbia and Montenegro 4.3      2.5     - 6.2 6.5014002         87.0         - 124.2 4002
Turkey 7.6      2.5     - 5.0 3.0445002         377.4       - 503.2 5002
West & Central Europe
Andorra 7.6 5002
Austria 4.4      3.8     - 5.0       27.0     2005 1,069.3     880.6       - 1,258.0       19.0      2005
Belgium 6.2 5.076,24002 4002
Cyprus 10.8 1.822,35002 5002
Czech Republic 7.3      0.9     - 15.2     21.0     2005 4,428.3     880.6       - 10,819.1     11.0      2005
Estonia 10.1 6.038,25002 5002
Finland 22.0    18.9   - 25.2 3.223,115002 0.41       2005
France 7.6      6.3     - 8.8 1.541,35002      2,641.9    - 5,032.1       2.0        - 16.0     2005
Germany 9.1 0.11      2005 4,289.9 5002
Greece 2.8      1.9     - 3.8 0.9265002         377.4       - 880.6 5002
Hungary 11.0    10.6   - 11.5     6.00     2005 2,780.3 5002
Iceland
Ireland 3.7      2.5     - 5.0 5002
Italy 7.8      6.4     - 7.8 5.014,15002      1,155.0    - 1,666.0 5002
Latvia 18.9 8.186,55002 5002
Liechtenstein 6.8      5.1     - 8.5 5002
Lithuania 10.9    5.5     - 14.6 5002
Luxembourg 9.2 0.1        - 22.0    2005 4,403.1     3,774.1    - 5,032.1 5002
Malta 2.3 0.001,15002      1,000.0    - 1,200.0       10.0      2005
Netherlands 9.8      4.4     - 15.1 9.072,35002      2,641.9    - 3,899.9 5002
Norway
3.2 (0.1-14) 
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Region / country or territory Ty TraeYlacip y raeYlacip
CANNABIS HERB
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
)margolikrep(ECIRPELASELOHW)margrep(ECIRPLIATER
ytiruPegnaRytiruPegnaR
Poland 7.9      3.2     - 12.6 8.357,25002 5002
Portugal 4.0 3.0395002 4002
Slovakia 6.5      3.3     - 9.8       32.0     2005 2,442.7     1,628.5    - 3,256.9 5002
Slovenia 6.9 1.643,15002 5002
Spain 3.5 4.950,25002 5002
Sweden 11.5    8.6     - 14.4 5002
Switzerland 6.4      3.4     - 17.0     1.0       - 25.0    2005 4,661.0     2,118.6    - 8,474.6 5002
United Kingdom 5.0 8.347,25002      943.4       - 4,717.0 5002
Oceania
Australia 26.2    15.5   - 31.0 7.240,55002      3,879.0    - 6,206.4 4002
Marshall Isl. 575.0        500.0       - 650.0 4002
New Zealand 16.1    14.3   - 17.9 4.170,65002      5,000.0    - 7,142.9       3.0        2005
Region / country or territory Ty TraeYlacip y raeYlacip
Americas
Caribbean
Anguilla 12.5    10.0   - 15.0 0.005,215002    10,000.0 - 15,000.0 5002
Bahamas 35.0    20.0   - 50.0 0.000,44002      3,000.0    - 5,000.0 4002
North America
Canada 20.2    16.1   - 40.3     49.0     - 63.0    2005 6,451.6     6,451.6    - 9,677.4       49.0      - 63.0     2005
Asia
East and South-East Asia
Philippines 3,989.1 5002
South Asia
Maldives 11.6    9.3     - 14.0 9.267,75002      6,210.3    - 11,644.3 5002
Europe
Southeast Europe
Albania 1,250.0     1,000.0    - 1,500.0 5002
West and Central Europe
Spain 13.2 9.427,25002 5002
Oceania
New Zealand 89.3    35.7   - 142.9 7.582,985002    35,714.3 - 142,857.1 5002
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
)margolikrep(ECIRPELASELOHW)margrep(ECIRPLIATER
ytiruPegnaRytiruPegnaR
 CANNABIS OIL
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
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Region / country or territory Ty TraeYlacip y raeYlacip
Africa
East Africa
Eritrea 6.7        6.7      - 10.0      2.0      - 10.0  2005 666.7        666.7      - 800.0 5002
Kenya 0.9        0.8      - 1.0        2004
Madagascar 0.3        0.1      - 0.4        2004 125.8        88.1        - 188.7 5002
North Africa
Egypt 2.6        1.7      - 3.4        2005 2,740.0     1,370.0   - 4,110.0 5002
Libya 15.4      6.9      24.0 0.873,15002      1,181.1   - 1,574.8 5002
Southern Africa
South Africa 7.8 4002
Zambia 0.4 4002
West and Central Africa
Congo Rep. 0.3        0.3      - 0.5        2004 27.8          37.1        - 46.4 4002
Americas
Caribbean
Bahamas 20.0      20.0 - 50.0      2004
Turks & Caicos Islands 15.0 0.0084002         600.0      - 900.0 4002
North America
Canada 8.1        8.1      - 20.2      1.0      - 83.0  2005 8,064.5     7,258.1   - 9,677.4     1.0      - 83.0  2005
South America
Brazil 2.0        1.5      - 3.0        2005
Colombia 1.9 4002
Asia
Central Asia  and Transcaucasia
Armenia 15.0 0.07     - 80.0  2005 10,000.0 0.58     2005
Georgia 5.0        3.0      - 10.0 4002
Kazakhstan 3.5        1.5      - 7.2        2004 3,568.8     300.0      - 25,000.0 5002
Kyrgyzstan 1.3        1.0      - 1.5        2005 1,800.0     1,250.0   - 2,500.0 5002
Tajikistan 2.0        1.0      - 3.0        2005 400.0        150.0      - 800.0 5002
Uzbekistan
East and South-East Asia
Hong Kong SAR, China 12.0      5.4      - 17.2 2.477,15002      1,290.3   - 1,935.5 5002
Indonesia 7.3        6.5      - 8.1        2005
Japan 55.7      27.8 - 139.2 2.528,54002 5002
Macau SAR, China 12.0      10.0 - 15.0 5002
Philippines 0.5        0.4      0.5        2005 453.3        362.7      - 544.0        100.0  2005
Republic of Korea 39.2      29.4 - 49.0 5002
Near and Middle East /South-West Asia
Afghanistan 0.05      0.04    0.1        2005 47.0          37.0        - 57.0 5002
Bahrain 106.07  79.55 - 132.6 5.217,35002      3,182.2   - 3,977.7 5002
Iran ( Islamic Republic of) 0.5 0.6135002 5002
Israel 6.0        3.0      - 10.0 0.000,24002      1,500.0   - 3,000.0 5002
Jordan 0.6        0.4      - 0.8        2005 702.3        561.8      - 842.7 5002
Lebanon 9.0        8.0      - 10.0      70.0    - 90.0  2005 300.0        200.0      - 400.0 5002
Oman 26.0 8.570,25002 5002
Pakistan 0.1 9.295002           80.5        - 105.3 5002
Syrian Arab Republic 1.0        0.8      - 1.2        70.0    - 95.0  2005 800.0        600.0      - 1,000.0     70.0 - 90.0  2005
United Arab Emirates 85.0      80.0 - 90.0 0.058,15002      1,500.0   - 2,200.0 5002
South Asia
Bangladesh 1.2        1.0      - 1.4        7.0      - 10.0  2005 1,000.0     800.0      - 1,200.0     7.0      - 10.0  2005
India 345.8        276.6      - 691.6 5002
ytiruPegnaRytiruPegnaR
)margolikrep(ECIRPELASELOHW)margrep(ECIRPLIATER
CANNABIS RESIN
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
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Region / country or territory Ty TraeYlacip y raeYlacip ytiruPegnaRytiruPegnaR
)margolikrep(ECIRPELASELOHW)margrep(ECIRPLIATER
CANNABIS RESIN
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
Europe
East Europe
Belarus 14.0      10.0 - 17.5 0.005,015002    900.0      - 12,500.0 5002
Moldova R. 5.6        4.8      - 6.4        2005
Russian Federation 12.1      1.1      - 29.7 0.128,65002      1,361.3   - 20,942.4 5002
Southeast Europe
Albania 275.0        250.0      - 300.0 5002
FYR of Macedonia 2.8        1.9      - 3.8        2005 817.7        629.0      - 1,006.4 5002
Romania 7.6        5.0      - 7.6        2005 3,145.1     2,012.9   - 3,145.1 5002
Serbia and Montenegro 15.5      12.4 - 18.6 4002
Turkey 6.3        8.8      - 7.6        2005 1,320.9     1,132.2   - 1,509.6 5002
West and Central Europe
Austria 9.5        8.8      - 10.1      1.0      - 38.0  2005 2,830.6     2,516.1   - 3,145.1 5002
Belgium 6.8 1.224,24002 4002
Cyprus 12.9 0.503,45002 5002
Czech Republic 10.7      6.5      - 21.6      4.0      - 17.0  2005 6,164.4     2,138.7   - 10,819.1 5002
Denmark 7.0        4.4      - 19.3 9.072,35002 5002
Estonia 12.0 6.038,25002 5002
Finland 11.3      7.6      - 15.1 6.954,35002      2,516.1   - 4,403.1 5002
France 6.3        5.0      - 7.6        2005 1,887.1     1,635.5   - 2,516.1     6.0      - 16.0  2005
Germany 7.9 5.458,25002 5002
Greece 6.3        5.0      - 7.6        2005 1,824.2     1,132.2   - 2,516.1 5002
Hungary 11.9      11.7 - 12.0      6.0      2005 2,590.3 5002
Iceland 25.5 4002
Ireland 8.8        7.5      - 12.6 5002
Italy 9.2        8.3      - 10.2 0.426,25002      2,105.5   - 3,041.9 5002
Latvia 18.9      13.3 - 22.7 2.489,35002 5002
Liechtenstein 8.5        6.8      - 10.2 5002
Lithuania 8.0        5.5      - 10.9 9.998,35002      3,170.3   - 4,629.6 5002
Luxembourg 9.2 1.230,55002 5002
Malta 10.2 0.000,35002      3,000.0   - 3,400.0     7.0      - 10.0  2005
Monaco 2.5 5002
Netherlands 9.8        4.4      - 15.1 5002
Norway 25.2      18.9 - 31.5 2.477,35002      2,138.7   - 5,409.6 5002
Poland 11.0      7.9      - 14.2 5.107,25002 4002
Portugal 2.5 3.598,25002 4002
Slovakia 14.7      9.8      - 19.5      3.0      - 29.0  2005 4,071.1     3,256.9   - 4,885.4 5002
Slovenia 12.6 8.036,45002      3,931.4   - 4,717.6 5002
Spain 5.4 7.136,15002 5002
Sweden 11.5      8.6      - 14.4 6.613,45002      2,877.7   - 5,755.4 5002
Switzerland 8.5        3.4      - 17.0      9.0      - 28.0  2005 4,830.5     1,694.9   - 8,474.6 5002
United Kingdom 3.7        1.7      - 13.3 8.347,25002 5002
Oceania
Australia 18.5      19.4 - 38.8 5002
New Zealand 24.8 4002
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Region / country or territory Ty TraeYlacip y raeYlacip
Americas
South America
Chile 6.9       5.2    - 8.6 5002
Asia
Near and Middle East /South-West Asia
Bahrain 2.7       2.1    - 3.9 T5002
Iran (Islamic Republic of) 9.7 0.766,3D5002 5002
Jordan TD 8,426.6     7,022.2     - 9,831.1 5002
Oman 26.0 0.07     2005 25,947.7 5002
Qatar
Syrian Arab Republic 12.0     10.0 - 14.0 0.000,8DTD5002      6,000.0     - 12,000.0 5002
East and South-East Asia
Indonesia 2.0       1.8    - 2.3 5002
South Asia
Maldives 77.6     77.6 - 232.9 2.043,455002    38,814.5   - 77,628.9 5002
Europe
Eastern Europe
Belarus 29.0     20.0 - 43.0 0.000,315002    7,500.0     - 25,000.0 5002
Moldova R. 25.1     21.0 - 29.3 0.000,524002    20,000.0   - 30,000.0 5002
Southeast Europe
Bulgaria 7.5       3.1    - 12.4 4002
Croatia 26.0     17.4 - 34.7 7.614,015002    8,680.6     - 12,152.8 5002
Romania 9.4 2.092,65002 5002
Serbia and Montenegro 5.0       3.7    - 6.2 4002
West and Central Europe
Austria 25.2     18.9 - 31.5     1.0      - 100.0   2005 15,725.5   12,580.4   - 18,870.5   1.0       - 94.0    2005
Belgium 8.7 5.076,2D4002 4002
Cyprus 17.0 5.614,74002 4002
Czech Republic 40.9     26.0 - 43.4     3.0      - 75.0     2005 21,638.2   21,638.2   - 34,696.6 5002
Denmark 21.1     14.1 - 52.7 3.460,015002 5002
Estonia 21.4 6.038,25002 5002
Finland 25.2     18.9 - 31.5 3.608,85002      5,032.1     - 12,580.4 5002
France 17.0     8.8    - 25.2 1.615,2DT4002      1,258.0     - 3,774.1 5002
Germany 14.8 1.074,64002 5002
Greece 7.6       6.3    - 8.8 7.693,3D5002      3,019.3     - 3,774.1     1.0       - 5.0      2005
Hungary 15.1     14.7 - 15.5     1.0      - 54.0     2005 5,893.9 5002
Iceland 55.2 5002
Ireland 18.9 5002
Italy 22.8     21.7 - 23.9 5.080,65002      5,870.9     - 6,290.2 5002
Latvia 19.0     15.2 - 22.7     2.0      - 76.0     2005 3,787.9 5002
Liechtenstein 10.2     8.5    - 11.9 5002
Lithuania 8.7       5.5    - 14.6     76.0    2005 2,516.1     2,516.1     - 2,880.9     32 (0.42-76.5) 2005
Luxembourg 6.3 D5002
Netherlands 12.6     6.3    - 18.9 5002
Norway 78.6     31.0 - 124.2   20.0    - 80.0     2005 11,322.4   8,806.3     - 13,838.4   20.0     - 80.0    2005
Poland 9.4       6.3    - 15.7     10.0    80.0     2005 3,231.0 5002
Portugal 3.1 1.368,1DTD4002 4002
Slovenia 5.0 8.253,45002 5002
Spain 30.3 5.794,225002 5002
6.0 D5002
Sweden 34.5     11.5 - 57.6 9.170,015002    5,755.4     - 14,388.5 5002
Switzerland 25.4     10.2 - 42.4 5002
United Kingdom 18.9     5.7    - 75.5     1.0      - 73.0     2005 3,584.9     1,509.4     5,660.4     4.0       - 74.0    2005
Oceania
Australia 209.5   31.0 - 387.9 7.240,55002      3,879.0     - 6,206.4 4002
(*) in Gram or otherwise as indicated
(**) in Kilogram or otherwise as indicated
 D : Doses unit
 T : Tablets unit
TD: Thousand of doses
TT:  Thousand of tablets
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
)**rep(ECIRPELASELOHW)*rep(ECIRPLIATER
AMPHETAMINE
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
Range Purity
42.0 (0.1-93.0) 
Range Purity
30 (10-73)
3.4.3 Amphetamine-type stimulants: Wholesale, street prices and purity levels
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Region / country or territory Ty TraeYlacip y raeYlacip
Africa
Southern Africa
South Africa 7.1 2.174002 4002
Americas
North America
Canada 74.7    74.7    - 149.5  84.0   2004 11,290.3     7,661.3       - 14,516.1     2.0    - 100.0  2005
United States 160.0  20.0    - 300.0  73.0   2005
Asia
East and South-East Asia
Brunei Darussalam 361.9 5002
Cambodia 1.6      1.0      - 5.0 T5002
China 6.0      2.4      - 9.7      20.0   2004 T 6,650.0       6,000.0       - 12,000.0 5002
China (Hong Kong SAR) 45.2    33.9    - 53.0    93.0   - 99.0    2005 13,602.2     5,161.3       - 32,903.2 5002
Indonesia 44.4    40.3    - 48.4 5002
10.0    9.5      - 11.6 T5002
Japan 485.4  97.1    - 970.9 8.830,235002      11,650.5     - 53,398.1 5002
Laos 1.0      0.9      - 1.1 0.000,4T5002        3,000.0       - 5,000.0       27.0  2004
Macau SAR, China 18.0    12.0    - 25.0 5002
Malaysia 5.3 3.493,02T5002      15,789.0     - 21,052.6 5002
Myanmar 0.9      0.8      - 2.8 5002
2.0      1.8      - 2.2 T5002
Philippines 36.3    36.3    - 90.7 5002
Republic of Korea 902.0  588.2 - 980.4  56.0   2005 12,745.1 0.62 - 99.0    2005
Singapore 107.4  92.0    - 122.7  80.0   2005 105,828.3   101,227.0   - 110,429.5 5002
6.0      5.8      - 6.1      3.0     2005 T
Thailand 84.7    78.2    - 91.2 5002
8.0      6.0      - 8.6 T5002
Near and Middle East /South-West Asia
Bahrain 424.3  397.8 - 450.8 3.777,935002      26,518.2     - 53,036.3 5002
Europe
East Europe
Belarus 33.0    20.0    - 43.0 0.000,415002      7,500.0       - 25,000.0 5002
Moldova R. 4.0      3.6      - 4.8 0.005,45002        4,000.0       - 5,500.0 5002
West and Central Europe
Czech Republic 44.0    17.4    - 86.8    3.0     - 86.0    2005 30,922.5     12,957.8     - 43,402.2     67.0 - 78.0    2005
France TD 2,484.2       1,242.1       - 3,726.3 4002
Latvia 19.0    15.2    - 22.7    14.0   - 84.0    2005 3,787.9 5002
Liechtenstein 8.5      6.8      - 10.2 5002
Lithuania 10.9    7.3      - 14.6    67.0   2005 2,516.1       2,000.3       - 3,849.6       29 (0.19-66.5) 2005
Norway 78.7    31.5    - 125.8  10.0   - 80.0    2005 11,322.4     8,806.3       - 13,838.4     10.0 - 80.0    2005
Slovakia 65.1    48.9    - 81.4    4.0     - 89.0    2005
Spain 30.5 9.763,225002 5002
Sweden 34.5    11.5    - 57.6 9.170,015002      5,755.4       - 14,388.5 5002
Switzerland
United Kingdom 2004
Oceania
Australia 188.8  66.0    - 295.0 0.005,484002      44,313.0     - 118,168.0 4002
New Zealand 424.8  65.4    - 784.3 0.506,3524002    230,550.0   - 276,660.0 4002
(*) in Gram or otherwise as indicated
(**) in Kilogram or otherwise as indicated
 D : Doses unit
 T : Tablets unit
TD: Thousand of doses
TT:  Thousand of tablets
ytiruPegnaRytiruPegnaR
)77-7.3(83)88-3.0(33
METHAMPHETAMINE
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
39.8 (1 - 70)
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
)**(ECIRPELASELOHW)*(ECIRPLIATER
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Region / country or territory raeYlacipyTraeYlacipyT
Africa
North Africa
Egypt 18.8     12.0   - 25.7 0.472,015002      6,849.3    - 13,698.6 5002
Southern Africa
Namibia 20.3     10.1   - 20.3 3.561,815002 4002
South Africa 14.6 4002
Zimbabwe 19.7     17.5   - 21.9 4002
West and Central Africa
Ghana 6.0       5.0     - 7.0 4002
Americas
Caribbean
Dominican R. 16.0 0.000,615002 5002
Jamaica 20,000.0     15,000.0 - 25,000.0 4002
Central America
Costa Rica 16.3     10.9   - 21.7 5002
North America
Canada 8.1       4.0     - 16.1 6.223,045002      38,709.7 - 48,387.1       68.0   87.0     2005
United States 25.0     20.0   - 30.0 0.000,014002      5,000.0    - 13,000.0 4002
South America
Argentina 4,666.0 4002
Brazil 12.0     7.0     - 25.0 0.000,515002      10,000.0 - 30,000.0 4002
Chile 18.4     12.1   - 34.5 4.142,715002 5002
Colombia 22.6 5002
Ecuador 20.0     20.0   - 30.0 0.000,025002      20,000.0 - 30,000.0 5002
Uruguay 20,000.0     15,000.0 - 25,000.0 4002
Asia
East and South-East Asia
Brunei Darussalam 102.0 4002
Cambodia 5.0       5.0     - 15.0 5002
China 4.5       2.5     - 12.0 5002
Hong Kong SAR, China 10.7     5.9     - 14.2 8.453,35002        1,548.4    - 5,806.5 5002
Indonesia 9.7       8.6     - 10.8 5002
Japan 58.3     29.1   - 58.3 5002
Republic of Korea 34.3     29.4   - 39.2 8.069,15002 5002
Macau SAR, China 22.0     18.0   - 31.0 5002
Malaysia 19.0     9.2     - 21.0 5002
Philippines 21.8 8.857,125002 5002
Singapore 16.9     15.3   - 18.4 6.266,95002        8,895.7    - 10,429.5 5002
Thailand 18.3     15.6   - 20.9 5002
Vietnam 32.5     20.0   - 45.0 5002
Near and Middle East /South-West Asia
Iran ( Islamic Republic of) 6.2 5002
Israel 10.0     7.0     - 15.0 0.000,65002        4,500.0    - 11,000.0 5002
Europe
East Europe
Belarus 10.0     9.0     - 17.5 0.005,55002        5,000.0    - 9,000.0 5002
Moldova R. 12.0     2.4     - 20.0 0.000,515002      5,000.0    - 30,000.0 5002
Russian Federation 29.2     9.6     - 62.8   18.0     - 40.0    2005 16,509.0     3,490.0    - 31,414.0 5002
Southeast Europe
Bulgaria 6.2       4.4     - 12.4   45.0     2004
Croatia 6.9       5.2     - 8.7 4.670,65002        3,472.2    - 8,580.6 5002
FYR of Macedonia 11.3     10.1   - 12.6 1.304,45002        2,516.1    - 6,290.2 5002
Romania 18.9     16.4   - 18.9 1.230,55002        3,774.1    - 5,032.1 5002
Serbia and Montenegro 9.3       6.2     - 12.4 4002
Turkey 7.6       6.3     - 8.8 1.541,35002        2,516.1    - 3,774.1 5002
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
)stelbatdnasuohtrep(ECIRPELASELOHW)telbatrep(ECIRPLIATER
ytiruPegnaRytiruPegnaR
ECSTASY
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
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Region / country or territory raeYlacipyTraeYlacipyT
(prices expressed in US$ or converted equivalent, and purity levels in percentage)
)stelbatdnasuohtrep(ECIRPELASELOHW)telbatrep(ECIRPLIATER
ytiruPegnaRytiruPegnaR
ECSTASY
Retail and wholesale prices and purity levels:
breakdown by drug, region and country or territory
West and Central Europe
Andorra 6.3       3.8     - 7.6 5002
Austria 15.7     12.6   - 18.9   1.0       - 100.0  2005 7,862.7       6,290.2    - 9,435.3         2.0     - 100.0   2005
Belgium 6.8 4.824,14002 4002
Cyprus 15.1 5.754,65002 5002
Czech Republic 9.2       3.5     - 21.6   84.0     2005 4,906.3       1,736.1    - 8,680.5 5002
Denmark 8.8       6.2     - 17.6 7.393,45002        1,747.5    - 4,393.7 5002
Estonia 7.9 5.275,15002 5002
Finland 20.1     15.1   - 25.2 4.985,55002        4,968.3    - 6,210.4 4002
France 8.8       6.3     - 11.3 6.102,25002        1,258.0    - 3,145.1 5002
Germany 8.8 9.867,25002 5002
Greece 18.9     12.6   - 25.2 5002
Hungary 6.3       6.2     - 6.4     10.0     - 50.0    2005 1,510.9 5002
Iceland 24.6 5002
Ireland 12.6 5002
Italy 24.2     21.3   - 27.1 1.696,45002        4,226.0    - 5,171.4 5002
Latvia 7.6       5.7     - 9.5     8.0       - 94.0    2005 3,314.4       1,893.9    - 4,734.9 5002
Liechtenstein 12.7     8.5     - 17.0 5002
Lithuania 4.1 8.383,15002        1,258.0    - 1,446.7         4.0     - 58.0     2005
Luxembourg 6.3 5002
Malta 15.3 0.000,025002      18,000.0 - 22,000.0 5002
Netherlands 4.4       2.5     - 6.3 8.4575002           251.6        - 1,006.4 5002
Norway 44.0 3.159,115002      11,322.3 - 12,580.4       20.0   - 50.0     2005
Poland 3.2       2.5     - 4.7 0.989,15002 5002
Portugal 5.0 9.759,35002        2,326.4    - 5,589.4 4002
Slovakia 8.1       6.5     - 9.8     5.0       - 49.0    2005 5,178.1 5002
Slovenia 6.3 1.788,15002 5002
Spain 12.4 5002
Sweden 14.4     7.2     - 21.6 8.820,45002        2,158.3    - 5,755.4 5002
Switzerland 17.0     8.5     - 33.9   23.0     - 52.0    2005
United Kingdom 7.5       0.5     - 37.7   3.0       - 93.0    2005 1,829.2 5002
Oceania
Australia 31.5     18.0   - 60.0 0.158,614002      11,078.0 - 30,000.0 4002
New Zealand 53.6     42.9   - 64.3 5002
)1.77-7.3(64)6.09-5.1(13
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3.5 Consumption
3.5.1 Annual Prevalence
3.5.1.1 Opiates
ACIREMAEPORUE
aciremAlartneCeporuElartneCdnanretseW
3.04002,*rodavlaSlE5.14002,ainotsE
2.0*alametauG9.00002,gruobmexuL
2.0**amanaP9.03002,)agiR(,aivtaL
1.0*aciRatsoC9.04002,modgniKdetinU
40.05002,sarudnoH8.05002,ylatI
7.00002,lagutroP North America
6.00002,ASU6.04/2002,*ainauhtiL
3.05002,adanaC6.00002,dnalreztiwS
1.02002,ocixeM6.04002,atlaM
6.01002,dnalerI South America
5.05002,)56-21(,lizarB5.01002,kramneD
3.02002,*anayuG5.01002,ainevolS
2.05002,*anitnegrA5.02002,airtsuA
2.04002,elihC4.09991,ecnarF
2.03002,*yaugurU4.07991,muigleB
1.03002,*aleuzeneV4.07991,yawroN
1.04002,*aibmoloC4.05002,dnalecI
90.05002,*rodaucE3.03002,)45-81(,yragnuH
80.02002,*emaniruS3.04002,aikavolS
70.04002,*aiviloB3.01002,sdnalrehteN
3.04002,eceerG The Caribbean
2.03002,*samahaB2.02002,niapS
2.02002,*sodabraB2.04002,ynamreG
Liechtenstein*, 2005 0.2 Dominican Rep.*, 2001 0.1
1.01002,*aciamaJ2.03002,dnaloP
90.02002,*ogaboT&dadinirT2.04002,surpyC
70.02002,*.lsIsociaC&skruT1.03002,nedewS
50.00002,adubraBaugitnA1.04002,.peRhcezC
1.04002,dnalniF OCEANIA
Southeast Europe 5.04002,ailartsuA
5.01002,dnalaeZweN5.00002,*ainablA
5.01002,airagluB AFRICA
FYR of Macedonia, 2005 0.5 Eastern Africa
0.23002,suitiruaM3.05002,aitaorC
2.04002,ayneK2.04002,ainamoR
2.04002,ailamoS50.03002,yekruT
East Europe 1.04002,adnawR
50.0**aipoihtE0.24002,*noitaredeFnaissuR
50.04002,adnagU8.02002,*eniarkU
20.08991,.peRdetinU,ainaznaT4.03002,*suraleB
Moldova, Rep., 2000 0.07 North Africa
2.04002,*tpygE
1.04002,*aireglA
Libyan Arab Jamahiriya*, 2004 0.1
20.04002,occoroM
Tunisia, 2003 0.03
OPIATES
Annual prevalence of abuse as percentage of the population aged
15-64 (unless otherwise indicated)
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aisA tseW-htuoS dna tsaE elddiMacirfA nrehtuoS
South Africa*, 2005 0.4 Iran, Islamic Republic, 1999 2.8
4.15002 ,*natsinahgfA4.03002 ,*aibmaZ
7.0 n, 2007atsikaP2.0 4002 ,ognoC fo cilbupeR.meD
5.05002 ,)04-81( ,learsI2.04002 ,dnalizawS
3.08991 ,niarhaB40.04002 ,ewbabmiZ
2.01002 ,*nadroJ30.00002 ,aibimaN
West and Central Africa 2.04002 ,*tiawuK
2.03002 ,nonabeL6.09991 ,)+01( ,*airegiN
90.09991 ,namO3.01002 ,*alognA
90.09991 ,**nemeY2.05991 ,dahC
20.05002 ,*.peR barA nairyS2.04002 ,airebiL
Sierra Leone, 1997 0.2 United Arab Emirates*, 2004 0.02
10.06991 ,rataQ1.04002 ,cilbupeR nacirfA lartneC
10.00002 ,aibarA iduaS1.04002 ,.peR ognoC
1.04002 ,anahG South Asia
4.04/3002 ,*hsedalgnaB1.04002 ,regiN
4.01002 ,aidnI30.0**lageneS
Cote d'Ivoire, 1997 0.01 3.06991 ,lapeN
ASIA 3.04002 ,*aknaL irS
Central Asia and Transcaucasia 2.01002 ,**sevidlaM
0.16002 ,natshkazaK
8.06002 ,natszygryK
8.06002 ,natsikebzU
6.00002 ,aigroeG
5.06002 ,natsikijaT
3.05002 ,ainemrA
Turkmenistan**, 1998 0.3
2.00002 ,najiabrezA
East and South-East Asia
Macao SAR, China, 2003 1.1
Lao People's Dem. Rep., 2006 0.6
6.06002 ,ramnayM
Taiwan province*, China, 2002 0.3
3.05002 ,maN teiV
2.03002 ,anihC
Hong Kong SAR, China, 2005 0.2
2.05002 ,aisenodnI
2.00002 ,*aisyalaM
1.06002 ,dnaliahT
Japana 60.03002 ,
30.04002 ,aidobmaC
Brunei Darussalam, 1998 0.01
Singapore*, 2004 0.01
a/
 Life-time prevalence (15+)
OPIATES
Annual prevalence of abuse as percentage of the population aged
15-64 (unless otherwise indicated)
*UNODC estimates based on local studies, special population group studies, and /or
law enforcement agency assessments.
** Tentative estimates.
Sources: Annual Reports Questionnaires, Government Reports, US Department of
State, European Monitoring Center for Drugs and Drug Addiction (EMCDDA), Drug
Assessment Programme on Drug Abuse (GAP).
Abuse Information Network for Asia and the Pacific (DAINAP), UNODC Global
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AMERICA 6.05002,ecnarF
North America 5.04002,aikavolS
4.03002,*dnalneerG8.25002,ASU
4.03002,)45-81(,yragnuH3.24002,adanaC
3.04002,dnalniF4.02002,)56-21(,ocixeM
South America 3.04002,ainauhtiL
Bolivia, (12-50), 2005a 3.01002,)56-81(,atlaM9.1
3.01002,lagutroP8.14002,elihC
3.03002,*ainevolS2.15002,*rodaucE
2.04002,.peRhcezC1.11002,*aleuzeneV
2.03002,*nedewS8.03002,)56-81(,aibmoloC
2.03002,aivtaL7.01002,)56-21(,lizarB
1.04002,eceerG7.03002,)46-21(,ureP
1.02002,)+61(,dnaloP5.02002,*emaniruS
3.04002,anitnegrA Southeast Europe
3.05002,)06-81(,airagluB3.04002,yaugaraP
2.03002,*aitaorC3.01002,yaugurU
Central America 1.04002,ainamoR
80.05002,ainodecaMfoRYF2.13002,*alametauG
70.04002,*ainablA2.13002,)56-21(,amanaP
40.03002,*yekruT0.13002,*augaraciN
Honduras, (12-35), 2005 0.9 East Europe
1.03002,*eniarkU7.02002,*ezileB
20.03002,*suraleB5.05002,rodavlaSlE
20.05002,*.deFnaissuR4.01002,aciRatsoC
The Caribbean OCEANIA
2.14002,ailartsuA3.17991,*aburA
5.01002,*dnalaeZweN0.12002,*aicuL.tS
0.12002,*sodabraB AFRICA
Dominican Rep., (12-70), 2000 0.9 East Africa
1.0**ayneK9.03002,*adanerG
9.01002,*aciamaJ Southern Africa
8.05002,*acirfAhtuoS8.01002,*samahaB
2.00002,**aibmaZ7.02002,*senidanerGtnecniV.tS
2.08991,aibimaN7.02002,*sociaCdnaskruT
1.09991,alognA6.00002,*.sInamyaC
1.00002,ewbabmiZ3.00002,*itiaH
Antigua Barbuda, 2000 0.1 North Africa
EUROPE 50.04002,occoroM
acirfAlartneCdnatseWeporuElartneCdnatseW
1.18991,anahG0.35002,niapS
5.09991,airegiN4.26/5002,)95-61(,selaW&dnalgnE
20.07991,epicnirPemoToaS1.25002,ylatI
20.06991,enoeLarreiS5.14002,)95-61(,dnaltocS
10.05991,dahC1.13002,*dnalecI
1.13002,dnalerI ASIA
1.11002,sdnalrehteN East and  South-East Asia
30.05002,aisenodnI1.14002,)95-61(,dnalerInrehtroN
30.05002,*napaJ1.13002,*dnalreztiwS
30.05002,senippilihP0.13002,)95-81(,ynamreG
30.06002,dnaliahT9.04002,airtsuA
200.03002,)+11(,anihCRASgnoKgnoH9.04002,muigleB
2000.04002,eropagniS9.03002,*gruobmexuL
Denmark, (16-64), 2000 0.8 Near and Middle East / South-West Asia/C.Asia and Transcaucasia
6.05002,)04-81(,learsI8.05002,*nietsnethceiL
1.05002,ainemrA8.04002,yawroN
1.01002,*nonabeL7.03002,)56-51(,surpyC
50.0**nadroJ6.03002,ainotsE
a/  1.9% cocaine paste; 1.6% cocaine HCL 40.05002,*tiawuK
Syrian Arab Rep.*, 2005 0.001
COCAINE
Annual prevalence of abuse as percentage of the population aged
15-64 (unless otherwise indicated)
*UNODC estimates based on local studies, special population group studies, and /or law enforcement agency assessments.
** Tentative estimates.
Sources: Annual Reports Questionnaires, Government Reports, US Department of State, European Monitoring Center for Drugs and Drug Addiction (EMCDDA), Drug Abuse Information Network for Asia
and the Pacific (DAINAP), UNODC Global Assessment Programme on Drug Abuse (GAP).
3.5.1.2 Cocaine
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ACIREMAEPORUE
aciremAlartneCeporuElartneCdnanretseW
1.93002,alametauG1.413002,)56-51(surpyC
7.63002,*ezileB2.115002,ylatI
0.54002,)54-21(,rodavlaSlE2.115002,niapS
0.43002,*amanaP6.93002,*dnalreztiwS
2.22002,*augaraciN3.94002,)46-81(,.peRhcezC
5.14002,*sarudnoH7.86/5002,)95-61(,selaWdnadnalgnE
3.11/0002,)07-21(,aciRatsoC6.85002,ecnarF
6.85002,*nietsnethceiL North America
Greenland*, 2003 8.614002,adanaC6.7
6.215002,ASU6.73002,gruobmexuL
1.33002,*ocixeM5.74002,airtsuA
Germany, (18-59), 2003 6.9 South America
6.54002,elihC4.64002,)95-61(,dnalerInrehtroN
3.32002,*aleuzeneV3.64002,)95-61(,dnaltocS
2.35002,aiviloB2.60002,)46-61(,kramneD
0.35002,*anitnegrA2.63002,*ainevolS
6.22002,*anayuG1.61002,sdnalrehteN
1.25002,*rodaucE1.53/2002,dnalerI
0.22002,*emaniruS0.54002,)56-51(,muigleB
9.13002,)56-81(,aibmoloC6.43002,ainotsE
8.13002,)46-21(,ureP6.44002,yawroN
Iceland, (18-64), 2001 4.3 Paraguay*, (12-65), 2005 1.6
Slovakia, (18-64), 2004 4.1 Uruguay, (13-64), 2001 1.5
0.11002,)56-21(,lizarB9.33002,)45-81(,yragnuH
8.33002,)86-51(,aivtaL The Caribbean
07.011002,)55-21(*aciamaJ3.31002,lagutroP
Finland, 2004 03.72002,*sodabraB9.2
07.63002,*adanerG4.22002,)+61(,dnaloP
02.65002,itiaH2.24002,ainauhtiL
Sweden, (18-64), 2005 2.0 St. Vincent & the Grenadines*,2002 6.20
04.52002,*.sIsociaC&skruT7.14002,eceerG
07.43002,*samahaB8.01002,)56-81(,atlaM
Southeast Europe Trinidad & Tobago*,2002 3.70
09.10002,.peRnacinimoD0.43002,*aitaorC
Bosnia & Herzegovina*, 2005 3.0 OCEANIA
5.925991,aeniuGweNaupaP9.13002,*yekruT
1.925991,.etatS.deFaisenorciM8.14002,ainablA
4.311002,dnalaeZweN5.15002,)06-81(,airagluB
3.314002,ailartsuA9.04002,ainamoR
East Europe 9.1**ainodelaCweN
2.06991,ijiF9.33002,*noitaredeFnaissuR
1.07991,utaunaV6.33002,*eniarkU
6.23002,*suraleB
CANNABIS
Annual prevalence of abuse as percentage of the population aged
15-64 (unless otherwise indicated)
3.5.1.3 Cannabis
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AFRICA  East and South-East Asia
East Africa 2.44002,*senippilihP
5.33002,*aidobmaC1.94002,*racsagadaM
6.13002,*aisyalaM0.44991,*ayneK
9.05002,*ramnayM9.34002,suitiruaM
9.06002,)56-21(,dnaliahT9.22002,*soromoC
7.05002,aisenodnI6.29991,*aipoihtE
7.02002,*.peR.meDs'elpoePoaL5.22002,ailamoS
7.03002,*anihC,RASoacaM4.1**adnagU
Tanzania, United Rep.**, 1999 0.2 Taiwan province, China** 0.5
North Africa 3.02002,*maNteiV
1.02002,napaJ2.57991,**tpygE
20.06991,malassuraDienurB2.44002,occoroM
Libyan Arab Jamahiriya, 1998 0.05 Hong Kong SAR, China, 2005 0.02
Southern Africa 400.04002,eropagniS
200.04002,aeroKfocilbupeR7.713002,*aibmaZ
9.85002,*acirfAhtuoS Near and Middle East / South-West Asia
5.85002,)04-81(,learsI9.60002,ewbabmiZ
4.61002,nonabeL9.30002,aibimaN
2.49991,cilbupeRcimalsI,narI1.29991,alognA
West and Central Africa 9.30002,*natsikaP
6.35002,natsinahgfA5.128991,anahG
1.35002,*tiawuK1.616991,enoeLarreiS
1.21002,*nadroJ8.310002,airegiN
0.22002,*.peRbarAnairyS8.75991,*ilaM
4.0**niarhaB8.29991,lageneS
1.09991,namO9.05991,dahC
ASIA 1.06991,rataQ
aisAhtuoSaisacuacsnarTdnaaisAlartneC
3.37991,hsedalgnaB4.61002,*natszygryK
2.30002,aidnI2.40002,*natshkazaK
2.38991,*lapeN2.43002,*natsikebzU
5.10002,aknaLirS5.33002,*ainemrA
5.04991,sevidlaM5.34002,*najiabrezA
4.38991,*natsikijaT
CANNABIS
Annual prevalence of abuse as percentage of the population aged
15-64 (unless otherwise indicated)
*UNODC estimates based on local studies, special population group studies, and /or
law enforcement agency assessments.
** Tentative estimates.
Sources: Annual Reports Questionnaires, Government Reports, US Department of
State, European Monitoring Center for Drugs and Drug Addiction (EMCDDA), Drug
Assessment Programme on Drug Abuse (GAP).
Abuse Information Network for Asia and the Pacific (DAINAP), UNODC Global
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ACIREMAEPORUE
West and Central Europe Central America
0.35002,)56-21(,rodavlaSlE3.10002,kramneD
0.10002,aciRatsoC3.16/5002,)95-61(,selaW&dnalgnE
9.05002,*alametauG3.13002,ainotsE
8.05002,*sarudnoH1.13002,aivtaL
8.03002,*augaraciN1.14002,yawroN
6.03002,*amanaP0.14002,)95-61(,dnaltocS
0.15002,niapS North America
8.15002,ASU9.03002,)95-81(,ynamreG
8.04002,adanaC9.03002,*dnalecI
1.02002,ocixeM9.04002,)95-61(,dnalerInrehtroN
8.04002,airtsuA South America
7.05002,)56-21(,lizarB8.01002,*muigleB
6.02002,*emaniruS8.03002,yragnuH
6.02002,*aleuzeneV8.03002,*dnalreztiwS
6.05002,*anitnegrA7.04002,)46-81(,.peRhcezC
5.05002,*aibmoloC6.04002,dnalniF
5.05002,*yaugaraP6.01002,sdnalrehteN
4.04002,elihC6.02002,)+61(,dnaloP
3.04002,*aiviloB4.03002,dnalerI
2.05002,*rodaucE4.05002,ylatI
1.05002,*ureP4.09991,gruobmexuL
1.04002,yaugurU3.04002,ainauhtiL
Malta, (18-65), 2001 0.3 Caribbean
1.13002,*cilbupeRnacinimoD3.04002,aikavolS
8.02002,*ogaboT&dadinirT2.03002,surpyC
7.05002,adanerG2.05002,ecnarF
3.03002,*samahaB2.05002,*nietsnethceiL
3.03002,*sdnalsIsociaC&skruT2.09991,*ainevolS
2.02002,*sodabraB2.00002,nedewS
1.01002,lagutroP OCEANIA
8.34002,ailartsuA40.04002,eceerG
Southeast Europe 4.31002,dnalaeZweN
5.03002,*aitaorC
Bulgaria, (18-60), 2005 0.4
2.03002,*yekruT
1.04002,*ainamoR
20.04002,ainablA
East Europe
4.05002,*suraleB
Moldova, Rep., 1998 0.2
Russian Federation*, 2003 0.2
2.03002,*eniarkU
AMPHETAMINES
Annual prevalence of abuse as percentage of the population aged
15-64 (unless otherwise indicated)
3.5.1.4 Amphetamine-type stimulants (excluding ecstasy)
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AFRICA Near and Middle East / South-West Asia
East Africa Israel, (18-40), 2005 0.4
4.01002,nadroJ6.0**ayneK
4.01002,*nonabeL3.0**aipoihtE
North Africa 3.05002,*tiawuK
1.0**niarhaB5.0**tpygE
1.08991,namO20.05/4002,occoroM
West & Central Africa 20.06991,rataQ
300.08991,.peRbarAnairyS1.19991,airegiN
200.00002,aibarAiduaS0.1**anahG
9.0**nooremaC
10.06991,dahC
Southern Africa
South Africa*, 2005 0.5
1.00002,aibimaN
1.03002,*aibmaZ
1.00002,ewbabmiZ
ASIA
Central Asia and Transcaucasia
40.05002,ainemrA
10.07991,natsikebzU
East, South & South-East Asia
0.64002,*senippilihP
Taiwan province, China, 2000 1.2
8.06002,dnaliahT
7.04002,*RDPoaL
7.05002,*aisyalaM
6.04002,*aidobmaC
3.05002,aisenodnI
Japan(a) 3.05002,
2.05002,*ramnayM
2.03002,*maNteiV
Republic of Korea, 2004 0.1
Brunei Darussalam, 2000 0.06
Hong Kong SAR, China, 2005 0.04
20.01002,aidnI
500.04002,eropagniS
Macao SAR, China, 2001 0.002
a/  Life-time prevalence (15+)
AMPHETAMINES
Annual prevalence of abuse as percentage of the population aged
15-64 (unless otherwise indicated)
*UNODC estimates based on local studies, special population group studies, and /or
law enforcement agency assessments.
** Tentative estimates.
Sources: Annual Reports Questionnaires, Government Reports, US Department of
State, European Monitoring Center for Drugs and Drug Addiction (EMCDDA), Drug
Assessment Programme on Drug Abuse (GAP).
Abuse Information Network for Asia and the Pacific (DAINAP), UNODC Global
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EUROPE North America
West and Central Europe 1.14002,adanaC
0.14002,ASU5.34002,)46-81(,.peRhcezC
10.02002,ocixeM5.23002,surpyC
Northern Ireland, (16-59), 2004 1.9 South America
2.05002,*lizarB7.14002,)56-51(,ainotsE
2.04002,elihC6.16/5002,)95-61(,selaW&dnalgnE
2.05002,*aibmoloC5.11002,sdnalrehteN
2.05002,*rodaucE4.13002,)45-81(,yragnuH
2.01002,*aleuzeneV2.14002,)95-61(,dnaltocS
1.04002,anitnegrA2.14002,aikavolS
1.05002,aiviloB2.15002,niapS
1.02002,*anayuG1.13002,*muigleB
1.05002,*yaugaraP1.13002,dnalerI
1.03002,ureP9.04002,airtsuA
1.02002,*emaniruS9.03002,*ainevolS
1.05002,*yaugurU8.03002,)95-81(,ynamreG
8.03002,aivtaL The Caribbean
7.03002,*.sIsociaC&skruT8.03002,*dnalreztiwS
3.02002,*sodabraB6.03002,)56-51(,*dnalecI
2.00002,*.peRnacinimoD5.00002,kramneD
1.03002,*samahaB5.04002,dnalniF
1.05002,ogaboT&dadinirT5.05002,ecnarF
Liechtenstein*, 2005 0.5   AFRICA
4.04002,*acirfAhtuoS5.08991,)56-51(,*gruobmexuL
3.03002,*aibmaZ5.04002,yawroN
1.00002,aibimaN4.05002,)45-51(,ylatI
1.03002,*ewbabmiZ4.04002,ainauhtiL
20.03002,occoroM4.01002,lagutroP
10.05991,anahG4.03002,*nedewS
2.04002,eceerG   ASIA
Malta, (18-65), 2001 0.2 East and South-East Asia/South Asia/Transcaucasia
4.03002,*aisyalaM2.02002,)+61(,dnaloP
Southeast Europe 3.05002,aisenodnI
3.02002,*anihC,RASoacaM5.05002,)06-81(,airagluB
3.04002,aeroKfo.peR3.03002,)56-51(,*aitaorC
2.04002,senippilihP3.03002,*yekruT
2.03002,*maNteiV1.09991,*ainodecaMfoRYF
1.05002,ainemrA1.04002,*ainamoR
1.03002,*aidobmaC40.04002,ainablA
East Europe Japana 1.03002,
1.01002,dnaliahT1.03002,*eniarkU
30.05002,anihC,RASgnoKgnoH50.05002,*noitaredeFnaissuR
  AMERICA 10.04002,*aidnI
Central America Singapore, 2004 0.003
4.03002,*amanaP Near and Middle East / South-West Asia
7.05002,)04-81(,learsI2.03002,*ezileB
5.01002,*nonabeL1.03002,*rodavlaSlE
1.03002,*augaraciN OCEANIA
0.44002,ailartsuA1.05002,*alametauG
2.21002,*dnalaeZweN1.05002,*sarudnoH
a/  Life-time prevalence (15+)
ECSTASY
Annual prevalence of abuse as percentage of the population aged
15-64 (unless otherwise indicated)
*      UNODC estimates based on local studies, special population group studies, and /or law enforcement agency assessments.
**    Tentative estimates.
Sources: Annual Reports Questionnaires, Government Reports, US Department of State, European Monitoring Center for Drugs and Drug Addiction (EMCDDA), Drug Abuse Information
Network for Asia and the Pacific (DAINAP), UNODC Global Assessment Programme on Drug Abuse (GAP).
3.5.1.5 Ecstasy
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Sources of information
Under the International Drug Conventions, Member
States are formally required to provide drug related
information annually, as detailed by the Commission on
Narcotic Drugs, to the ‘Secretary General’ of the United
Nations (i.e. the Secretariat of UNODC). The Com-
mission on Narcotic Drugs developed the Annual
Reports Questionnaire (ARQ) to collect these data. 
The World Drug Report 2007 is based primarily on
data obtained from the ARQs returned by Governments
to UNODC over the June 2006 to May 2007 period.
The data collected during this period normally refer to
the drug situation in 2005. UNODC sent out the ques-
tionnaire to 192 countries. Some of them were for-
warded on to autonomous territories, thus bringing the
total to 198. UNODC received 104 replies to its ques-
tionnaire on Drug Abuse (Part II) and 120 replies to its
questionnaire on Illicit Supply of Drugs (Part III). The
best coverage was from countries in Europe (89% of all
countries in Europe filled in both Part II and Part III of
the ARQ), followed by the Americas (66% of the coun-
tries filling in the Supply and 42% the Demand ARQ)
and Asia (63% Supply / 58% Demand ARQ). In the
case of Africa, 40% of countries replied to the Supply
ARQ and 35% to the Demand ARQ. In the Oceania
region, the two largest countries supplied information,
equivalent to 13% of the countries in the region.
Member states’ responses to the ARQs are shown on the
subsequent maps.   
In general, the ability of Member States to provide
information on illicit drug supply is significantly better
than their ability to provide demand related informa-
tion. The analysis of the ‘Supply ARQs’ revealed, that
77% of them were ‘substantially’ completed compared
to just 54% of the ‘Demand ARQs’. (ARQs which were
more than 50% completed were classified as having
been ‘substantially filled in’; the rest were classified as
having been only partially filled in.) 
In order to identify to analyse the extent to which
Member States provided information, a number of key
questions in the ARQs were identified: 
• For the ‘Supply ARQs’, this included replies to the
questions on ‘seizures’, i.e. on the quantities seized
(replied by 97% of the countries returning the
ARQ), the number of seizure cases (75%), ‘traf-
ficking’ (origin of drugs (69%) and destination
(62%)), ‘drug prices’ (90%), ‘drug related
arrests’(87%) and ‘convictions’ (41%). The overall
analysis of these data revealed – as mentioned
before - that ‘Supply ARQs’ were 77% completed.
• For the Demand ARQs, the key questions used for
the analysis referred to ‘trends in drug abuse’
(replied by 92% of the Member States), ‘ranking
of drugs in terms of their prevalence among the
general population‘ (89%), ‘prevalence estimates’
(general population (35%), students (42%); prob-
lem drug use (30%)), ‘drug related deaths’ (35%),
and ‘treatment’ (53%). The overall response rate
of completion was 54% for the countries which
returned a ‘Demand ARQ’ to UNODC. 
Information provided by Member States in ARQs form
the basis for the estimates and trend analysis provided in
the World Drug Report. Often, this information and
data is not sufficient to provide an accurate or compre-
hensive picture of the world’s drug markets. When nec-
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Considerable efforts have been made over the last few
years to improve the estimates presented in this report.
Nonetheless, the data must still be interpreted with cau-
tion because of the clandestine nature of drug produc-
tion, trafficking and abuse. Apart from the ‘hidden’
nature of the phenomenon being measured, the main
problems with regard to data relate to the irregularity
and incompleteness in reporting. This affects the quan-
tity, quality and comparability of information received.
First, the irregular intervals at which some Governments
report may result in absence of data in some years but
availability in others. The lack of regular data, for which
UNODC tries to compensate by reference to other
sources, can influence trend patterns. Secondly, submit-
ted questionnaires are not always complete or suffi-
ciently comprehensive. All figures should thus be seen as
likely orders of magnitude of the drug problem, but not
as precise results. It should be also noted that all figures
provided, particularly those of more recent years, are
subject to updating.
essary and where available, the data from the ARQs are
thus supplemented with data from other sources. 
As in previous years, seizure data made available to
UNODC via the ARQs was complemented primarily
with data from Interpol/ICPO, data provided to
UNODC by the Heads of National Law Enforcement
Agencies (HONLEA) at their regional meetings, data
provided through UNODC’s ‘Data for Africa‘ project,
and UNODC’s, ‘Drug Abuse Information Network for
Asia and the Pacific’ (DAINAP). In addition, Govern-
ment reports have been used, wherever available. Other
sources considered, included data published by the
United States Department of State’s Bureau for Interna-
tional Narcotics and Law Enforcement Affairs in its
International Narcotics Control Strategy Report.
Price data for Europe was complemented with data from
Europol. Precursor data presented are basically those col-
lected by the International Narcotics Control Board
(INCB). Demand related information was obtained
through a number of additional channels, including
UNODC’s Global Assessment Program (GAP), the
drug control agencies participating in UNODC’s, ‘Drug
Abuse Information Network for Asia and the Pacific’
(DAINAP), as well as various national and regional epi-
demiological networks such as the European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) or
the Inter-American Drug Abuse Control Commission
(CICAD). National government reports published in
the scientific literature were also used as sources of infor-
mation. This type of supplementary information is
useful and necessary as long as Member States lack the
monitoring systems necessary to produce reliable, com-
prehensive and internationally comparable data.
To this end, UNODC encourages and supports the
improvement of national monitoring systems. Major
progress has been made over the last few years in some
of the main drug producer countries. In close coopera-
tion with UNODC’s Illicit Crop Monitoring Program
(ICMP) and with the support of major donors – these
countries have developed impressive monitoring sys-
tems designed to identify extent of and trends in the
cultivation of narcotic plants. These data form another
fundamental basis for the trend analysis presented in the
World Drug Report. 
There remain significant data limitations on the
demand side. Despite commendable progress made in a
number of Member States, in the area of prevalence esti-
mates for example, far more remains to be done to pro-
vide a truly reliable basis for trend and policy analysis
and needs assessments. The work being done on the
World Drug Report 2007 provides yet another oppor-
tunity to emphasise the global need for improving data
collection and monitoring to improve the evidence base
for effective policy. 
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Reporting of Annual Report Questionnaires (ARQ) Part II, Drug Abuse, for the year 2005
Cultivation, production and manufacture 
Global estimates are, in general, more robust on the pro-
duction side, notably data for plant based drugs, than
on the demand side. In line with decisions of the
Member States (1998 UNGASS and subsequent Com-
mission on Narcotic Drugs resolutions), UNODC
launched an Illicit Crop Monitoring Programme
(ICMP) in 1999. The objective of the programme is to
assist Member States in establishing national systems to
monitor the extent and evolution of the illicit cultiva-
tion of narcotics crops on their territories. The results
are compiled by UNODC to present global estimates
on an annual basis. Data on cultivation of opium poppy
and coca bush and production of opium and coca leaf,
presented in this report for the main producing coun-
tries (Afghanistan, Myanmar and Laos for opium and
Colombia, Peru and Bolivia for coca) have been derived
from these national monitoring systems operating in the
countries of illicit production, covering the period up
to, and including 2006. The Government of Morocco,
in cooperation with UNODC, also conducted surveys
on illicit cannabis cultivation and cannabis resin pro-
duction in 2003, 2004 and 2005. Estimates for other
countries presented in this report have been drawn from
replies to UNODC’s Annual Reports Questionnaire,
from various other sources including reports from Gov-
ernments, UNODC field offices and the United States
Department of State’s Bureau for International Nar-
cotics and Law Enforcement Affairs.
The key indicator for measuring progress made towards
the supply reduction goals set out in the UNGASS
Political Declaration of June 1998 is the area under cul-
tivation of narcotic crops. Since 1999, UNODC has
been supporting the establishment of national monitor-
ing systems in the main narcotics production countries.
These monitoring systems are tailored to national speci-
ficities. The direct participation of UNODC ensures the
transparency of the survey activities. Through its net-
work of monitoring experts at headquarters and in the
field, UNODC ensures the conformity of the national
systems so that they meet international methodological
standards and the information requirements of the
international community. Most of these monitoring sys-
tems rely on remote sensing technology (i.e. analysis of
satellite imagery) in combination with extensive field
visits which is made possible through UNODC’s field
presence in all of the main narcotics producing coun-
tries. Satellite images, in combination with ground
information, offer a reliable and objective way of esti-
mating illicit crops. Depending on the local conditions,
the surveys are conducted either on a census approach
(coca cultivation in Colombia, Peru and Bolivia,
cannabis cultivation in Morocco) or a sample approach
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Reporting of Annual Report Questionnaires (ARQ) Part III, Ilicit supply of drugs, for the year 2005
Sources and limitations of data 
on the supply side
(opium poppy cultivation in Afghanistan, Myanmar
and Laos). The accuracy assessment of the individual
estimates differs, but is often close to 90%, i.e. ‘ground
truthing’ shows that about 90% of the areas analysed
from satellite photos were correctly identified as poppy
fields or coca fields. In the case of sampling, the poten-
tial error depends on the number of villages investigated
and/or on the number of satellite photos taken which
form the basis for subsequent extrapolations to the agri-
cultural land. In the case of Afghanistan, for instance,
the estimated area under poppy cultivation in the 2006
opium poppy survey ranged, within the confidence
interval (α= 0.1) between 150,000 and 180,000
hectares, or +/-9 percent of the calculated value of
165,000 hectares. 
In addition, ground surveys, assist UNODC to obtain
information on yields, drug prices and various other
socio-economic data that is useful for alternative devel-
opment interventions. Detailed discussion of the
methodological approaches can be found in the
methodology section of each survey. (http://
www.unodc.org/unodc/en/crop_monitoring.html)
UNODC has also started to conduct yield surveys in
some countries, measuring the yield of test fields, and to
develop methodologies to extrapolate the yields from
proxy variables, such as the volume of poppy capsules or
the number of plants per plot. This approach is used in
South-East Asia as well as in Afghanistan. All of this is
intended to improve yield estimates, aiming at informa-
tion that is independent from farmers’ reports. The
accuracy of the calculated yields depends on a number
of factors, including the number of sites investigated. In
the case of Afghanistan the confidence interval for the
mean yield results in the 2006 survey was, for instance,
+/- 3% of the mean value (α= 0.1). 
In areas in which UNODC has not, as yet, undertaken
yield surveys, results from other surveys conducted at
the national level are used instead. This is currently still
the case for some parts of Bolivia (Chapare) while in
other parts of the country (Yungas) as well as in Colom-
bia and in Peru UNODC has already conducted yield
surveys in cooperation with the local authorities. The
disadvantage of having to take recourse to yield data
from other sources is that the sampling strategies does
not necessarily fit UNODC’s definition of an area under
cultivation, and that year on year variations due to
weather conditions or due to the introduction of
improved seeds, fertilizers and pesticides, are not prop-
erly reflected in the end results. The new surveys found
higher yields than previous estimates had suggested. As
a consequence, a number of figures had to be retro-
actively adjusted and the global cocaine estimates are
now slightly higher than those published in previous
World Drug Reports. 
The transformation ratios used to calculate the poten-
tial cocaine production from coca leaf or the heroin pro-
duction from opium are even more problematic. In
order to be precise, these calculations would require
detailed information at the local level on the morphine
content in opium or the cocaine content in the coca
leaf, as well as detailed information on the clandestine
laboratory efficiency, which in turn is a function of
know-how, equipment and precursor chemicals. This
information is not available. A number of studies con-
ducted by enforcement agencies in the main drug pro-
ducing countries have provided some orders of
magnitude for the transformation from the raw material
to the end product. The problem is that this informa-
tion is usually based on just a few case studies which are
not necessarily typical for the production process in gen-
eral. Potential margins of error in this rapidly changing
environment, with new laboratories coming on stream
while others are being dismantled, are thus, substantial.
This also applies to the question of the psychoactive
content of the narcotic plants. One study conducted in
Afghanistan by UNODC over a couple of years, indi-
cated, for instance, that the morphine content of
Afghan opium was significantly higher than had been
thought earlier. Based on this study, in combination
with information on the price structure (which sug-
gested that at a 10:1 conversion ratio of opium to heroin
laboratory owners would lose money), it became clear
that this conversion ratio had to be changed. In 2005,
the transformation ratio was finally changed to 7:1, fol-
lowing, additional information obtained from inter-
views with morphine/heroin producers in Afghanistan.
This ratio remained unchanged for 2006 as well.a
For cocaine, a number of studies have been conducted
in the Andean region over the last decade investigating
the transformation ratios of coca leaf to cocaine base
and cocaine HCL - which also form the basis for
UNODC’s estimates. However, some of the conversion
ratios are not in line with reported price patterns of
these substances, raising some questions as to their
appropriateness and indicating a need to revisit them.
At the same time, it is obviously impossible for
UNODC to set up clandestine laboratories and hire
‘cooks’ in order to improve its statistical basis. All of this
underlines the ongoing difficulties to accurately assess
global heroin and cocaine production, despite the
progress made in assessing the area under cultivation
and other aspects of cultivation and production. 
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a Details are summarised in UNODC, Afghanistan Opium Survey 2006, pp. 122-124.
‘Potential’ heroin or cocaine production shows the level
of production of heroin or cocaine if the opium or coca
leaf were transformed into the end products in the
respective producer country. Part of the opium or the
coca leaf is directly consumed in the producing coun-
tries or in neighbouring countries, prior to the transfor-
mation into heroin or cocaine. In addition, significant
quantities of the intermediate products, coca paste or
morphine, are also consumed in the producing coun-
tries. These factors are partly taken into account. Coca
leaf considered licit in Bolivia and Peru is not taken into
account for the transformation into cocaine. Similarly,
opium consumed in Afghanistan, Iran and Pakistan is
not considered to be available for heroin production. As
a result, global estimates of ‘potential’ production
should be rather close to ‘actual’ production. Moreover,
as the transformation ratios used are rather conservative,
total ‘potential’ production may well be close to ‘actual’
production of the end products if one takes the de-facto
lower amounts available for starting the transformation
process into account. 
The use of the concept of ‘potential production’ at the
country level also means that ‘actual’ heroin or cocaine
production is under-estimated in some countries, and
over-estimated in others while the estimate for the
global level should be only slightly affected by this. The
calculation of ‘potential’ cocaine production estimates
for Peru, for instance, exceeds actual local cocaine pro-
duction as some of the coca paste or coca base produced
in Peru is exported to neighbouring Colombia and other
countries for further processing into cocaine. Based on
the same reasoning, potential cocaine production esti-
mates for Colombia under-estimate actual cocaine pro-
duction in the country. Actual cocaine manufacture in
Colombia takes place from locally produced coca leaf as
well as from coca base imported from Peru.
Despite all of these difficulties, the overall accuracy of
the global heroin and cocaine estimates has certainly
improved over the last few years and can be considered
to be reasonably good. 
The situation is less satisfactory when it comes to
cannabis. In the case of cannabis herb, the globally most
dispersed illegal drug, all available production estimates
were aggregated. In most cases, these estimates are, how-
ever, not based on scientific studies (often reflecting
potential yields of eradicated areas rather than actual
production) and often refer to different years (as only a
limited number of countries provide such estimates in
their annual reports questionnaires). A significant
number of countries do not provide any estimates.
Therefore, a systematic review was undertaken, once
again, of all those countries which over the last decade
were identified by other countries as a significant
cannabis source countries or which reported the seizures
of whole cannabis plants (which is indicative of domes-
tic cultivation). For those countries, production was
estimated to cover domestic demand, multiplying the
number of estimated cannabis users by the average
global cannabis herb consumption rate, derived from
previous calculations. For countries that were identified
as cannabis producing countries but were not identified
as major cannabis exporting countries, a certain per-
centage of domestic demand was used to estimate local
production. The percentages chosen depended on quan-
titative and qualitative information available for differ-
ent regions. Clearly, this is not an ideal estimation
technique but the best that is currently available. 
In the case of cannabis resin, scientific information on
the – most likely - largest cannabis resin producing
country is available which, in combination with seizure
statistics, forms a basis for extrapolations to the global
level. Another estimate was based on global cannabis
herb production estimates and the proportion of resin
to herb seizures, assuming that cannabis resin and
cannabis herb have the same likelihood to be seized. The
average of these two estimates forms UNODC’s
cannabis resin estimate. 
The approach taken to come up with ATS production
estimates is one of triangulation, estimating production
based on reported seizures of the end products in com-
bination with some assumptions of law enforcement
effectiveness, seizure data of precursor chemicals and
estimates based on the number of consumers and their
likely levels of per capita consumption. The average of
these three estimates is then used to arrive at UNODC’s
global estimates for amphetamine, methamphetamine
and ecstasy production.  The estimation procedure
remained largely unchanged from the one used since the
2004 World Drug Report, which was based on the
methodology developed for UNODC’s Study on Ecstasy
and Amphetamines, Global Survey 2003.
Trafficking 
The information on trafficking, as presented in this
report, is mainly drawn from the Annual Reports Ques-
tionnaires (ARQ), submitted by Governments to
UNODC in 2006 and early 2007 and refers to the year
2005 (and previous years). Additional sources, such as
other Government reports, Interpol, the World Cus-
toms Organization (WCO), reports by the Heads of
National Law Enforcement Agency (HONLEA), data
provided via UNODC’s ‘Data for Africa‘ project, data
provided via UNODC’s, ‘Drug Abuse Information Net-
work for Asia and the Pacific’ (DAINAP), and
UNODC’s field offices, were used to supplement the
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information. Priority was, however, given to officially
transmitted data in the Annual Reports Questionnaire.
The analysis of quantities seized, shown in this report,
was based on ARQ’s returned by 120 countries over the
June 2006–May 2007 period, of which 118 countries
provided seizure information. Including information
from other sources, UNODC has in its data base
(DELTA) seizure data from 165 countries for the year
2005, up from 156 countries in 2004. Seizures are thus
the most comprehensive indicator of the drug situation
and its evolution at the global level. Although they may
not always reflect trafficking trends correctly at the
national level, they tend to show good representations of
trafficking trends at the regional and global levels.
There are some technical problems as – depending on
the drugs - some countries report seizures in weight
terms (kg), in volume terms (litres) while other coun-
tries report seizures in ‘unit terms’. In the online inter-
active seizure report (http://www.unodc.org/ unodc/en/
world_drug_report.html), seizures are shown as
reported. In the World Drug Report, seizure data have
been aggregated and transformed into a unique meas-
urement: seizures in ‘kilogram equivalents’. For the pur-
poses of the calculations a ‘typical consumption unit’ (at
street purity) was assumed to be: cannabis herb: 0.5
grams, cannabis resin: 0.135 grams; cocaine and ecstasy:
0.1 grams, heroin and amphetamines: 0.03 grams, LSD:
0.00005 grams (50 micrograms). A litre of seizures was
assumed to be equivalent to a kilogram. For opiate
seizures (unless specified differently in the text), it was
assumed that 10 kg of opium were equivalent to 1 kg of
morphine or heroin. Though all of these transformation
ratios can be disputed, they at least provide a possibility
of combining all the different seizure reports into one
comprehensive measure. The transformation ratios have
been derived from those used by law enforcement agen-
cies, in the scientific literature, by the International Nar-
cotics Control Board, and were established in
consultation with UNODC’s Laboratory and Scientific
Section. No changes in the transformation ratios used in
last year’s World Drug Report were made. 
Seizures are used as an indicator for trends and patterns
in trafficking. In combination with changes in drug
prices or drug purities, changes in seizures can indicate
whether trafficking has increased or declined. Increases
in seizures in combination with stable or falling drug
prices is a strong indication of rising trafficking activi-
ties. Increasing seizures and rising drug prices, in con-
trast, may be a reflection of improved enforcement
effectiveness. Changes in trafficking can also serve as an
indirect indicator for global production and abuse of
drugs. Seizures are, of course, only an indirect indicator
for trafficking activities, influenced by a number of
additional factors, such as variations in law enforcement
practices and changes in reporting modalities. Thus, the
extent to which seizure statistics from some countries
constitute all reported national cases, regardless of the
final destination of the illicit drug, can vary and makes
it sometimes difficult to assess actual trafficking activi-
ties. The problem is exacerbated by increasing amounts
of drugs being seized in countries along the main tran-
sit routes, the increasing use of ‘controlled deliveries’, in
which countries forego the possibility of seizing drugs
immediately in order to identify whole trafficking net-
works operating across countries, and ‘upstream disrup-
tions’, making use of intelligence information to inform
partner countries and enable them to seize such deliver-
ies prior to entering the country of final destination.
Some of the increase of cocaine seizures in the Andean
region in recent years, for instance, may have been
linked to such upstream market disruptions.
However, over longer periods of time and over larger
geographical entities, seizures have proven to be a good
indicator to reveal underlying trafficking trends. While
seizures at the national level may be influenced by large
quantities of drugs in transit or by shifts in law enforce-
ment priorities, it is not very likely that the same is true
at the regional or at the global level. If a large drug ship-
ment, while in transit, is taken out of the market in one
country, fewer drugs will be probably seized in the neigh-
bouring countries. Similarly, if enforcement efforts and
thus seizures decline in one country, the neighbouring
countries are likely to suffer from intensified trafficking
activities, resulting in rising levels of seizures. The net
results, emerging from changes of enforcement priorities
of an individual country, are thus, in general, not signif-
icant at the regional or at the global level. Actual changes
in trafficking can thus be considered to be among the
main reasons for changes in seizures at the regional level
or the global level. Indeed, comparisons, on a time-series
basis, of different indicators with statistical dependence
have shown strong correlations (e.g. global opium pro-
duction estimates and global seizures of opiates, or global
coca leaf production and global cocaine seizures), sup-
porting the statistical worth of seizure statistics at
regional and global levels. At the same time, data also
show that interception rates have gradually increased
over the last decade, reflecting improved law enforce-
ment effectiveness at the global level.
Price and purity data 
UNODC also collects and publishes price and purity
data. Price and purity data, if properly collected, can be
very powerful indicators for the identification of market
trends. As supply changes in the short-run are usually
stronger than changes on the demand side (which tend
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to take place over longer time periods), shifts in prices
and purities are a good indicator for actual increases or
declines of market supply. Research has also shown that
short-term changes in the consumer markets are – first
of all - reflected in purity changes while prices tend to
be rather stable over longer periods as traffickers and
drug consumers at the retail level prefer ‘round‘ prices.
UNODC collects its price data from the Annual
Reports Questionnaire, and supplements this data set
by other sources, such as price data collected by Europol
and other organisations. Prices are collected for the
farm-gate level, the wholesale level (‘kilogram prices’)
and for the retail level (‘gram prices’). Countries are
asked to provide minimum, maximum and typical
prices and purities. In case no typical prices/purities are
provided, UNODC calculates the mid-point of these
estimates as a proxy for the ‘typical’ prices/purities
(unless scientific studies are available which provide
better estimates). What is not known, in general, is the
manner in which the data were collected and their
actual statistical representativeness. While some
improvements have been made in some countries over
the last few years, a number of law enforcement bodies
in several countries have not, as yet, discovered the pow-
erful strategic value of such data, once collected in a sys-
tematic way, at regular intervals, so that it can be used
for statistical analysis, drug market analysis and as an
early warning system.
Sources and limitations 
of data on consumption
Extent of drug abuse
a. Overview
UNODC estimates of the extent of illicit drug use in
the world have been published periodically since 1997
(see World Drug Reports 1997, 2000, 2004, 2005, 2006
and Global Illicit Drug Trends 2002 and 2003). The sev-
enth round of estimates, presented in this report, is
based on information received until May 2007. 
Assessing the extent of drug use (the number of drug
users) is a particularly difficult undertaking because it
involves measuring the size of a hidden population.
Margins of error are considerable, and tend to multiply
as the scale of estimation is raised, from local to
national, regional and global levels. Despite some
improvements in recent years, estimates provided by
Member States to UNODC are still very heterogeneous
in terms of quality and reliability. These estimates
cannot simply be aggregated globally to arrive at the
total number of drug users in the world. Yet it is both
desirable and possible to establish basic orders of mag-
nitude - which are obviously subject to revision as new
and better information is generated. 
A global estimate of the level of abuse of specific drugs
involves the following steps:
1. Identification and analysis of appropriate sources; 
2. Identification of key benchmark figures for the
level of drug abuse in selected countries (annual
prevalence of drug abuse among the general pop-
ulation age 15-64) which then serve as ‘anchor
points’ for subsequent calculations;
3. ‘Standardization’ of existing data (e.g. from age
group 12 and above to a standard age group of 15-
64);
4. Extrapolation of existing results based on infor-
mation from neighbouring countries with similar
cultural, social and economic situations (e.g. life-
time prevalence or current use to annual preva-
lence, or school survey results to annual prevalence
among the general population);
5. Extrapolation of available results from countries in
a region to the region as a whole, using all avail-
able quantitative and qualitative information;
6. Aggregation of regional results to arrive at global
results.
The approach taken to arrive at the global estimates has
remained essentially the same since the first attempt was
made in 1997. 
Estimates of illicit consumption for a large number of
countries have been received by UNODC over the years
(in the form of Annual Reports Questionnaires (ARQ)
submitted by Governments), and have been identified
from additional sources, such as other governmental
reports and research results from scientific literature.
Officially transmitted information in any specific year,
however, would not suffice to establish global estimates.
Over the period June 2006 to May 2007, for instance,
104 countries provided UNODC with responses to the
ARQ on Drug Abuse (Part II), but only 24 countries
provided new quantitative estimates of their drug situa-
tion for the year 2005, including 14 countries provid-
ing estimates of the prevalence of drug consumption
among the general population and 16 countries provid-
ing estimates of prevalence of drug use among their stu-
dent populations. With the inclusion of estimates
referring to previous years, UNODC has obtained over
the years quantitative estimates of the drug situation
from 109 countries, including 87 countries providing
drug use estimates among the general population and
95 countries providing student population estimates. In
cases of estimates referring to previous years, the preva-
lence rates were left unchanged and applied to new pop-
ulation estimates for the year 2005. For countries that
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did not submit information, other sources, where avail-
able, were identified. Other sources were also looked for
when the officially transmitted prevalence rates in the
ARQ were already old. In addition, a number of esti-
mates needed to be ‘adjusted’ (see below). Using all of
these sources, estimates were established for 145 coun-
tries, territories and areas. Results from these countries
were extrapolated to the sub-regional level and then
aggregated into the global estimate.
Detailed information is available from countries in
North America, a large number of countries in Europe,
a number of countries in South America, a few countries
in Oceania (though including the two largest countries)
and a limited number of countries in Asia and in Africa.
For other countries, available qualitative information on
the drug use situation only allows for some ‘guess esti-
mates’. In the case of complete data gaps for individual
countries, it was assumed that drug use was likely to be
close to the respective sub-regional average, unless other
available indicators suggested that they were likely to be
above or below such an average.
One key problem in currently available prevalence esti-
mates from countries is still the level of accuracy, which
varies strongly from country to country. While a
number of estimates are based on sound epidemiologi-
cal surveys, some are obviously the result of guesswork.
In other cases, the estimates simply reflect the aggregate
number of drug addicts found in drug registries which
probably cover only a small fraction of the total drug
abusing population in a country.
Even in cases where detailed information is available,
there is often considerable divergence in definitions
used - registry data (people in contact with the treat-
ment system or the judicial system) versus survey data
(usually extrapolation of results obtained through inter-
views of a selected sample); general population versus
specific surveys of groups in terms of age (e.g. school
surveys), special settings (such as hospitals or prisons),
life-time, annual, or monthly prevalence, etc.
In order to reduce the error from simply aggregating
such diverse estimates, an attempt was made to stan-
dardize - as a far as possible - the very heterogeneous
data set. Thus, all available estimates were transformed
into one single indicator – annual prevalence among the
general population age 15 to 64 and above - using trans-
formation ratios derived from analysis of the situation in
neighbouring countries, and if such data were not avail-
able, on estimates from the USA, the most studied
country worldwide with regard to drug use.
The basic assumption is that the level of drug use differs
between countries, but that there are general patterns
(e.g. lifetime time prevalence is higher than annual
prevalence; young people consume more drugs than
older people) which apply universally. It is also assumed
that the ratio between lifetime prevalence and annual
prevalence among the general population or between
lifetime prevalence among young people and annual
prevalence among the general population, do not vary
too much among countries with similar social, cultural
and economic situation. Various calculations of long-
term data from a number of countries seem to confirm
these assumptions.
In order to minimize the potential error from the use of
different methodological approaches, all available esti-
mates for the same country - after transformation - were
taken into consideration and - unless methodological
considerations suggested a clear superiority of one
method over another - the mean of the various estimates
was calculated and used as UNODC’s country estimate.
b. Indicators used
The most widely used indicator at the global level is the
annual prevalence rate: the number of people who have
consumed an illicit drug at least once in the last twelve
months prior to the survey. As “annual prevalence” is
the most commonly used indicator to measure preva-
lence, it has been adopted by UNODC as the key indi-
cator to measure the extent of drug use. It is also part of
the Lisbon Consensusb (20-21 January 2000) on core
epidemiological demand indicators (CN.7/2000/
CRP.3). The use of “annual prevalence” is a compromise
between “life-time prevalence” data (drug use at least
once in a life-time) and data on current use (drug use at
least once over the last month). Lifetime prevalence data
are, in general, easier to generate but are not very illus-
trative. Data on current use are of more value. However,
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b The basic indicators to monitor drug abuse, agreed by all participating organizations that formed part of the Lisbon Consensus in 2000, are:
- Drug consumption among the general population (estimates of prevalence and  incidence);
- Drug consumption among the youth population (estimates of prevalence and incidence);
- High-risk drug abuse (estimates of the number of injecting drug users and the proportion engaged in high-risk behaviour, estimates of the
number of daily drug users);
- Utilization of services for drug problems (number of individuals seeking help for drug problems);
- Drug-related morbidity (prevalence of HIV, hepatitis B virus and hepatitis C virus among illicit drug consumers);
- Drug-related mortality (deaths directly attributable to drug consumption).
While in the analysis of the drug abuse situation and drug abuse trends all these indicators were considered, when it came to provide a global com
parison a choice was made to rely on the one key indicator that is most available and provides an idea of the magnitude for the drug abuse situa-
tion: annual prevalence among the population aged 15 to 64.
they often require larger samples in order to obtain
meaningful results, and are thus more costly to generate,
notably if it comes to other drugs than cannabis which
is widespread. 
The “annual prevalence” rate is usually shown as a per-
centage of the youth and adult population. The defini-
tions of the age groups vary, however, from country to
country. Given a highly skewed distribution of drug use
among the different age cohorts in most countries
(youth and young adults tend to have substantially
higher prevalence rates than older adults or retired per-
sons), differences in the age groups can lead to substan-
tially diverging results. Typical age groups used by
UNODC Member States are: 12+; 14+: 15+; 18+; 12-
60; 16-59; 18-60; 15-45; 15-75; and increasingly age
15-64. The revised version of the Annual Reports Ques-
tionnaire (ARQ), adopted by Member States, which
since 2001/02 has replaced the previous ARQ, stipulates
the age group 15-64 as the key population group for
which drug use to be measured against. Prevalence data
in this report are thus reported for the age group 15-64.
In case the age groups reported by Member States did
not differ significantly from this age group, they were
presented as reported and the age group was explicitly
added. In cases where studies were based on significantly
different age groups, results were adjusted to the age
group of 15-64. (See below).
The methods used for collecting data on illicit activities
vary from country to country. This reduces comparabil-
ity. Possibilities to reduce differences – ex post – arising
due to different methodological approaches are limited.
UNODC thus welcomes efforts at the regional level to
arrive at more comparable data (as is currently the case
in Europe under the auspices of EMCDDA and in the
Americas under the auspices of CICAD).
In a number of cases, diverging results are also obtained
for the same country, applying differing methodological
approaches. In such cases, the sources were analysed in-
depth and priority was given to the methodological
approaches that are usually also used in other countries.
For example, it is generally accepted that household sur-
veys are reasonably good instruments to estimate
cannabis, ATS or cocaine use among the general popu-
lation. Thus household survey results were usually given
priority over other sources of prevalence estimates, such
as reported registry data from the police or from treat-
ment providers. 
However, when it comes to heroin abuse (or drug inject-
ing), there seems to be a general agreement that annual
prevalence data derived from national household sur-
veys tend to grossly under-estimate such abuse because
severe heroin addicts often do not live in households.c
They may be homeless, in hospitals or in prisons. More-
over, heroin abuse is highly stigmatized so that the will-
ingness to openly report a heroin abuse problem is
limited. However, a number of indirect methods have
been developed over the last two decades to provide
estimates for this group of problem drug users. They
include various multiplier methods (e.g. treatment mul-
tipliers, police data multipliers, HIV/AIDS multipliers
or mortality multipliers), capture-recapture methods,
and multivariate indicators.
Whenever such indirect estimates for problem drug use
were available, they were given priority over household
survey results. Most of the estimates for problem drug
use were obtained from European countries. Unless
there was evidence that a significant proportion of prob-
lem drug use was related to the use of other drugs, it was
assumed that the problem drug use concerned opiates.
In the case of some of the Nordic countries, where
amphetamine use is known to account for a significant
proportion of overall problem drug use, the data of
reported problem drug users were corrected by applying
the proportion of opiate consumers in treatment in
order to arrive at estimates for opiate abuse. This also
applied to estimates for Spain, where cocaine has gained
a significant proportion among problem drug users. 
For other drugs, priority was given to annual prevalence
data found by means of household surveys. A number
of countries, however, did not report annual prevalence
data, but lifetime or current use of drug consumption,
or they provided annual prevalence data but for a dif-
ferent age group. In order to arrive at basically compa-
rable results, it was thus necessary to extrapolate from
reported current use or lifetime prevalence data to
annual prevalence rates and/or to adjust results for dif-
ferences in age groups. 
265
Methodology
c The problem of under-estimation is more widespread for heroin, but it is not excluded for other drugs such as cocaine or methamphetamine.
c. Extrapolation methods used 
The methods used for these adjustments and extrapola-
tions are best explained by providing a number of con-
crete examples: 
Adjustment for differences in the age groups:
New Zealand, for instance, carried out a household
survey in 2001, covering the population age 15-45.
According to this survey, annual prevalence of ecstasy
use was found to affect 3.4% of the population 15-45,
equivalent to about 56,000 people. Given the strong
association between ecstasy use and younger age groups
it can be assumed that there is little ecstasy use in the
45+ age group. Thus, dividing the ecstasy using popu-
lation established above by the age group 15-64 gives an
estimated prevalence rate of 2.2%. 
The situation is slightly more complex when it comes to
cocaine. The same approach for New Zealand would
lower the annual cocaine prevalence rate from 0.6% of
the population age 15-45 to 0.4% of the population age
15-64. In this case, however, it must be assumed that
there are still some people above the age of 45 consum-
ing cocaine. A rate of 0.4% is thus a minimum estimate.
An alternative estimation approach is indicated. Thus,
the relationship between cocaine consumption among
the group of those age 15-45 and those age 15-64 in
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Indirect methods to measure problem drug use 
Treatment multiplier: If a survey among heroin addicts
reveals, for instance, that one quarter of them was in
treatment in the last year, the multiplication of the reg-
istered treatment population with a multiplier of four
provides an estimate of the likely total number of prob-
lem heroin users in a country. 
Police data multiplier: Similarly, if a survey among
heroin addicts reveals that one out of five addicts was
arrested in the previous year, a multiplication of the per-
sons arrested for heroin possession by the multiplier
(five) provides another estimate for the number of
heroin users. Establishing various multipliers and apply-
ing them to the registered drug using population, pro-
vides a range of likely estimates of the heroin abuse
population in a country. Either the mid-point of the
range, the median or the mean of these estimates can be
subsequently used to arrive at a national estimate.
Capture-recapture models are another method based on
probability considerations, which can be undertaken
without additional field research.d If in one register (e.g.
arrest register) 5000 persons are found (for possession of
heroin) and in a second register (e.g. treatment register)
2000 persons are found (for treatment of heroin abuse),
and there are 400 persons who appear in both registries,
it can be assumed that 20% (400/2000) of the drug
addicts have been arrested, so that the total heroin
addict population could be around 25,000
(5000/20%), five times larger than the total number of
arrested heroin users.e Results can usually be improved
if data from more than two registers are analysed (e.g.
data from arrest register, treatment register, ambulance
register, mortality register, substitution treatment regis-
ter, HIV register etc). More sophisticated capture-recap-
ture models exist, and are used by some advanced
countries, in order to make calculations based on more
than two registries. However, in order to arrive at rea-
sonable orders of magnitude of the heroin problem in a
particular country it is probably sufficient to calculate
the various combinations shown above and subse-
quently report the mid-point, the median or the mean
of the resulting estimates. 
Another interesting approach is the use of multivariate
indicators. For this approach, a number of
local/regional studies are conducted, using various mul-
tiplier and/or capture-recapture methods. Such local
studies are usually far cheaper than comprehensive
national studies. They serve as anchor points for the
subsequent estimation procedures. The subsequent
assumption is that drug abuse at the local level corre-
lates with other data that are readily available. For
instance, heroin arrest data, heroin treatment data, IDU
related HIV data, etc. are likely to be higher in com-
munities where heroin abuse is high and lower in com-
munities where heroin abuse is low. In addition, heroin
abuse may correlate with some readily available social
indicators (higher levels in deprived areas than in afflu-
ent areas; higher levels in urban than in rural areas etc).
Taking all of this additional information into account,
results from the local studies are then extrapolated to
the national level.
d Such methods were originally developed to estimate the size of animal population. If, for instance, 200 fish are caught (‘ capture’), marked, and
released back into the lake, and then the next day 100 fish are caught, of which 10 were already marked (‘re-captured’), probability considerations
suggest that the number of fish captured the first day were a 10% sample of the total population. Thus the total population of the lake can be esti-
mated at around 2000 fish. 
e The advantage of this method is that no additional field research is necessary. There are, however, problems as the two ‘ sampling processes’ for the
registries in practice are not independent from each other so that some of the underlying assumptions of the model may be violated (e.g. the ratio
could be higher as some of the people arrested are likely to be transferred to a treatment facility; thus the ratio does not correspond any longer to
the true proportion of people arrested among the addicts population, and may lead to an under-estimation of the total heroin addict population).
other countries was investigated. The finding was that
the prevalence rate of cocaine use among those age 15-
64 tends to be around 75% of the prevalence rate of
those age 15-45. Instead of 0.4%, the cocaine preva-
lence rate in New Zealand has thus been estimated to
affect 0.45% of the population age 15-64.
Similar considerations were also used for the age-group
adjustment of data from other countries. A number of
countries reported prevalence rates for the age groups
15+ or 18+. In these cases it was generally assumed that
there was no significant drug use above the age of 65.
The number of drug users based on the population age
15+ (or age 18+) was thus simply shown as a proportion
of the population age 15-64. 
Extrapolation of results from lifetime prevalence 
to annual prevalence 
Some countries have conducted surveys in recent years,
but did not ask the question whether drug consump-
tion took place over the last year. In such cases, results
can be still extrapolated to arrive at annual prevalence
estimates and reasonably good estimates can be
expected. Taking data for life-time and annual preva-
lence of cocaine use in countries of Western Europe, for
instance, it can be shown that there is a rather strong
positive correlation between the two measures (correla-
tion coefficient R = 0.94); i.e. the higher the life-time
prevalence, the higher is, in general, annual prevalence
and vice versa. Based on the resulting regression curve
(y = 0.3736 * x - 0.0455 with y = annual prevalence and
x = life-time prevalence) it can be estimated that a West
European country with a life-time prevalence of 2% is
likely to have an annual prevalence of around 0.7%
(also see figure).
Almost the same result is obtained by calculating the
ratio of the unweighted annual prevalence rates of the
West European countries and the unweighted life-time
prevalence rate (0.93/2.61 = 0.356) and multiplying
this ratio with the life-time prevalence of the country
concerned (2% * 0.356 = 0.7%). 
A similar approach was used to calculate the overall ratio
by averaging the annual/life-time ratios, calculated for
each country.f Multiplying the resulting average ratio
(0.387) with the lifetime prevalence of the country con-
cerned provides the estimate for the annual prevalence
(0.387 * 2% = 0.8%). This approach also enables the
calculation of a confidence interval for the estimate.
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Sources: UNODC, Annual Reports Questionnaire Data / EMCDDA, Annual Report.
f For each country the ratio between annual prevalence and lifetime prevalence is calculated. The results are than averaged: In our example: 
( 0.64 + 0.32 + 0.43 + 0.14 + 0.32 + 0.38 + 0.35 + 0.32 + 0.75 + 0.31 + 0.32 + 0.33 + 0.46+ 0.34) : 14 = 0.387 
With a 95% probability the likely annual prevalence
estimate for the country concerned falls within a range
of 0.6% to 1%.g Given this close relationship between
life-time and annual prevalence (and an even stronger
correlation between annual prevalence and monthly
prevalence), extrapolations from life-time or current use
data to annual prevalence data was usually given prefer-
ence to other kinds of possible extrapolations.
But, good estimation results (showing only a small
potential error) can only be expected from extrapola-
tions done for a country located within the same region.
If instead of using the West European average (0.387),
the ratio found in the USA was used (0.17), the estimate
for a country with a lifetime prevalence of cocaine use
of 2% would decline to 0.3% (2% * 0.17). Such an esti-
mate is likely to be correct for a country with a drug his-
tory similar to the United States. The USA has had a
cocaine problem for more than two decades and is thus
confronted with very high lifetime prevalence rates
while it made considerable progress in reducing cocaine
consumption as compared to the mid 1980s. All of this
leads to a small proportion of annual prevalence to life-
time prevalence. In Western Europe, by contrast, the
cocaine problem is a phenomenon of the last decade and
still growing.
Against this background, data from countries in the
same region were used, wherever possible, for extrapola-
tion purposes. Thus, data from Central and Eastern
Europe were used to extrapolate results for other coun-
tries in the region which did not collect annual preva-
lence rates. Most of these countries had very low drug
abuse levels during the cold war, which, however, grew
rapidly in the 1990s. 
Extrapolations based on treatment data
For a number of developing countries, the only drug
related data available on the demand side was treatment
demand. In such cases, the approach taken was to look
for other countries in the region with a similar socio-
economic structure, which reported annual prevalence
data and treatment data. As a next step, the ratio of
people treated per 1000 drug users was calculated for
each country. The results from different countries were
then averaged and the resulting ratio was used to extrap-
olate the likely number of drug users from the number
of people in treatment.  
Extrapolations based on school surveys
Analysis of countries which have conducted both school
surveys and national household surveys shows that there
is, in general, a positive correlation between the two
variables, particularly for cannabis, ATS and cocaine.
The correlation, however, is weaker than that of lifetime
and annual prevalence or current use and annual preva-
lence among the general population but stronger than
the correlation between opiate use and IDU-related
HIV cases and, stronger than the link between treat-
ment and drug use.
Extrapolation to regional and global level
The next step, after having filled, as far as possible, the
data gaps, was to calculate the average prevalence for
each sub-region. For this purpose the reported/esti-
mated prevalence rates of countries were applied to the
population aged 15-64, as provided by the United
Nations Population Division for the year 2005. For the
remaining countries, for which no estimate could be
made, the average prevalence rate of the respective sub-
region was applied, unless some additional information
suggested that the sub-regional average would be too
high or too low for the countries concerned. All of these
‘adjustments’, based on qualitative information, affected
the overall estimate only slightly. 
Following the detailed calculation of all of the sub-
regional estimates, the individual sub-regional estimates
(‘number of drug users’) were aggregated to form a
regional estimate, and the regional estimates were then
aggregated to arrive at the global estimates. 
d. Concluding remarks 
It goes without saying that each method of extrapolat-
ing results from other countries is not without problems
and despite of efforts made, results of these estimations
for individual countries must be still interpreted with
caution. However, this should not influence the overall
results as some under-estimates are, most probably,
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g The calculation of the confidence interval can be done as follows: VVVVVVVVVVVVVVVVVVV
1).Determination of alpha (usually 0.05); 
2).Determination of the number of observations (14 in this case) and 3. Calculation of the standard deviation (0.1502 in this example). This
allows to calculate the standard error (standard deviation : (square root of n), i.e. (0.1502 : (square root of 14)) = 0.040)). The z value for alpha
equalling 0.05 is 1.96. Multiplying the standard error with the z-value (0.040*1.96) would give the confidence interval (+/- 0.078). But, given the
low number of observations (where n< 30), the use of t-statistics is indicated instead. In this case, the standard error must be multiplied with the
appropriate t-value (2.145 for n-1 degrees of freedom (14-1) and alpha equalling 0.05 for two-sided t-statistics as can be found in t-value
statistics). The result is a confidence interval of +/- 0.0858 (=0.040 * 2.145). Several spreadsheet programs provide such statistics automatically. In
Excel, for instance, the ‘descriptive statistics’ in tool menu under ‘data analysis’ calculates the confidence interval automatically and uses the t-statis-
tics, wherever appropriate. Applying the +/-0.086 confidence interval to the average ratio calculated above to the mean ratio of 0.387 gives a range
of ratios of 0.301 to 0.473. Using the two ratios one arrives at a minimum estimate of the annual prevalence rate of 0.6% (2% * 0.301) and a
maximum estimate of the annual prevalence rate of 0.95% (2% * 0.473).
offset by over-estimates, and vice-versa, and every
attempt has been made to avoid any systematic bias in
the estimation process.  Moreover, in order to reduce
the risk of any systematic bias, estimations were based,
as far as possible, on the data from neighbouring coun-
tries in the region. 
It is, however, recognized that the currently provided
estimations can change considerably once survey data
becomes available. UNODC’s methodology to arrive at
global estimates by extrapolating results from a sample
of countries (for which data is available) to a sub-region,
also means that methodological changes can have a sig-
nificant impact on the final estimates. In many cases
though, actual survey data received from Member States
turned out to be rather close to UNODC’s estimates.
The global estimates presented in this report must,
nonetheless, be treated with caution. They provide
likely orders of magnitude, as opposed to precise statis-
tics on the prevalence and evolution of global drug
abuse. Further changes can be still expected as countries
provide more robust estimates based on rigorous scien-
tific methods. Nonetheless, in the absence of global
studies on drug abuse, the estimations and the estima-
tion procedures provided in this report guarantee the
best picture that is currently obtainable. 
Trends in drug use
a. Overview
Ideally, global trends in drug use should be monitored
by comparing estimates of drug use in one year with
those found in a subsequent year. In practice, however,
this approach does not always work as some changes in
the global estimates are always due to methodological
improvements and not due to underlying changes in
drug use. Moreover, general population surveys are very
expensive to conduct and only a few countries have an
ongoing monitoring system based on these instruments. 
Many countries collect, however, routine data such as
the number of persons arrested for drug abuse, urine
testing of arrestees, number of persons undergoing drug
treatment, drug hotlines, drug related emergency
department visits, drug related interventions by ambu-
lances, or they monitor drug use based on school sur-
veys. In addition, drug experts dealing on a regular basis
with drug issues – even without having precise data at
hand – often have a good feeling about whether use of
certain drugs is increasing, stabilizing or declining in
their constituency.
This knowledge base is regularly tapped by UNODC.
Member States usually pass the Annual Reports Ques-
tionnaire to drug experts in their country (often in the
ministry of health) who provide UNODC with their
perception, on a five-point scale, of whether there has
been a ‘large increase’, ‘ some increase’, ‘ no great
change’, some decrease’ or a ‘large decrease’ in the use of
the various drugs over the past year. The perceptions
may be influenced by a number of factors and partial
information, including police reports on seizures and
arrests, reports from drug treatment centres, reports
from social workers, press reports, personal impressions,
etc. Any of these influencing factors could contain a
reporting bias which has the potential to skew the data
towards a misleading increase or decrease. Prioritization
of the drug issue is another factor which influences
reporting. It can probably be assumed that the countries
which reply regularly to the ARQ are those which take
the drug problem more seriously. In a number of cases
this is a consequence of rising levels of drug use and thus
increased public awareness of the problem. All of this
suggests that the sample of countries replying to the
ARQs may be slightly biased towards countries faced
with a deteriorating drug problem. Results based on
trend data must thus be treated with caution and should
not be over-interpreted. 
Despite these caveats, trend data provide interesting
insights into the growth patterns of individual drugs as
well as into regional and global growth patterns. They
represent the most comprehensive data set of expert
opinion available on the development of the drug abuse
problem at the global level, provided in a consistent
manner over more than a decade.
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Replies to the Annual Report Questionnaire (ARQ) on
trends in drug use are far more comprehensive than on
estimating the number of drug users. The analysis on
drug use trends for the year 2005 was based on the
replies of 96 countries and areas, about the same
number as a year earlier, up from 52 countries and areas
in 1992. Including information gathered from other
sources (Government reports, UNODC Field Offices,
UNODC’s Data for Africa Project, UNODC’s Drug
Abuse Information Network for Asia and the Pacific
(DAINAP), EMCDDA, CICAD, HONLEA reports
and local studies) trend data from 110 countries and ter-
ritories formed the basis for the subsequent analysis.
The distribution of countries reporting in 2005 was
roughly the same as in previous years and provides a rea-
sonably good coverage across all regions.
b. Aggregating trend data
Various methods have been developed and have been
used in this report for the trend aggregation. The ‘tradi-
tional’ method consists of simply counting the number
of countries reporting increasing, stable and declining
levels of drug abuse. Changes in the net results, i.e.
number of respondents reporting increases less those
reporting declines, have proven to be a good and useful
indicator for showing overall changes in the trend. This
is in line with business cycle trend analysis where enter-
prises are asked on a routine basis about their percep-
tions of whether production is expected to increase,
remain stable, or fall over the new few months, and
where the net results (number of increasing trends less
number of falling trends) are recorded and presented in
order to identify changes in trends. For the purpose of
calculating this indicator, the categories ‘strong increase’
and ‘some increase’ are aggregated into a new category
‘INCREASE’. Similarly, the categories ‘strong decline’
and ‘some decline’ are aggregated into a new category
‘DECLINE’. ‘INCREASE’ less ‘DECLINE’ gives the
‘net change’. 
The advantage of this method for describing drug
trends at the global level is that a large number of actors,
independent of each other, express their views on the
trends in their countries. Though some experts may well
report wrong trend data, it is unlikely that mistakes all
go in the same direction. The disadvantage of this
approach is that it gives equal weight to the reports of
small and big countries, which can be potentially mis-
leading if global trends are to be identified. 
Drug Use Trends as perceived by experts
Another analytical tool, referred to in this report as
Drug Use Trends as perceived by experts, has been
designed by UNODC to allow for a different presenta-
tion of regional and global trends in drug use, reported
by Member States to UNODC. The Drug Use Trend as
perceived by experts builds on previous work of
UNODC which resulted in the concept of a Weighted
Analysis on Drug Abuse Trends (WADAT) in 2004. 
The trend is constructed as follows: each degree of trend
estimation is given a numerical value ranging from –2
to +2 (–2 representing a ‘large decrease’; –1, ‘some
decrease’; 0, ‘no great change’; +1, ‘some increase’; and
+2, ‘a large increase’). Estimates for each drug type are
then multiplied by the proportion of the drug using
population of the country in relation to the drug using
population at the global level. The national estimates are
subsequently added to represent a global trend estimate
for each drug type. The results are shown as a cumula-
tive trend curve.h
In the 2004 World Drug Report, the trends provided by
Member States had been weighted by the size of a coun-
try’s population, in line with the original WADAT con-
cept. Using the population as the weighting instrument
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Regional distribution of reports received on drug
use trends for the years 2002-2005
Source: UNODC, Annual Reports Questionnaire Data.
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h If country X, which has 2% of the world cocaine population, reports a ‘strong increase’ in cocaine use, the calculation is as follows: 
2 * 0.02 = 0.04. If country Y, which has 3% of the world population reports ‘some decline’, the calculation is: -1*0.03 = -0.03. The values of all
other countries are then calculated the same way and aggregated. For 2005, the net result for cocaine was -0.19. This number is then added to last
year’s number: 103.41 + (-0.19) = 103.22. 
shows, in general, reasonable results at the regional level
when drug prevalence rates do not differ drastically
among countries. It creates, however, a serious problem
once an attempt is made to apply the concept to the
global level, notably for drugs which have distinct
regional distribution patterns. For instance, cocaine use
is concentrated in the Americas and in Western Europe
while consumption levels in Asia are still minimal. If a
highly populated country in Asia, like India, reports a
rise in cocaine use, this rise is typically from very low
levels. It must not be ignored, but it has, for the time
being, not much impact on global cocaine consumption.
Weighting the trend data with population data would,
however, raise the global trend for cocaine consumption
sharply. Such results could be potentially misleading.
Thus, an alternative solution was sought to overcome
this problems. The option chosen was to use for
cocaine, for instance, UNODC’s estimates on the
number of cocaine users per country as the weighting
factor. For countries, for which no prevalence estimates
exist, the average prevalence rate of the respective sub-
region is taken as a proxy for the unknown actual preva-
lence rate. Based on this approach, prevalence estimates
become available for all countries of the world. Of
course, for some countries the ’weight’ given to their
trend data may be slightly too small and for others
slightly too big, but the potential error resulting from
this procedure is less than the potential error from
weighting the trend with the general population. 
The following graph shows the results for cocaine, start-
ing with 1992 as a baseline (=100). The graph shows an
upward trend over the 1992-2003 period, followed by a
moderate downward trend over the 2003-2005 period.
This suggests that after an increase over the 1992-2003
period cocaine use has declined slightly at the global
level over the subsequent two years. The fact that the
trend line is now at 103.2, and thus above 100, indicates
that there was a net-increase in cocaine consumption
over the 1992-2005 period. But, how important was the
increase? If all countries had reported a ‘strong’ increase
every year from 1992 to 2005, the composite perception
trend would have reached a level of 126 (2 points per
year); if all countries had reported ‘some increase’ every
year, the trend would be now at 113 (1 point per year);
if countries had considered the trend to have been stable,
the line would have remained stable at 100. If countries
had reported every year ‘some decline’, the trend would
be at 87, and in case of a ‘strong decline’ at 74.
One advantage of this tool is that it takes the trends
reported by Member States and the size of their drug
using population into account. In other words, the
trend gives more weight to the results reported from
countries with a large cocaine using population than to
those with small numbers of cocaine users. This is in
line with the observation that the impact of a rise in
drug consumption in a country with large numbers of
drug users has a greater impact on global drug con-
sumption than the rise in some other countries where
drug use has just started. Another advantage is that the
trend takes into account the degree of change in drug
use levels, thus making better use of all information
made available to UNODC by Member States. 
There are, of course, also limitations that need to be
taken into account when interpreting the results. The
information provided remains, in most cases, an expert
opinion and is not necessarily based on scientific evi-
dence. While this tool assists in the analysis of trends,
the quality of these perceptions remains the key issue. A
mistake made by an expert in a country with a large
drug using population can seriously distort the global
trend estimates. There is also a danger that some experts
may have a political agenda. Thus, this tool cannot be
seen as substitute for serious scientific studies on the
prevalence of drug consumption in a country. Moreover,
it cannot be taken for granted that the differences
between various degrees of drug use trends (“some
decrease” and “large decrease”) are interpreted the same
way across countries, or even in the same country in dif-
ferent reporting years. 
Reporting trends in the use of a drug type may be also
biased by opposing trends for the individual substances
(cocaine HCL, coca paste/base, crack-cocaine). For the
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purpose of this report, not just the drug group but each
individual drug has been taken into consideration. The
unweighted average of all reported trends within a drug
group are calculated. While for some countries, the
detailed profile of substance use is known (which could
give more accurate results), this is not the case for many
others. Thus the general rule of averaging all drugs
within one category has been applied. 
It should also be noted that the Drug Use Trend as per-
ceived by experts is limited in that it only provides gen-
eral directions with regard to the main drug types
reported by Member States, inevitably leading to very
broad generalization. Thus, there remains a need for more
drug-specific trend analysis to support the conclusions.
Development of other innovative methods to measure the
extent and trends in drug consumption: the analysis of
waste-water
Given the difficulties to measure drug consumption
based on self-reports (house-hold surveys) and to iden-
tify trends based on various indirect indicators (treat-
ment demand, arrests etc.), scientists have also started to
explore the possibility to develop alternative approaches
to measure the extent of drug consumption. UNODC
has not been involved in this exercise but it considers
such attempts to be potentially interesting avenues. 
Starting in Italy in 2005,i and later in the UK and in Ger-
many,j several groups of scientists have started to experi-
ment with the analysis of residuals in waste-water, in
order to calculate backwards the amounts of cocaine con-
sumed. The assumption is that cocaine that has been
consumed is eventually leaving the human body and - in
developed areas - most of this will land in waste-water
systems in the form of benzoylecgonine, a breakdown
product from cocaine after it had been processed by the
human liver. The analysis is thus based on the identifica-
tion of benzoylecgonine in waste water. This is an inter-
esting marker as it – apparently - does not come from
any other source than the organic processing of cocaine.
There can be no doubt that this is a highly innovative
approach, making use of the capabilities of modern sci-
ence. First publications provide reasonable orders of
magnitude of the problem as will be shown below. 
The studies suggest, for instance, that the Hudson River
carries the waste of some 16 tons of cocaine consumed
per year in New York. The Rhine in Germany carries the
waste of some 9 tons of cocaine consumed along its
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i In the first Italian tests, 500 ml samples of waste water were collected every 40 minutes on 4 days from the Po at Mezzano, Pavia. The analysis
found 25 nanograms of benzoylegonine (BE) per litre waste-water as well as 1.2 nanograms of cocaine per litre. The flow rate of the Po was found
to be 1 m3 per sec-1; The BE/cocaine molecular mass ratio is 0.954; 45% of a cocaine dose is typically being excreted as BE. Based on this infor-
mation the cocaine load of the Po could be calculated to amount to 3.8 kg per day or 1387 kg per year (based on the assumption in these four
days was typical for the consumption during the year). Ettore Zuccato Mario Negri Institute for Pharmacological Research, Chiara Chiabrando,
Sara Castiglioni , Davide Calamari, Renzo Bagnati, Silvia Schiarea and Roberto Fanelli, “Cocaine in surface waters: a new evidence-based tool to
monitor community drug abuse” in Environmental Health: August 2005 (http://www.ehjournal.net/content/4/1/14)
j Institute for Biomedical and pharmaceutical Research, Fist ever comparative multi-country study of cocaine use by a new measurement technique,
Nürnberg, November 2006.
k But, even this would be surprising as Frankfurt airport constitutes one of the main supply routes of cocaine into Germany.
* 1 line was here assumed to be equivalent to 100 milligram of cocaine.
Source: Institute for Biomedical and pharmaceutical Research, Fist ever comparative multi-country study of cocaine use by a new 
measurement technique, Nürnberg, November 2006.
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Cocaine use in selected sites - results from waste-water studies, 2005-2006
Country Town River Estimated cocaineper year (tons)
Number of lines
(100 mg) 
per day
Lines per 
1000 inhabitants
per day
USA
New York Hudson River 16.400 449,814 90
Washington Potomac river 7.360 201,725 38
San Francisco Bay 6.070 166,179 21
unweighted average 272,573 50
Spain
Miranda de Ebro Ebro 0.532 14,576 65
Madrid Manzanares 1.420 38,937 13
Aranda de Duero Duero 0.015 417 3
unweighted average 17,977 27
Italy Pavia Po 2.850 78,187 14
United Kingdom London Thames 0.975 26,709 13
Netherlands Utrecht Vecht 0.145 3,981 13
Switzerland
St. Moritz Inn 0.029 795 15
Zurich Limmat 0.103 2,814 13
Basel Rhie 0.944 25,864 5
Bern Aare 0.025 687 3
unweighted average 7,540 9
France Paris Seine 1.760 48,353 7
Germany
Mannheim Rhine 9.400 257,599 10
Cologne Rhine 9.050 248,004 5
Munich Isar 0.283 7,767 4
Düsseldorf Rhine 4.450 121,912 2
Ingolstadt Danube 0.129 3,532 2
Nürnberg Pegnitz 0.070 1,926 1
Frankfurt Main 0.372 10,205 1
unweighted average 92,992 4
Austria Vienna Danube 1.010 27,536 3
Czech Republic Prague Moldau 0.132 3,611 3
Romania - Arges* - - -
Unweighted average of all sites in Europe 43,972 9
Weighted* average of Europe 50,222 11
Unweighted average of all sites - global 72,547 14
Source: Institute for Biomedical and Pharmaceutical Research, Fist ever comparative multi-country study of cocaine use by a new 
measurement technique, Nürnberg, November 2006.
banks. The Potamic River in Washington carries the
waste of some 7 tons of cocaine consumed, etc. If meas-
ured against the size of the population, data show very
high levels of cocaine consumption in New York (134
lines of cocaine per day per 1000 inhabitants age 15-64)
and in Washington D.C. (56) while consumption
appears to be still non-existent in some parts of Roma-
nia (Arges river), and at relatively low levels in Prague (4
lines per 1000 inhabitants). This is again plausible as
methamphetamine is the drug of choice in this city and
cocaine is mostly consumed by foreign tourists. High
levels of cocaine use in Europe were found along the
Ebro (Spain), along the Po (Italy) and along the Thames
(UK). The studies in Italy found high levels of cocaine
waste along the Po in northern Italy, but low levels along
rivers in Sardinia and southern Italy, which is very much
in line with all existing epidemiological information.
But, there were also some surprising results, such as the
very low values found for Frankfurt (2 lines per 1000
inhabitants age 15-64). Existing epidemiological data
would have predicted higher figures. There could have
been a temporary shortage on the market when the
analysis took place,k or some other reasons to explain
this potential anomaly. 
The overall highest levels of cocaine consumption were
found in the United States, followed by Spain, Italy and
the UK. All of this is basically in line with other infor-
mation, suggesting that the measurement techniques
used for these studies are, in general, precise enough to
generate reasonably accurate data to differentiate
between locations. 
While UNODC is not in a position to verify the accu-
racy of all individual city results, there are still possibil-
ities to undertake some broad plausibility checks,
cross-checking the waste-water results with information
from other sources. 
If the average per capita values for each country are
taken and multiplied with the population of the coun-
try, data suggest that cocaine consumption in the ten
European countries, where such analyses took place,
could be close to 140 metric tons. Extrapolated to the
whole of West and Central Europe (based on a calcu-
lated weighted average of 11 lines of cocaine per day per
1000 inhabitants), one could reckon with a market of
some 190 metric tons. As the selection of the cities has
not been representative for each country but biased
toward location with higher levels of cocaine consump-
tion - which is particularly obvious in cases where only
one location per country was tested (such as London or
Paris) - total European consumption can be expected to
be still smaller. In order to account for this about a quar-
ter could be probably subtracted, leaving a net con-
sumption of some 140 metric tons of cocaine.l In fact,
this estimate turns out to be very similar to the estimate
of Europol that some 250 metric tons of cocaine are
being shipped to Europe. Deducting seizures made by
the European law enforcement agencies, leaves some
140 metric tons for domestic consumption. 
A calculation for the US market, based on the average
of the three selected cities of New York, Washington and
San Francisco (50 lines per day per 1000 inhabitants)
would result in an over-estimate, reflecting the fact that
in many parts of the US cocaine consumption is known
to be substantially lower than in New York. Disregard-
ing the high results from New York and extrapolating
from data from Washington D.C. (38 lines per 1000
inhabitants per day) and San Franciso (21 lines per day
per 1000 inhabitants), the average US estimate could be
around 270 metric tons. This would be a reasonable
estimate for the size of the US market, in line with pre-
viously reported estimates on the size of the US market. 
Though it is clear that currently available waste-water
studies are not, as yet, sufficient in terms of number of
studies to come up with reliable national, regional or
global estimates, data published so-far show that the
results are largely in line with what one could expect,
thus lending an additional element of credibility to
these results.  
In some of the studies, attempts have also been made to
estimate the number of cocaine users, based on the
amounts consumed. This would work fine if the average
per capita consumption levels of cocaine were known.
For most cities, this is not the case. With regard to these
final back-calculations, from the quantities consumed
to the number of users, views between UNODC and
the authors of some of the studies differ. Information
available to UNODC suggests that the ‘average user’
consumes far higher quantities of cocaine than it is
assumed in these studies. This has important implica-
tions. The number of cocaine users, deduced from the
amounts consumed, tends to be very high in some of
these studies which may not reflect reality. UNODC is
currently involved in a multi-city study in Europe to
find out more detailed information on the amounts of
drugs (including cocaine) consumed, on average, by a
drug user, which should assist, inter alia, such studies to
work with assumptions that are closer to reality. 
In conclusion, UNODC is carefully monitoring the
development of new approaches to come up with more
reliable data on drug consumption. A first round of
waste-water studies in Europe and North America has
already provided promising results, which are probably
not too far off reality. Most assumptions used in these
studies, derived from scientific literature, seem to be rea-
sonable, except for the very last element, the back-cal-
culation from the amounts used to the number of
potential drug users. But this is, in fact, an issue which
has been long neglected and still needs more research at
the local, national and international levels. The
approach to identify the amounts consumed seems to
work fine whenever a specific marker can be identified
for a drug (such as benzoylecgonine for cocaine) and as
long as a city or a region has a functioning waste water
system, where the water eventually ends up in a river.
For the time being, this seems to be a promising new
approach for developed countries, less so for developing
countries where the basic infrastructure is often not
available.  
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l There is also another alternative calculation which leads to similar results. If t the selected sites in each country were those with the highest level of
cocaine consumption, one can calculate – for the countries for which info is available - the ratio between the average and the highest cocaine use
figure. The average of the averages shows a ratio of 0.5, which means that the highest value is, on average, about twice as high as the national aver-
age. Correcting the data for the countries where only one site was investigated, would reduce the figure for the selected 10 countries to 96 tons,
which - extrapolated to West and Central Europe as a whole – would result in an estimate of 132 metric tons. 
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